ID ATM_HUMAN Reviewed; 3056 AA. AC Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 22-JAN-2014, sequence version 4. DT 28-JAN-2026, entry version 269. DE RecName: Full=Serine-protein kinase ATM; DE EC=2.7.11.1 {ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:28508083, ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; DE AltName: Full=Ataxia telangiectasia mutated; DE Short=A-T mutated; GN Name=ATM; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT AT ASP-3003. RX PubMed=8589678; DOI=10.1093/hmg/4.11.2025; RA Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., RA Shiloh Y., Rotman G.; RT "The complete sequence of the coding region of the ATM gene reveals RT similarity to cell cycle regulators in different species."; RL Hum. Mol. Genet. 4:2025-2032(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT AT ASP-3003, AND VARIANTS RP CYS-49; ARG-1054; PHE-1420; ILE-2079 AND ALA-2287. RX PubMed=8665503; RA Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L., RA Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R., Russo G., RA Croce C.M., Negrini M.; RT "The ATM gene and susceptibility to breast cancer: analysis of 38 breast RT tumors reveals no evidence for mutation."; RL Cancer Res. 56:2726-2732(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9199932; DOI=10.1101/gr.7.6.592; RA Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A., RA Gilad S., Shiloh Y., Rosenthal A.; RT "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human genomic RT DNA containing the entire ATM gene."; RL Genome Res. 7:592-605(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT 2546-SER--ILE-2548 RP DEL. RX PubMed=8789452; DOI=10.1093/hmg/5.1.145; RA Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T., RA McGuire G.M., Thick J.A., Taylor A.M.R.; RT "Mutations revealed by sequencing the 5' half of the gene for ataxia RT telangiectasia."; RL Hum. Mol. Genet. 5:145-149(1996). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24. RX PubMed=9108147; DOI=10.1093/nar/25.9.1678; RA Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A., RA Elroy-Stein O., Shiloh Y., Rotman G.; RT "Ataxia-telangiectasia: structural diversity of untranslated sequences RT suggests complex post-transcriptional regulation of ATM gene expression."; RL Nucleic Acids Res. 25:1678-1684(1997). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS 2427-LEU-ARG-2428 RP DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND ASP-3003. RC TISSUE=Fibroblast; RX PubMed=7792600; DOI=10.1126/science.7792600; RA Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., RA Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., RA Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., RA Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., RA Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y.; RT "A single ataxia telangiectasia gene with a product similar to PI-3 RT kinase."; RL Science 268:1749-1753(1995). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056. RX PubMed=8521392; RA Rasio D., Negrini M., Croce C.M.; RT "Genomic organization of the ATM locus involved in ataxia-telangiectasia."; RL Cancer Res. 55:6053-6057(1995). RN [12] RP PHOSPHORYLATION. RX PubMed=8969240; DOI=10.1074/jbc.271.52.33693; RA Chen G., Lee E.Y.-H.P.; RT "The product of the ATM gene is a 370-kDa nuclear phosphoprotein."; RL J. Biol. Chem. 271:33693-33697(1996). RN [13] RP SUBCELLULAR LOCATION. RX PubMed=9050866; DOI=10.1073/pnas.94.5.1840; RA Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S., Shiloh Y., RA Tagle D.A.; RT "The ataxia-telangiectasia gene product, a constitutively expressed nuclear RT protein that is not up-regulated following genome damage."; RL Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997). RN [14] RP SUBCELLULAR LOCATION, AND VARIANTS 2546-SER--ILE-2548 DEL AND TYR-2824. RX PubMed=9150358; DOI=10.1038/sj.onc.1201037; RA Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., RA Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., RA Ramsay J., Gatti R.A., Lavin M.F.; RT "Cellular localisation of the ataxia-telangiectasia (ATM) gene product and RT discrimination between mutated and normal forms."; RL Oncogene 14:1911-1921(1997). RN [15] RP CATALYTIC ACTIVITY. RX PubMed=8988033; RA Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.; RT "ATM gene product phosphorylates I kappa B-alpha."; RL Cancer Res. 57:24-27(1997). RN [16] RP INTERACTION WITH ABL1. RX PubMed=9168117; DOI=10.1038/387520a0; RA Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T., Hobson K., RA Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y., Kharbanda S., RA Kufe D., Lavin M.F.; RT "Interaction between ATM protein and c-Abl in response to DNA damage."; RL Nature 387:520-523(1997). RN [17] RP ACTIVITY REGULATION. RX PubMed=9766667; RA Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E., RA Abraham R.T.; RT "Inhibition of phosphoinositide 3-kinase related kinases by the RT radiosensitizing agent wortmannin."; RL Cancer Res. 58:4375-4382(1998). RN [18] RP FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY. RX PubMed=9843217; DOI=10.1038/3882; RA Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., RA Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.; RT "ATM associates with and phosphorylates p53: mapping the region of RT interaction."; RL Nat. Genet. 20:398-400(1998). RN [19] RP SUBCELLULAR LOCATION. RX PubMed=9707615; DOI=10.1073/pnas.95.17.10146; RA Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S., RA Darnell R.B., Shiloh Y., Kastan M.B.; RT "ATM binds to beta-adaptin in cytoplasmic vesicles."; RL Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998). RN [20] RP FUNCTION IN PHOSPHORYLATION OF TP53. RX PubMed=9733514; DOI=10.1126/science.281.5383.1674; RA Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L., RA Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.; RT "Enhanced phosphorylation of p53 by ATM in response to DNA damage."; RL Science 281:1674-1677(1998). RN [21] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND RP ASN-2875. RX PubMed=9733515; DOI=10.1126/science.281.5383.1677; RA Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., RA Appella E., Kastan M.B., Siliciano J.D.; RT "Activation of the ATM kinase by ionizing radiation and phosphorylation of RT p53."; RL Science 281:1677-1679(1998). RN [22] RP DNA-BINDING. RX PubMed=10500142; DOI=10.1073/pnas.96.20.11134; RA Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J., RA Jackson S.P.; RT "Purification and DNA binding properties of the ataxia-telangiectasia gene RT product ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999). RN [23] RP FUNCTION IN PHOSPHORYLATION OF BRCA1. RX PubMed=10550055; DOI=10.1126/science.286.5442.1162; RA Cortez D., Wang Y., Qin J., Elledge S.J.; RT "Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage RT response to double-strand breaks."; RL Science 286:1162-1166(1999). RN [24] RP IDENTIFICATION OF ATM AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [25] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10766245; DOI=10.1038/35007091; RA Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J., RA Kastan M.B.; RT "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway."; RL Nature 404:613-617(2000). RN [26] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10839545; DOI=10.1038/35013089; RA Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., RA O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., RA Livingston D.M., Weaver D.T.; RT "ATM phosphorylation of Nijmegen breakage syndrome protein is required in a RT DNA damage response."; RL Nature 405:477-482(2000). RN [27] RP FUNCTION IN PHOSPHORYLATION OF CTIP. RX PubMed=10910365; DOI=10.1038/35018134; RA Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y., Lee E.Y.-H.P., RA Lee W.-H.; RT "Functional link of BRCA1 and ataxia telangiectasia gene product in DNA RT damage response."; RL Nature 406:210-215(2000). RN [28] RP FUNCTION IN PHOSPHORYLATION OF NBN. RX PubMed=10802669; DOI=10.1038/75508; RA Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., RA Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.; RT "ATM-dependent phosphorylation of nibrin in response to radiation RT exposure."; RL Nat. Genet. 25:115-119(2000). RN [29] RP FUNCTION IN PHOSPHORYLATION OF CHEK2. RX PubMed=10973490; DOI=10.1073/pnas.190030497; RA Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.; RT "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro."; RL Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000). RN [30] RP FUNCTION IN PHOSPHORYLATION OF TERF1. RX PubMed=11375976; DOI=10.1074/jbc.m011534200; RA Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.; RT "Telomeric protein Pin2/TRF1 as an important ATM target in response to RT double strand DNA breaks."; RL J. Biol. Chem. 276:29282-29291(2001). RN [31] RP INTERACTION WITH RAD17. RX PubMed=11418864; DOI=10.1038/35082110; RA Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A., Ali A., RA Chen S.M., Abraham R.T., Wang X.-F.; RT "ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic RT stress responses."; RL Nature 411:969-974(2001). RN [32] RP FUNCTION IN PHOSPHORYLATION OF FANCD2. RX PubMed=12086603; DOI=10.1016/s0092-8674(02)00747-x; RA Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., RA Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.; RT "Convergence of the Fanconi anemia and ataxia telangiectasia signaling RT pathways."; RL Cell 109:459-472(2002). RN [33] RP PHOSPHORYLATION BY NUAK1. RX PubMed=12409306; DOI=10.1074/jbc.m206025200; RA Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F., Esumi H.; RT "Identification of a novel protein kinase mediating Akt survival signaling RT to the ATM protein."; RL J. Biol. Chem. 278:48-53(2003). RN [34] RP PHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF RP SER-1981. RX PubMed=12556884; DOI=10.1038/nature01368; RA Bakkenist C.J., Kastan M.B.; RT "DNA damage activates ATM through intermolecular autophosphorylation and RT dimer dissociation."; RL Nature 421:499-506(2003). RN [35] RP FUNCTION IN DNA DAMAGE RESPONSE. RX PubMed=14871926; DOI=10.1101/gad.1176004; RA Ali A., Zhang J., Bao S., Liu I., Otterness D., Dean N.M., Abraham R.T., RA Wang X.F.; RT "Requirement of protein phosphatase 5 in DNA-damage-induced ATM RT activation."; RL Genes Dev. 18:249-254(2004). RN [36] RP FUNCTION IN PHOSPHORYLATION OF DCLRE1C. RX PubMed=15456891; DOI=10.1128/mcb.24.20.9207-9220.2004; RA Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D., RA Legerski R.J.; RT "Artemis is a phosphorylation target of ATM and ATR and is involved in the RT G2/M DNA damage checkpoint response."; RL Mol. Cell. Biol. 24:9207-9220(2004). RN [37] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=15448695; DOI=10.1038/ncb1170; RA Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., RA Jansson M., La Thangue N.B.; RT "A new effector pathway links ATM kinase with the DNA damage response."; RL Nat. Cell Biol. 6:968-976(2004). RN [38] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=15064416; DOI=10.1126/science.1091496; RA Lee J.-H., Paull T.T.; RT "Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 RT complex."; RL Science 304:93-96(2004). RN [39] RP INTERACTION WITH EEF1E1. RX PubMed=15680327; DOI=10.1016/j.cell.2004.11.054; RA Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H., RA Choi Y.H., Choi D., Lee K.S., Kim S.; RT "The haploinsufficient tumor suppressor p18 upregulates p53 via RT interactions with ATM/ATR."; RL Cell 120:209-221(2005). RN [40] RP FUNCTION. RX PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015; RA Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N., Ronai Z.; RT "ATM-dependent phosphorylation of ATF2 is required for the DNA damage RT response."; RL Mol. Cell 18:577-587(2005). RN [41] RP INTERACTION WITH KAT8. RX PubMed=15923642; DOI=10.1128/mcb.25.12.5292-5305.2005; RA Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R., Paull T.T., RA Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.; RT "Involvement of human MOF in ATM function."; RL Mol. Cell. Biol. 25:5292-5305(2005). RN [42] RP FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY. RX PubMed=16086026; DOI=10.1038/nsmb972; RA Kaygun H., Marzluff W.F.; RT "Regulated degradation of replication-dependent histone mRNAs requires both RT ATR and Upf1."; RL Nat. Struct. Mol. Biol. 12:794-800(2005). RN [43] RP PHOSPHORYLATION AT SER-1981, AND ACETYLATION. RX PubMed=16141325; DOI=10.1073/pnas.0504211102; RA Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.; RT "A role for the Tip60 histone acetyltransferase in the acetylation and RT activation of ATM."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005). RN [44] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND RP PHOSPHORYLATION AT SER-1981. RX PubMed=15790808; DOI=10.1126/science.1108297; RA Lee J.H., Paull T.T.; RT "ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 RT complex."; RL Science 308:551-554(2005). RN [45] RP PHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, CATALYTIC RP ACTIVITY, MUTAGENESIS OF SER-367; SER-1893 AND SER-1981, AND IDENTIFICATION RP BY MASS SPECTROMETRY. RX PubMed=16858402; DOI=10.1038/sj.emboj.7601231; RA Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.; RT "Involvement of novel autophosphorylation sites in ATM activation."; RL EMBO J. 25:3504-3514(2006). RN [46] RP INTERACTION WITH ATMIN. RX PubMed=17525732; DOI=10.1038/sj.emboj.7601733; RA Kanu N., Behrens A.; RT "ATMIN defines an NBS1-independent pathway of ATM signalling."; RL EMBO J. 26:2933-2941(2007). RN [47] RP ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND RP LYS-3018. RX PubMed=17923702; DOI=10.1128/mcb.01382-07; RA Sun Y., Xu Y., Roy K., Price B.D.; RT "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase RT activity."; RL Mol. Cell. Biol. 27:8502-8509(2007). RN [48] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-1983, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [49] RP INTERACTION WITH CEP164. RX PubMed=18283122; DOI=10.1101/gad.1627708; RA Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.; RT "Cep164 is a mediator protein required for the maintenance of genomic RT stability through modulation of MDC1, RPA, and CHK1."; RL Genes Dev. 22:587-600(2008). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [51] RP INTERACTION WITH NABP2. RX PubMed=18449195; DOI=10.1038/nature06883; RA Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K., RA Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J., Pandita R.K., RA Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T., Pandita T.K., RA White M.F., Khanna K.K.; RT "Single-stranded DNA-binding protein hSSB1 is critical for genomic RT stability."; RL Nature 453:677-681(2008). RN [52] RP INTERACTION WITH DDX1. RX PubMed=18710941; DOI=10.1128/mcb.01053-08; RA Li L., Monckton E.A., Godbout R.; RT "A role for DEAD box 1 at DNA double-strand breaks."; RL Mol. Cell. Biol. 28:6413-6425(2008). RN [53] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2996, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [54] RP FUNCTION AS DYRK2 KINASE. RX PubMed=19965871; DOI=10.1074/jbc.m109.042341; RA Taira N., Yamamoto H., Yamaguchi T., Miki Y., Yoshida K.; RT "ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 285:4909-4919(2010). RN [55] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [56] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [57] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [58] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [59] RP PHOSPHORYLATION AT SER-1981. RX PubMed=21144835; DOI=10.1016/j.bbrc.2010.12.005; RA Kang Y., Cheong H.M., Lee J.H., Song P.I., Lee K.H., Kim S.Y., Jun J.Y., RA You H.J.; RT "Protein phosphatase 5 is necessary for ATR-mediated DNA repair."; RL Biochem. Biophys. Res. Commun. 404:476-481(2011). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=22977523; DOI=10.3892/etm.2011.232; RA So E.Y., Ouchi T.; RT "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK RT catalytic subunit."; RL Exp. Ther. Med. 2:443-447(2011). RN [61] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21757780; DOI=10.1074/jbc.m111.258152; RA Gatei M., Jakob B., Chen P., Kijas A.W., Becherel O.J., Gueven N., RA Birrell G., Lee J.H., Paull T.T., Lerenthal Y., Fazry S., RA Taucher-Scholz G., Kalb R., Schindler D., Waltes R., Doerk T., Lavin M.F.; RT "ATM protein-dependent phosphorylation of Rad50 protein regulates DNA RT repair and cell cycle control."; RL J. Biol. Chem. 286:31542-31556(2011). RN [62] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [63] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [64] RP FUNCTION. RX PubMed=24534091; DOI=10.1002/embj.201386064; RA Wang Q., Goldstein M., Alexander P., Wakeman T.P., Sun T., Feng J., Lou Z., RA Kastan M.B., Wang X.F.; RT "Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular RT response to DNA double-strand breaks."; RL EMBO J. 33:862-877(2014). RN [65] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [66] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PEX5, RP AND MUTAGENESIS OF ARG-3047. RX PubMed=26344566; DOI=10.1038/ncb3230; RA Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., RA Dere R., Tait-Mulder J., Lee J.H., Paull T.T., Pandita R.K., Charaka V.K., RA Pandita T.K., Kastan M.B., Walker C.L.; RT "ATM functions at the peroxisome to induce pexophagy in response to ROS."; RL Nat. Cell Biol. 17:1259-1269(2015). RN [67] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26240375; DOI=10.1093/nar/gkv754; RA Kijas A.W., Lim Y.C., Bolderson E., Cerosaletti K., Gatei M., Jakob B., RA Tobias F., Taucher-Scholz G., Gueven N., Oakley G., Concannon P., RA Wolvetang E., Khanna K.K., Wiesmueller L., Lavin M.F.; RT "ATM-dependent phosphorylation of MRE11 controls extent of resection during RT homology directed repair by signalling through Exonuclease 1."; RL Nucleic Acids Res. 43:8352-8367(2015). RN [68] RP FUNCTION IN PHOSPHORYLATION OF FBXW7. RX PubMed=26774286; DOI=10.1016/j.molcel.2015.12.010; RA Zhang Q., Karnak D., Tan M., Lawrence T.S., Morgan M.A., Sun Y.; RT "FBXW7 facilitates nonhomologous end-joining via K63-linked RT polyubiquitylation of XRCC4."; RL Mol. Cell 61:419-433(2016). RN [69] RP FUNCTION. RX PubMed=29203878; DOI=10.1038/s41467-017-02114-x; RA Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D., RA Zhu X.D.; RT "ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair RT pathway choice."; RL Nat. Commun. 8:1921-1921(2017). RN [70] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [71] RP FUNCTION. RX PubMed=30612738; DOI=10.1016/j.cell.2018.11.024; RA Jachimowicz R.D., Beleggia F., Isensee J., Velpula B.B., Goergens J., RA Bustos M.A., Doll M.A., Shenoy A., Checa-Rodriguez C., Wiederstein J.L., RA Baranes-Bachar K., Bartenhagen C., Hertwig F., Teper N., Nishi T., RA Schmitt A., Distelmaier F., Luedecke H.J., Albrecht B., Krueger M., RA Schumacher B., Geiger T., Hoon D.S.B., Huertas P., Fischer M., Hucho T., RA Peifer M., Ziv Y., Reinhardt H.C., Wieczorek D., Shiloh Y.; RT "UBQLN4 represses homologous recombination and is overexpressed in RT aggressive tumors."; RL Cell 0:0-0(2019). RN [72] RP FUNCTION IN PHOSPHORYLATION OF UFL1, AND CATALYTIC ACTIVITY. RX PubMed=30886146; DOI=10.1038/s41467-019-09175-0; RA Qin B., Yu J., Nowsheen S., Wang M., Tu X., Liu T., Li H., Wang L., Lou Z.; RT "UFL1 promotes histone H4 ufmylation and ATM activation."; RL Nat. Commun. 10:1242-1242(2019). RN [73] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=30952868; DOI=10.1038/s41467-019-09641-9; RA Ha G.H., Ji J.H., Chae S., Park J., Kim S., Lee J.K., Kim Y., Min S., RA Park J.M., Kang T.H., Lee H., Cho H., Lee C.W.; RT "Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at RT DNA double-strand breaks."; RL Nat. Commun. 10:1577-1577(2019). RN [74] RP ACETYLATION AT LYS-3016, PHOSPHORYLATION AT SER-1981, AND MUTAGENESIS OF RP LYS-3016. RX PubMed=30944854; DOI=10.1126/sciadv.aav1118; RA Tang M., Li Z., Zhang C., Lu X., Tu B., Cao Z., Li Y., Chen Y., Jiang L., RA Wang H., Wang L., Wang J., Liu B., Xu X., Wang H., Zhu W.G.; RT "SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA RT damage repair."; RL Sci. Adv. 5:EAAV1118-EAAV1118(2019). RN [75] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=38128537; DOI=10.1016/j.cell.2023.11.022; RA Chen Y., Wu J., Zhai L., Zhang T., Yin H., Gao H., Zhao F., Wang Z., RA Yang X., Jin M., Huang B., Ding X., Li R., Yang J., He Y., Wang Q., RA Wang W., Kloeber J.A., Li Y., Hao B., Zhang Y., Wang J., Tan M., Li K., RA Wang P., Lou Z., Yuan J.; RT "Metabolic regulation of homologous recombination repair by MRE11 RT lactylation."; RL Cell 187:294-311(2024). RN [76] {ECO:0007744|PDB:5NP0, ECO:0007744|PDB:5NP1} RP STRUCTURE BY ELECTRON MICROSCOPY (5.70 ANGSTROMS), CATALYTIC ACTIVITY, AND RP SUBUNIT. RX PubMed=28508083; DOI=10.1126/sciadv.1700933; RA Baretic D., Pollard H.K., Fisher D.I., Johnson C.M., Santhanam B., RA Truman C.M., Kouba T., Fersht A.R., Phillips C., Williams R.L.; RT "Structures of closed and open conformations of dimeric human ATM."; RL Sci. Adv. 3:E1700933-E1700933(2017). RN [77] {ECO:0007744|PDB:7SIC, ECO:0007744|PDB:7SID} RP STRUCTURE BY ELECTRON MICROSCOPY (2.51 ANGSTROMS) IN COMPLEX WITH NBN, RP FUNCTION, INTERACTION WITH NBN, AND ACTIVITY REGULATION. RX PubMed=35076389; DOI=10.7554/elife.74218; RA Warren C., Pavletich N.P.; RT "Structure of the human ATM kinase and mechanism of Nbs1 binding."; RL Elife 11:0-0(2022). RN [78] RP VARIANTS GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827. RX PubMed=8755918; RA McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y., RA Lennox G.G., Taylor A.M.R.; RT "Mutations associated with variant phenotypes in ataxia-telangiectasia."; RL Am. J. Hum. Genet. 59:320-330(1996). RN [79] RP VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438. RX PubMed=8808599; RA Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D., RA Concannon P.; RT "A high frequency of distinct ATM gene mutations in ataxia- RT telangiectasia."; RL Am. J. Hum. Genet. 59:839-846(1996). RN [80] RP VARIANTS 705-TYR--SER-707 DELINS PHE-ILE-PRO AND 2546-SER--ILE-2548 DEL, RP AND VARIANTS CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691. RX PubMed=8797579; RA Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B., RA Croce C.M., Hammarstroem L.; RT "ATM mutations in cancer families."; RL Cancer Res. 56:4130-4133(1996). RN [81] RP VARIANT AT 705-TYR--SER-707 DELINS PHE-ILE-PRO, AND VARIANTS LEU-858 AND RP ARG-1054. RX PubMed=9043869; DOI=10.1159/000472231; RA Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M., RA James M.R., Negrini M., Webster A.D.B., Hammarstroem L.; RT "Exon-scanning mutation analysis of the ATM gene in patients with ataxia- RT telangiectasia."; RL Eur. J. Hum. Genet. 4:352-355(1996). RN [82] RP VARIANT AT ARG-2867. RX PubMed=8698354; DOI=10.1007/s004390050202; RA Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.; RT "New mutations in the ataxia telangiectasia gene."; RL Hum. Genet. 98:246-249(1996). RN [83] RP VARIANTS 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860 DEL AND RP GLY-2904. RX PubMed=8845835; DOI=10.1093/hmg/5.4.433; RA Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., RA Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., RA Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A., Lenoir G., Lavin M.F., RA Tatsumi K., Wegner R.-D., Shiloh Y., Bar-Shira A.; RT "Predominance of null mutations in ataxia-telangiectasia."; RL Hum. Mol. Genet. 5:433-439(1996). RN [84] RP POSSIBLE INVOLVEMENT IN TPLL AND BNHL, AND VARIANTS VAL-1040; THR-1407; RP SER-1463; HIS-1682; HIS-1910; LYS-2164; SER-2396; GLY-2424; PRO-2442; RP 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722; VAL-2725; LEU-2732; LYS-2810 RP DEL; CYS-2832 AND 2871-ARG-HIS-2872 DELINS SER AND VAL-2890. RX PubMed=9288106; DOI=10.1038/ng0997-96; RA Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L., Yaxley J.C., RA Foroni L., Hammarstroem L., Webster A.D.B., Yuille M.A.R.; RT "Clustering of missense mutations in the ataxia-telangiectasia gene in a RT sporadic T-cell leukaemia."; RL Nat. Genet. 17:96-99(1997). RN [85] RP POSSIBLE INVOLVEMENT IN TPLL, AND VARIANTS GLY-2725; PRO-3006 AND CYS-3008. RX PubMed=9334731; DOI=10.1038/nm1097-1155; RA Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., RA Bar-Shira A., James M.R., Lichter P., Doehner H.; RT "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia."; RL Nat. Med. 3:1155-1159(1997). RN [86] RP VARIANT AT CYS-2832. RX PubMed=9443866; DOI=10.1086/301673; RA Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T., Castellvi-Bel S., RA Udar N., Boerresen-Dale A.-L., Chessa L., Bernatowska-Matuszkiewicz E., RA Porras O., Watanabe M., Junker A., Concannon P., Gatti R.A.; RT "Ataxia-telangiectasia: identification and detection of founder-effect RT mutations in the ATM gene in ethnic populations."; RL Am. J. Hum. Genet. 62:86-97(1998). RN [87] RP POSSIBLE INVOLVEMENT IN TALL, AND VARIANTS AT LEU-292; ASP-768; GLN-1001; RP ARG-1691; ILE-1743; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 RP DEL; ASP-2554; GLY-2668 AND CYS-2827. RX PubMed=9463314; DOI=10.1086/301706; RA Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., RA Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G., Haites N., RA Byrd P.J., Taylor A.M.R.; RT "ATM mutations and phenotypes in ataxia-telangiectasia families in the RT British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, RT and breast cancer."; RL Am. J. Hum. Genet. 62:334-345(1998). RN [88] RP VARIANT AT 1812-ALA-PHE-1813 DELINS VAL. RX PubMed=9497252; DOI=10.1086/301755; RA Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M., RA Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.; RT "Genotype-phenotype relationships in ataxia-telangiectasia and variants."; RL Am. J. Hum. Genet. 62:551-561(1998). RN [89] RP VARIANT AT PRO-2656. RX PubMed=9450874; RX DOI=10.1002/(sici)1096-8628(19980113)75:2<141::aid-ajmg4>3.3.co;2-8; RA Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E., RA Ohno K., Hori N., Sato K., Takeshita K.; RT "Ataxia-telangiectasia without immunodeficiency: novel point mutations RT within and adjacent to the phosphatidylinositol 3-kinase-like domain."; RL Am. J. Med. Genet. 75:141-144(1998). RN [90] RP VARIANT TPLL GLY-2486. RX PubMed=9573030; RA Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F., RA Stern M.-H.; RT "Inactivation of the ATM gene in T-cell prolymphocytic leukemias."; RL Blood 91:3920-3926(1998). RN [91] RP VARIANTS 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND VARIANT RP VAL-1853. RX PubMed=9872980; DOI=10.1101/gr.8.12.1245; RA Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C., RA Fodor S.P.A., Tagle D.A., Collins F.S.; RT "Strategies for mutational analysis of the large multiexon ATM gene using RT high-density oligonucleotide arrays."; RL Genome Res. 8:1245-1258(1998). RN [92] RP VARIANT AT 2625-ASP-ALA-2626 DELINS GLU-PRO. RX PubMed=9521587; DOI=10.1007/s004390050675; RA van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M., RA van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.; RT "A double missense mutation in the ATM gene of a Dutch family with ataxia RT telangiectasia."; RL Hum. Genet. 102:187-191(1998). RN [93] RP VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853. RX PubMed=9711876; RX DOI=10.1002/(sici)1098-1004(1998)12:3<186::aid-humu6>3.0.co;2-f; RA Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T., Yamauchi M., RA Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K., Nikaido O., RA Hayashi K.; RT "ATM mutations in patients with ataxia telangiectasia screened by a RT hierarchical strategy."; RL Hum. Mutat. 12:186-195(1998). RN [94] RP VARIANTS AT LEU-858; ARG-1054; ASP-1091 AND ARG-1566. RX PubMed=9792409; RX DOI=10.1002/(sici)1098-1004(1998)12:5<330::aid-humu6>3.0.co;2-h; RA Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J., RA Jaspers N.G.J., van 't Veer L.J.; RT "ATM germline mutations in classical ataxia-telangiectasia patients in the RT Dutch population."; RL Hum. Mutat. 12:330-337(1998). RN [95] RP VARIANTS AT ARG-2491 AND GLY-2909. RX PubMed=9792410; RX DOI=10.1002/(sici)1098-1004(1998)12:5<338::aid-humu7>3.0.co;2-9; RA Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T., RA Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J., RA Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.; RT "Ataxia-telangiectasia in the Japanese population: identification of RT R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two being RT relatively common mutations."; RL Hum. Mutat. 12:338-343(1998). RN [96] RP VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008. RX PubMed=9488043; DOI=10.1038/sj.onc.1201603; RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RT "ATM is usually rearranged in T-cell prolymphocytic leukaemia."; RL Oncogene 16:789-796(1998). RN [97] RP ERRATUM OF PUBMED:9488043. RA Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L., Matutes E., RA Brito-Babapulle V., Vorechovsky I., Dyer M.J.S., Catovsky D.; RL Oncogene 16:2955-2955(1998). RN [98] RP POSSIBLE INVOLVEMENT IN BCLL AND MCL, AND VARIANTS ASN-1853; VAL-1853; RP ARG-1953; LYS-2418 INS; PRO-2420; GLY-2423; HIS-3008 AND ASN-3018. RX PubMed=10397742; RA Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.; RT "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic RT lymphocytic leukemia."; RL Blood 94:748-753(1999). RN [99] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS CYS-332; ARG-1691 AND GLY-2424. RX PubMed=9892178; RA Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M., RA Albitar M., Reed J.C., Croce C.M.; RT "ATM mutations in B-cell chronic lymphocytic leukemia."; RL Cancer Res. 59:24-27(1999). RN [100] RP VARIANT AT PRO-1465. RX PubMed=10234507; DOI=10.1038/sj.ejhg.5200288; RA Izatt L., Vessey C., Hodgson S.V., Solomon E.; RT "Rapid and efficient ATM mutation detection by fluorescent chemical RT cleavage of mismatch: identification of four novel mutations."; RL Eur. J. Hum. Genet. 7:310-320(1999). RN [101] RP VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570; ASN-1853 RP AND SER-2765. RX PubMed=10534763; RX DOI=10.1002/(sici)1098-2264(199912)26:4<286::aid-gcc2>3.3.co;2-o; RA Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G., RA Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.; RT "Identification of germline missense mutations and rare allelic variants in RT the ATM gene in early-onset breast cancer."; RL Genes Chromosomes Cancer 26:286-294(1999). RN [102] RP VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227; RP ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49; RP LEU-858; ARG-1054; ASN-1853 AND VAL-1853. RX PubMed=9887333; DOI=10.1093/hmg/8.1.69; RA Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R., Skawran B., RA Stuhrmann M., Wegner R.-D., Sperling K., Banin S., Shiloh Y., Baumer A., RA Bernthaler U., Sennefelder H., Brohm M., Weber B.H.F., Schindler D.; RT "Characterization of ATM gene mutations in 66 ataxia telangiectasia RT families."; RL Hum. Mol. Genet. 8:69-79(1999). RN [103] RP VARIANTS AT 375-GLN--VAL-3056 DEL; 1466-ARG--VAL-3056 DEL; RP 1730-ARG--VAL-3056 DEL; GLY-2016; 2224-MET--ARG-2227 DELINS ILE-SER; RP 2246-CYS--THR-2252 DELINS HIS; VAL-2664 DEL; VAL-2726; 2849-ARG--VAL-3056 RP DEL AND ARG-2855, AND VARIANT CYS-49. RX PubMed=10425038; RX DOI=10.1002/(sici)1098-1004(1999)14:2<156::aid-humu7>3.0.co;2-e; RA Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J., RA Wang Z., Yang Z., Cheng R., Gatti R.A.; RT "New mutations, polymorphisms, and rare variants in the ATM gene detected RT by a novel SSCP strategy."; RL Hum. Mutat. 14:156-162(1999). RN [104] RP POSSIBLE INVOLVEMENT IN BCLL, AND VARIANTS THR-350; THR-352; ARG-1054; RP THR-2274 AND ALA-2695. RX PubMed=10023947; DOI=10.1016/s0140-6736(98)10117-4; RA Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J., RA Moss P.A.H., Taylor A.M.R.; RT "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic RT lymphocytic leukaemia."; RL Lancet 353:26-29(1999). RN [105] RP VARIANT ARG-1054. RX PubMed=10217116; DOI=10.1016/s0140-6736(05)75199-0; RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RT "Missense mutations at ATM gene and cancer risk."; RL Lancet 353:1276-1276(1999). RN [106] RP ERRATUM OF PUBMED:10217116. RA Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.; RL Lancet 354:780-780(1999). RN [107] RP VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548 DEL; RP GLN-2625; CYS-2832; 2855-SER-VAL-2856 DELINS ARG-ILE AND CYS-3008, AND RP VARIANTS VAL-1853 AND ILE-2438. RX PubMed=10817650; RX DOI=10.1002/(sici)1096-8628(20000529)92:3<170::aid-ajmg3>3.0.co;2-#; RA Li A., Swift M.; RT "Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A- RT T patients."; RL Am. J. Med. Genet. 92:170-177(2000). RN [108] RP VARIANTS AT 35-ARG--VAL-3056 DEL; LEU-292; 393-TRP--VAL-3056 DEL; ARG-950; RP LEU-1082; 1171-GLN--VAL-3056 DEL; 1839-GLN--VAL-3056 DEL; GLU-2063; RP CYS-2227; 2246-CYS--THR-2252 DELINS HIS; 2547-ARG--SER-2549 DEL; GLU-2625; RP PRO-2626 AND ARG-2702, AND VARIANT CYS-49. RX PubMed=10873394; DOI=10.1006/mgme.2000.2998; RA Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O., RA Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.; RT "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein RT expression, mutations, and radiosensitivity."; RL Mol. Genet. Metab. 70:122-133(2000). RN [109] RP VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008. RX PubMed=10706620; DOI=10.1073/pnas.050400997; RA Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.; RT "Mantle cell lymphoma is characterized by inactivation of the ATM gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000). RN [110] RP VARIANTS TRP-45 AND CYS-49. RX PubMed=11897822; DOI=10.1136/jmg.39.3.192; RA Allinen M., Launonen V., Laake K., Jansen L., Huusko P., Kaeaeriaeinen H., RA Boerresen-Dale A.L., Winqvist R.; RT "ATM mutations in Finnish breast cancer patients."; RL J. Med. Genet. 39:192-196(2002). RN [111] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140; GLN-250; RP PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514; TYR-540; VAL-546; RP LEU-582; PRO-707; GLN-848; LEU-858; SER-872; TRP-924; ALA-935; ARG-1054; RP PHE-1179; ILE-1321; TYR-1380; SER-1382; PHE-1420; MET-1469; CYS-1475; RP SER-1650; THR-1739; ASN-1853; VAL-1853; ILE-1916; THR-1945; CYS-1961; RP ASP-1991; PHE-2307; PRO-2332; PHE-2356; LEU-2408; PRO-2442; GLN-2443; RP ARG-2464; ARG-2492; ALA-2666; HIS-2719; ARG-2842 AND ASN-2870. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [112] RP VARIANTS CYS-49; LEU-858; ARG-1054; VAL-1255; ASN-1853; THR-2105; SER-2396 RP AND HIS-2719. RX PubMed=18384426; DOI=10.1111/j.1399-0004.2008.00987.x; RA Brunet J., Gutierrez-Enriquez S., Torres A., Berez V., Sanjose S., RA Galceran J., Izquierdo A., Menendez J.A., Guma J., Borras J.; RT "ATM germline mutations in Spanish early-onset breast cancer patients RT negative for BRCA1/BRCA2 mutations."; RL Clin. Genet. 73:465-473(2008). RN [113] RP FUNCTION, CHARACTERIZATION OF VARIANTS AT LEU-292; PRO-1465; ILE-1743; RP THR-2274; GLY-2424; 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; RP ASP-2554; GLY-2668; CYS-2827; 2855-SER-VAL-2856 DELINS ARG-ILE AND RP CYS-3008, CHARACTERIZATION OF VARIANTS VAL-546; ARG-1054; ILE-1322; RP ARG-1691; CYS-1961 AND SER-2765, VARIANT ILE-1322, AND MUTAGENESIS OF RP LYS-1807; VAL-1941; TYR-2019; GLU-2039; LEU-2338; SER-2394; LEU-2452; RP SER-2685; PRO-2699; ASP-2708 AND GLN-2730. RX PubMed=19431188; DOI=10.1002/humu.21034; RA Barone G., Groom A., Reiman A., Srinivasan V., Byrd P.J., Taylor A.M.; RT "Modeling ATM mutant proteins from missense changes confirms retained RT kinase activity."; RL Hum. Mutat. 30:1222-1230(2009). RN [114] RP VARIANTS ALA-661; PRO-707; LEU-858; TRP-924; ARG-1054; ARG-1691 AND RP VAL-1853. RX PubMed=28202063; DOI=10.1186/s12920-017-0244-7; RA Jalkh N., Chouery E., Haidar Z., Khater C., Atallah D., Ali H., RA Marafie M.J., Al-Mulla M.R., Al-Mulla F., Megarbane A.; RT "Next-generation sequencing in familial breast cancer patients from RT Lebanon."; RL BMC Med. Genomics 10:8-8(2017). RN [115] RP VARIANTS AT VAL-323; PRO-1046; ARG-2023; SER-2068; ASP-2080; HIS-2627; RP LEU-2834 AND ASP-3003, CHARACTERIZATION OF VARIANTS AT VAL-323; PRO-1046; RP ARG-2023; SER-2068; ASP-2080; HIS-2627; LEU-2834 AND ASP-3003, AND RP PHOSPHORYLATION. RX PubMed=27664052; DOI=10.1007/s12017-016-8440-8; RA Carranza D., Vega A.K., Torres-Rusillo S., Montero E., Martinez L.J., RA Santamaria M., Santos J.L., Molina I.J.; RT "Molecular and functional characterization of a cohort of Spanish patients RT with ataxia-telangiectasia."; RL NeuroMolecular Med. 19:161-174(2017). RN [116] RP VARIANTS VAL-68; ILE-341; LEU-597; GLY-699; GLY-759; SER-813; GLY-869; RP ILE-897; ASP-1474; VAL-1488; CYS-1961; ALA-2287; PHE-2307; ARG-2464; RP PRO-2524; THR-2531; GLN-2810; HIS-2832; LEU-2974; ASP-3029 AND LEU-3056. RX PubMed=28726808; DOI=10.1038/gim.2017.85; RA Chaffee K.G., Oberg A.L., McWilliams R.R., Majithia N., Allen B.A., RA Kidd J., Singh N., Hartman A.R., Wenstrup R.J., Petersen G.M.; RT "Prevalence of germ-line mutations in cancer genes among pancreatic cancer RT patients with a positive family history."; RL Genet. Med. 20:119-127(2018). CC -!- FUNCTION: Serine/threonine protein kinase which activates checkpoint CC signaling upon double strand breaks (DSBs), apoptosis and genotoxic CC stresses such as ionizing ultraviolet A light (UVA), thereby acting as CC a DNA damage sensor (PubMed:10550055, PubMed:10839545, PubMed:10910365, CC PubMed:12556884, PubMed:14871926, PubMed:15064416, PubMed:15448695, CC PubMed:15456891, PubMed:15790808, PubMed:15916964, PubMed:17923702, CC PubMed:21757780, PubMed:24534091, PubMed:35076389, PubMed:9733514). CC Recognizes the substrate consensus sequence [ST]-Q (PubMed:10550055, CC PubMed:10839545, PubMed:10910365, PubMed:12556884, PubMed:14871926, CC PubMed:15448695, PubMed:15456891, PubMed:15916964, PubMed:17923702, CC PubMed:24534091, PubMed:9733514). Phosphorylates 'Ser-139' of histone CC variant H2AX at double strand breaks (DSBs), thereby regulating DNA CC damage response mechanism (By similarity). Also plays a role in pre-B CC cell allelic exclusion, a process leading to expression of a single CC immunoglobulin heavy chain allele to enforce clonality and monospecific CC recognition by the B-cell antigen receptor (BCR) expressed on CC individual B-lymphocytes. After the introduction of DNA breaks by the CC RAG complex on one immunoglobulin allele, acts by mediating a CC repositioning of the second allele to pericentromeric heterochromatin, CC preventing accessibility to the RAG complex and recombination of the CC second allele. Also involved in signal transduction and cell cycle CC control. May function as a tumor suppressor. Necessary for activation CC of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FBXW7, FANCD2, CC NFKBIA, BRCA1, CREBBP/CBP, RBBP8/CTIP, FBXO46, MRE11, nibrin (NBN), CC RAD50, RAD17, PELI1, TERF1, UFL1, RAD9, UBQLN4 and DCLRE1C CC (PubMed:10550055, PubMed:10766245, PubMed:10802669, PubMed:10839545, CC PubMed:10910365, PubMed:10973490, PubMed:11375976, PubMed:12086603, CC PubMed:15456891, PubMed:19965871, PubMed:21757780, PubMed:24534091, CC PubMed:26240375, PubMed:26774286, PubMed:30171069, PubMed:30612738, CC PubMed:30886146, PubMed:30952868, PubMed:38128537, PubMed:9733515, CC PubMed:9843217). May play a role in vesicle and/or protein transport. CC Could play a role in T-cell development, gonad and neurological CC function. Plays a role in replication-dependent histone mRNA CC degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in CC response to genotoxic stress prevents its MDM2-mediated ubiquitination CC and subsequent proteasome degradation (PubMed:19965871). Phosphorylates CC ATF2 which stimulates its function in DNA damage response CC (PubMed:15916964). Phosphorylates ERCC6 which is essential for its CC chromatin remodeling activity at DNA double-strand breaks CC (PubMed:29203878). Phosphorylates TTC5/STRAP at 'Ser-203' in the CC cytoplasm in response to DNA damage, which promotes TTC5/STRAP nuclear CC localization (PubMed:15448695). Also involved in pexophagy by mediating CC phosphorylation of PEX5: translocated to peroxisomes in response to CC reactive oxygen species (ROS), and catalyzes phosphorylation of PEX5, CC promoting PEX5 ubiquitination and induction of pexophagy CC (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10550055, ECO:0000269|PubMed:10766245, CC ECO:0000269|PubMed:10802669, ECO:0000269|PubMed:10839545, CC ECO:0000269|PubMed:10910365, ECO:0000269|PubMed:10973490, CC ECO:0000269|PubMed:11375976, ECO:0000269|PubMed:12086603, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, CC ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15456891, CC ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:19965871, CC ECO:0000269|PubMed:21757780, ECO:0000269|PubMed:24534091, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:26344566, CC ECO:0000269|PubMed:26774286, ECO:0000269|PubMed:29203878, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30612738, CC ECO:0000269|PubMed:30886146, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:9733514, ECO:0000269|PubMed:9733515, CC ECO:0000269|PubMed:9843217}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:15448695, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:26240375, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30886146, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:38128537, CC ECO:0000269|PubMed:8988033, ECO:0000269|PubMed:9843217}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:21757780, CC ECO:0000269|PubMed:26240375, ECO:0000269|PubMed:30952868, CC ECO:0000269|PubMed:9843217, ECO:0000305|PubMed:15448695}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:24534091, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:30952868, ECO:0000269|PubMed:8988033, CC ECO:0000269|PubMed:9843217}; CC -!- ACTIVITY REGULATION: Activated by the MRN (MRE11-RAD50-NBS1) complex in CC response to DNA double strand breaks (DSBs), which recruits ATM to DSBs CC and promotes its activation (PubMed:15064416, PubMed:15790808, CC PubMed:35076389). Inhibited by wortmannin (PubMed:9766667). CC {ECO:0000269|PubMed:15064416, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9766667}. CC -!- SUBUNIT: Homodimer (PubMed:12556884, PubMed:15790808, PubMed:28508083). CC Dimers or tetramers in inactive state (PubMed:12556884, CC PubMed:15790808, PubMed:28508083). On DNA damage, autophosphorylation CC dissociates ATM into monomers rendering them catalytically active CC (PubMed:12556884, PubMed:28508083). Binds p53/TP53, ABL1, BRCA1 and CC TERF1 (PubMed:15790808, PubMed:9168117, PubMed:9843217). Interacts with CC NBN (via FxF/Y motif) (PubMed:35076389). Part of the BRCA1-associated CC genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, CC MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). Interacts with RAD17; DNA damage promotes the CC association (PubMed:11418864). Interacts with EEF1E1; the interaction, CC induced on DNA damage, up-regulates TP53 (PubMed:15680327). Interacts CC with KAT8, NABP2, ATMIN and CEP164 (PubMed:15923642, PubMed:17525732, CC PubMed:18283122, PubMed:18449195). Interacts with AP2B1 and AP3B2; the CC interaction occurs in cytoplasmic vesicles (By similarity). Interacts CC with TELO2 and TTI1 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with DDX1 (PubMed:18710941). Interacts with CC BRAT1 (PubMed:22977523). Interacts with CYREN (via XLF motif) (By CC similarity). Interacts (via microbody targeting signal) with PEX5; CC promoting translocation to peroxisomes in response to reactive oxygen CC species (ROS) (PubMed:26344566). {ECO:0000250|UniProtKB:Q62388, CC ECO:0000269|PubMed:10783165, ECO:0000269|PubMed:11418864, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15680327, CC ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:15923642, CC ECO:0000269|PubMed:17525732, ECO:0000269|PubMed:18283122, CC ECO:0000269|PubMed:18449195, ECO:0000269|PubMed:18710941, CC ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523, CC ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:28508083, CC ECO:0000269|PubMed:35076389, ECO:0000269|PubMed:9168117, CC ECO:0000269|PubMed:9843217}. CC -!- INTERACTION: CC Q13315; Q9NY61: AATF; NbExp=3; IntAct=EBI-495465, EBI-372428; CC Q13315; P00519: ABL1; NbExp=4; IntAct=EBI-495465, EBI-375543; CC Q13315; P31749: AKT1; NbExp=5; IntAct=EBI-495465, EBI-296087; CC Q13315; O43313: ATMIN; NbExp=5; IntAct=EBI-495465, EBI-7422202; CC Q13315; Q6PJG6: BRAT1; NbExp=3; IntAct=EBI-495465, EBI-10826195; CC Q13315; P62508-3: ESRRG; NbExp=3; IntAct=EBI-495465, EBI-12001340; CC Q13315; Q5XUX0: FBXO31; NbExp=2; IntAct=EBI-495465, EBI-6162477; CC Q13315; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-495465, EBI-81279; CC Q13315; Q13007: IL24; NbExp=2; IntAct=EBI-495465, EBI-3915542; CC Q13315; Q14676: MDC1; NbExp=3; IntAct=EBI-495465, EBI-495644; CC Q13315; Q9BQ15: NABP2; NbExp=4; IntAct=EBI-495465, EBI-2120336; CC Q13315; P11245: NAT2; NbExp=2; IntAct=EBI-495465, EBI-9057228; CC Q13315; O60934: NBN; NbExp=2; IntAct=EBI-495465, EBI-494844; CC Q13315; P46531: NOTCH1; NbExp=8; IntAct=EBI-495465, EBI-636374; CC Q13315; Q9BZ95: NSD3; NbExp=3; IntAct=EBI-495465, EBI-3390132; CC Q13315; Q7LG56: RRM2B; NbExp=3; IntAct=EBI-495465, EBI-9009083; CC Q13315; Q9Y4R8: TELO2; NbExp=4; IntAct=EBI-495465, EBI-1043674; CC Q13315; P54274: TERF1; NbExp=3; IntAct=EBI-495465, EBI-710997; CC Q13315; P54274-2: TERF1; NbExp=5; IntAct=EBI-495465, EBI-711018; CC Q13315; Q15554: TERF2; NbExp=2; IntAct=EBI-495465, EBI-706637; CC Q13315; Q12888: TP53BP1; NbExp=2; IntAct=EBI-495465, EBI-396540; CC Q13315; O43156: TTI1; NbExp=5; IntAct=EBI-495465, EBI-1055680; CC Q13315; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-495465, EBI-6904388; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358}. Cytoplasmic vesicle CC {ECO:0000269|PubMed:9050866, ECO:0000269|PubMed:9150358}. Cytoplasm, CC cytoskeleton, microtubule organizing center, centrosome CC {ECO:0000250|UniProtKB:Q62388}. Peroxisome matrix CC {ECO:0000269|PubMed:26344566}. Note=Primarily nuclear (PubMed:9050866, CC PubMed:9150358). Found also in endocytic vesicles in association with CC beta-adaptin (PubMed:9707615). Translocated to peroxisomes in response CC to reactive oxygen species (ROS) by PEX5 (PubMed:26344566). CC {ECO:0000269|PubMed:26344566, ECO:0000269|PubMed:9050866, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9707615}. CC -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle, liver, CC lung, placenta, brain, heart, spleen, thymus, testis, ovary, small CC intestine, colon and leukocytes. CC -!- INDUCTION: By ionizing radiation. CC -!- DOMAIN: The FATC domain is required for interaction with KAT5. CC {ECO:0000269|PubMed:16141325}. CC -!- PTM: Phosphorylated by NUAK1/ARK5 (PubMed:12409306). CC Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA CC damage-mediated activation of the kinase (PubMed:12556884, CC PubMed:15790808, PubMed:16141325, PubMed:16858402, PubMed:21144835, CC PubMed:27664052). During the late stages of DNA damage response, CC dephosphorylated following deacetylation by SIRT7, leading to ATM CC deactivation (PubMed:30944854). {ECO:0000269|PubMed:12409306, CC ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:15790808, CC ECO:0000269|PubMed:16141325, ECO:0000269|PubMed:16858402, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:30944854}. CC -!- PTM: Acetylation, on DNA damage, is required for activation of the CC kinase activity, dimer-monomer transition, and subsequent CC autophosphorylation on Ser-1981 (PubMed:12556884, PubMed:16141325, CC PubMed:16858402, PubMed:17923702, PubMed:21144835). Acetylated in vitro CC by KAT5/TIP60 (PubMed:16141325). Deacetylated by SIRT7 during the late CC stages of DNA damage response, promoting ATM dephosphorylation and CC subsequent deactivation (PubMed:30944854). CC {ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:16141325, CC ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, CC ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:30944854}. CC -!- DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive CC disorder characterized by progressive cerebellar ataxia, dilation of CC the blood vessels in the conjunctiva and eyeballs, immunodeficiency, CC growth retardation and sexual immaturity. Patients have a strong CC predisposition to cancer; about 30% of patients develop tumors, CC particularly lymphomas and leukemias. Cells from affected individuals CC are highly sensitive to damage by ionizing radiation and resistant to CC inhibition of DNA synthesis following irradiation. CC {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, CC ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, CC ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:27664052, CC ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, CC ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, CC ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, CC ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, CC ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, CC ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, CC ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, CC ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, CC ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, CC ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, CC ECO:0000269|PubMed:9887333}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in ATM may contribute to T-cell acute CC lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). CC TPLL is characterized by a high white blood cell count, with a CC predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, CC skin lesions and serous effusion. The clinical course is highly CC aggressive, with poor response to chemotherapy and short survival time. CC TPLL occurs both in adults as a sporadic disease and in younger AT CC patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, CC ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, CC ECO:0000269|PubMed:9573030}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell non-Hodgkin CC lymphomas (BNHL), including mantle cell lymphoma (MCL). CC {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, CC ECO:0000269|PubMed:9288106}. CC -!- DISEASE: Note=Defects in ATM may contribute to B-cell chronic CC lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in CC the elderly. It is characterized by the accumulation of mature CD5+ B- CC lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. CC {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, CC ECO:0000269|PubMed:9892178}. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA86520.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=EAW67111.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/123/ATM"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated entry; CC URL="https://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U33841; AAC50289.1; -; mRNA. DR EMBL; U55757; AAB38309.1; -; Genomic_DNA. DR EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA. DR EMBL; U55757; AAB38310.1; -; Genomic_DNA. DR EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA. DR EMBL; U82828; AAB65827.1; -; Genomic_DNA. DR EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF455499; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA. DR EMBL; X91196; CAA62603.1; -; mRNA. DR EMBL; U67092; AAC51298.1; -; Genomic_DNA. DR EMBL; AY220758; AAO26044.1; -; Genomic_DNA. DR EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA. DR EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA. DR CCDS; CCDS31669.1; -. DR PIR; A43100; A43100. DR RefSeq; NP_000042.3; NM_000051.3. DR RefSeq; NP_001338763.1; NM_001351834.2. DR RefSeq; XP_005271619.2; XM_005271562.6. DR RefSeq; XP_006718906.1; XM_006718843.5. DR RefSeq; XP_006718908.1; XM_006718845.1. DR RefSeq; XP_011541142.1; XM_011542840.4. DR RefSeq; XP_016873279.1; XM_017017790.3. DR RefSeq; XP_047282931.1; XM_047426975.1. DR RefSeq; XP_047282932.1; XM_047426976.1. DR RefSeq; XP_054224846.1; XM_054368871.1. DR RefSeq; XP_054224847.1; XM_054368872.1. DR RefSeq; XP_054224848.1; XM_054368873.1. DR RefSeq; XP_054224849.1; XM_054368874.1. DR RefSeq; XP_054224850.1; XM_054368875.1. DR RefSeq; XP_054224851.1; XM_054368876.1. DR PDB; 5NP0; EM; 5.70 A; A/B=1-3056. DR PDB; 5NP1; EM; 5.70 A; A=1-3056. DR PDB; 6HKA; NMR; -; A=3024-3056. DR PDB; 6K9K; EM; 7.82 A; A=1-3056. DR PDB; 6K9L; EM; 4.27 A; A/B=1-3056. DR PDB; 7NI4; EM; 3.00 A; A/B=1-3056. DR PDB; 7NI5; EM; 2.78 A; A/B=1-3056. DR PDB; 7NI6; EM; 2.80 A; A/B=1-3056. DR PDB; 7SIC; EM; 2.51 A; A/B=1-3056. DR PDB; 7SID; EM; 2.53 A; A/C=1-3056. DR PDB; 8OXM; EM; 3.30 A; A/B=1-3056. DR PDB; 8OXO; EM; 3.00 A; A/B=1-3056. DR PDB; 8OXP; EM; 2.60 A; A/B=1-3056. DR PDB; 8OXQ; EM; 2.50 A; A/B=1-3056. DR PDBsum; 5NP0; -. DR PDBsum; 5NP1; -. DR PDBsum; 6HKA; -. DR PDBsum; 6K9K; -. DR PDBsum; 6K9L; -. DR PDBsum; 7NI4; -. DR PDBsum; 7NI5; -. DR PDBsum; 7NI6; -. DR PDBsum; 7SIC; -. DR PDBsum; 7SID; -. DR PDBsum; 8OXM; -. DR PDBsum; 8OXO; -. DR PDBsum; 8OXP; -. DR PDBsum; 8OXQ; -. DR EMDB; EMD-12350; -. DR EMDB; EMD-12351; -. DR EMDB; EMD-12352; -. DR EMDB; EMD-17265; -. DR EMDB; EMD-17266; -. DR EMDB; EMD-17267; -. DR EMDB; EMD-17268; -. DR EMDB; EMD-25140; -. DR EMDB; EMD-25141; -. DR EMDB; EMD-3669; -. DR EMDB; EMD-3672; -. DR EMDB; EMD-9949; -. DR EMDB; EMD-9950; -. DR SMR; Q13315; -. DR BioGRID; 106962; 345. DR CORUM; Q13315; -. DR DIP; DIP-182N; -. DR FunCoup; Q13315; 3527. DR IntAct; Q13315; 175. DR MINT; Q13315; -. DR STRING; 9606.ENSP00000278616; -. DR BindingDB; Q13315; -. DR ChEMBL; CHEMBL3797; -. DR DrugBank; DB02289; 2-Aminopropanedioic Acid. DR DrugBank; DB00201; Caffeine. DR GuidetoPHARMACOLOGY; 1934; -. DR GlyCosmos; Q13315; 4 sites, 2 glycans. DR GlyGen; Q13315; 7 sites, 2 O-linked glycans (6 sites). DR iPTMnet; Q13315; -. DR PhosphoSitePlus; Q13315; -. DR BioMuta; ATM; -. DR DMDM; 317373479; -. DR CPTAC; CPTAC-2874; -. DR CPTAC; CPTAC-2875; -. DR CPTAC; CPTAC-2876; -. DR CPTAC; CPTAC-3210; -. DR CPTAC; CPTAC-3211; -. DR CPTAC; CPTAC-3212; -. DR CPTAC; CPTAC-3213; -. DR CPTAC; CPTAC-5976; -. DR CPTAC; CPTAC-5977; -. DR CPTAC; CPTAC-5978; -. DR CPTAC; CPTAC-5979; -. DR CPTAC; CPTAC-912; -. DR CPTAC; CPTAC-913; -. DR jPOST; Q13315; -. DR MassIVE; Q13315; -. DR PaxDb; 9606-ENSP00000278616; -. DR PeptideAtlas; Q13315; -. DR ProteomicsDB; 59303; -. DR Pumba; Q13315; -. DR Antibodypedia; 3596; 1462 antibodies from 49 providers. DR CPTC; Q13315; 4 antibodies. DR DNASU; 472; -. DR Ensembl; ENST00000278616.10; ENSP00000278616.4; ENSG00000149311.23. DR Ensembl; ENST00000452508.7; ENSP00000388058.2; ENSG00000149311.23. DR Ensembl; ENST00000601453.3; ENSP00000469471.2; ENSG00000149311.23. DR Ensembl; ENST00000675843.1; ENSP00000501606.1; ENSG00000149311.23. DR Ensembl; ENST00000713844.1; ENSP00000519149.1; ENSG00000149311.23. DR GeneID; 472; -. DR KEGG; hsa:472; -. DR MANE-Select; ENST00000675843.1; ENSP00000501606.1; NM_000051.4; NP_000042.3. DR UCSC; uc001pkb.1; human. DR AGR; HGNC:795; -. DR CIViC; 472; 50 evidence items across 37 molecular profiles. DR ClinPGx; PA61; -. DR CTD; 472; -. DR DisGeNET; 472; -. DR GeneCards; ATM; -. DR GeneReviews; ATM; -. DR HGNC; HGNC:795; ATM. DR HPA; ENSG00000149311; Low tissue specificity. DR MalaCards; ATM; -. DR MIM; 208900; phenotype. DR MIM; 607585; gene. DR OpenTargets; ENSG00000149311; -. DR Orphanet; 100; Ataxia-telangiectasia. DR Orphanet; 370109; Ataxia-telangiectasia variant. DR Orphanet; 67038; B-cell chronic lymphocytic leukemia. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 227535; Hereditary breast cancer. DR Orphanet; 52416; Mantle cell lymphoma. DR VEuPathDB; HostDB:ENSG00000149311; -. DR eggNOG; KOG0892; Eukaryota. DR GeneTree; ENSGT00670000098061; -. DR HOGENOM; CLU_000178_3_1_1; -. DR InParanoid; Q13315; -. DR OMA; SEVYMKW; -. DR OrthoDB; 381190at2759; -. DR PAN-GO; Q13315; 7 GO annotations based on evolutionary models. DR PhylomeDB; Q13315; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q13315; -. DR Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence. DR Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response. DR Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693548; Sensing of DNA Double Strand Breaks. DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks. DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ). DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release. DR Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-69541; Stabilization of p53. DR Reactome; R-HSA-912446; Meiotic recombination. DR Reactome; R-HSA-9664873; Pexophagy. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q13315; -. DR SIGNOR; Q13315; -. DR Agora; ENSG00000149311; -. DR BioGRID-ORCS; 472; 54 hits in 1215 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; A0DCDA94; DNA damage foci. DR ChiTaRS; ATM; human. DR GeneWiki; Ataxia_telangiectasia_mutated; -. DR GenomeRNAi; 472; -. DR Pharos; Q13315; Tchem. DR PRO; PR:Q13315; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; Q13315; protein. DR Bgee; ENSG00000149311; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q13315; baseline and differential. DR GO; GO:0005813; C:centrosome; ISS:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:1990391; C:DNA repair complex; IDA:MGI. DR GO; GO:0098850; C:extrinsic component of synaptic vesicle membrane; IEA:Ensembl. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL. DR GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB. DR GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB. DR GO; GO:0005819; C:spindle; IEA:Ensembl. DR GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL. DR GO; GO:0035979; F:histone H2AXS139 kinase activity; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:BHF-UCL. DR GO; GO:0007420; P:brain development; IEA:Ensembl. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA. DR GO; GO:0071500; P:cellular response to nitrosative stress; IDA:ParkinsonsUK-UCL. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0071300; P:cellular response to retinoic acid; ISS:ARUK-UCL. DR GO; GO:0033554; P:cellular response to stress; IDA:UniProt. DR GO; GO:0071481; P:cellular response to X-ray; IDA:ParkinsonsUK-UCL. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0000077; P:DNA damage checkpoint signaling; IDA:UniProtKB. DR GO; GO:0006974; P:DNA damage response; IDA:CAFA. DR GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0000729; P:DNA double-strand break processing; IDA:UniProt. DR GO; GO:0006302; P:double-strand break repair; IDA:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProt. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome. DR GO; GO:0097695; P:establishment of protein-containing complex localization to telomere; IMP:BHF-UCL. DR GO; GO:0097694; P:establishment of RNA localization to telomere; IMP:BHF-UCL. DR GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IBA:GO_Central. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; IMP:BHF-UCL. DR GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; IMP:UniProtKB. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IMP:UniProtKB. DR GO; GO:1904354; P:negative regulation of telomere capping; IMP:BHF-UCL. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0048599; P:oocyte development; IEA:Ensembl. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IMP:MGI. DR GO; GO:0000425; P:pexophagy; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; IMP:BHF-UCL. DR GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:1904884; P:positive regulation of telomerase catalytic core complex assembly; IMP:BHF-UCL. DR GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISS:BHF-UCL. DR GO; GO:1904358; P:positive regulation of telomere maintenance via telomere lengthening; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:ARUK-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:UniProt. DR GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome. DR GO; GO:2000785; P:regulation of autophagosome assembly; IC:UniProt. DR GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL. DR GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0032210; P:regulation of telomere maintenance via telomerase; IGI:BHF-UCL. DR GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL. DR GO; GO:0010212; P:response to ionizing radiation; IDA:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0000723; P:telomere maintenance; IBA:GO_Central. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl. DR CDD; cd05171; PIKKc_ATM; 1. DR FunFam; 1.10.1070.11:FF:000011; Serine-protein kinase ATM; 1. DR FunFam; 3.30.1010.10:FF:000015; Serine-protein kinase ATM; 1. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR038980; ATM_plant. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR044107; PIKKc_ATM. DR InterPro; IPR021668; TAN. DR PANTHER; PTHR37079; SERINE/THREONINE-PROTEIN KINASE ATM; 1. DR PANTHER; PTHR37079:SF4; SERINE_THREONINE-PROTEIN KINASE ATM; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR Pfam; PF11640; TAN; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01342; TAN; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell cycle; Cytoplasm; KW Cytoplasmic vesicle; Cytoskeleton; Disease variant; DNA damage; KW DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus; KW Peroxisome; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Tumor suppressor. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..3056 FT /note="Serine-protein kinase ATM" FT /id="PRO_0000088840" FT DOMAIN 1940..2566 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT DOMAIN 2686..2998 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 3024..3056 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1373..1382 FT /note="Interaction with ABL1" FT /evidence="ECO:0000269|PubMed:9168117" FT REGION 2692..2698 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2867..2875 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2887..2911 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT MOTIF 3046..3048 FT /note="Microbody targeting signal; atypical" FT /evidence="ECO:0000269|PubMed:26344566" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 367 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1893 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:16858402" FT MOD_RES 1981 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:15790808, ECO:0000269|PubMed:16141325, FT ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:21144835, FT ECO:0000269|PubMed:30944854, ECO:0007744|PubMed:17525332" FT MOD_RES 1983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 2996 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195" FT MOD_RES 3016 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:17923702, FT ECO:0000269|PubMed:30944854" FT VARIANT 23 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587779858)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041545" FT VARIANT 35..3056 FT /note="Missing (in AT; dbSNP:rs55861249)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085060" FT VARIANT 45 FT /note="R -> W (found in a patient with breast cancer; FT uncertain significance; dbSNP:rs3218684)" FT /evidence="ECO:0000269|PubMed:11897822" FT /id="VAR_056678" FT VARIANT 49 FT /note="S -> C (in dbSNP:rs1800054)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10534763, ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:11897822, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9887333" FT /id="VAR_010798" FT VARIANT 68 FT /note="I -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083373" FT VARIANT 126 FT /note="D -> E (in dbSNP:rs2234997)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010799" FT VARIANT 140 FT /note="D -> H (in dbSNP:rs55633650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041546" FT VARIANT 182 FT /note="V -> L (in dbSNP:rs3218707)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010800" FT VARIANT 224 FT /note="K -> E (in AT; uncertain significance; FT dbSNP:rs145053092)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010801" FT VARIANT 250 FT /note="R -> Q (in dbSNP:rs56123940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041547" FT VARIANT 292 FT /note="P -> L (in AT; decrease phosphorylation of target FT proteins; increases protein abundance; dbSNP:rs747727055)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9463314" FT /id="VAR_010802" FT VARIANT 323 FT /note="I -> V (in AT; loss of protein expression; FT dbSNP:rs587781511)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:27664052" FT /id="VAR_010803" FT VARIANT 332 FT /note="Y -> C (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9892178" FT /id="VAR_010804" FT VARIANT 333 FT /note="S -> F (in dbSNP:rs28904919)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041548" FT VARIANT 337 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs138398778)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041549" FT VARIANT 337 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs202160435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041550" FT VARIANT 341 FT /note="V -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083374" FT VARIANT 350 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs371713984)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010805" FT VARIANT 352 FT /note="I -> T (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs369203092)" FT /evidence="ECO:0000269|PubMed:10023947" FT /id="VAR_010806" FT VARIANT 374..3056 FT /note="Missing (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085061" FT VARIANT 393..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085062" FT VARIANT 410 FT /note="V -> A (in dbSNP:rs56128736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041551" FT VARIANT 504 FT /note="N -> S (in dbSNP:rs56365018)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041552" FT VARIANT 514 FT /note="G -> D (in dbSNP:rs2235000)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9711876" FT /id="VAR_010807" FT VARIANT 540 FT /note="C -> Y (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041553" FT VARIANT 546 FT /note="L -> V (no effect on phosphorylation of target FT proteins; dbSNP:rs2227924)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188" FT /id="VAR_041554" FT VARIANT 570 FT /note="F -> S (in AT; dbSNP:rs777301065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010808" FT VARIANT 582 FT /note="F -> L (in dbSNP:rs2235006)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041555" FT VARIANT 597 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083375" FT VARIANT 661 FT /note="D -> A (found in a patient with familial breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28202063" FT /id="VAR_083376" FT VARIANT 699 FT /note="E -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083377" FT VARIANT 705..707 FT /note="YSS -> FIP (in AT)" FT /evidence="ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869" FT /id="VAR_010809" FT VARIANT 707 FT /note="S -> P (in dbSNP:rs4986761)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:28202063" FT /id="VAR_010810" FT VARIANT 759 FT /note="S -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083378" FT VARIANT 761 FT /note="T -> S (in dbSNP:rs2235011)" FT /id="VAR_056679" FT VARIANT 768 FT /note="N -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010812" FT VARIANT 785 FT /note="R -> C (in AT; dbSNP:rs587778065)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010813" FT VARIANT 788 FT /note="S -> R (in dbSNP:rs641252)" FT /id="VAR_056680" FT VARIANT 813 FT /note="N -> S (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083379" FT VARIANT 814 FT /note="D -> E (in dbSNP:rs3218695)" FT /id="VAR_056681" FT VARIANT 848 FT /note="E -> Q (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254046)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041556" FT VARIANT 858 FT /note="F -> L (in dbSNP:rs1800056)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9792409, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010814" FT VARIANT 869 FT /note="A -> G (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083380" FT VARIANT 872 FT /note="P -> S (in dbSNP:rs3218673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041557" FT VARIANT 897 FT /note="F -> I (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083381" FT VARIANT 924 FT /note="R -> W (found in a patient with familial breast FT cancer; uncertain significance; dbSNP:rs55723361)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063" FT /id="VAR_041558" FT VARIANT 935 FT /note="T -> A (in dbSNP:rs35813135)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041559" FT VARIANT 935 FT /note="T -> M (in dbSNP:rs3218708)" FT /id="VAR_056682" FT VARIANT 942 FT /note="L -> F (in dbSNP:rs3218688)" FT /id="VAR_056683" FT VARIANT 950 FT /note="L -> R (in AT; dbSNP:rs786203054)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010815" FT VARIANT 1001 FT /note="L -> Q (in AT; risk factor for T-cell acute FT lymphoblastic leukemia)" FT /evidence="ECO:0000269|PubMed:9463314" FT /id="VAR_010816" FT VARIANT 1040 FT /note="M -> V (in dbSNP:rs3092857)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010817" FT VARIANT 1046 FT /note="L -> P (in AT; loss of protein expression; FT dbSNP:rs568461905)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077237" FT VARIANT 1054 FT /note="P -> R (in AT; likely benign; no effect on FT phosphorylation of target proteins; dbSNP:rs1800057)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:10217116, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:9043869, FT ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9887333" FT /id="VAR_010818" FT VARIANT 1082 FT /note="H -> L (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010819" FT VARIANT 1091 FT /note="E -> D (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010820" FT VARIANT 1171..3056 FT /note="Missing (in AT; uncertain significance; increases FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085063" FT VARIANT 1179 FT /note="S -> F (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041560" FT VARIANT 1255 FT /note="L -> V (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083382" FT VARIANT 1313 FT /note="E -> Q (in dbSNP:rs3092841)" FT /id="VAR_056684" FT VARIANT 1321 FT /note="M -> I (in dbSNP:rs35184530)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041561" FT VARIANT 1322 FT /note="L -> I (no effect on phosphorylation of target FT proteins; dbSNP:rs144535256)" FT /evidence="ECO:0000269|PubMed:19431188" FT /id="VAR_080300" FT VARIANT 1380 FT /note="H -> Y (in dbSNP:rs3092856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041562" FT VARIANT 1382 FT /note="P -> S (in dbSNP:rs55859590)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041563" FT VARIANT 1407 FT /note="I -> T (in T-prolymphocytic leukemia; FT dbSNP:rs1234250980)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010821" FT VARIANT 1420 FT /note="L -> F (in dbSNP:rs1800058)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8665503, FT ECO:0000269|PubMed:8797579" FT /id="VAR_010822" FT VARIANT 1420 FT /note="L -> P (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010823" FT VARIANT 1427 FT /note="A -> T (in dbSNP:rs2229021)" FT /id="VAR_056685" FT VARIANT 1463 FT /note="F -> S (found in B-cell non-Hodgkin lymphoma; FT uncertain significance)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010825" FT VARIANT 1465 FT /note="L -> P (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs730881391)" FT /evidence="ECO:0000269|PubMed:10234507, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010826" FT VARIANT 1466..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs730881369)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085064" FT VARIANT 1469 FT /note="I -> M (in a renal papillary cancer sample; somatic FT mutation; dbSNP:rs775047783)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041564" FT VARIANT 1474 FT /note="H -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083383" FT VARIANT 1475 FT /note="Y -> C (in dbSNP:rs34640941)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041565" FT VARIANT 1488 FT /note="L -> V (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083384" FT VARIANT 1541 FT /note="L -> F (in dbSNP:rs3092849)" FT /id="VAR_056686" FT VARIANT 1566 FT /note="P -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792409" FT /id="VAR_010827" FT VARIANT 1570 FT /note="V -> A (in dbSNP:rs140856217)" FT /evidence="ECO:0000269|PubMed:10534763" FT /id="VAR_010828" FT VARIANT 1650 FT /note="N -> S (in dbSNP:rs55870064)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041566" FT VARIANT 1682 FT /note="D -> H (in T-prolymphocytic leukemia; FT dbSNP:rs121434217)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010829" FT VARIANT 1691 FT /note="S -> R (in AT, B-cell chronic lymphocytic leukemia FT and familial cancer patients; no effect on phosphorylation FT of target proteins; dbSNP:rs1800059)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:8797579, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010830" FT VARIANT 1729 FT /note="V -> L (in dbSNP:rs3092907)" FT /id="VAR_056687" FT VARIANT 1730..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs764389018)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085065" FT VARIANT 1739 FT /note="N -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041567" FT VARIANT 1743 FT /note="T -> I (in AT; decreased phosphorylation of target FT proteins; dbSNP:rs587779844)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010831" FT VARIANT 1812..1813 FT /note="AF -> V (in AT)" FT /evidence="ECO:0000269|PubMed:9497252" FT /id="VAR_010832" FT VARIANT 1839..3056 FT /note="Missing (in AT; uncertain significance; reduces FT protein abundance)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085066" FT VARIANT 1853 FT /note="D -> N (in dbSNP:rs1801516)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9887333" FT /id="VAR_010833" FT VARIANT 1853 FT /note="D -> V (might contribute to B-cell chronic FT lymphocytic leukemia; dbSNP:rs1801673)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28202063, ECO:0000269|PubMed:9872980, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010834" FT VARIANT 1910 FT /note="L -> H (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010835" FT VARIANT 1913 FT /note="V -> G (in AT; dbSNP:rs1060501688)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010836" FT VARIANT 1916 FT /note="M -> I (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041568" FT VARIANT 1945 FT /note="A -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041569" FT VARIANT 1953 FT /note="T -> R (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010837" FT VARIANT 1961 FT /note="Y -> C (found in a patient with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; decreased FT phosphorylation of target proteins; dbSNP:rs56399311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:28726808" FT /id="VAR_041570" FT VARIANT 1983 FT /note="S -> N (in dbSNP:rs659243)" FT /evidence="ECO:0000269|PubMed:16554811" FT /id="VAR_041571" FT VARIANT 1991 FT /note="E -> D (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs587782274)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041572" FT VARIANT 2016 FT /note="D -> G (in AT; uncertain significance; FT dbSNP:rs587781302)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010838" FT VARIANT 2023 FT /note="G -> R (in AT; loss of protein expression; FT dbSNP:rs11212587)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077238" FT VARIANT 2034 FT /note="R -> Q (in dbSNP:rs3218670)" FT /id="VAR_056688" FT VARIANT 2063 FT /note="G -> E (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs866290641)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010839" FT VARIANT 2067 FT /note="A -> D (in AT; dbSNP:rs397514577)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010840" FT VARIANT 2068 FT /note="L -> S (in AT; decreased protein abundance; loss of FT DNA damage induced protein autophosphorylation; FT dbSNP:rs1555114558)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077239" FT VARIANT 2079 FT /note="V -> I (in dbSNP:rs1800060)" FT /evidence="ECO:0000269|PubMed:8665503" FT /id="VAR_010841" FT VARIANT 2080 FT /note="Y -> D (in AT; loss of DNA damage induced protein FT autophosphorylation; dbSNP:rs1064795467)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077240" FT VARIANT 2105 FT /note="R -> T (found in a patient with early-onset breast FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:18384426" FT /id="VAR_083385" FT VARIANT 2139 FT /note="E -> G (in T-prolymphocytic leukemia; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:9488043" FT /id="VAR_010842" FT VARIANT 2164 FT /note="E -> K (in T-prolymphocytic leukemia; FT dbSNP:rs1317619286)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010843" FT VARIANT 2218 FT /note="S -> C (in AT)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010844" FT VARIANT 2224..2227 FT /note="MALR -> IS (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010845" FT VARIANT 2227 FT /note="R -> C (in AT; uncertain significance; reduces FT protein abundance; dbSNP:rs564652222)" FT /evidence="ECO:0000269|PubMed:10873394, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010846" FT VARIANT 2246..2252 FT /note="CIKDILT -> H (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038, FT ECO:0000269|PubMed:10873394" FT /id="VAR_010847" FT VARIANT 2274 FT /note="A -> T (in B-cell chronic lymphocytic leukemia; FT uncertain significance; no effect on phosphorylation of FT target proteins; dbSNP:rs567060474)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010848" FT VARIANT 2287 FT /note="G -> A (found in a patient with familial pancreatic FT cancer; uncertain significance; dbSNP:rs1800061)" FT /evidence="ECO:0000269|PubMed:28726808, FT ECO:0000269|PubMed:8665503" FT /id="VAR_010849" FT VARIANT 2307 FT /note="L -> F (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a lung FT adenocarcinoma sample; uncertain significance; FT dbSNP:rs56009889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041573" FT VARIANT 2332 FT /note="L -> P (in dbSNP:rs4988111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041574" FT VARIANT 2335 FT /note="T -> K (in dbSNP:rs3092831)" FT /id="VAR_056689" FT VARIANT 2356 FT /note="I -> F (in a renal clear cell carcinoma sample; FT somatic mutation; dbSNP:rs876658517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041575" FT VARIANT 2396 FT /note="T -> S (found in a patient with T-prolymphocytic FT leukemia; uncertain significance; also found in a patient FT with early-onset breast cancer; uncertain significance; FT dbSNP:rs370559102)" FT /evidence="ECO:0000269|PubMed:18384426, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010850" FT VARIANT 2408 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs730881315)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041576" FT VARIANT 2418 FT /note="K -> KK (in mantle cell lymphoma)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010851" FT VARIANT 2420 FT /note="A -> P (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010852" FT VARIANT 2423 FT /note="E -> G (in mantle cell lymphoma; dbSNP:rs121434221)" FT /evidence="ECO:0000269|PubMed:10397742, FT ECO:0000269|PubMed:10706620" FT /id="VAR_010853" FT VARIANT 2424 FT /note="V -> G (in AT; also found in B-cell chronic FT lymphocytic leukemia and T-prolymphocytic leukemia; risk FT factor for breast cancer; decreased phosphorylation of FT target proteins; dbSNP:rs28904921)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9892178" FT /id="VAR_010854" FT VARIANT 2427..2428 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia; lack of phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8845835, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010855" FT VARIANT 2438 FT /note="T -> I (in dbSNP:rs147604227)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:8808599" FT /id="VAR_010856" FT VARIANT 2442 FT /note="Q -> P (in T-prolymphocytic leukemia; also in a lung FT adenocarcinoma sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010857" FT VARIANT 2443 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs587782310)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041577" FT VARIANT 2464 FT /note="C -> R (found in patients with familial pancreatic FT cancer; uncertain significance; also found in a small cell FT lung cancer sample; uncertain significance; FT dbSNP:rs55801750)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:28726808" FT /id="VAR_041578" FT VARIANT 2470 FT /note="Y -> D (in AT; dbSNP:rs876659365)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010858" FT VARIANT 2486 FT /note="R -> G (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9573030" FT /id="VAR_010859" FT VARIANT 2491 FT /note="W -> R (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010860" FT VARIANT 2492 FT /note="L -> R (in dbSNP:rs56399857)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041579" FT VARIANT 2524 FT /note="A -> P (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083386" FT VARIANT 2531 FT /note="M -> T (found in patients with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083387" FT VARIANT 2546..2548 FT /note="Missing (in AT; also found in T-prolymphocytic FT leukemia and T-cell acute lymphoblastic leukemia; lack of FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, FT ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, FT ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9150358, FT ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9463314" FT /id="VAR_010861" FT VARIANT 2547..2549 FT /note="Missing (in AT; dbSNP:rs587776547)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085067" FT VARIANT 2554 FT /note="H -> D (in AT; lack of phosphorylation of target FT proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010862" FT VARIANT 2570 FT /note="E -> G (in dbSNP:rs28904920)" FT /id="VAR_056690" FT VARIANT 2625..2626 FT /note="DA -> EP (in AT; dbSNP:rs267606668)" FT /evidence="ECO:0000269|PubMed:9521587" FT /id="VAR_010864" FT VARIANT 2625 FT /note="D -> E (in AT; uncertain significance; FT dbSNP:rs1196903858)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085068" FT VARIANT 2625 FT /note="D -> Q (in AT; requires 2 nucleotide substitutions)" FT /evidence="ECO:0000269|PubMed:10817650" FT /id="VAR_010863" FT VARIANT 2626 FT /note="A -> P (in AT; uncertain significance; FT dbSNP:rs267606669)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_085069" FT VARIANT 2627 FT /note="Y -> H (in AT; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077241" FT VARIANT 2640 FT /note="T -> I (in dbSNP:rs4988125)" FT /id="VAR_056691" FT VARIANT 2656 FT /note="L -> P (in AT; dbSNP:rs121434218)" FT /evidence="ECO:0000269|PubMed:9450874" FT /id="VAR_010865" FT VARIANT 2662 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010866" FT VARIANT 2664 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs1471563800)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085070" FT VARIANT 2666 FT /note="T -> A (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs745775382)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041580" FT VARIANT 2668 FT /note="E -> G (in AT; uncertain significance; no effect on FT phosphorylation of target proteins)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9463314" FT /id="VAR_010868" FT VARIANT 2695 FT /note="G -> A (in T-prolymphocytic leukemia and B-cell FT chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10023947, FT ECO:0000269|PubMed:9288106" FT /id="VAR_010869" FT VARIANT 2702 FT /note="I -> R (in AT; dbSNP:rs876659735)" FT /evidence="ECO:0000269|PubMed:10873394" FT /id="VAR_010870" FT VARIANT 2709 FT /note="G -> S (in dbSNP:rs3218680)" FT /id="VAR_056692" FT VARIANT 2719 FT /note="R -> H (found in a patient with early-onset breast FT cancer; uncertain significance; dbSNP:rs55982963)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:18384426" FT /id="VAR_041581" FT VARIANT 2722 FT /note="L -> R (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010871" FT VARIANT 2725 FT /note="D -> G (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs1555128314)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010872" FT VARIANT 2725 FT /note="D -> V (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010873" FT VARIANT 2726 FT /note="A -> V (in AT; uncertain significance)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010874" FT VARIANT 2732 FT /note="F -> L (in T-prolymphocytic leukemia; FT dbSNP:rs876659619)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010875" FT VARIANT 2765 FT /note="G -> S (may contribute to breast cancer; lack of FT phosphorylation of target proteins; dbSNP:rs748634900)" FT /evidence="ECO:0000269|PubMed:10534763, FT ECO:0000269|PubMed:19431188" FT /id="VAR_010876" FT VARIANT 2810 FT /note="K -> Q (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083388" FT VARIANT 2810 FT /note="Missing (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010877" FT VARIANT 2824 FT /note="C -> Y (in AT; dbSNP:rs876660927)" FT /evidence="ECO:0000269|PubMed:9150358" FT /id="VAR_010878" FT VARIANT 2827 FT /note="F -> C (in AT; mild; decreased phosphorylation of FT target proteins; dbSNP:rs121434216)" FT /evidence="ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:9463314" FT /id="VAR_010879" FT VARIANT 2829 FT /note="P -> L (in AT; dbSNP:rs938431501)" FT /evidence="ECO:0000269|PubMed:9711876" FT /id="VAR_010880" FT VARIANT 2832 FT /note="R -> C (in AT; also found in B-cell non-Hodgkin FT lymphoma; increases protein abundance; dbSNP:rs587779872)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9443866" FT /id="VAR_010881" FT VARIANT 2832 FT /note="R -> H (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083389" FT VARIANT 2834 FT /note="F -> L (in AT; decreased protein abundance)" FT /evidence="ECO:0000269|PubMed:27664052" FT /id="VAR_077242" FT VARIANT 2842 FT /note="P -> R (in a lung adenocarcinoma sample; somatic FT mutation; dbSNP:rs879254065)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041582" FT VARIANT 2849..3056 FT /note="Missing (in AT; uncertain significance; FT dbSNP:rs587778080)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_085071" FT VARIANT 2849 FT /note="R -> P (in AT; dbSNP:rs587782202)" FT /evidence="ECO:0000269|PubMed:9887333" FT /id="VAR_010882" FT VARIANT 2855..2856 FT /note="SV -> RI (in AT; lack of phosphorylation of target FT proteins; dbSNP:rs587781353)" FT /evidence="ECO:0000269|PubMed:10817650, FT ECO:0000269|PubMed:19431188, ECO:0000269|PubMed:9872980" FT /id="VAR_010884" FT VARIANT 2855 FT /note="S -> R (in AT; uncertain significance; FT dbSNP:rs780905851)" FT /evidence="ECO:0000269|PubMed:10425038" FT /id="VAR_010883" FT VARIANT 2860 FT /note="Missing (in AT)" FT /evidence="ECO:0000269|PubMed:7792600, FT ECO:0000269|PubMed:8845835" FT /id="VAR_010885" FT VARIANT 2867 FT /note="G -> R (in AT)" FT /evidence="ECO:0000269|PubMed:8698354, FT ECO:0000269|PubMed:9887333" FT /id="VAR_010886" FT VARIANT 2870 FT /note="D -> N (in dbSNP:rs55798854)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041583" FT VARIANT 2871..2872 FT /note="RH -> S (in T-prolymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:9288106" FT /id="VAR_010887" FT VARIANT 2890 FT /note="L -> V (in T-prolymphocytic leukemia; FT dbSNP:rs587779874)" FT /evidence="ECO:0000269|PubMed:9288106, FT ECO:0000269|PubMed:9488043" FT /id="VAR_010888" FT VARIANT 2904 FT /note="E -> G (in AT; dbSNP:rs786202826)" FT /evidence="ECO:0000269|PubMed:8845835" FT /id="VAR_010889" FT VARIANT 2909 FT /note="R -> G (in AT)" FT /evidence="ECO:0000269|PubMed:9792410" FT /id="VAR_010890" FT VARIANT 2974 FT /note="P -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083390" FT VARIANT 3003 FT /note="N -> D (in AT; decreased protein abundance; FT dbSNP:rs1137889)" FT /evidence="ECO:0000269|PubMed:27664052, FT ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, FT ECO:0000269|PubMed:8665503" FT /id="VAR_077243" FT VARIANT 3006 FT /note="A -> P (found in T-prolymphocytic leukemia; FT uncertain significance; dbSNP:rs876658767)" FT /evidence="ECO:0000269|PubMed:9334731" FT /id="VAR_010892" FT VARIANT 3008 FT /note="R -> C (in AT; also found in T-prolymphocytic FT leukemia and mantle cell lymphoma; lack of phosphorylation FT of target proteins; dbSNP:rs587782292)" FT /evidence="ECO:0000269|PubMed:10706620, FT ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:19431188, FT ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9488043, FT ECO:0000269|PubMed:9872980" FT /id="VAR_010893" FT VARIANT 3008 FT /note="R -> H (in B-cell chronic lymphocytic leukemia; FT dbSNP:rs587781894)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010894" FT VARIANT 3018 FT /note="K -> N (in B-cell chronic lymphocytic leukemia)" FT /evidence="ECO:0000269|PubMed:10397742" FT /id="VAR_010895" FT VARIANT 3029 FT /note="G -> D (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083391" FT VARIANT 3056 FT /note="V -> L (found in a patient with familial pancreatic FT cancer; uncertain significance)" FT /evidence="ECO:0000269|PubMed:28726808" FT /id="VAR_083392" FT MUTAGEN 367 FT /note="S->A: Loss of IR-induced S-367 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-1893 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1807 FT /note="K->E: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1893 FT /note="S->A: Loss of IR-induced S-1893 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1981 FT autophosphorylation." FT /evidence="ECO:0000269|PubMed:16858402" FT MUTAGEN 1941 FT /note="V->L: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 1981 FT /note="S->A: Loss of IR-induced S-1981 autophosphorylation. FT Reduced correction of cell cycle checkpoint defects and FT DNA-repair activity. No effect on S-367 nor S-1893 FT autophosphorylation. No dimer disruption." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 1981 FT /note="S->D,E: Disrupts the dimer." FT /evidence="ECO:0000269|PubMed:12556884, FT ECO:0000269|PubMed:16858402" FT MUTAGEN 2019 FT /note="Y->C: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2039 FT /note="E->K: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2338 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2394 FT /note="S->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2452 FT /note="L->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2685 FT /note="S->T: No effect on phosphorylation of target FT proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2699 FT /note="P->L: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2708 FT /note="D->N: Decreased phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2730 FT /note="Q->P: Loss of phosphorylation of target proteins." FT /evidence="ECO:0000269|PubMed:19431188" FT MUTAGEN 2870 FT /note="D->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 2875 FT /note="N->K: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:9733515" FT MUTAGEN 3016 FT /note="K->Q: Mimics acetylation, preventing FT dephosphorylation and subsequent ATM deactivation during FT the late stage of DNA damage response." FT /evidence="ECO:0000269|PubMed:30944854" FT MUTAGEN 3016 FT /note="K->R: Loss of DNA damage-inducible acetylation. FT Retains constitutive kinase activity, but blocks DNA FT damage-induced kinase activation. Disrupts dimer and FT abolishes S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3018 FT /note="K->R: Retains DNA damage-inducible acetylation and FT S-1981 autophosphorylation." FT /evidence="ECO:0000269|PubMed:17923702" FT MUTAGEN 3047 FT /note="R->Q: Abolished interaction with PEX5 and FT translocation to peroxisomes in response to reactive oxygen FT species (ROS)." FT /evidence="ECO:0000269|PubMed:26344566" FT CONFLICT 46 FT /note="H -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 56 FT /note="N -> I (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 313 FT /note="Y -> N (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 488 FT /note="W -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 554 FT /note="T -> A (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="K -> N (in Ref. 1; AAC50289)" FT /evidence="ECO:0000305" FT CONFLICT 754 FT /note="Q -> K (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="E -> G (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1003 FT /note="Q -> L (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1049 FT /note="L -> W (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT CONFLICT 1089 FT /note="A -> V (in Ref. 7; CAA62603)" FT /evidence="ECO:0000305" FT HELIX 6..17 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 20..33 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 36..41 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 57..73 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 90..108 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 109..112 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 117..129 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 130..133 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 135..148 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 149..151 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 153..158 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 161..176 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 183..201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 207..209 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 210..222 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 223..225 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 229..242 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 244..246 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 248..268 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 273..290 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 292..294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 298..300 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 306..323 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 324..326 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 343..356 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 393..402 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 407..409 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 410..422 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 424..426 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 429..431 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 432..442 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 445..447 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 452..466 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 474..492 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 493..496 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 498..500 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 501..513 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 521..524 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 525..527 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 528..530 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 536..548 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 572..580 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 597..600 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 605..607 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 608..615 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 617..619 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 620..628 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 684..704 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 713..731 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 732..735 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 737..741 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 744..765 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 771..786 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 792..794 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 795..806 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 809..822 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 887..889 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 892..911 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 920..930 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 941..953 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 957..959 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 973..979 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 980..982 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 984..994 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 995..997 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 998..1002 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1009..1030 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1031..1033 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1036..1052 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1060..1063 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1066..1069 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1070..1076 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1077..1079 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1083..1092 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1093..1096 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1113..1132 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1144..1164 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1169..1181 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1187..1201 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1206..1212 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1214..1223 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1227..1229 FT /evidence="ECO:0007829|PDB:7NI5" FT TURN 1231..1233 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1236..1238 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1244..1261 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1265..1275 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1279..1285 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1287..1294 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1295..1297 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1299..1303 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1306..1322 FT /evidence="ECO:0007829|PDB:7SIC" FT TURN 1325..1327 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1328..1330 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1332..1338 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1340..1348 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1383..1396 FT /evidence="ECO:0007829|PDB:7SIC" FT STRAND 1397..1399 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1404..1408 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1413..1428 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1432..1450 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1453..1455 FT /evidence="ECO:0007829|PDB:7SID" FT TURN 1456..1460 FT /evidence="ECO:0007829|PDB:7NI5" FT HELIX 1461..1477 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1485..1508 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1513..1515 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1517..1527 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1528..1530 FT /evidence="ECO:0007829|PDB:7SID" FT HELIX 1532..1545 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1546..1551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1553..1560 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1567..1569 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1572..1582 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1583..1585 FT /evidence="ECO:0007829|PDB:7NI6" FT HELIX 1590..1601 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1607..1610 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1611..1623 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1625..1634 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1635..1637 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 1639..1641 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 1643..1658 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1661..1663 FT /evidence="ECO:0007829|PDB:8OXM" FT HELIX 1664..1677 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1694..1702 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1706..1721 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1723..1725 FT /evidence="ECO:0007829|PDB:8OXO" FT HELIX 1727..1742 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1744..1753 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1754..1756 FT /evidence="ECO:0007829|PDB:7NI4" FT HELIX 1759..1763 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1764..1767 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 1785..1789 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1792..1795 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1802..1815 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1822..1825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1828..1831 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1835..1851 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1857..1874 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1903..1917 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 1922..1924 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1927..1930 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1938..1947 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1951..1973 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 1986..1997 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2001..2012 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2016..2019 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2023..2028 FT /evidence="ECO:0007829|PDB:7SIC" FT HELIX 2029..2038 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2042..2051 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2057..2070 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2074..2087 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2093..2105 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2124..2136 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2140..2159 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2166..2168 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2170..2190 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2195..2210 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2211..2214 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2217..2236 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2240..2242 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2245..2264 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2269..2281 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2290..2301 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2305..2322 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2328..2348 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2353..2359 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2361..2370 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2377..2406 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2408..2421 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2437..2475 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2481..2483 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2484..2493 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2494..2496 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2498..2507 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2508..2510 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2513..2516 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2520..2525 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2529..2531 FT /evidence="ECO:0007829|PDB:7SID" FT STRAND 2533..2535 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2537..2551 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2553..2564 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2565..2567 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2568..2572 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2593..2612 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2614..2632 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2637..2640 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2652..2655 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2659..2663 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2665..2667 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2673..2675 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2682..2686 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2688..2692 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2695..2697 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2700..2706 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2707..2709 FT /evidence="ECO:0007829|PDB:7NI4" FT STRAND 2711..2717 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2723..2740 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2743..2748 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2757..2759 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2761..2763 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2765..2768 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2773..2775 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2776..2780 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2783..2785 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2787..2791 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2798..2807 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2808..2810 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2813..2825 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2833..2838 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2842..2866 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2873..2875 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2876..2879 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2880..2882 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2885..2887 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2894..2899 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2900..2902 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 2906..2908 FT /evidence="ECO:0007829|PDB:8OXP" FT HELIX 2912..2916 FT /evidence="ECO:0007829|PDB:8OXQ" FT TURN 2920..2925 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2926..2940 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2942..2953 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 2964..2970 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3002..3017 FT /evidence="ECO:0007829|PDB:8OXQ" FT STRAND 3020..3025 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3028..3040 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3042..3047 FT /evidence="ECO:0007829|PDB:8OXQ" FT HELIX 3050..3052 FT /evidence="ECO:0007829|PDB:8OXQ" SQ SEQUENCE 3056 AA; 350687 MW; C0B4866E1E3199E2 CRC64; MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV // ID EPCAM_HUMAN Reviewed; 314 AA. AC P16422; P18180; Q6FG26; Q6FG49; Q96C47; Q9UCD0; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 13-NOV-2007, sequence version 2. DT 28-JAN-2026, entry version 223. DE RecName: Full=Epithelial cell adhesion molecule; DE Short=Ep-CAM; DE AltName: Full=Adenocarcinoma-associated antigen; DE AltName: Full=Cell surface glycoprotein Trop-1; DE AltName: Full=Epithelial cell surface antigen; DE AltName: Full=Epithelial glycoprotein; DE Short=EGP; DE AltName: Full=Epithelial glycoprotein 314; DE Short=EGP314; DE Short=hEGP314; DE AltName: Full=KS 1/4 antigen; DE AltName: Full=KSA; DE AltName: Full=Major gastrointestinal tumor-associated protein GA733-2; DE AltName: Full=Tumor-associated calcium signal transducer 1; DE AltName: CD_antigen=CD326; DE Flags: Precursor; GN Name=EPCAM; Synonyms=GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RC TISSUE=Lung adenocarcinoma; RX PubMed=2463074; RA Strnad J., Hamilton A.E., Beavers L.S., Gamboa G.C., Apelgren L.D., RA Taber L.D., Sportsman J.R., Bumol T.F., Sharp J.D., Gadski R.A.; RT "Molecular cloning and characterization of a human RT adenocarcinoma/epithelial cell surface antigen complementary DNA."; RL Cancer Res. 49:314-317(1989). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2469722; RA Perez M.S., Walker L.E.; RT "Isolation and characterization of a cDNA encoding the KS1/4 epithelial RT carcinoma marker."; RL J. Immunol. 142:3662-3667(1989). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-115. RX PubMed=2108441; DOI=10.1073/pnas.87.7.2755; RA Simon B., Podolsky D.K., Moldenhauer G., Isselbacher K.J., RA Gattoni-Celli S., Brand S.J.; RT "Epithelial glycoprotein is a member of a family of epithelial cell surface RT antigens homologous to nidogen, a matrix adhesion protein."; RL Proc. Natl. Acad. Sci. U.S.A. 87:2755-2759(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Colon carcinoma; RX PubMed=2333300; DOI=10.1073/pnas.87.9.3542; RA Szala S., Froehlich M., Scollon M., Kasai Y., Steplewski Z., Koprowski H., RA Linnenbach A.J.; RT "Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2."; RL Proc. Natl. Acad. Sci. U.S.A. 87:3542-3546(1990). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Lymphoma; RX PubMed=8382772; DOI=10.1128/mcb.13.3.1507-1515.1993; RA Linnenbach A.J., Seng B.A., Wu S., Robbins S., Scollon M., Pyrc J.J., RA Druck T., Huebner K.; RT "Retroposition in a family of carcinoma-associated antigen genes."; RL Mol. Cell. Biol. 13:1507-1515(1993). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-115. RC TISSUE=Ovary; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PRELIMINARY PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 81-126. RC TISSUE=Placenta; RX PubMed=2911574; DOI=10.1073/pnas.86.1.27; RA Linnenbach A.J., Wojcierowski J., Wu S., Pyrc J.J., Ross A.H., RA Dietzschold B., Speicher D., Koprowski H.; RT "Sequence investigation of the major gastrointestinal tumor-associated RT antigen gene family, GA733."; RL Proc. Natl. Acad. Sci. U.S.A. 86:27-31(1989). RN [11] RP PROTEIN SEQUENCE OF 82-100, AND SUBUNIT. RX PubMed=7693697; DOI=10.1016/s0021-9258(20)80515-8; RA Bjoerk P., Joensson U., Svedberg H., Larsson K., Lind P., Dillner J., RA Hedlund G., Dohlsten M., Kalland T.; RT "Isolation, partial characterization, and molecular cloning of a human RT colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse RT monoclonal antibody."; RL J. Biol. Chem. 268:24232-24241(1993). RN [12] RP DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-74 AND ASN-111. RX PubMed=11080501; DOI=10.1074/jbc.m008839200; RA Chong J.M., Speicher D.W.; RT "Determination of disulfide bond assignments and N-glycosylation sites of RT the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, RT KSA, and Ep-CAM)."; RL J. Biol. Chem. 276:5804-5813(2001). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15195135; DOI=10.1038/sj.onc.1207610; RA Muenz M., Kieu C., Mack B., Schmitt B., Zeidler R., Gires O.; RT "The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell RT proliferation."; RL Oncogene 23:5748-5758(2004). RN [14] RP FUNCTION. RX PubMed=15922867; DOI=10.1016/j.canlet.2004.11.048; RA Muenz M., Zeidler R., Gires O.; RT "The tumour-associated antigen EpCAM upregulates the fatty acid binding RT protein E-FABP."; RL Cancer Lett. 225:151-157(2005). RN [15] RP SUBCELLULAR LOCATION, AND INTERACTION WITH CLDN7. RX PubMed=16054130; DOI=10.1016/j.yexcr.2005.06.013; RA Ladwein M., Pape U.F., Schmidt D.S., Schnoelzer M., Fiedler S., RA Langbein L., Franke W.W., Moldenhauer G., Zoeller M.; RT "The cell-cell adhesion molecule EpCAM interacts directly with the tight RT junction protein claudin-7."; RL Exp. Cell Res. 309:345-357(2005). RN [16] RP GLYCOSYLATION AT ASN-74; ASN-111 AND ASN-198, AND MUTAGENESIS OF ASN-74; RP ASN-111 AND ASN-198. RX PubMed=18508581; DOI=10.2741/3075; RA Munz M., Fellinger K., Hofmann T., Schmitt B., Gires O.; RT "Glycosylation is crucial for stability of tumour and cancer stem cell RT antigen EpCAM."; RL Front. Biosci. 13:5195-5201(2008). RN [17] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-198. RC TISSUE=Liver; RX PubMed=19159218; DOI=10.1021/pr8008012; RA Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; RT "Glycoproteomics analysis of human liver tissue by combination of multiple RT enzyme digestion and hydrazide chemistry."; RL J. Proteome Res. 8:651-661(2009). RN [18] RP INVOLVEMENT IN LYNCH8. RX PubMed=19098912; DOI=10.1038/ng.283; RA Ligtenberg M.J., Kuiper R.P., Chan T.L., Goossens M., Hebeda K.M., RA Voorendt M., Lee T.Y., Bodmer D., Hoenselaar E., Hendriks-Cornelissen S.J., RA Tsui W.Y., Kong C.K., Brunner H.G., van Kessel A.G., Yuen S.T., RA van Krieken J.H., Leung S.Y., Hoogerbrugge N.; RT "Heritable somatic methylation and inactivation of MSH2 in families with RT Lynch syndrome due to deletion of the 3' exons of TACSTD1."; RL Nat. Genet. 41:112-117(2009). RN [19] RP FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=20064925; DOI=10.1074/jbc.m109.077081; RA Lu T.Y., Lu R.M., Liao M.Y., Yu J., Chung C.H., Kao C.F., Wu H.C.; RT "Epithelial cell adhesion molecule regulation is associated with the RT maintenance of the undifferentiated phenotype of human embryonic stem RT cells."; RL J. Biol. Chem. 285:8719-8732(2010). RN [20] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19785009; DOI=10.1002/stem.221; RA Ng V.Y., Ang S.N., Chan J.X., Choo A.B.; RT "Characterization of epithelial cell adhesion molecule as a surface marker RT on undifferentiated human embryonic stem cells."; RL Stem Cells 28:29-35(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP VARIANT DIAR5 TYR-66, AND INVOLVEMENT IN DIAR5. RX PubMed=18572020; DOI=10.1053/j.gastro.2008.05.036; RA Sivagnanam M., Mueller J.L., Lee H., Chen Z., Nelson S.F., Turner D., RA Zlotkin S.H., Pencharz P.B., Ngan B.Y., Libiger O., Schork N.J., RA Lavine J.E., Taylor S., Newbury R.O., Kolodner R.D., Hoffman H.M.; RT "Identification of EpCAM as the gene for congenital tufting enteropathy."; RL Gastroenterology 135:429-437(2008). RN [23] RP VARIANTS DIAR5 76-SER--ALA-314 DEL; ARG-103; CYS-105; ILE-120 AND RP 132-GLU--ALA-314 DEL, AND INVOLVEMENT IN DIAR5. RX PubMed=24142340; DOI=10.1007/s00439-013-1380-6; RA Salomon J., Goulet O., Canioni D., Brousse N., Lemale J., Tounian P., RA Coulomb A., Marinier E., Hugot J.P., Ruemmele F., Dufier J.L., Roche O., RA Bodemer C., Colomb V., Talbotec C., Lacaille F., Campeotto F., RA Cerf-Bensussan N., Janecke A.R., Mueller T., Koletzko S., Bonnefont J.P., RA Lyonnet S., Munnich A., Poirier F., Smahi A.; RT "Genetic characterization of congenital tufting enteropathy: epcam RT associated phenotype and involvement of SPINT2 in the syndromic form."; RL Hum. Genet. 133:299-310(2014). CC -!- FUNCTION: May act as a physical homophilic interaction molecule between CC intestinal epithelial cells (IECs) and intraepithelial lymphocytes CC (IELs) at the mucosal epithelium for providing immunological barrier as CC a first line of defense against mucosal infection. Plays a role in CC embryonic stem cells proliferation and differentiation. Up-regulates CC the expression of FABP5, MYC and cyclins A and E. CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:15922867, CC ECO:0000269|PubMed:19785009, ECO:0000269|PubMed:20064925}. CC -!- SUBUNIT: Monomer. Interacts with phosphorylated CLDN7. CC {ECO:0000269|PubMed:16054130, ECO:0000269|PubMed:7693697}. CC -!- INTERACTION: CC P16422; P27797: CALR; NbExp=3; IntAct=EBI-1171184, EBI-1049597; CC P16422; P12830: CDH1; NbExp=3; IntAct=EBI-1171184, EBI-727477; CC P16422; Q15078: CDK5R1; NbExp=3; IntAct=EBI-1171184, EBI-746189; CC P16422; P36957: DLST; NbExp=3; IntAct=EBI-1171184, EBI-351007; CC P16422; Q8TDX7: NEK7; NbExp=3; IntAct=EBI-1171184, EBI-1055945; CC -!- SUBCELLULAR LOCATION: Lateral cell membrane CC {ECO:0000269|PubMed:15195135, ECO:0000269|PubMed:16054130, CC ECO:0000269|PubMed:19785009}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:16054130}. Cell junction, tight junction CC {ECO:0000269|PubMed:16054130}. Note=Colocalizes with CLDN7 at the CC lateral cell membrane and tight junction. CC {ECO:0000269|PubMed:16054130}. CC -!- TISSUE SPECIFICITY: Highly and selectively expressed by CC undifferentiated rather than differentiated embryonic stem cells (ESC). CC Levels rapidly diminish as soon as ESC's differentiate (at protein CC levels). Expressed in almost all epithelial cell membranes but not on CC mesodermal or neural cell membranes. Found on the surface of CC adenocarcinoma. {ECO:0000269|PubMed:20064925}. CC -!- PTM: Hyperglycosylated in carcinoma tissue as compared with autologous CC normal epithelia. Glycosylation at Asn-198 is crucial for protein CC stability. {ECO:0000269|PubMed:11080501, ECO:0000269|PubMed:18508581, CC ECO:0000269|PubMed:19159218}. CC -!- DISEASE: Diarrhea 5, with tufting enteropathy, congenital (DIAR5) CC [MIM:613217]: An intractable diarrhea of infancy characterized by CC villous atrophy and absence of inflammation, with intestinal epithelial CC cell dysplasia manifesting as focal epithelial tufts in the duodenum CC and jejunum. {ECO:0000269|PubMed:18572020, CC ECO:0000269|PubMed:24142340}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lynch syndrome 8 (LYNCH8) [MIM:613244]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:19098912}. Note=The disease is caused by variants CC affecting the gene represented in this entry. LYNCH8 results from CC heterozygous deletion of 3-prime exons of EPCAM and intergenic regions CC directly upstream of MSH2, resulting in transcriptional read-through CC and epigenetic silencing of MSH2 in tissues expressing EPCAM. CC -!- SIMILARITY: Belongs to the EPCAM family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42459/TACSTD1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M32325; AAA36151.1; -; mRNA. DR EMBL; X14758; CAA32870.1; -; mRNA. DR EMBL; M26481; AAA59543.1; -; mRNA. DR EMBL; M32306; AAA35723.1; -; mRNA. DR EMBL; M33011; AAA35861.1; -; mRNA. DR EMBL; M93036; AAB00775.1; -; Genomic_DNA. DR EMBL; M93029; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93030; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93031; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93032; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93033; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93034; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; M93035; AAB00775.1; JOINED; Genomic_DNA. DR EMBL; CR542259; CAG47055.1; -; mRNA. DR EMBL; CR542283; CAG47078.1; -; mRNA. DR EMBL; AC079775; AAY15095.1; -; Genomic_DNA. DR EMBL; CH471053; EAX00218.1; -; Genomic_DNA. DR EMBL; BC014785; AAH14785.1; -; mRNA. DR CCDS; CCDS1833.1; -. DR PIR; B48149; B48149. DR RefSeq; NP_002345.2; NM_002354.3. DR PDB; 4MZV; X-ray; 1.86 A; A=24-265. DR PDB; 6I07; X-ray; 2.35 A; C/D=24-265. DR PDBsum; 4MZV; -. DR PDBsum; 6I07; -. DR AlphaFoldDB; P16422; -. DR SMR; P16422; -. DR BioGRID; 110250; 42. DR CORUM; P16422; -. DR FunCoup; P16422; 328. DR IntAct; P16422; 26. DR MINT; P16422; -. DR STRING; 9606.ENSP00000263735; -. DR ChEMBL; CHEMBL3580493; -. DR DrugBank; DB06607; Catumaxomab. DR DrugBank; DB06072; Citatuzumab Bogatox. DR DrugBank; DB11075; Hypromellose. DR DrugBank; DB05831; ING-1. DR DrugBank; DB05319; Oportuzumab monatox. DR DrugBank; DB09336; Technetium Tc-99m nofetumomab merpentan. DR GlyConnect; 1217; 34 N-Linked glycans (3 sites). DR GlyCosmos; P16422; 3 sites, 34 glycans. DR GlyGen; P16422; 6 sites, 63 N-linked glycans (3 sites), 2 O-linked glycans (3 sites). DR iPTMnet; P16422; -. DR MetOSite; P16422; -. DR PhosphoSitePlus; P16422; -. DR SwissPalm; P16422; -. DR BioMuta; EPCAM; -. DR DMDM; 160266056; -. DR CPTAC; CPTAC-502; -. DR CPTAC; CPTAC-503; -. DR jPOST; P16422; -. DR MassIVE; P16422; -. DR PaxDb; 9606-ENSP00000263735; -. DR PeptideAtlas; P16422; -. DR ProteomicsDB; 53359; -. DR Pumba; P16422; -. DR ABCD; P16422; 30 sequenced antibodies. DR Antibodypedia; 3539; 5006 antibodies from 64 providers. DR DNASU; 4072; -. DR Ensembl; ENST00000263735.9; ENSP00000263735.4; ENSG00000119888.12. DR GeneID; 4072; -. DR KEGG; hsa:4072; -. DR MANE-Select; ENST00000263735.9; ENSP00000263735.4; NM_002354.3; NP_002345.2. DR UCSC; uc002rvx.4; human. DR AGR; HGNC:11529; -. DR CIViC; 4072; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA35493; -. DR CTD; 4072; -. DR DisGeNET; 4072; -. DR GeneCards; EPCAM; -. DR GeneReviews; EPCAM; -. DR HGNC; HGNC:11529; EPCAM. DR HPA; ENSG00000119888; Tissue enhanced (intestine). DR MalaCards; EPCAM; -. DR MIM; 185535; gene. DR MIM; 613217; phenotype. DR MIM; 613244; phenotype. DR OpenTargets; ENSG00000119888; -. DR Orphanet; 92050; Congenital tufting enteropathy. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000119888; -. DR eggNOG; ENOG502QVSU; Eukaryota. DR GeneTree; ENSGT00390000018245; -. DR HOGENOM; CLU_075326_0_0_1; -. DR InParanoid; P16422; -. DR OMA; CQCKSIG; -. DR OrthoDB; 8953056at2759; -. DR PAN-GO; P16422; 2 GO annotations based on evolutionary models. DR PhylomeDB; P16422; -. DR BRENDA; 2.4.1.37; 2681. DR BRENDA; 2.4.1.40; 2681. DR PathwayCommons; P16422; -. DR Reactome; R-HSA-202733; Cell surface interactions at the vascular wall. DR Reactome; R-HSA-9638630; Attachment of bacteria to epithelial cells. DR Reactome; R-HSA-9927432; Developmental Lineage of Mammary Gland Myoepithelial Cells. DR Reactome; R-HSA-9938206; Developmental Lineage of Mammary Stem Cells. DR SignaLink; P16422; -. DR SIGNOR; P16422; -. DR Agora; ENSG00000119888; -. DR BioGRID-ORCS; 4072; 34 hits in 1164 CRISPR screens. DR ChiTaRS; EPCAM; human. DR EvolutionaryTrace; P16422; -. DR GeneWiki; Epithelial_cell_adhesion_molecule; -. DR GenomeRNAi; 4072; -. DR Pharos; P16422; Tbio. DR PRO; PR:P16422; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P16422; protein. DR Bgee; ENSG00000119888; Expressed in jejunal mucosa and 176 other cell types or tissues. DR ExpressionAtlas; P16422; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IDA:MGI. DR GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI. DR GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0016328; C:lateral plasma membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; IBA:GO_Central. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB. DR GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IMP:UniProtKB. DR GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd00191; TY; 1. DR FunFam; 4.10.800.10:FF:000015; Epithelial cell adhesion molecule; 1. DR Gene3D; 4.10.800.10; Thyroglobulin type-1; 1. DR InterPro; IPR049420; EPCAM-Trop-2_C. DR InterPro; IPR043406; EPCAM/Trop-2. DR InterPro; IPR041630; EpCAM_N. DR InterPro; IPR000716; Thyroglobulin_1. DR InterPro; IPR036857; Thyroglobulin_1_sf. DR PANTHER; PTHR14168:SF2; EPITHELIAL CELL ADHESION MOLECULE; 1. DR PANTHER; PTHR14168; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER; 1. DR Pfam; PF21283; EPCAM-Trop-2_C; 1. DR Pfam; PF18635; EpCAM_N; 1. DR Pfam; PF00086; Thyroglobulin_1; 1. DR SMART; SM00211; TY; 1. DR SUPFAM; SSF57610; Thyroglobulin type-1 domain; 1. DR PROSITE; PS00484; THYROGLOBULIN_1_1; 1. DR PROSITE; PS51162; THYROGLOBULIN_1_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Cell junction; Cell membrane; Direct protein sequencing; KW Disease variant; Disulfide bond; Glycoprotein; KW Hereditary nonpolyposis colorectal cancer; Membrane; KW Proteomics identification; Reference proteome; Repeat; Signal; KW Tight junction; Transmembrane; Transmembrane helix; Tumor antigen. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..314 FT /note="Epithelial cell adhesion molecule" FT /id="PRO_0000022467" FT TOPO_DOM 24..265 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 266..288 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 289..314 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 63..135 FT /note="Thyroglobulin type-1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500" FT CARBOHYD 74 FT /note="N-linked (GlcNAc...) asparagine; partial" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 111 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:11080501, FT ECO:0000269|PubMed:18508581" FT CARBOHYD 198 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:18508581, FT ECO:0000269|PubMed:19159218" FT DISULFID 27..46 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 29..59 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 38..48 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 66..99 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 110..116 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT DISULFID 118..135 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00500, FT ECO:0000269|PubMed:11080501" FT VARIANT 66 FT /note="C -> Y (in DIAR5; dbSNP:rs267606785)" FT /evidence="ECO:0000269|PubMed:18572020" FT /id="VAR_063829" FT VARIANT 76..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089317" FT VARIANT 103 FT /note="G -> R (in DIAR5; uncertain significance; FT dbSNP:rs1346393896)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089318" FT VARIANT 105 FT /note="F -> C (in DIAR5; uncertain significance)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089319" FT VARIANT 115 FT /note="M -> T (in dbSNP:rs1126497)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:2108441, ECO:0000269|PubMed:2463074, FT ECO:0000269|PubMed:2469722" FT /id="VAR_018329" FT VARIANT 120 FT /note="N -> I (in DIAR5; uncertain significance; FT dbSNP:rs2103747763)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089320" FT VARIANT 132..314 FT /note="Missing (in DIAR5; likely pathogenic)" FT /evidence="ECO:0000269|PubMed:24142340" FT /id="VAR_089321" FT MUTAGEN 74 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-111 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 111 FT /note="N->A: Changed glycosylation pattern. Complete loss FT of glycosylation and substantial decrease in protein FT expression; when associated with A-74 and A-198." FT /evidence="ECO:0000269|PubMed:18508581" FT MUTAGEN 198 FT /note="N->A: Decreased glycosylation, reduced protein FT stability and significant decrease in protein expression. FT Complete loss of glycosylation and substantial decrease in FT protein expression; when associated with A-74 and A-111." FT /evidence="ECO:0000269|PubMed:18508581" FT CONFLICT 277 FT /note="I -> M (in Ref. 1; AAA36151/CAA32870 and 2; FT AAA59543)" FT /evidence="ECO:0000305" FT CONFLICT 303 FT /note="K -> R (in Ref. 6; CAG47055)" FT /evidence="ECO:0000305" FT STRAND 35..40 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 46..50 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 65..72 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 73..75 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 107..111 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 112..114 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 115..120 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 141..150 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 159..173 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 178..180 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 181..187 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4MZV" FT TURN 199..201 FT /evidence="ECO:0007829|PDB:4MZV" FT HELIX 209..220 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 226..228 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 234..237 FT /evidence="ECO:0007829|PDB:6I07" FT HELIX 244..246 FT /evidence="ECO:0007829|PDB:4MZV" FT STRAND 248..255 FT /evidence="ECO:0007829|PDB:4MZV" SQ SEQUENCE 314 AA; 34932 MW; 023FCE418B2F1079 CRC64; MAPPQVLAFG LLLAAATATF AAAQEECVCE NYKLAVNCFV NNNRQCQCTS VGAQNTVICS KLAAKCLVMK AEMNGSKLGR RAKPEGALQN NDGLYDPDCD ESGLFKAKQC NGTSMCWCVN TAGVRRTDKD TEITCSERVR TYWIIIELKH KAREKPYDSK SLRTALQKEI TTRYQLDPKF ITSILYENNV ITIDLVQNSS QKTQNDVDIA DVAYYFEKDV KGESLFHSKK MDLTVNGEQL DLDPGQTLIY YVDEKAPEFS MQGLKAGVIA VIVVVVIAVV AGIVVLVISR KKRMAKYEKA EIKEMGEMHR ELNA // ID HNF1B_HUMAN Reviewed; 557 AA. AC P35680; B4DKM3; E0YMJ9; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 1. DT 28-JAN-2026, entry version 246. DE RecName: Full=Hepatocyte nuclear factor 1-beta; DE Short=HNF-1-beta; DE Short=HNF-1B; DE AltName: Full=Homeoprotein LFB3; DE AltName: Full=Transcription factor 2; DE Short=TCF-2; DE AltName: Full=Variant hepatic nuclear factor 1; DE Short=vHNF1; GN Name=HNF1B; Synonyms=TCF2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A). RC TISSUE=Liver; RX PubMed=1677179; DOI=10.1093/nar/19.13.3553; RA Bach I., Mattei M.-G., Cereghini S., Yaniv M.; RT "Two members of an HNF1 homeoprotein family are expressed in human liver."; RL Nucleic Acids Res. 19:3553-3559(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A; B AND C), AND FUNCTION. RC TISSUE=Liver; RX PubMed=7900999; DOI=10.1002/j.1460-2075.1993.tb06107.x; RA Bach I., Yaniv M.; RT "More potent transcriptional activators or a transdominant inhibitor of the RT HNF1 homeoprotein family are generated by alternative RNA processing."; RL EMBO J. 12:4229-4242(1993). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9398836; DOI=10.1038/ng1297-384; RA Horikawa Y., Iwasaki N., Hara M., Furuta H., Hinokio Y., Cockburn B.N., RA Lindner T., Yamagata K., Ogata M., Tomonaga O., Kuroki H., Kasahara T., RA Iwamoto Y., Bell G.I.; RT "Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with RT MODY."; RL Nat. Genet. 17:384-385(1997). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). RA Yang C.-W., Tsai D.-Y.; RT "Homo sapiens HNF1 beta A mRNA splicing variant 4."; RL Submitted (APR-2010) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B). RC TISSUE=Colon; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INVOLVEMENT IN RCAD. RX PubMed=10484768; DOI=10.1093/hmg/8.11.2001; RA Lindner T.H., Njoelstad P.R., Horikawa Y., Bostad L., Bell G.I., Soevik O.; RT "A novel syndrome of diabetes mellitus, renal dysfunction and genital RT malformation associated with a partial deletion of the pseudo-POU domain of RT hepatocyte nuclear factor-1beta."; RL Hum. Mol. Genet. 8:2001-2008(1999). RN [9] RP STRUCTURE BY NMR OF 233-321. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the homeobox domain of hepatocyte nuclear factor 1- RT beta (HNF-1beta)."; RL Submitted (DEC-2006) to the PDB data bank. RN [10] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 91-310 IN COMPLEX WITH DNA, AND RP FUNCTION. RX PubMed=17924661; DOI=10.1021/bi7010527; RA Lu P., Rha G.B., Chi Y.I.; RT "Structural basis of disease-causing mutations in hepatocyte nuclear factor RT 1beta."; RL Biochemistry 46:12071-12080(2007). RN [11] RP VARIANT RCAD THR-241, AND VARIANT SER-492. RX PubMed=10672455; DOI=10.1007/s001250050018; RA Weng J.P., Lehto M., Forsblom C., Huang X., Li H., Groop L.C.; RT "Hepatocyte nuclear factor-1 beta (MODY5) gene mutations in Scandinavian RT families with early-onset diabetes or kidney disease or both."; RL Diabetologia 43:131-132(2000). RN [12] RP VARIANT RCAD PHE-36, AND CHARACTERIZATION OF VARIANT RCAD PHE-36. RX PubMed=11845238; DOI=10.1007/s125-002-8259-5; RA Yoshiuchi I., Yamagata K., Zhu Q., Tamada I., Takahashi Y., Onigata K., RA Takeda J., Miyagawa J., Matsuzawa Y.; RT "Identification of a gain-of-function mutation in the HNF-1beta gene in a RT Japanese family with MODY."; RL Diabetologia 45:154-155(2002). RN [13] RP VARIANT RCAD PRO-151. RX PubMed=11918730; DOI=10.1046/j.1523-1755.2002.00272.x; RA Bingham C., Ellard S., Cole T.R.P., Jones K.E., Allen L.I.S., RA Goodship J.A., Goodship T.H.J., Bakalinova-Pugh D., Russell G.I., RA Woolf A.S., Nicholls A.J., Hattersley A.T.; RT "Solitary functioning kidney and diverse genital tract malformations RT associated with hepatocyte nuclear factor-1beta mutations."; RL Kidney Int. 61:1243-1251(2002). RN [14] RP VARIANT T2D ARG-465. RX PubMed=12161522; DOI=10.1210/jcem.87.8.8776; RA Furuta H., Furuta M., Sanke T., Ekawa K., Hanabusa T., Nishi M., Sasaki H., RA Nanjo K.; RT "Nonsense and missense mutations in the human hepatocyte nuclear factor-1 RT beta gene (TCF2) and their relation to type 2 diabetes in Japanese."; RL J. Clin. Endocrinol. Metab. 87:3859-3863(2002). RN [15] RP VARIANT RCAD ASP-260, AND CHARACTERIZATION OF VARIANT RCAD ASP-260. RX PubMed=14583183; DOI=10.1016/s1056-8727(02)00221-0; RA So W.Y., Ng M.C.Y., Horikawa Y., Njoelstad P.R., Li J.K.Y., Ma R.C.W., RA Bell G.I., Chan J.C.N.; RT "Genetic variants of hepatocyte nuclear factor-1beta in Chinese young-onset RT diabetic patients with nephropathy."; RL J. Diabetes Complications 17:369-373(2003). RN [16] RP VARIANTS RCAD PRO-112; GLU-136; GLN-164; HIS-165 AND HIS-295. RX PubMed=15068978; DOI=10.7326/0003-4819-140-7-200404060-00009; RA Bellanne-Chantelot C., Chauveau D., Gautier J.-F., Dubois-Laforgue D., RA Clauin S., Beaufils S., Wilhelm J.-M., Boitard C., Noeel L.-H., Velho G., RA Timsit J.; RT "Clinical spectrum associated with hepatocyte nuclear factor-1beta RT mutations."; RL Ann. Intern. Med. 140:510-517(2004). RN [17] RP VARIANT RCAD ASN-153, AND CHARACTERIZATION OF VARIANT RCAD ASN-153. RX PubMed=15001636; DOI=10.1210/jc.2003-031308; RA Kitanaka S., Miki Y., Hayashi Y., Igarashi T.; RT "Promoter-specific repression of hepatocyte nuclear factor (HNF)-1beta and RT HNF-1alpha transcriptional activity by an HNF-1beta missense mutant RT associated with type 5 maturity-onset diabetes of the young with hepatic RT and biliary manifestations."; RL J. Clin. Endocrinol. Metab. 89:1369-1378(2004). RN [18] RP VARIANT RCAD TRP-148. RX PubMed=15181075; DOI=10.1210/jc.2003-031828; RA Yorifuji T., Kurokawa K., Mamada M., Imai T., Kawai M., Nishi Y., RA Shishido S., Hasegawa Y., Nakahata T.; RT "Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: RT phenotypically discordant recurrence of a mutation in the hepatocyte RT nuclear factor-1beta gene due to germline mosaicism."; RL J. Clin. Endocrinol. Metab. 89:2905-2908(2004). RN [19] RP VARIANTS RCAD CYS-76; PRO-112; GLU-136; GLN-164; HIS-165; GLN-235; GLY-276; RP ASP-285; CYS-295; HIS-295 AND SER-370. RX PubMed=16249435; DOI=10.2337/diabetes.54.11.3126; RA Bellanne-Chantelot C., Clauin S., Chauveau D., Collin P., Daumont M., RA Douillard C., Dubois-Laforgue D., Dusselier L., Gautier J.-F., Jadoul M., RA Laloi-Michelin M., Jacquesson L., Larger E., Louis J., Nicolino M., RA Subra J.-F., Wilhem J.-M., Young J., Velho G., Timsit J.; RT "Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) RT gene are the most frequent cause of maturity-onset diabetes of the young RT type 5."; RL Diabetes 54:3126-3132(2005). RN [20] RP VARIANTS RCAD GLY-61; GLY-110; LEU-148; GLU-156; GLN-276 AND PRO-295. RX PubMed=15930087; DOI=10.1136/jmg.2005.032854; RA Edghill E.L., Bingham C., Ellard S., Hattersley A.T.; RT "Mutations in hepatocyte nuclear factor-1beta and their related RT phenotypes."; RL J. Med. Genet. 43:84-90(2006). RN [21] RP INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER. RX PubMed=18264097; DOI=10.1038/ng.90; RG The UK genetic prostate cancer study collaborators; RG British association of urological surgeons section of oncology; RG The UK protecT study collaborators; RA Eeles R.A., Kote-Jarai Z., Giles G.G., Al Olama A.A., Guy M., RA Jugurnauth S.K., Mulholland S., Leongamornlert D.A., Edwards S.M., RA Morrison J., Field H.I., Southey M.C., Severi G., Donovan J.L., Hamdy F.C., RA Dearnaley D.P., Muir K.R., Smith C., Bagnato M., Ardern-Jones A.T., RA Hall A.L., O'Brien L.T., Gehr-Swain B.N., Wilkinson R.A., Cox A., Lewis S., RA Brown P.M., Jhavar S.G., Tymrakiewicz M., Lophatananon A., Bryant S.L., RA Horwich A., Huddart R.A., Khoo V.S., Parker C.C., Woodhouse C.J., RA Thompson A., Christmas T., Ogden C., Fisher C., Jamieson C., Cooper C.S., RA English D.R., Hopper J.L., Neal D.E., Easton D.F.; RT "Multiple newly identified loci associated with prostate cancer RT susceptibility."; RL Nat. Genet. 40:316-321(2008). RN [22] RP CHARACTERIZATION OF VARIANTS RCAD GLU-156 AND GLY-276, FUNCTION, RP INTERACTION WITH PCBD1, AND MUTAGENESIS OF 1-MET--LEU-30 AND GLN-253. RX PubMed=24204001; DOI=10.1681/asn.2013040337; RA Ferre S., de Baaij J.H., Ferreira P., Germann R., de Klerk J.B., RA Lavrijsen M., van Zeeland F., Venselaar H., Kluijtmans L.A., RA Hoenderop J.G., Bindels R.J.; RT "Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting."; RL J. Am. Soc. Nephrol. 25:574-586(2014). CC -!- FUNCTION: Transcription factor that binds to the inverted palindrome CC 5'-GTTAATNATTAAC-3' (PubMed:17924661, PubMed:7900999). Binds to the FPC CC element in the cAMP regulatory unit of the PLAU gene (By similarity). CC Transcriptional activity is increased by coactivator PCBD1 CC (PubMed:24204001). {ECO:0000250|UniProtKB:Q03365, CC ECO:0000269|PubMed:17924661, ECO:0000269|PubMed:24204001, CC ECO:0000269|PubMed:7900999}. CC -!- SUBUNIT: Binds DNA as a dimer. Can form homodimer or heterodimer with CC HNF1-alpha. Interacts (via HNF-p1 domain) with PCBD1; the interaction CC increases its transactivation activity (PubMed:24204001). CC {ECO:0000269|PubMed:17924661, ECO:0000269|PubMed:24204001}. CC -!- INTERACTION: CC P35680; Q9NP55: BPIFA1; NbExp=3; IntAct=EBI-2798841, EBI-953896; CC P35680; Q5SWW7: C10orf55; NbExp=3; IntAct=EBI-2798841, EBI-12809220; CC P35680; O43186: CRX; NbExp=3; IntAct=EBI-2798841, EBI-748171; CC P35680; P20823: HNF1A; NbExp=2; IntAct=EBI-2798841, EBI-636034; CC P35680; Q6PEX3: KRTAP26-1; NbExp=3; IntAct=EBI-2798841, EBI-3957672; CC P35680; P55197-2: MLLT10; NbExp=3; IntAct=EBI-2798841, EBI-12853322; CC P35680; P32243-2: OTX2; NbExp=3; IntAct=EBI-2798841, EBI-9087860; CC P35680; Q8TDS5: OXER1; NbExp=3; IntAct=EBI-2798841, EBI-12813389; CC P35680; P61457: PCBD1; NbExp=8; IntAct=EBI-2798841, EBI-740475; CC P35680; P78424: POU6F2; NbExp=3; IntAct=EBI-2798841, EBI-12029004; CC P35680; Q6NVU6: UFSP1; NbExp=3; IntAct=EBI-2798841, EBI-12068150; CC P35680; Q70EL1-9: USP54; NbExp=3; IntAct=EBI-2798841, EBI-11975223; CC P35680; Q08AM6: VAC14; NbExp=3; IntAct=EBI-2798841, EBI-2107455; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=A; CC IsoId=P35680-1; Sequence=Displayed; CC Name=B; CC IsoId=P35680-2; Sequence=VSP_002254; CC Name=C; CC IsoId=P35680-3; Sequence=VSP_002255, VSP_002256; CC Name=4; CC IsoId=P35680-4; Sequence=VSP_053327, VSP_002254, VSP_053328, CC VSP_053329; CC -!- DISEASE: Renal cysts and diabetes syndrome (RCAD) [MIM:137920]: An CC autosomal dominant disorder comprising non-diabetic renal disease CC resulting from abnormal renal development, and diabetes, which in some CC cases occurs earlier than age 25 years and is thus consistent with a CC diagnosis of maturity-onset diabetes of the young (MODY5). The renal CC disease is highly variable and includes renal cysts, glomerular tufts, CC aberrant nephrogenesis, primitive tubules, irregular collecting CC systems, oligomeganephronia, enlarged renal pelves, abnormal calyces, CC small kidney, single kidney, horseshoe kidney, and hyperuricemic CC nephropathy. Affected individuals may also have abnormalities of the CC genital tract. {ECO:0000269|PubMed:10484768, CC ECO:0000269|PubMed:10672455, ECO:0000269|PubMed:11845238, CC ECO:0000269|PubMed:11918730, ECO:0000269|PubMed:14583183, CC ECO:0000269|PubMed:15001636, ECO:0000269|PubMed:15068978, CC ECO:0000269|PubMed:15181075, ECO:0000269|PubMed:15930087, CC ECO:0000269|PubMed:16249435, ECO:0000269|PubMed:24204001}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Type 2 diabetes mellitus (T2D) [MIM:125853]: A multifactorial CC disorder of glucose homeostasis caused by a lack of sensitivity to CC insulin. Affected individuals usually have an obese body habitus and CC manifestations of a metabolic syndrome characterized by diabetes, CC insulin resistance, hypertension and hypertriglyceridemia. The disease CC results in long-term complications that affect the eyes, kidneys, CC nerves, and blood vessels. {ECO:0000269|PubMed:12161522}. Note=Disease CC susceptibility may be associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Prostate cancer, hereditary, 11 (HPC11) [MIM:611955]: A CC condition associated with familial predisposition to cancer of the CC prostate. Most prostate cancers are adenocarcinomas that develop in the CC acini of the prostatic ducts. Other rare histopathologic types of CC prostate cancer that occur in approximately 5% of patients include CC small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, CC transitional cell carcinoma, squamous cell carcinoma, basal cell CC carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:18264097}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- SIMILARITY: Belongs to the HNF1 homeobox family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Wikipedia; Note=Hepatocyte nuclear factors entry; CC URL="https://en.wikipedia.org/wiki/Hepatocyte_nuclear_factors"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X58840; CAA41652.1; -; mRNA. DR EMBL; X71348; CAB59223.1; -; mRNA. DR EMBL; U90287; AAC63388.1; -; Genomic_DNA. DR EMBL; U90279; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90280; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90281; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90282; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90283; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90284; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90285; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; U90286; AAC63388.1; JOINED; Genomic_DNA. DR EMBL; HM116556; ADM43493.1; -; mRNA. DR EMBL; AK296633; BAG59235.1; -; mRNA. DR EMBL; AC091199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC113211; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC017714; AAH17714.1; -; mRNA. DR CCDS; CCDS11324.1; -. [P35680-1] DR CCDS; CCDS58538.1; -. [P35680-2] DR PIR; S34412; S34412. DR RefSeq; NP_000449.1; NM_000458.4. [P35680-1] DR RefSeq; NP_001159395.1; NM_001165923.4. [P35680-2] DR RefSeq; NP_001291215.1; NM_001304286.1. DR PDB; 2DA6; NMR; -; A=233-321. DR PDB; 2H8R; X-ray; 3.20 A; A/B=91-310. DR PDB; 5K9S; X-ray; 2.40 A; B/C=227-237. DR PDBsum; 2DA6; -. DR PDBsum; 2H8R; -. DR PDBsum; 5K9S; -. DR AlphaFoldDB; P35680; -. DR BMRB; P35680; -. DR SMR; P35680; -. DR BioGRID; 112790; 196. DR FunCoup; P35680; 1333. DR IntAct; P35680; 140. DR STRING; 9606.ENSP00000480291; -. DR iPTMnet; P35680; -. DR PhosphoSitePlus; P35680; -. DR BioMuta; HNF1B; -. DR DMDM; 547664; -. DR jPOST; P35680; -. DR MassIVE; P35680; -. DR PaxDb; 9606-ENSP00000480291; -. DR PeptideAtlas; P35680; -. DR ProteomicsDB; 15199; -. DR ProteomicsDB; 55134; -. [P35680-1] DR ProteomicsDB; 55135; -. [P35680-2] DR ProteomicsDB; 55136; -. [P35680-3] DR Antibodypedia; 72795; 548 antibodies from 39 providers. DR DNASU; 6928; -. DR Ensembl; ENST00000610754.4; ENSP00000484591.1; ENSG00000276194.4. [P35680-1] DR Ensembl; ENST00000617811.5; ENSP00000480291.1; ENSG00000275410.7. [P35680-1] DR Ensembl; ENST00000621123.4; ENSP00000482711.1; ENSG00000275410.7. [P35680-2] DR Ensembl; ENST00000633792.1; ENSP00000488080.1; ENSG00000276194.4. [P35680-2] DR GeneID; 6928; -. DR KEGG; hsa:6928; -. DR MANE-Select; ENST00000617811.5; ENSP00000480291.1; NM_000458.4; NP_000449.1. DR UCSC; uc010wdi.3; human. [P35680-1] DR AGR; HGNC:11630; -. DR ClinPGx; PA162391083; -. DR CTD; 6928; -. DR DisGeNET; 6928; -. DR GeneCards; HNF1B; -. DR GeneReviews; HNF1B; -. DR HGNC; HGNC:11630; HNF1B. DR HPA; ENSG00000275410; Tissue enhanced (kidney, pancreas). DR MalaCards; HNF1B; -. DR MIM; 125853; phenotype. DR MIM; 137920; phenotype. DR MIM; 189907; gene. DR MIM; 611955; phenotype. DR OpenTargets; ENSG00000275410; -. DR Orphanet; 261265; 17q12 microdeletion syndrome. DR Orphanet; 97364; Bilateral multicystic dysplastic kidney. DR Orphanet; 1331; Familial prostate cancer. DR Orphanet; 93111; HNF1B-related autosomal dominant tubulointerstitial kidney disease. DR Orphanet; 2578; Mayer-Rokitansky-Kuester-Hauser syndrome type 2. DR Orphanet; 1309; Medullary sponge kidney. DR Orphanet; 93173; Renal dysplasia, bilateral. DR Orphanet; 93172; Renal dysplasia, unilateral. DR Orphanet; 97363; Unilateral multicystic dysplastic kidney. DR VEuPathDB; HostDB:ENSG00000275410; -. DR eggNOG; ENOG502QRPW; Eukaryota. DR GeneTree; ENSGT00940000153818; -. DR HOGENOM; CLU_035503_0_0_1; -. DR InParanoid; P35680; -. DR OMA; GQSDDTC; -. DR OrthoDB; 10069265at2759; -. DR PAN-GO; P35680; 4 GO annotations based on evolutionary models. DR PhylomeDB; P35680; -. DR PathwayCommons; P35680; -. DR Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells. DR Reactome; R-HSA-210747; Regulation of gene expression in early pancreatic precursor cells. DR Reactome; R-HSA-9831926; Nephron development. DR Reactome; R-HSA-9925561; Developmental Lineage of Pancreatic Acinar Cells. DR Reactome; R-HSA-9925563; Developmental Lineage of Pancreatic Ductal Cells. DR Reactome; R-HSA-9937080; Developmental Lineage of Multipotent Pancreatic Progenitor Cells. DR SignaLink; P35680; -. DR SIGNOR; P35680; -. DR Agora; ENSG00000275410; -. DR BioGRID-ORCS; 6928; 78 hits in 1179 CRISPR screens. DR ChiTaRS; HNF1B; human. DR EvolutionaryTrace; P35680; -. DR GeneWiki; HNF1B; -. DR GenomeRNAi; 6928; -. DR Pharos; P35680; Tbio. DR PRO; PR:P35680; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P35680; protein. DR Bgee; ENSG00000275410; Expressed in metanephros cortex and 54 other cell types or tissues. DR ExpressionAtlas; P35680; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central. DR GO; GO:0001221; F:transcription coregulator binding; IPI:UniProtKB. DR GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl. DR GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl. DR GO; GO:0048557; P:embryonic digestive tract morphogenesis; IEA:Ensembl. DR GO; GO:0031018; P:endocrine pancreas development; IMP:UniProtKB. DR GO; GO:0001714; P:endodermal cell fate specification; IEA:Ensembl. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0048806; P:genitalia development; IMP:UniProtKB. DR GO; GO:0061017; P:hepatoblast differentiation; IEA:Ensembl. DR GO; GO:0030902; P:hindbrain development; IEA:Ensembl. DR GO; GO:0001826; P:inner cell mass cell differentiation; IEA:Ensembl. DR GO; GO:0030073; P:insulin secretion; IEA:Ensembl. DR GO; GO:0001822; P:kidney development; IDA:UniProtKB. DR GO; GO:1900200; P:mesenchymal cell apoptotic process involved in metanephros development; IEA:Ensembl. DR GO; GO:0072181; P:mesonephric duct formation; IEA:Ensembl. DR GO; GO:0061296; P:negative regulation of mesenchymal cell apoptotic process involved in mesonephric nephron morphogenesis; IEA:Ensembl. DR GO; GO:1900212; P:negative regulation of mesenchymal cell apoptotic process involved in metanephros development; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0031016; P:pancreas development; IEA:InterPro. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0039020; P:pronephric nephron tubule development; IGI:UniProtKB. DR GO; GO:0048793; P:pronephros development; IMP:UniProtKB. DR GO; GO:0072095; P:regulation of branch elongation involved in ureteric bud branching; IEA:Ensembl. DR GO; GO:0035565; P:regulation of pronephros size; IMP:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0030111; P:regulation of Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0009749; P:response to glucose; IEA:Ensembl. DR GO; GO:0060677; P:ureteric bud elongation; IEA:Ensembl. DR CDD; cd00086; homeodomain; 1. DR DisProt; DP03135; -. DR FunFam; 1.10.10.60:FF:000043; Hepatocyte nuclear factor 1-beta; 1. DR FunFam; 1.10.260.40:FF:000009; Hepatocyte nuclear factor 1-beta; 1. DR Gene3D; 1.10.10.60; Homeodomain-like; 1. DR Gene3D; 1.10.260.40; lambda repressor-like DNA-binding domains; 1. DR InterPro; IPR001356; HD. DR InterPro; IPR039066; HNF-1. DR InterPro; IPR006899; HNF-1_N. DR InterPro; IPR044869; HNF-1_POU. DR InterPro; IPR023219; HNF1_dimer_N_dom_sf. DR InterPro; IPR006897; HNF1b_C. DR InterPro; IPR044866; HNF_P1. DR InterPro; IPR009057; Homeodomain-like_sf. DR InterPro; IPR010982; Lambda_DNA-bd_dom_sf. DR PANTHER; PTHR11568; HEPATOCYTE NUCLEAR FACTOR 1; 1. DR PANTHER; PTHR11568:SF2; HEPATOCYTE NUCLEAR FACTOR 1-BETA; 1. DR Pfam; PF04814; HNF-1_N; 1. DR Pfam; PF04812; HNF-1B_C; 1. DR SMART; SM00389; HOX; 1. DR SUPFAM; SSF100957; Dimerization cofactor of HNF-1 alpha; 1. DR SUPFAM; SSF46689; Homeodomain-like; 1. DR SUPFAM; SSF47413; lambda repressor-like DNA-binding domains; 1. DR PROSITE; PS51937; HNF_P1; 1. DR PROSITE; PS00027; HOMEOBOX_1; 1. DR PROSITE; PS50071; HOMEOBOX_2; 1. DR PROSITE; PS51936; POU_4; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; Diabetes mellitus; KW Disease variant; DNA-binding; Homeobox; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..557 FT /note="Hepatocyte nuclear factor 1-beta" FT /id="PRO_0000049121" FT DOMAIN 1..32 FT /note="HNF-p1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01286" FT DOMAIN 93..188 FT /note="POU-specific atypical" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01285" FT DNA_BIND 231..311 FT /note="Homeobox; HNF1-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00108" FT REGION 1..31 FT /note="Dimerization" FT /evidence="ECO:0000250" FT REGION 64..85 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 324..352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 328..344 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 49 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P27889" FT MOD_RES 52 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P27889" FT MOD_RES 75 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P27889" FT MOD_RES 80 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P27889" FT VAR_SEQ 96..125 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_053327" FT VAR_SEQ 183..208 FT /note="Missing (in isoform B and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7900999, ECO:0000303|Ref.4" FT /id="VSP_002254" FT VAR_SEQ 350..400 FT /note="VRYSQQGNNEITSSSTISHHGNSAMVTSQSVLQQVSPASLDPGHNLLSPDG FT -> KQRLGLTASATQPSWFLPRILSGLRVFRGANAFEMILGPLSHCQNILPWK (in FT isoform C)" FT /evidence="ECO:0000303|PubMed:7900999" FT /id="VSP_002255" FT VAR_SEQ 401..557 FT /note="Missing (in isoform C)" FT /evidence="ECO:0000303|PubMed:7900999" FT /id="VSP_002256" FT VAR_SEQ 447..483 FT /note="SLNTSQAQSVPVINSVAGSLAALQPVQFSQQLHSPHQ -> MSSTSLVMPTH FT HLLRAQQQGPCFPHHHPLGSCHGKAQ (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_053328" FT VAR_SEQ 484..557 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|Ref.4" FT /id="VSP_053329" FT VARIANT 36 FT /note="S -> F (in RCAD; gain-of-function mutation; FT dbSNP:rs544890850)" FT /evidence="ECO:0000269|PubMed:11845238" FT /id="VAR_046012" FT VARIANT 61 FT /note="V -> G (in RCAD; dbSNP:rs147816724)" FT /evidence="ECO:0000269|PubMed:15930087" FT /id="VAR_046013" FT VARIANT 76 FT /note="G -> C (in RCAD; uncertain significance; FT dbSNP:rs144425830)" FT /evidence="ECO:0000269|PubMed:16249435" FT /id="VAR_046014" FT VARIANT 110 FT /note="V -> G (in RCAD; dbSNP:rs894213416)" FT /evidence="ECO:0000269|PubMed:15930087" FT /id="VAR_046015" FT VARIANT 112 FT /note="R -> P (in RCAD)" FT /evidence="ECO:0000269|PubMed:15068978, FT ECO:0000269|PubMed:16249435" FT /id="VAR_046016" FT VARIANT 136 FT /note="Q -> E (in RCAD)" FT /evidence="ECO:0000269|PubMed:15068978, FT ECO:0000269|PubMed:16249435" FT /id="VAR_046017" FT VARIANT 148 FT /note="S -> L (in RCAD)" FT /evidence="ECO:0000269|PubMed:15930087" FT /id="VAR_046018" FT VARIANT 148 FT /note="S -> W (in RCAD; dbSNP:rs121918674)" FT /evidence="ECO:0000269|PubMed:15181075" FT /id="VAR_046019" FT VARIANT 151 FT /note="S -> P (in RCAD)" FT /evidence="ECO:0000269|PubMed:11918730" FT /id="VAR_046020" FT VARIANT 153 FT /note="H -> N (in RCAD; has diminished transcriptional FT activity by loss of DNA binding activity)" FT /evidence="ECO:0000269|PubMed:15001636" FT /id="VAR_046021" FT VARIANT 156 FT /note="K -> E (in RCAD; no impact on interaction with FT PCBD1; reduced coactivation by PCBD1)" FT /evidence="ECO:0000269|PubMed:15930087, FT ECO:0000269|PubMed:24204001" FT /id="VAR_046022" FT VARIANT 164 FT /note="K -> Q (in RCAD)" FT /evidence="ECO:0000269|PubMed:15068978, FT ECO:0000269|PubMed:16249435" FT /id="VAR_046023" FT VARIANT 165 FT /note="R -> H (in RCAD; dbSNP:rs121918675)" FT /evidence="ECO:0000269|PubMed:15068978, FT ECO:0000269|PubMed:16249435" FT /id="VAR_046024" FT VARIANT 235 FT /note="R -> Q (in RCAD)" FT /evidence="ECO:0000269|PubMed:16249435" FT /id="VAR_046025" FT VARIANT 241 FT /note="A -> T (in RCAD; dbSNP:rs761415487)" FT /evidence="ECO:0000269|PubMed:10672455" FT /id="VAR_046026" FT VARIANT 260 FT /note="E -> D (in RCAD; insignificant differences in FT transactivation ability between wild-type and mutated FT HNF1B; dbSNP:rs536638039)" FT /evidence="ECO:0000269|PubMed:14583183" FT /id="VAR_046027" FT VARIANT 276 FT /note="R -> G (in RCAD; no impact on interaction with FT PCBD1; reduced coactivation by PCBD1)" FT /evidence="ECO:0000269|PubMed:16249435, FT ECO:0000269|PubMed:24204001" FT /id="VAR_046028" FT VARIANT 276 FT /note="R -> Q (in RCAD)" FT /evidence="ECO:0000269|PubMed:15930087" FT /id="VAR_046029" FT VARIANT 285 FT /note="G -> D (in RCAD)" FT /evidence="ECO:0000269|PubMed:16249435" FT /id="VAR_046030" FT VARIANT 295 FT /note="R -> C (in RCAD)" FT /evidence="ECO:0000269|PubMed:16249435" FT /id="VAR_046031" FT VARIANT 295 FT /note="R -> H (in RCAD; dbSNP:rs886043813)" FT /evidence="ECO:0000269|PubMed:15068978, FT ECO:0000269|PubMed:16249435" FT /id="VAR_046032" FT VARIANT 295 FT /note="R -> P (in RCAD)" FT /evidence="ECO:0000269|PubMed:15930087" FT /id="VAR_046033" FT VARIANT 370 FT /note="G -> S (in RCAD; dbSNP:rs113042313)" FT /evidence="ECO:0000269|PubMed:16249435" FT /id="VAR_046034" FT VARIANT 465 FT /note="S -> R (in T2D; 22% reduction in activity; FT dbSNP:rs121918673)" FT /evidence="ECO:0000269|PubMed:12161522" FT /id="VAR_017665" FT VARIANT 492 FT /note="G -> S (found in patients with early-onset diabetes; FT uncertain significance; dbSNP:rs187556368)" FT /evidence="ECO:0000269|PubMed:10672455" FT /id="VAR_012058" FT MUTAGEN 1..32 FT /note="Missing: Loss of interaction with PCBD1. Loss of FT PCBD1 recruitment to the nucleus." FT /evidence="ECO:0000269|PubMed:24204001" FT MUTAGEN 253 FT /note="Q->P: No impact on interaction with PCBD1. Reduced FT PCBD1 recruitment to the nucleus. Reduced coactivation by FT PCBD1." FT /evidence="ECO:0000269|PubMed:24204001" FT HELIX 91..98 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 101..113 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 118..132 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 136..143 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 147..154 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 162..181 FT /evidence="ECO:0007829|PDB:2H8R" FT TURN 182..185 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 240..252 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 258..275 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 283..286 FT /evidence="ECO:0007829|PDB:2H8R" FT HELIX 293..304 FT /evidence="ECO:0007829|PDB:2H8R" FT STRAND 316..321 FT /evidence="ECO:0007829|PDB:2DA6" SQ SEQUENCE 557 AA; 61324 MW; 9E1ECC7423B73980 CRC64; MVSKLTSLQQ ELLSALLSSG VTKEVLVQAL EELLPSPNFG VKLETLPLSP GSGAEPDTKP VFHTLTNGHA KGRLSGDEGS EDGDDYDTPP ILKELQALNT EEAAEQRAEV DRMLSEDPWR AAKMIKGYMQ QHNIPQREVV DVTGLNQSHL SQHLNKGTPM KTQKRAALYT WYVRKQREIL RQFNQTVQSS GNMTDKSSQD QLLFLFPEFS QQSHGPGQSD DACSEPTNKK MRRNRFKWGP ASQQILYQAY DRQKNPSKEE REALVEECNR AECLQRGVSP SKAHGLGSNL VTEVRVYNWF ANRRKEEAFR QKLAMDAYSS NQTHSLNPLL SHGSPHHQPS SSPPNKLSGV RYSQQGNNEI TSSSTISHHG NSAMVTSQSV LQQVSPASLD PGHNLLSPDG KMISVSGGGL PPVSTLTNIH SLSHHNPQQS QNLIMTPLSG VMAIAQSLNT SQAQSVPVIN SVAGSLAALQ PVQFSQQLHS PHQQPLMQQS PGSHMAQQPF MAAVTQLQNS HMYAHKQEPP QYSHTSRFPS AMVVTDTSSI STLTNMSSSK QCPLQAW // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MLH3_HUMAN Reviewed; 1453 AA. AC Q9UHC1; P49751; Q56DK9; Q9P292; Q9UHC0; DT 27-APR-2001, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 3. DT 28-JAN-2026, entry version 202. DE RecName: Full=DNA mismatch repair protein Mlh3; DE AltName: Full=MutL protein homolog 3; GN Name=MLH3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND RP VARIANTS ASP-826 AND LEU-844. RX PubMed=10615123; DOI=10.1038/71643; RA Lipkin S.M., Wang V., Jacoby R., Banerjee-Basu S., Baxevanis A.D., RA Lynch H.T., Elliott R.M., Collins F.S.; RT "MLH3: a DNA mismatch repair gene associated with mammalian microsatellite RT instability."; RL Nat. Genet. 24:27-35(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH MLH1, AND VARIANT ASP-826. RX PubMed=11292842; DOI=10.1093/nar/29.8.1695; RA Kondo E., Horii A., Fukushige S.; RT "The interacting domains of three MutL heterodimers in man: hMLH1 interacts RT with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2."; RL Nucleic Acids Res. 29:1695-1702(2001). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-93; SER-120; GLN-231; RP ILE-420; VAL-492; GLN-600; PRO-606; GLN-624; CYS-647; CYS-720; ILE-723; RP PHE-741; HIS-797; ASP-826; LEU-844; GLY-845; ILE-942; PRO-966; ASN-1073; RP GLU-1105; ASP-1163 AND ARG-1319. RG NIEHS SNPs program; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12508121; DOI=10.1038/nature01348; RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C., RA Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A., RA Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H., RA Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T., RA Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B., RA Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D., RA Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R., RA Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S., RA Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C., RA Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S., RA Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., RA Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., RA Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M., RA Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V., RA Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J., RA Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F., RA Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F., RA Waterston R., Hood L., Weissenbach J.; RT "The DNA sequence and analysis of human chromosome 14."; RL Nature 421:601-607(2003). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1189-1453. RC TISSUE=Brain; RX PubMed=7596406; DOI=10.1038/375754a0; RA Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., RA Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.-F., RA Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., RA Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., RA da Silva H.A.R., Haines J.L., Pericak-Vance M.A., Tanzi R.E., Roses A.D., RA Fraser P.E., Rommens J.M., St George-Hyslop P.H.; RT "Cloning of a gene bearing missense mutations in early-onset familial RT Alzheimer's disease."; RL Nature 375:754-760(1995). RN [6] RP INVOLVEMENT IN SOMATIC COLORECTAL CANCER. RX PubMed=11317354; DOI=10.1002/humu.1114; RA Lipkin S.M., Wang V., Stoler D.L., Anderson G.R., Kirsch I., Hadley D., RA Lynch H.T., Collins F.S.; RT "Germline and somatic mutation analyses in the DNA mismatch repair gene RT MLH3: evidence for somatic mutation in colorectal cancers."; RL Hum. Mutat. 17:389-396(2001). RN [7] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [8] RP VARIANTS HNPCC7 GLU-24; SER-499; GLN-624; CYS-647; GLY-817; SER-981; RP SER-1007; THR-1394 AND LYS-1451. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). CC -!- FUNCTION: Probably involved in the repair of mismatches in DNA. CC -!- SUBUNIT: Heterodimer of MLH1 and MLH3. Interacts with MTMR15/FAN1. CC {ECO:0000269|PubMed:11292842, ECO:0000269|PubMed:20603073}. CC -!- INTERACTION: CC Q9UHC1; P40692: MLH1; NbExp=7; IntAct=EBI-3893094, EBI-744248; CC Q9UHC1-2; G5E9A7: DMWD; NbExp=3; IntAct=EBI-9089845, EBI-10976677; CC Q9UHC1-2; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-9089845, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q9UHC1-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UHC1-2; Sequence=VSP_003290; CC -!- TISSUE SPECIFICITY: Ubiquitous. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 7 (HNPCC7) CC [MIM:614385]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:11586295}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:11317354}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC42005.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAC42005.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF195657; AAF23904.1; -; mRNA. DR EMBL; AF195658; AAF23905.1; -; Genomic_DNA. DR EMBL; AB039667; BAA92353.1; -; mRNA. DR EMBL; AY963685; AAX59030.1; -; Genomic_DNA. DR EMBL; AL049780; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L40399; AAC42005.1; ALT_SEQ; mRNA. DR CCDS; CCDS32123.1; -. [Q9UHC1-1] DR CCDS; CCDS9837.1; -. [Q9UHC1-2] DR RefSeq; NP_001035197.1; NM_001040108.2. [Q9UHC1-1] DR RefSeq; NP_055196.2; NM_014381.3. [Q9UHC1-2] DR RefSeq; XP_006720179.1; XM_006720116.5. [Q9UHC1-1] DR RefSeq; XP_016876708.1; XM_017021219.3. [Q9UHC1-2] DR AlphaFoldDB; Q9UHC1; -. DR SMR; Q9UHC1; -. DR BioGRID; 117961; 62. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR FunCoup; Q9UHC1; 1826. DR IntAct; Q9UHC1; 48. DR MINT; Q9UHC1; -. DR STRING; 9606.ENSP00000348020; -. DR CarbonylDB; Q9UHC1; -. DR GlyGen; Q9UHC1; 2 sites, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHC1; -. DR PhosphoSitePlus; Q9UHC1; -. DR BioMuta; MLH3; -. DR DMDM; 317373417; -. DR jPOST; Q9UHC1; -. DR MassIVE; Q9UHC1; -. DR PaxDb; 9606-ENSP00000348020; -. DR PeptideAtlas; Q9UHC1; -. DR ProteomicsDB; 84305; -. [Q9UHC1-1] DR ProteomicsDB; 84306; -. [Q9UHC1-2] DR Antibodypedia; 25763; 155 antibodies from 27 providers. DR DNASU; 27030; -. DR Ensembl; ENST00000355774.7; ENSP00000348020.2; ENSG00000119684.17. [Q9UHC1-1] DR Ensembl; ENST00000380968.6; ENSP00000370355.3; ENSG00000119684.17. [Q9UHC1-2] DR GeneID; 27030; -. DR KEGG; hsa:27030; -. DR MANE-Select; ENST00000355774.7; ENSP00000348020.2; NM_001040108.2; NP_001035197.1. DR UCSC; uc001xrd.1; human. [Q9UHC1-1] DR AGR; HGNC:7128; -. DR ClinPGx; PA30845; -. DR CTD; 27030; -. DR DisGeNET; 27030; -. DR GeneCards; MLH3; -. DR HGNC; HGNC:7128; MLH3. DR HPA; ENSG00000119684; Low tissue specificity. DR MalaCards; MLH3; -. DR MIM; 114500; phenotype. DR MIM; 604395; gene. DR MIM; 614385; phenotype. DR OpenTargets; ENSG00000119684; -. DR VEuPathDB; HostDB:ENSG00000119684; -. DR eggNOG; KOG1977; Eukaryota. DR GeneTree; ENSGT00800000124176; -. DR HOGENOM; CLU_002376_0_0_1; -. DR InParanoid; Q9UHC1; -. DR OMA; HIGREGH; -. DR OrthoDB; 429932at2759; -. DR PAN-GO; Q9UHC1; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHC1; -. DR PathwayCommons; Q9UHC1; -. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; Q9UHC1; -. DR Agora; ENSG00000119684; -. DR BioGRID-ORCS; 27030; 15 hits in 1154 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH3; human. DR GeneWiki; MLH3; -. DR GenomeRNAi; 27030; -. DR Pharos; Q9UHC1; Tbio. DR PRO; PR:Q9UHC1; -. DR Proteomes; UP000005640; Chromosome 14. DR RNAct; Q9UHC1; protein. DR Bgee; ENSG00000119684; Expressed in monocyte and 191 other cell types or tissues. DR ExpressionAtlas; Q9UHC1; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0032300; C:mismatch repair complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:InterPro. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0030983; F:mismatched DNA binding; IEA:InterPro. DR GO; GO:0003696; F:satellite DNA binding; TAS:ProtInc. DR GO; GO:0007144; P:female meiosis I; IEA:Ensembl. DR GO; GO:0008104; P:intracellular protein localization; IEA:Ensembl. DR GO; GO:0007140; P:male meiotic nuclear division; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IBA:GO_Central. DR GO; GO:0007131; P:reciprocal meiotic recombination; NAS:UniProtKB. DR GO; GO:0007130; P:synaptonemal complex assembly; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03486; MutL_Trans_MLH3; 1. DR FunFam; 3.30.1370.100:FF:000003; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.230.10:FF:000028; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.565.10:FF:000031; DNA mismatch repair protein Mlh3; 1. DR FunFam; 3.30.1540.20:FF:000005; MutL homolog 3; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR Gene3D; 3.30.1540.20; MutL, C-terminal domain, dimerisation subdomain; 1. DR Gene3D; 3.30.1370.100; MutL, C-terminal domain, regulatory subdomain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR014790; MutL_C. DR InterPro; IPR042120; MutL_C_dimsub. DR InterPro; IPR042121; MutL_C_regsub. DR InterPro; IPR037198; MutL_C_sf. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF47; DNA MISMATCH REPAIR PROTEIN MLH3; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF08676; MutL_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SMART; SM00853; MutL_C; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF118116; DNA mismatch repair protein MutL; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW Alternative splicing; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleus; KW Proteomics identification; Reference proteome. FT CHAIN 1..1453 FT /note="DNA mismatch repair protein Mlh3" FT /id="PRO_0000178003" FT REGION 624..650 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 933..960 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 935..944 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 945..960 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VAR_SEQ 1215..1238 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_003290" FT VARIANT 24 FT /note="Q -> E (in HNPCC7; dbSNP:rs28937870)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012946" FT VARIANT 93 FT /note="R -> G (in dbSNP:rs28756978)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023338" FT VARIANT 120 FT /note="F -> S (in dbSNP:rs28756979)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023339" FT VARIANT 231 FT /note="K -> Q (in dbSNP:rs28756981)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023340" FT VARIANT 420 FT /note="V -> I (in dbSNP:rs28756982)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023341" FT VARIANT 492 FT /note="L -> V (in dbSNP:rs28756983)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023342" FT VARIANT 494 FT /note="H -> R (in dbSNP:rs760778201)" FT /id="VAR_010790" FT VARIANT 499 FT /note="N -> S (in HNPCC7; dbSNP:rs28937871)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012947" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs28756984)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023343" FT VARIANT 606 FT /note="T -> P (in dbSNP:rs28756985)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023344" FT VARIANT 624 FT /note="E -> Q (in HNPCC7; dbSNP:rs28756986)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012948" FT VARIANT 647 FT /note="R -> C (in HNPCC7; dbSNP:rs28756987)" FT /evidence="ECO:0000269|PubMed:11586295, ECO:0000269|Ref.3" FT /id="VAR_012949" FT VARIANT 720 FT /note="Y -> C (in dbSNP:rs28756988)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023345" FT VARIANT 723 FT /note="V -> I (in dbSNP:rs28756989)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023346" FT VARIANT 741 FT /note="V -> F (in dbSNP:rs28756990)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023347" FT VARIANT 797 FT /note="R -> H (in dbSNP:rs28756991)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023348" FT VARIANT 817 FT /note="S -> G (in HNPCC7; dbSNP:rs143278116)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012950" FT VARIANT 826 FT /note="N -> D (in dbSNP:rs175081)" FT /evidence="ECO:0000269|PubMed:10615123, FT ECO:0000269|PubMed:11292842, ECO:0000269|Ref.3" FT /id="VAR_036781" FT VARIANT 844 FT /note="P -> L (in dbSNP:rs175080)" FT /evidence="ECO:0000269|PubMed:10615123, ECO:0000269|Ref.3" FT /id="VAR_023349" FT VARIANT 845 FT /note="S -> G (in dbSNP:rs28756992)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023350" FT VARIANT 942 FT /note="T -> I (in dbSNP:rs17102999)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023351" FT VARIANT 966 FT /note="S -> P (in dbSNP:rs17782839)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023352" FT VARIANT 981 FT /note="G -> S (in HNPCC7; dbSNP:rs377337763)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012951" FT VARIANT 1007 FT /note="N -> S (in HNPCC7; dbSNP:rs776639203)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012952" FT VARIANT 1073 FT /note="D -> N (in dbSNP:rs28756993)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023353" FT VARIANT 1105 FT /note="D -> E (in dbSNP:rs28757008)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023354" FT VARIANT 1163 FT /note="G -> D (in dbSNP:rs28757011)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023355" FT VARIANT 1319 FT /note="G -> R (in dbSNP:rs2139384512)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_023356" FT VARIANT 1394 FT /note="A -> T (in HNPCC7; dbSNP:rs138006166)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012953" FT VARIANT 1451 FT /note="E -> K (in HNPCC7; dbSNP:rs28939071)" FT /evidence="ECO:0000269|PubMed:11586295" FT /id="VAR_012954" SQ SEQUENCE 1453 AA; 163711 MW; 3D063427457DB033 CRC64; MIKCLSVEVQ AKLRSGLAIS SLGQCVEELA LNSIDAEAKC VAVRVNMETF QVQVIDNGFG MGSDDVEKVG NRYFTSKCHS VQDLENPRFY GFRGEALANI ADMASAVEIS SKKNRTMKTF VKLFQSGKAL KACEADVTRA SAGTTVTVYN LFYQLPVRRK CMDPRLEFEK VRQRIEALSL MHPSISFSLR NDVSGSMVLQ LPKTKDVCSR FCQIYGLGKS QKLREISFKY KEFELSGYIS SEAHYNKNMQ FLFVNKRLVL RTKLHKLIDF LLRKESIICK PKNGPTSRQM NSSLRHRSTP ELYGIYVINV QCQFCEYDVC MEPAKTLIEF QNWDTLLFCI QEGVKMFLKQ EKLFVELSGE DIKEFSEDNG FSLFDATLQK RVTSDERSNF QEACNNILDS YEMFNLQSKA VKRKTTAENV NTQSSRDSEA TRKNTNDAFL YIYESGGPGH SKMTEPSLQN KDSSCSESKM LEQETIVASE AGENEKHKKS FLEHSSLENP CGTSLEMFLS PFQTPCHFEE SGQDLEIWKE STTVNGMAAN ILKNNRIQNQ PKRFKDATEV GCQPLPFATT LWGVHSAQTE KEKKKESSNC GRRNVFSYGR VKLCSTGFIT HVVQNEKTKS TETEHSFKNY VRPGPTRAQE TFGNRTRHSV ETPDIKDLAS TLSKESGQLP NKKNCRTNIS YGLENEPTAT YTMFSAFQEG SKKSQTDCIL SDTSPSFPWY RHVSNDSRKT DKLIGFSKPI VRKKLSLSSQ LGSLEKFKRQ YGKVENPLDT EVEESNGVTT NLSLQVEPDI LLKDKNRLEN SDVCKITTME HSDSDSSCQP ASHILNSEKF PFSKDEDCLE QQMPSLRESP MTLKELSLFN RKPLDLEKSS ESLASKLSRL KGSERETQTM GMMSRFNELP NSDSSRKDSK LCSVLTQDFC MLFNNKHEKT ENGVIPTSDS ATQDNSFNKN SKTHSNSNTT ENCVISETPL VLPYNNSKVT GKDSDVLIRA SEQQIGSLDS PSGMLMNPVE DATGDQNGIC FQSEESKARA CSETEESNTC CSDWQRHFDV ALGRMVYVNK MTGLSTFIAP TEDIQAACTK DLTTVAVDVV LENGSQYRCQ PFRSDLVLPF LPRARAERTV MRQDNRDTVD DTVSSESLQS LFSEWDNPVF ARYPEVAVDV SSGQAESLAV KIHNILYPYR FTKGMIHSMQ VLQQVDNKFI ACLMSTKTEE NGEAGGNLLV LVDQHAAHER IRLEQLIIDS YEKQQAQGSG RKKLLSSTLI PPLEITVTEE QRRLLWCYHK NLEDLGLEFV FPDTSDSLVL VGKVPLCFVE REANELRRGR STVTKSIVEE FIREQLELLQ TTGGIQGTLP LTVQKVLASQ ACHGAIKFND GLSLQESCRL IEALSSCQLP FQCAHGRPSM LPLADIDHLE QEKQIKPNLT KLRKMAQAWR LFGKAECDTR QSLQQSMPPC EPP // ID MSH2_HUMAN Reviewed; 934 AA. AC P43246; B4E2Z2; O75488; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=DNA mismatch repair protein Msh2; DE Short=hMSH2; DE AltName: Full=MutS protein homolog 2; GN Name=MSH2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8252616; DOI=10.1016/0092-8674(93)90546-3; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RT "The human mutator gene homolog MSH2 and its association with hereditary RT nonpolyposis colon cancer."; RL Cell 75:1027-1038(1993). RN [2] RP ERRATUM OF PUBMED:8252616. RX PubMed=8156592; RA Fishel R., Lescoe M., Rao M., Copeland N.G., Jenkins N.A., Garber J., RA Kane M.F., Kolodner R.D.; RL Cell 77:167-167(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS LYNCH1 LEU-622 AND RP TYR-639. RX PubMed=8261515; DOI=10.1016/0092-8674(93)90330-s; RA Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., RA Peltomaeki P., Sistonen P., Aaltonen L.A., Nystroem-Lahti M., Guan X.-Y., RA Zhang J., Meltzer P.S., Yu J.-W., Kao F.-T., Chen D.J., Cerosaletti K.M., RA Fournier R.E.K., Todd S., Lewis T., Leach R.J., Naylor S.L., RA Weissenbach J., Mecklin J.-P., Jaervinen H., Petersen G.M., Hamilton S.R., RA Green J., Jass J., Watson P., Lynch H.T., Trent J.M., de la Chapelle A., RA Kinzler K.W., Vogelstein B.; RT "Mutations of a mutS homolog in hereditary nonpolyposis colorectal RT cancer."; RL Cell 75:1215-1225(1993). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN MRTES. RX PubMed=7713503; DOI=10.1006/geno.1994.1661; RA Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R.S., Morrison P., RA Wirth L., Finan P.J., Burn J., Chapman P., Earabino C., Merchant E., RA Bishop D.T.; RT "Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds RT for msh2 mutations."; RL Genomics 24:516-526(1994). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT HIS-96. RX PubMed=7726159; RA Wijnen J., Vasen H., Khan P.M., Menko F.H., van der Klift H., RA van Leeuwen C., van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer A., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Fodde R.; RT "Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing RT gradient-gel electrophoresis."; RL Am. J. Hum. Genet. 56:1060-1066(1995). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-8; CYS-43; SER-127; RP ASP-322 AND PHE-390. RG NIEHS SNPs program; RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 375-425. RC TISSUE=Blood; RA Corvello C.M., Bevilacqua R.A.U., Rossi B.M., Simpson A.J.G.; RT "A novel germline mutation at exon 7 of the hMSH2 gene (417 del G) in a RT large HNPCC Brazilian kindred."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [12] RP DNA-BINDING. RX PubMed=7923193; RA Fishel R., Ewel A., Lescoe M.K.; RT "Purified human MSH2 protein binds to DNA containing mismatched RT nucleotides."; RL Cancer Res. 54:5539-5542(1994). RN [13] RP DNA-BINDING. RX PubMed=8769132; DOI=10.1006/bbrc.1996.1168; RA Whitehouse A., Taylor G.R., Deeble J., Phillips S.E., Meredith D.M., RA Markham A.F.; RT "A carboxy terminal domain of the hMSH-2 gene product is sufficient for RT binding specific mismatched oligonucleotides."; RL Biochem. Biophys. Res. Commun. 225:289-295(1996). RN [14] RP INTERACTION WITH MSH3 AND MSH6. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [15] RP INTERACTION WITH EXO1. RX PubMed=9788596; RA Schmutte C., Marinescu R.C., Sadoff M.M., Guerrette S., Overhauser J., RA Fishel R.; RT "Human exonuclease I interacts with the mismatch repair protein hMSH2."; RL Cancer Res. 58:4537-4542(1998). RN [16] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [17] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [18] RP FUNCTION, AND MUTAGENESIS OF LYS-675. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [19] RP MISMATCH-BINDING, AND CHARACTERIZATION OF VARIANT LYNCH1 PRO-524. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [20] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [21] RP IDENTIFICATION OF MSH2 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [22] RP INTERACTION WITH EXO1, AND TISSUE SPECIFICITY. RX PubMed=10856833; DOI=10.1016/s0921-8777(00)00012-4; RA Rasmussen L.J., Rasmussen M., Lee B.-I., Rasmussen A.K., Wilson D.M. III, RA Nielsen F.C., Bisgaard H.C.; RT "Identification of factors interacting with hMSH2 in the fetal liver RT utilizing the yeast two-hybrid system. In vivo interaction through the C- RT terminal domains of hEXO1 and hMSH2 and comparative expression analysis."; RL Mutat. Res. 460:41-52(2000). RN [23] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [24] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=11306449; RA Schweizer P., Moisio A.L., Kuismanen S.A., Truninger K., Vierumaeki R., RA Salovaara R., Arola J., Butzow R., Jiricny J., Peltomaeki P., RA Nystroem-Lahti M.; RT "Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas RT in hereditary nonpolyposis colorectal cancer."; RL Cancer Res. 61:2813-2815(2001). RN [25] RP INTERACTION WITH EXO1. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [26] RP INTERACTION WITH EXO1. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [27] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [28] RP INVOLVEMENT IN MMRCS2. RX PubMed=12549480; DOI=10.1086/345297; RA Bougeard G., Charbonnier F., Moerman A., Martin C., Ruchoux M.M., RA Drouot N., Frebourg T.; RT "Early onset brain tumor and lymphoma in MSH2-deficient children."; RL Am. J. Hum. Genet. 72:213-216(2003). RN [29] RP INTERACTION WITH ATR, AND IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=14657349; DOI=10.1073/pnas.2536810100; RA Wang Y., Qin J.; RT "MSH2 and ATR form a signaling module and regulate two branches of the RT damage response to DNA methylation."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15387-15392(2003). RN [30] RP INTERACTION WITH EXO1. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [31] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [32] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [33] RP INVOLVEMENT IN MMRCS2. RX PubMed=16372347; DOI=10.1002/ajmg.a.31070; RA Mueller A., Schackert H.K., Lange B., Rueschoff J., Fuezesi L., Willert J., RA Burfeind P., Shah P., Becker H., Epplen J.T., Stemmler S.; RT "A novel MSH2 germline mutation in homozygous state in two brothers with RT colorectal cancers diagnosed at the age of 11 and 12 years."; RL Am. J. Med. Genet. A 140:195-199(2006). RN [34] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [35] RP FUNCTION. RX PubMed=17611581; DOI=10.1038/sj.jid.5700941; RA Seifert M., Scherer S.J., Edelmann W., Bohm M., Meineke V., Lobrich M., RA Tilgen W., Reichrath J.; RT "The DNA-mismatch repair enzyme hMSH2 modulates UV-B-induced cell cycle RT arrest and apoptosis in melanoma cells."; RL J. Invest. Dermatol. 128:203-213(2008). RN [36] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-555, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-921, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [40] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-845; LYS-847; LYS-871 AND LYS-892, RP DEACETYLATION BY HDAC6, UBIQUITINATION AT LYS-845; LYS-847; LYS-871 AND RP LYS-892, AND MUTAGENESIS OF LYS-845; LYS-847; LYS-871 AND LYS-892. RX PubMed=24882211; DOI=10.1016/j.molcel.2014.04.028; RA Zhang M., Xiang S., Joo H.Y., Wang L., Williams K.A., Liu W., Hu C., RA Tong D., Haakenson J., Wang C., Zhang S., Pavlovicz R.E., Jones A., RA Schmidt K.H., Tang J., Dong H., Shan B., Fang B., Radhakrishnan R., RA Glazer P.M., Matthias P., Koomen J., Seto E., Bepler G., Nicosia S.V., RA Chen J., Li C., Gu L., Li G.M., Bai W., Wang H., Zhang X.; RT "HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of RT MutSalpha."; RL Mol. Cell 55:31-46(2014). RN [41] RP FUNCTION, IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND RP MCM8, AND SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [42] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-430, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [43] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; MET-44; VAL-45; SER-127; RP MET-145; ASP-161; ARG-162; ARG-164; PRO-173; ARG-187; PRO-187; VAL-272; RP TYR-333; LEU-519; ASN-603; PRO-636; ALA-674; VAL-688; PHE-697; RP 745-ILE-ILE-746 DEL; LYS-749; THR-834; GLY-886 AND GLU-923, RP CHARACTERIZATION OF VARIANTS ASP-322 AND ILE-722, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [44] RP REVIEW. RX PubMed=8036718; DOI=10.1016/0168-9525(94)90093-0; RA Jiricny J.; RT "Colon cancer and DNA repair: have mismatches met their match?"; RL Trends Genet. 10:164-168(1994). RN [45] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [46] RP REVIEW. RX PubMed=17080293; DOI=10.1007/s10735-006-9062-5; RA Seifert M., Reichrath J.; RT "The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell RT cycle control and apoptosis: implications for pathogenesis, progression and RT therapy of cancer."; RL J. Mol. Histol. 37:301-307(2006). RN [47] RP INTERACTION WITH SMARCAD1. RX PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031; RA Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T., RA Ohara O., Koga H.; RT "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of RT TSS."; RL J. Mol. Biol. 382:257-265(2008). RN [48] RP INTERACTION WITH SLX4. RX PubMed=19596235; DOI=10.1016/j.cell.2009.06.030; RA Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P., RA Elledge S.J., Harper J.W.; RT "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is RT required for DNA repair."; RL Cell 138:63-77(2009). RN [49] RP POSSIBLE INVOLVEMENT IN ENDMC. RX PubMed=21642682; DOI=10.1001/jama.2011.743; RG French Cancer Genetics Network; RA Bonadona V., Bonaiti B., Olschwang S., Grandjouan S., Huiart L., Longy M., RA Guimbaud R., Buecher B., Bignon Y.J., Caron O., Colas C., Nogues C., RA Lejeune-Dumoulin S., Olivier-Faivre L., Polycarpe-Osaer F., Nguyen T.D., RA Desseigne F., Saurin J.C., Berthet P., Leroux D., Duffour J., RA Manouvrier S., Frebourg T., Sobol H., Lasset C., Bonaiti-Pellie C.; RT "Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 RT genes in Lynch syndrome."; RL JAMA 305:2304-2310(2011). RN [50] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [51] RP VARIANT LYNCH1 ASN-596 DEL. RX PubMed=7874129; RA Mary J.-L., Bishop T., Kolodner R.D., Lipford J.R., Kane M.F., Weber W., RA Torhorst J., Mueller H., Spycher M., Scott R.J.; RT "Mutational analysis of the hMSH2 gene reveals a three base pair deletion RT in a family predisposed to colorectal cancer development."; RL Hum. Mol. Genet. 3:2067-2069(1994). RN [52] RP VARIANTS PHE-390 AND LYS-419. RX PubMed=8690195; DOI=10.1053/gast.1996.v111.pm8690195; RA Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., RA Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., RA Nomizu S., Konishi F., Utsunomiya J., Miyaki M.; RT "Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, RT familial polyposis, and sporadic colon cancer."; RL Gastroenterology 111:307-317(1996). RN [53] RP VARIANT ASP-322. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [54] RP VARIANT LYNCH1 ASN-596 DEL, AND VARIANT HIS-167. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [55] RP VARIANT LYNCH1 TYR-506. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [56] RP VARIANT LYNCH1 GLN-46. RX PubMed=8700523; RA Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., RA Morris R.G., White S., Bird C.C., Wyllie A.H.; RT "Microsatellite instability and the role of hMSH2 in sporadic colorectal RT cancer."; RL Oncogene 12:2641-2649(1996). RN [57] RP VARIANTS LYNCH1 THR-305; ASN-596 DEL AND THR-834. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [58] RP VARIANT LYNCH1 CYS-323. RX PubMed=9240418; DOI=10.1006/bbrc.1997.6942; RA Akiyama Y., Tsubouchi N., Yuasa Y.; RT "Frequent somatic mutations of hMSH3 with reference to microsatellite RT instability in hereditary nonpolyposis colorectal cancers."; RL Biochem. Biophys. Res. Commun. 236:248-252(1997). RN [59] RP VARIANTS LYNCH1 THR-110; ARG-639; LYS-647; HIS-656; THR-679; VAL-729 AND RP ILE-732. RX PubMed=9419403; RA Nakahara M., Yokozaki H., Yasui W., Dohi K., Tahara E.; RT "Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in RT Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Cancer Epidemiol. Biomarkers Prev. 6:1057-1064(1997). RN [60] RP VARIANT SER-596. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [61] RP VARIANT ASP-322. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [62] RP VARIANT LYNCH1 VAL-562. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [63] RP VARIANT LYNCH1 PHE-697, AND VARIANT ASP-322. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [64] RP VARIANT LYNCH1 265-VAL--GLN-314 DEL, AND VARIANTS GLY-641 AND VAL-770. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [65] RP VARIANT ARG-199. RX PubMed=9777949; DOI=10.1016/s0002-9440(10)65662-3; RA Leung S.Y., Chan T.L., Chung L.P., Chan A.S.Y., Fan Y.W., Hung K.N., RA Kwong W.K., Ho J.W.C., Yuen S.T.; RT "Microsatellite instability and mutation of DNA mismatch repair genes in RT gliomas."; RL Am. J. Pathol. 153:1181-1188(1998). RN [66] RP VARIANT CRC TYR-506, AND VARIANT LYNCH1 ILE-688. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [67] RP VARIANT ASP-322. RX PubMed=10023327; DOI=10.1016/s0959-8049(98)00217-2; RA Liu T., Stathopoulos P., Lindblom P., Rubio C., Wasteson Arver B., RA Iselius L., Holmberg E., Groenberg H., Lindblom A.; RT "MSH2 codon 322 Gly to Asp does not seem to confer an increased risk for RT colorectal cancer susceptibility."; RL Eur. J. Cancer 34:1981-1981(1998). RN [68] RP VARIANT LYNCH1 PHE-390. RX PubMed=9621522; DOI=10.1007/s100380050057; RA Okamura S., Koyama K., Miyoshi Y., Monden M., Takami M.; RT "Novel germline mutations of hMSH2 in a patient with hereditary RT nonpolyposis colorectal cancer 'HNPCC' and in a patient with six primary RT cancers."; RL J. Hum. Genet. 43:143-145(1998). RN [69] RP VARIANTS LYNCH1 SER-336 AND ASN-596 DEL. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [70] RP CHARACTERIZATION OF VARIANTS ASP-322; PHE-390; LYS-419; TYR-506; PRO-524; RP LEU-622 AND PHE-697. RX PubMed=10469597; DOI=10.1016/s0960-9822(99)80396-0; RA Drotschmann K., Clark A.B., Kunkel T.A.; RT "Mutator phenotypes of common polymorphisms and missense mutations in RT MSH2."; RL Curr. Biol. 9:907-910(1999). RN [71] RP VARIANTS LYNCH1 GLN-246; SER-596 AND THR-834, AND VARIANT ASP-322. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [72] RP VARIANT LYNCH1 PHE-390. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH1 PRO-636. RX PubMed=10528862; DOI=10.1136/jmg.36.10.792; RA Yuan Z.Q., Wong N., Foulkes W.D., Alpert L., Manganaro F., RA Andreutti-Zaugg C., Iggo R., Anthony K., Hsieh E., Redston M., Pinsky L., RA Trifiro M., Gordon P.H., Lasko D.; RT "A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC RT kindred: implications for clinical screening."; RL J. Med. Genet. 36:790-793(1999). RN [74] RP VARIANTS LYNCH1 ILE-688 AND GLU-845, AND VARIANT MET-8. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANT ASP-322. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANTS LYNCH1 ARG-692 AND ARG-697. RX PubMed=10612836; RX DOI=10.1002/(sici)1098-1004(200001)15:1<116::aid-humu24>3.0.co;2-q; RA Isidro G., Veiga I., Matos P., Almeida S., Bizarro S., Marshall B., RA Baptista M., Leite J., Regateiro F., Soares J., Castedo S., Boavida M.G.; RT "Four novel MSH2 / MLH1 gene mutations in Portuguese HNPCC families."; RL Hum. Mutat. 15:116-116(2000). RN [77] RP VARIANT LYNCH1 ASN-603, AND VARIANT ASP-322. RX PubMed=10829038; DOI=10.1200/jco.2000.18.11.2193; RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RT "Population-based molecular detection of hereditary nonpolyposis colorectal RT cancer."; RL J. Clin. Oncol. 18:2193-2200(2000). RN [78] RP ERRATUM OF PUBMED:10829038. RA Salovaara R., Loukola A., Kristo P., Kaeaeriaeinen H., Ahtola H., RA Eskelinen M., Haerkoenen N., Julkunen R., Kangas E., Ojala S., RA Tulikoura J., Valkamo E., Jaervinen H., Mecklin J.-P., Aaltonen L.A., RA de la Chapelle A.; RL J. Clin. Oncol. 18:3456-3456(2000). RN [79] RP VARIANTS GASTRIC CANCER PHE-17; GLU-824; ALA-868; GLY-870 AND GLY-873, AND RP VARIANTS LYNCH1 CYS-98; TYR-323; ILE-335; ARG-629 AND VAL-714. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [80] RP VARIANTS LYNCH1 ASP-161; VAL-216 AND ARG-554. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [81] RP CHARACTERIZATION OF VARIANTS ASP-322; LEU-622 AND TYR-639. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [82] RP VARIANT LYNCH1 VAL-813. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [83] RP VARIANTS LYNCH1 VAL-600 AND PHE-723. RX PubMed=11920458; DOI=10.1002/cncr.10332.abs; RA Furukawa T., Konishi F., Shitoh K., Kojima M., Nagai H., Tsukamoto T.; RT "Evaluation of screening strategy for detecting hereditary nonpolyposis RT colorectal carcinoma."; RL Cancer 94:911-920(2002). RN [84] RP VARIANTS LYNCH1 HIS-167; MET-393; PRO-524; ASN-596 DEL; LEU-622; SER-674 RP AND ARG-905, AND CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; MET-393; RP PRO-524; ASN-596 DEL; LEU-622; SER-674 AND ARG-905. RX PubMed=12124176; DOI=10.1016/s1535-6108(02)00073-9; RA Heinen C.D., Wilson T., Mazurek A., Berardini M., Butz C., Fishel R.; RT "HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch RT functions."; RL Cancer Cell 1:469-478(2002). RN [85] RP INVOLVEMENT IN MULTIPLE CAFE-AU-LAIT SPOTS WITH LEUKEMIA. RX PubMed=11809679; RA Whiteside D., McLeod R., Graham G., Steckley J.L., Booth K., RA Somerville M.J., Andrew S.E.; RT "A homozygous germ-line mutation in the human MSH2 gene predisposes to RT hematological malignancy and multiple cafe-au-lait spots."; RL Cancer Res. 62:359-362(2002). RN [86] RP VARIANT ASP-322. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [87] RP VARIANTS LYNCH1 MET-44; VAL-45; ASN-596 DEL; GLY-886 AND GLU-923. RX PubMed=12112654; DOI=10.1002/humu.10083; RA Bisgaard M.L., Jaeger A.C., Myrhoej T., Bernstein I., Nielsen F.C.; RT "Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype RT correlation between patients with and without identified mutation."; RL Hum. Mutat. 20:20-27(2002). RN [88] RP VARIANTS LYNCH1 ILE-102; ASP-163 AND ALA-564, AND VARIANT ASP-322. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [89] RP VARIANTS LYNCH1 HIS-167 AND SER-359. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [90] RP VARIANTS LYNCH1 LEU-92 DEL AND ALA-853, AND VARIANT ASP-322. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [91] RP VARIANTS LYNCH1 PRO-552; SER-583 AND PRO-636. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [92] RP VARIANTS CRC ILE-13 AND ILE-342, AND VARIANT ASP-322. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [93] RP VARIANT LYNCH1 SER-127. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [94] RP VARIANT LYNCH1 PRO-175. RX PubMed=12655568; DOI=10.1002/humu.9127; RA Bartosova Z., Fridrichova I., Bujalkova M., Wolf B., Ilencikova D., RA Krizan P., Hlavcak P., Palaj J., Lukac L., Lukacova M., Boeoer A., RA Haider R., Jiricny J., Nystroem-Lahti M., Marra G.; RT "Novel MLH1 and MSH2 germline mutations in the first HNPCC families RT identified in Slovakia."; RL Hum. Mutat. 21:449-449(2003). RN [95] RP VARIANTS LYNCH1 GLY-163 AND GLY-660. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [96] RP VARIANTS CRC SER-40; VAL-169; ARG-203; PHE-390; LYS-419; CYS-619 AND RP ARG-629, AND VARIANT MET-8. RX PubMed=12792735; RA Yamada K., Zhong X., Kanazawa S., Koike J., Tsujita K., Hemmi H.; RT "Oncogenic pathway of sporadic colorectal cancer with novel germline RT missense mutations in the hMSH2 gene."; RL Oncol. Rep. 10:859-866(2003). RN [97] RP VARIANT LYNCH1 THR-931. RX PubMed=15046096; RA Sun M.H., Cai Q., Fu G., Ren S., Mo S., Xu Y., Ding C., Zhang T., Zhu X., RA Xu X., Min D., Cai S., Luo D., Shi Y., Shi D.; RT "Gene symbol: hMSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 114:409-409(2004). RN [98] RP VARIANT LYNCH1 TYR-671. RX PubMed=15300854; DOI=10.1002/humu.9267; RA Sharp A., Pichert G., Lucassen A., Eccles D.; RT "RNA analysis reveals splicing mutations and loss of expression defects in RT MLH1 and BRCA1."; RL Hum. Mutat. 24:272-272(2004). RN [99] RP VARIANTS LYNCH1 LEU-440 DEL; TYR-506; ARG-629 AND ILE-688. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [100] RP VARIANT LYNCH1 ARG-839, AND VARIANT ARG-629. RX PubMed=15613555; DOI=10.1093/jjco/hyh121; RA Yuan Y., Huang Y.-Q., Cai S.-R., Song Y.-M., Zheng S., Zhang S.-Z.; RT "Genetic characterization of Chinese hereditary non-polyposis colorectal RT cancer by DHPLC and multiplex PCR."; RL Jpn. J. Clin. Oncol. 34:660-666(2004). RN [101] RP VARIANTS LYNCH1 LEU-349 AND ASN-596 DEL. RX PubMed=15342696; DOI=10.1136/jmg.2004.020651; RA Domingo E., Laiho P., Ollikainen M., Pinto M., Wang L., French A.J., RA Westra J., Frebourg T., Espin E., Armengol M., Hamelin R., Yamamoto H., RA Hofstra R.M.W., Seruca R., Lindblom A., Peltomaeki P., Thibodeau S.N., RA Aaltonen L.A., Schwartz S. Jr.; RT "BRAF screening as a low-cost effective strategy for simplifying HNPCC RT genetic testing."; RL J. Med. Genet. 41:664-668(2004). RN [102] RP VARIANT LYNCH1 PHE-93. RX PubMed=15896463; DOI=10.1016/j.canlet.2004.09.051; RA Baudi F., Fersini G., Lavecchia A., Terracciano R., Leone F., Quaresima B., RA Faniello M.C., De Paola L., Doldo P., Cuda G., Costanzo F., Venuta S.; RT "A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC RT family from Southern Italy."; RL Cancer Lett. 223:285-291(2005). RN [103] RP VARIANTS LYNCH1 VAL-169; PHE-390; ALA-564 AND ARG-629, AND VARIANT CRC RP LYS-419. RX PubMed=15996210; DOI=10.1111/j.1399-0004.2005.00469.x; RA Lee S.-C., Guo J.-Y., Lim R., Soo R., Koay E., Salto-Tellez M., Leong A., RA Goh B.-C.; RT "Clinical and molecular characteristics of hereditary non-polyposis RT colorectal cancer families in Southeast Asia."; RL Clin. Genet. 68:137-145(2005). RN [104] RP VARIANT LYNCH1 TYR-283. RX PubMed=15870828; DOI=10.1038/sj.ejhg.5201421; RA Wehner M., Mangold E., Sengteller M., Friedrichs N., Aretz S., Friedl W., RA Propping P., Pagenstecher C.; RT "Hereditary nonpolyposis colorectal cancer: pitfalls in deletion screening RT in MSH2 and MLH1 genes."; RL Eur. J. Hum. Genet. 13:983-986(2005). RN [105] RP VARIANT LYNCH1 ARG-162. RX PubMed=15991316; RA Kohonen-Corish M.R.J., Otway R., Tetlow N., Hornby J., Doe W.F.; RT "Gene symbol: MSH2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 116:539-539(2005). RN [106] RP VARIANTS LYNCH1 THR-2; LEU-92 DEL; MET-145; PHE-390 AND ALA-853, AND RP VARIANT ASP-322. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [107] RP VARIANTS LYNCH1 PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; RP TYR-333; ASN-603; PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, RP VARIANTS VAL-272; THR-834 AND GLU-923, CHARACTERIZATION OF VARIANTS LYNCH1 RP PRO-33; ASP-161; ARG-162; ARG-164; PRO-173; PRO-187; TYR-333; ASN-603; RP PRO-636; PHE-697; 745-ILE-ILE-746 DEL AND LYS-749, AND CHARACTERIZATION OF RP VARIANTS VAL-272; THR-834 AND GLU-923. RX PubMed=17101317; DOI=10.1053/j.gastro.2006.08.044; RA Ollila S., Sarantaus L., Kariola R., Chan P., Hampel H., Holinski-Feder E., RA Macrae F., Kohonen-Corish M., Gerdes A.-M., Peltomaeki P., Mangold E., RA de la Chapelle A., Greenblatt M., Nystroem M.; RT "Pathogenicity of MSH2 missense mutations is typically associated with RT impaired repair capability of the mutated protein."; RL Gastroenterology 131:1408-1417(2006). RN [108] RP VARIANT LYNCH1 ALA-162. RX PubMed=17128465; RA Leonardis D.; RT "Gene symbol: msh2. Disease: hereditary nonpolyposis colorectal cancer."; RL Hum. Genet. 119:675-675(2006). RN [109] RP VARIANT LYNCH1 ARG-674. RX PubMed=18625694; DOI=10.1136/gut.2008.156695; RA Ramsoekh D., Wagner A., van Leerdam M.E., Dinjens W.N., Steyerberg E.W., RA Halley D.J., Kuipers E.J., Dooijes D.; RT "A high incidence of MSH6 mutations in Amsterdam criteria II-negative RT families tested in a diagnostic setting."; RL Gut 57:1539-1544(2008). RN [110] RP VARIANTS GLN-46; LYS-106; ASP-322; SER-596; LEU-670; ILE-779; SER-807; RP HIS-835 AND ARG-911. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [111] RP CHARACTERIZATION OF VARIANTS LYNCH1 PRO-33; SER-127; ASP-161; ARG-162; RP ARG-164; PRO-173; PRO-187; VAL-272; TYR-333; ASN-603; PRO-636; ALA-674; RP PHE-697; 745-ILE-ILE-746 DEL; LYS-749; THR-834 AND GLU-923, AND RP CHARACTERIZATION OF VARIANT ASP-322. RX PubMed=18951462; DOI=10.1002/humu.20893; RA Ollila S., Dermadi Bebek D., Jiricny J., Nystroem M.; RT "Mechanisms of pathogenicity in human MSH2 missense mutants."; RL Hum. Mutat. 29:1355-1363(2008). RN [112] RP VARIANTS LYNCH1 LEU-92 DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; RP GLU-645; LEU-696; TYR-748 AND GLN-839, VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723, CHARACTERIZATION OF VARIANTS LYNCH1 LEU-92 RP DEL; ARG-199; ASP-331; GLU-470; ASN-610; GLY-638; GLU-645; LEU-696; TYR-748 RP AND GLN-839, AND CHARACTERIZATION OF VARIANTS VAL-272; ASN-596 DEL; RP TYR-671; ARG-697 AND PHE-723. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [113] RP CHARACTERIZATION OF VARIANTS LYNCH1 ARG-162; HIS-167 AND SER-359. RX PubMed=18781619; DOI=10.1002/humu.20875; RA Belvederesi L., Bianchi F., Galizia E., Loretelli C., Bracci R., RA Catalani R., Amati M., Cellerino R.; RT "MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a RT human expression system."; RL Hum. Mutat. 29:E296-E309(2008). RN [114] RP CHARACTERIZATION OF VARIANTS LYNCH1 HIS-167; THR-305: LEU-622; ARG-639; RP ARG-674; PHE-697 AND THR-834. RX PubMed=18822302; DOI=10.1016/j.mrfmmm.2008.08.015; RA Lutzen A., de Wind N., Georgijevic D., Nielsen F.C., Rasmussen L.J.; RT "Functional analysis of HNPCC-related missense mutations in MSH2."; RL Mutat. Res. 645:44-55(2008). RN [115] RP CHARACTERIZATION OF VARIANTS LYNCH1 MET-44; VAL-45; HIS-167; THR-305; RP PHE-390; ASN-596 DEL; ARG-639; ARG-674; PHE-697; PHE-723 AND GLY-886, AND RP CHARACTERIZATION OF VARIANTS ASP-165; HIS-177; VAL-272; LEU-385; LEU-519; RP ALA-675; GLU-759; VAL-805; GLY-843 AND LEU-860. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [116] RP CHARACTERIZATION OF VARIANTS SER-127; MET-145; GLN-205; ASP-322; PRO-328; RP ILE-367; GLU-487 AND ILE-909. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). RN [117] RP VARIANT LYNCH1 ARG-669. RX PubMed=22371642; DOI=10.3748/wjg.v18.i8.814; RA Zahary M.N., Kaur G., Abu Hassan M.R., Singh H., Naik V.R., Ankathil R.; RT "Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome RT patients."; RL World J. Gastroenterol. 18:814-820(2012). RN [118] RP VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839, AND CHARACTERIZATION RP OF VARIANTS GLN-5; GLY-55; PRO-534; ILE-813 AND ARG-839. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 CC heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA CC mismatches thereby initiating DNA repair. When bound, heterodimers bend CC the DNA helix and shields approximately 20 base pairs. MutS alpha CC recognizes single base mismatches and dinucleotide insertion-deletion CC loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion CC loops up to 13 nucleotides long. After mismatch binding, MutS alpha or CC beta forms a ternary complex with the MutL alpha heterodimer, which is CC thought to be responsible for directing the downstream MMR events, CC including strand discrimination, excision, and resynthesis. Recruits CC DNA helicase MCM9 to chromatin which unwinds the mismatch containing CC DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. In melanocytes may CC modulate both UV-B-induced cell cycle regulation and apoptosis. CC {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:17611581, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:26300262, CC ECO:0000269|PubMed:9564049, ECO:0000269|PubMed:9822679, CC ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) or MSH2-MSH3 (MutS beta) CC (PubMed:8942985). Both heterodimers form a ternary complex with MutL CC alpha (MLH1-PMS1) (PubMed:10856833, PubMed:11427529, PubMed:11429708, CC PubMed:12414623, PubMed:14676842, PubMed:9788596). Interacts with MCM9; CC the interaction recruits MCM9 to chromatin (PubMed:26300262). Interacts CC with MCM8 (PubMed:26300262). Interacts with EXO1 (PubMed:10856833, CC PubMed:11427529, PubMed:11429708, PubMed:12414623, PubMed:14676842, CC PubMed:9788596). Part of the BRCA1-associated genome surveillance CC complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 CC and the RAD50-MRE11-NBS1 protein complex (PubMed:10783165). This CC association could be a dynamic process changing throughout the cell CC cycle and within subnuclear domains (PubMed:10783165). Interacts with CC ATR (PubMed:14657349). Interacts with SLX4/BTBD12; this interaction is CC direct and links MutS beta to SLX4, a subunit of different structure- CC specific endonucleases (PubMed:19596235). Interacts with SMARCAD1 CC (PubMed:18675275). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:10856833, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, CC ECO:0000269|PubMed:14657349, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:18675275, ECO:0000269|PubMed:19596235, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:8942985, CC ECO:0000269|PubMed:9788596}. CC -!- INTERACTION: CC P43246; Q92624: APPBP2; NbExp=3; IntAct=EBI-355888, EBI-743771; CC P43246; Q9UQ84-1: EXO1; NbExp=3; IntAct=EBI-355888, EBI-944694; CC P43246; P09429: HMGB1; NbExp=2; IntAct=EBI-355888, EBI-389432; CC P43246; P20585: MSH3; NbExp=14; IntAct=EBI-355888, EBI-1164205; CC P43246; P52701: MSH6; NbExp=11; IntAct=EBI-355888, EBI-395529; CC P43246; Q8IY92: SLX4; NbExp=5; IntAct=EBI-355888, EBI-2370740; CC P43246; P39875: EXO1; Xeno; NbExp=2; IntAct=EBI-355888, EBI-6738; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24882211, CC ECO:0000269|PubMed:26300262}. Chromosome {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P43246-1; Sequence=Displayed; CC Name=2; CC IsoId=P43246-2; Sequence=VSP_045536; CC -!- TISSUE SPECIFICITY: Ubiquitously expressed. CC {ECO:0000269|PubMed:10856833}. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- PTM: Sequentially deacetylated and polyubiquitinated by HDAC6, leading CC to MSH2 degradation. {ECO:0000269|PubMed:24882211}. CC -!- DISEASE: Lynch syndrome 1 (LYNCH1) [MIM:120435]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10375096, ECO:0000269|PubMed:10386556, CC ECO:0000269|PubMed:10528862, ECO:0000269|PubMed:10573010, CC ECO:0000269|PubMed:10612836, ECO:0000269|PubMed:10777691, CC ECO:0000269|PubMed:10829038, ECO:0000269|PubMed:11726306, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:11920458, CC ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:12655568, CC ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14635101, CC ECO:0000269|PubMed:15046096, ECO:0000269|PubMed:15300854, CC ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15870828, CC ECO:0000269|PubMed:15896463, ECO:0000269|PubMed:15991316, CC ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:17128465, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18625694, CC ECO:0000269|PubMed:18781619, ECO:0000269|PubMed:18822302, CC ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22371642, CC ECO:0000269|PubMed:7874129, ECO:0000269|PubMed:8261515, CC ECO:0000269|PubMed:8700523, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9048925, CC ECO:0000269|PubMed:9240418, ECO:0000269|PubMed:9298827, CC ECO:0000269|PubMed:9311737, ECO:0000269|PubMed:9419403, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9621522, CC ECO:0000269|PubMed:9718327, ECO:0000269|PubMed:9889267}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:7713503}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000305|PubMed:11306449, CC ECO:0000305|PubMed:21642682}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 2 (MMRCS2) [MIM:619096]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:12549480, CC ECO:0000269|PubMed:16372347}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12792735, CC ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:15996210, CC ECO:0000269|PubMed:9559627}. Note=Disease susceptibility may be CC associated with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC27930.1; Type=Frameshift; Note=The frameshift is caused by a single nucleotide deletion which is found in a HNPCC kindred.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/340/MSH2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U03911; AAA18643.1; -; mRNA. DR EMBL; U04045; AAA61870.1; -; mRNA. DR EMBL; U41221; AAA82080.1; ALT_SEQ; Genomic_DNA. DR EMBL; U41206; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41207; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41208; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41210; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41211; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41212; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41213; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41214; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41215; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41216; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41217; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41218; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41219; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; U41220; AAA82080.1; JOINED; Genomic_DNA. DR EMBL; L47583; AAB59564.1; -; mRNA. DR EMBL; L47582; AAB59565.1; -; mRNA. DR EMBL; L47581; AAA76858.1; -; mRNA. DR EMBL; AY601851; AAS99351.1; -; Genomic_DNA. DR EMBL; AK304496; BAG65304.1; -; mRNA. DR EMBL; BX649122; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AC079775; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC021566; AAH21566.1; -; mRNA. DR EMBL; AF066081; AAC27930.1; ALT_FRAME; Genomic_DNA. DR CCDS; CCDS1834.1; -. [P43246-1] DR CCDS; CCDS58709.1; -. [P43246-2] DR PIR; I64819; I64819. DR RefSeq; NP_000242.1; NM_000251.3. [P43246-1] DR RefSeq; NP_001245210.1; NM_001258281.1. [P43246-2] DR RefSeq; NP_001393570.1; NM_001406641.1. [P43246-1] DR PDB; 2O8B; X-ray; 2.75 A; A=1-934. DR PDB; 2O8C; X-ray; 3.37 A; A=1-934. DR PDB; 2O8D; X-ray; 3.00 A; A=1-934. DR PDB; 2O8E; X-ray; 3.30 A; A=1-934. DR PDB; 2O8F; X-ray; 3.25 A; A=1-934. DR PDB; 3THW; X-ray; 3.09 A; A=1-934. DR PDB; 3THX; X-ray; 2.70 A; A=1-934. DR PDB; 3THY; X-ray; 2.89 A; A=1-934. DR PDB; 3THZ; X-ray; 4.30 A; A=1-934. DR PDB; 8AG6; EM; 2.80 A; A=1-934. DR PDB; 8OLX; EM; 3.10 A; A=1-934. DR PDB; 8OM5; EM; 3.52 A; A=1-934. DR PDB; 8OM9; EM; 3.32 A; A=1-934. DR PDB; 8OMA; EM; 3.29 A; A=1-934. DR PDB; 8OMO; EM; 3.43 A; A=1-934. DR PDB; 8OMQ; EM; 3.11 A; A=1-934. DR PDB; 8R7C; X-ray; 2.82 A; A/E=1-930. DR PDB; 8R7E; X-ray; 2.78 A; A/E=1-930. DR PDB; 8R7V; EM; 3.12 A; A=1-934. DR PDB; 8RAU; X-ray; 2.33 A; A=1-934. DR PDB; 8RAV; X-ray; 2.63 A; A=1-934. DR PDB; 8RAW; X-ray; 2.69 A; A=1-934. DR PDB; 8RAX; X-ray; 3.16 A; A=1-934. DR PDB; 8RAZ; X-ray; 2.84 A; A=1-934. DR PDB; 8RB0; X-ray; 2.67 A; A=1-934. DR PDB; 8RB1; X-ray; 2.08 A; A=1-934. DR PDB; 8RB2; X-ray; 2.53 A; A/E=1-934. DR PDB; 8RZ7; EM; 3.37 A; A=1-934. DR PDB; 8RZ8; EM; 3.06 A; A=1-934. DR PDB; 8RZ9; EM; 3.02 A; A=1-934. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 3THW; -. DR PDBsum; 3THX; -. DR PDBsum; 3THY; -. DR PDBsum; 3THZ; -. DR PDBsum; 8AG6; -. DR PDBsum; 8OLX; -. DR PDBsum; 8OM5; -. DR PDBsum; 8OM9; -. DR PDBsum; 8OMA; -. DR PDBsum; 8OMO; -. DR PDBsum; 8OMQ; -. DR PDBsum; 8R7C; -. DR PDBsum; 8R7E; -. DR PDBsum; 8R7V; -. DR PDBsum; 8RAU; -. DR PDBsum; 8RAV; -. DR PDBsum; 8RAW; -. DR PDBsum; 8RAX; -. DR PDBsum; 8RAZ; -. DR PDBsum; 8RB0; -. DR PDBsum; 8RB1; -. DR PDBsum; 8RB2; -. DR PDBsum; 8RZ7; -. DR PDBsum; 8RZ8; -. DR PDBsum; 8RZ9; -. DR AlphaFoldDB; P43246; -. DR EMDB; EMD-15417; -. DR EMDB; EMD-15518; -. DR EMDB; EMD-15519; -. DR EMDB; EMD-16964; -. DR EMDB; EMD-16969; -. DR EMDB; EMD-16971; -. DR EMDB; EMD-16972; -. DR EMDB; EMD-16973; -. DR EMDB; EMD-16974; -. DR EMDB; EMD-18992; -. DR EMDB; EMD-19605; -. DR EMDB; EMD-19606; -. DR EMDB; EMD-19607; -. DR SMR; P43246; -. DR BioGRID; 110573; 329. DR ComplexPortal; CPX-77; DNA mismatch repair MutSbeta complex. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P43246; -. DR DIP; DIP-35054N; -. DR FunCoup; P43246; 3266. DR IntAct; P43246; 111. DR MINT; P43246; -. DR STRING; 9606.ENSP00000233146; -. DR ChEMBL; CHEMBL4296019; -. DR GlyGen; P43246; 3 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P43246; -. DR PhosphoSitePlus; P43246; -. DR SwissPalm; P43246; -. DR BioMuta; MSH2; -. DR DMDM; 1171032; -. DR jPOST; P43246; -. DR MassIVE; P43246; -. DR PaxDb; 9606-ENSP00000233146; -. DR PeptideAtlas; P43246; -. DR ProteomicsDB; 55601; -. [P43246-1] DR ProteomicsDB; 5866; -. DR Pumba; P43246; -. DR Antibodypedia; 4037; 803 antibodies from 50 providers. DR CPTC; P43246; 1 antibody. DR DNASU; 4436; -. DR Ensembl; ENST00000233146.7; ENSP00000233146.2; ENSG00000095002.17. [P43246-1] DR Ensembl; ENST00000543555.6; ENSP00000442697.1; ENSG00000095002.17. [P43246-2] DR GeneID; 4436; -. DR KEGG; hsa:4436; -. DR MANE-Select; ENST00000233146.7; ENSP00000233146.2; NM_000251.3; NP_000242.1. DR UCSC; uc002rvy.3; human. [P43246-1] DR AGR; HGNC:7325; -. DR CIViC; 4436; 8 evidence items across 9 molecular profiles. DR ClinPGx; PA31133; -. DR CTD; 4436; -. DR DisGeNET; 4436; -. DR GeneCards; MSH2; -. DR GeneReviews; MSH2; -. DR HGNC; HGNC:7325; MSH2. DR HPA; ENSG00000095002; Low tissue specificity. DR MalaCards; MSH2; -. DR MIM; 114500; phenotype. DR MIM; 120435; phenotype. DR MIM; 158320; phenotype. DR MIM; 608089; phenotype. DR MIM; 609309; gene. DR MIM; 619096; phenotype. DR OpenTargets; ENSG00000095002; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000095002; -. DR eggNOG; KOG0219; Eukaryota. DR GeneTree; ENSGT00550000074867; -. DR HOGENOM; CLU_002472_10_0_1; -. DR InParanoid; P43246; -. DR OMA; LVRFPQK; -. DR OrthoDB; 295033at2759; -. DR PAN-GO; P43246; 5 GO annotations based on evolutionary models. DR PhylomeDB; P43246; -. DR PathwayCommons; P43246; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5632927; Defective Mismatch Repair Associated With MSH3. DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; P43246; -. DR SIGNOR; P43246; -. DR Agora; ENSG00000095002; -. DR BioGRID-ORCS; 4436; 27 hits in 1168 CRISPR screens. DR ChiTaRS; MSH2; human. DR EvolutionaryTrace; P43246; -. DR GeneWiki; MSH2; -. DR GenomeRNAi; 4436; -. DR Pharos; P43246; Tbio. DR PRO; PR:P43246; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P43246; protein. DR Bgee; ENSG00000095002; Expressed in secondary oocyte and 194 other cell types or tissues. DR ExpressionAtlas; P43246; baseline and differential. DR GO; GO:0000781; C:chromosome, telomeric region; HDA:BHF-UCL. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0032302; C:MutSbeta complex; IDA:HGNC-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:Ensembl. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0019237; F:centromeric DNA binding; IEA:Ensembl. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0032137; F:guanine/thymine mispair binding; IMP:MGI. DR GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL. DR GO; GO:0030183; P:B cell differentiation; ISS:BHF-UCL. DR GO; GO:0019724; P:B cell mediated immunity; ISS:BHF-UCL. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006301; P:DNA damage tolerance; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0006302; P:double-strand break repair; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0043570; P:maintenance of DNA repeat elements; IMP:HGNC-UCL. DR GO; GO:0008584; P:male gonad development; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IEA:Ensembl. DR GO; GO:0006312; P:mitotic recombination; IBA:GO_Central. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL. DR GO; GO:0006119; P:oxidative phosphorylation; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0010224; P:response to UV-B; ISS:BHF-UCL. DR GO; GO:0010165; P:response to X-ray; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IEA:Ensembl. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0002204; P:somatic recombination of immunoglobulin genes involved in immune response; IBA:GO_Central. DR CDD; cd03285; ABC_MSH2_euk; 1. DR FunFam; 1.10.1420.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000009; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000003; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000523; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00048; -. DR InterPro; IPR011184; DNA_mismatch_repair_Msh2. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR032642; Msh2_ATP-bd. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF35; DNA MISMATCH REPAIR PROTEIN MSH2; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR PIRSF; PIRSF005813; MSH2; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Disease variant; DNA damage; DNA repair; DNA-binding; KW Hereditary nonpolyposis colorectal cancer; Isopeptide bond; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..934 FT /note="DNA mismatch repair protein Msh2" FT /id="PRO_0000115183" FT REGION 601..671 FT /note="Interaction with EXO1" FT BINDING 669..676 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 555 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 567 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:P43247" FT MOD_RES 845 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 847 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 871 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 892 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:24882211" FT MOD_RES 921 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 430 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 845 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 847 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 871 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT CROSSLNK 892 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:24882211" FT VAR_SEQ 1..66 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:17974005" FT /id="VSP_045536" FT VARIANT 2 FT /note="A -> T (in LYNCH1; likely benign; dbSNP:rs63750466)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_054511" FT VARIANT 5 FT /note="P -> Q (decreases protein levels; dbSNP:rs56170584)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079822" FT VARIANT 8 FT /note="T -> M (in dbSNP:rs17217716)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:12792735, ECO:0000269|Ref.9" FT /id="VAR_013171" FT VARIANT 13 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63749907)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043736" FT VARIANT 17 FT /note="V -> F (in gastric cancer; uncertain significance; FT cryptic acceptor splice site suppressed on ex vivo splicing FT assay; dbSNP:rs63750966)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043737" FT VARIANT 33 FT /note="T -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751107)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043738" FT VARIANT 40 FT /note="G -> S (in CRC; uncertain significance; FT dbSNP:rs63751260)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043739" FT VARIANT 43 FT /note="Y -> C (in dbSNP:rs17217723)" FT /evidence="ECO:0000269|Ref.9" FT /id="VAR_019233" FT VARIANT 44 FT /note="T -> M (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs587779085)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043740" FT VARIANT 45 FT /note="A -> V (in LYNCH1; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs63750285)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043741" FT VARIANT 46 FT /note="H -> Q (in LYNCH1; likely benign; dbSNP:rs33946261)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:8700523" FT /id="VAR_004470" FT VARIANT 55 FT /note="R -> G (decreases protein levels; FT dbSNP:rs587782354)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079823" FT VARIANT 92 FT /note="Missing (in LYNCH1; uncertain significance)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18561205" FT /id="VAR_043742" FT VARIANT 93 FT /note="L -> F (in LYNCH1; dbSNP:rs63751429)" FT /evidence="ECO:0000269|PubMed:15896463" FT /id="VAR_043743" FT VARIANT 96 FT /note="R -> H (in dbSNP:rs63750002)" FT /evidence="ECO:0000269|PubMed:7726159" FT /id="VAR_004471" FT VARIANT 98 FT /note="Y -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750887)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043744" FT VARIANT 102 FT /note="V -> I (in LYNCH1; likely benign; FT dbSNP:rs193922373)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043745" FT VARIANT 106 FT /note="R -> K (in dbSNP:rs41295286)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038026" FT VARIANT 110 FT /note="K -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043746" FT VARIANT 127 FT /note="N -> S (in LYNCH1; benign; presumed to enhance FT cancer risk considerably when associated with P-328; shows FT significantly decreased repair efficiency when associated FT with variant P-328; dbSNP:rs17217772)" FT /evidence="ECO:0000269|PubMed:12655564, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22581703, ECO:0000269|Ref.9" FT /id="VAR_019234" FT VARIANT 139 FT /note="N -> S (in LYNCH1; dbSNP:rs1553350676)" FT /id="VAR_004472" FT VARIANT 145 FT /note="I -> M (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750124)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_004473" FT VARIANT 161 FT /note="V -> D (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750126)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012936" FT VARIANT 162 FT /note="G -> A (in LYNCH1; dbSNP:rs63750773)" FT /evidence="ECO:0000269|PubMed:17128465" FT /id="VAR_054512" FT VARIANT 162 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; associated with an abnormal subcellular FT localization pattern; affects protein stability; loss of FT protein expression; dbSNP:rs63750624)" FT /evidence="ECO:0000269|PubMed:15991316, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043747" FT VARIANT 163 FT /note="V -> D (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:12200596" FT /id="VAR_043748" FT VARIANT 163 FT /note="V -> G (in LYNCH1; dbSNP:rs63750214)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022670" FT VARIANT 164 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750582)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043749" FT VARIANT 165 FT /note="Y -> D (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779163)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067284" FT VARIANT 167 FT /note="D -> H (in LYNCH1; benign; shows reduced mismatch FT binding; does not show a decreased expression level of the FT MutS alpha complex; not associated with an abnormal FT subcellular localization pattern; normal mismatch repair FT activity; dbSNP:rs63750255)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:18781619, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:8872463" FT /id="VAR_004474" FT VARIANT 169 FT /note="I -> V (in LYNCH1 and CRC; likely benign; FT dbSNP:rs63750716)" FT /evidence="ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043750" FT VARIANT 173 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750070)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043751" FT VARIANT 175 FT /note="L -> P (in LYNCH1; dbSNP:rs63751291)" FT /evidence="ECO:0000269|PubMed:12655568" FT /id="VAR_043752" FT VARIANT 177 FT /note="E -> H (in LYNCH1; uncertain significance; normal FT mismatch repair activity; requires 2 nucleotide FT substitutions)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067285" FT VARIANT 187 FT /note="L -> P (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043753" FT VARIANT 187 FT /note="L -> R (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63751444)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076352" FT VARIANT 198 FT /note="E -> G (in dbSNP:rs63750327)" FT /id="VAR_054513" FT VARIANT 199 FT /note="C -> R (in LYNCH1; also found in a patient with FT glioma; no effect on MSH2 splicing; dbSNP:rs63751110)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9777949" FT /id="VAR_012937" FT VARIANT 203 FT /note="G -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs587779973)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043754" FT VARIANT 205 FT /note="E -> Q (shows no defects; normal mismatch repair FT activity; dbSNP:rs63749984)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068705" FT VARIANT 216 FT /note="I -> V (in LYNCH1; uncertain significance; shows FT slightly reduced mismatch binding or release efficiency; FT dbSNP:rs63749936)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012938" FT VARIANT 246 FT /note="K -> Q (in LYNCH1; uncertain significance; FT dbSNP:rs63750881)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043755" FT VARIANT 265..314 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004475" FT VARIANT 272 FT /note="A -> V (in LYNCH1; benign; shows slightly reduced FT mismatch binding or release efficiency; results in partial FT MSH2 exon 5 skipping; normal mismatch repair activity; FT dbSNP:rs34136999)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043756" FT VARIANT 283 FT /note="D -> Y (in LYNCH1; dbSNP:rs63750381)" FT /evidence="ECO:0000269|PubMed:15870828" FT /id="VAR_043757" FT VARIANT 305 FT /note="A -> T (in LYNCH1; normal mismatch repair activity; FT dbSNP:rs63751454)" FT /evidence="ECO:0000269|PubMed:22102614, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004476" FT VARIANT 322 FT /note="G -> D (in dbSNP:rs4987188)" FT /evidence="ECO:0000269|PubMed:10023327, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:14504054, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703, FT ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:9087566, FT ECO:0000269|PubMed:9298827, ECO:0000269|Ref.9" FT /id="VAR_004477" FT VARIANT 323 FT /note="S -> C (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:9240418" FT /id="VAR_012939" FT VARIANT 323 FT /note="S -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63750732)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043758" FT VARIANT 328 FT /note="A -> P (shows significantly decreased repair FT efficiency when associated with variant S-127; presumed to FT enhance cancer risk considerably when associated with FT variant S-127; dbSNP:rs753237286)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068706" FT VARIANT 331 FT /note="N -> D (in LYNCH1; uncertain significance; no effect FT on MSH2 splicing; dbSNP:rs267607938)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054514" FT VARIANT 333 FT /note="C -> Y (in LYNCH1; decreased mismatch repair FT activity; affects protein stability; loss of protein FT expression; dbSNP:rs63750828)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043759" FT VARIANT 335 FT /note="T -> I (in LYNCH1; uncertain significance; FT dbSNP:rs63750602)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043760" FT VARIANT 336 FT /note="P -> S (in LYNCH1; dbSNP:rs63751062)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043761" FT VARIANT 342 FT /note="V -> I (in CRC; uncertain significance; FT dbSNP:rs63749879)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043762" FT VARIANT 349 FT /note="P -> L (in LYNCH1; dbSNP:rs587779067)" FT /evidence="ECO:0000269|PubMed:15342696" FT /id="VAR_043763" FT VARIANT 359 FT /note="R -> S (in LYNCH1; shows a decreased expression FT level of the MutS alpha complex; associated with an FT abnormal subcellular localization pattern; FT dbSNP:rs63751617)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:18781619" FT /id="VAR_043764" FT VARIANT 367 FT /note="V -> I (shows no defects; normal mismatch repair FT activity; dbSNP:rs80285180)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068707" FT VARIANT 385 FT /note="P -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs564736113)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067286" FT VARIANT 390 FT /note="L -> F (in LYNCH1 and CRC; benign; may decrease FT mismatch repair activity; dbSNP:rs17224367)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:10469597, ECO:0000269|PubMed:12792735, FT ECO:0000269|PubMed:15996210, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:8690195, FT ECO:0000269|PubMed:9621522, ECO:0000269|Ref.9" FT /id="VAR_004478" FT VARIANT 393 FT /note="K -> M (in LYNCH1; dbSNP:rs1558478490)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_043765" FT VARIANT 419 FT /note="Q -> K (in CRC; likely benign; decreased mismatch FT repair activity; dbSNP:rs63750006)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15996210, FT ECO:0000269|PubMed:8690195" FT /id="VAR_012940" FT VARIANT 440 FT /note="Missing (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043766" FT VARIANT 470 FT /note="V -> E (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607959)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054515" FT VARIANT 487 FT /note="D -> E (decreased mismatch repair activity; FT dbSNP:rs35107951)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068708" FT VARIANT 492 FT /note="M -> V (in LYNCH1)" FT /id="VAR_043767" FT VARIANT 506 FT /note="D -> Y (in LYNCH1 and CRC; sporadic early-onset CRC; FT decreased mismatch repair activity; dbSNP:rs63750492)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_012941" FT VARIANT 519 FT /note="F -> L (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1371291280)" FT /evidence="ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614" FT /id="VAR_067287" FT VARIANT 524 FT /note="R -> P (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63751207)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:12124176, ECO:0000269|PubMed:9889267" FT /id="VAR_004479" FT VARIANT 534 FT /note="R -> P (no effect on protein levels; FT dbSNP:rs587778523)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079824" FT VARIANT 552 FT /note="T -> P (in LYNCH1; dbSNP:rs63750838)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043768" FT VARIANT 554 FT /note="S -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751656)" FT /evidence="ECO:0000269|PubMed:11726306" FT /id="VAR_012942" FT VARIANT 562 FT /note="E -> V (in LYNCH1; dbSNP:rs63750997)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004480" FT VARIANT 564 FT /note="T -> A (in LYNCH1; benign; dbSNP:rs55778204)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:15996210" FT /id="VAR_043769" FT VARIANT 583 FT /note="N -> S (in LYNCH1; dbSNP:rs201118107)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043770" FT VARIANT 596 FT /note="N -> S (in LYNCH1; uncertain significance; FT dbSNP:rs41295288)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8993976" FT /id="VAR_012943" FT VARIANT 596 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63749831)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12112654, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:15342696, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:7874129, FT ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:9311737" FT /id="VAR_004481" FT VARIANT 600 FT /note="A -> V (in LYNCH1; dbSNP:rs63751236)" FT /evidence="ECO:0000269|PubMed:11920458" FT /id="VAR_043771" FT VARIANT 603 FT /note="D -> N (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; affects protein stability; loss FT of protein expression; dbSNP:rs63750657)" FT /evidence="ECO:0000269|PubMed:10829038, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043772" FT VARIANT 610 FT /note="H -> N (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607980)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054516" FT VARIANT 619 FT /note="Y -> C (in CRC; uncertain significance; FT dbSNP:rs63749982)" FT /evidence="ECO:0000269|PubMed:12792735" FT /id="VAR_043773" FT VARIANT 622 FT /note="P -> L (in LYNCH1; decreased mismatch repair FT activity; confers multiple biochemical defects; FT dbSNP:rs28929483)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:11555625, ECO:0000269|PubMed:12124176, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:8261515" FT /id="VAR_004482" FT VARIANT 629 FT /note="Q -> R (in LYNCH1; benign; dbSNP:rs61756468)" FT /evidence="ECO:0000269|PubMed:12132870, FT ECO:0000269|PubMed:12792735, ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:15613555, ECO:0000269|PubMed:15996210" FT /id="VAR_043774" FT VARIANT 636 FT /note="A -> P (in LYNCH1; decreased mismatch binding FT activity; dbSNP:rs63750875)" FT /evidence="ECO:0000269|PubMed:10528862, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_012944" FT VARIANT 638 FT /note="R -> G (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607981)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054517" FT VARIANT 639 FT /note="H -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs587779116)" FT /evidence="ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9419403" FT /id="VAR_043775" FT VARIANT 639 FT /note="H -> Y (in LYNCH1; the equivalent substitution in FT yeast does not affect mismatch repair efficiency in vitro; FT dbSNP:rs28929484)" FT /evidence="ECO:0000269|PubMed:11555625, FT ECO:0000269|PubMed:8261515" FT /id="VAR_004483" FT VARIANT 641 FT /note="C -> G (in dbSNP:rs63749946)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004484" FT VARIANT 645 FT /note="Q -> E (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267607982)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054518" FT VARIANT 647 FT /note="E -> K (in LYNCH1)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043776" FT VARIANT 656 FT /note="Y -> H (in LYNCH1; somatic mutation; FT dbSNP:rs1573567393)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043777" FT VARIANT 660 FT /note="D -> G (in LYNCH1; dbSNP:rs1085308057)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022671" FT VARIANT 669 FT /note="G -> R (in LYNCH1; uncertain significance; FT dbSNP:rs63751668)" FT /evidence="ECO:0000269|PubMed:22371642" FT /id="VAR_067761" FT VARIANT 670 FT /note="P -> L (in dbSNP:rs41294982)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038027" FT VARIANT 671 FT /note="N -> Y (in LYNCH1; uncertain significance; FT dbSNP:rs63751232)" FT /evidence="ECO:0000269|PubMed:15300854, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043778" FT VARIANT 674 FT /note="G -> A (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs267607996)" FT /evidence="ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_076353" FT VARIANT 674 FT /note="G -> R (in LYNCH1; decreased mismatch repair FT activity; dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:18625694, FT ECO:0000269|PubMed:18822302, ECO:0000269|PubMed:22102614" FT /id="VAR_067288" FT VARIANT 674 FT /note="G -> S (in LYNCH1; somatic mutation; FT dbSNP:rs63750234)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004485" FT VARIANT 675 FT /note="K -> A (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; requires 2 nucleotide FT substitutions; dbSNP:rs587779128)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067289" FT VARIANT 679 FT /note="I -> T (in LYNCH1; somatic mutation)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043779" FT VARIANT 688 FT /note="M -> I (in LYNCH1; dbSNP:rs63750790)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:9559627" FT /id="VAR_012945" FT VARIANT 688 FT /note="M -> V (in LYNCH1; loss of protein expression; FT dbSNP:rs1573569964)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076354" FT VARIANT 692 FT /note="G -> R (in LYNCH1; dbSNP:rs63750232)" FT /evidence="ECO:0000269|PubMed:10612836" FT /id="VAR_009250" FT VARIANT 696 FT /note="P -> L (in LYNCH1; has no effect on ex vivo splicing FT assay; dbSNP:rs267607994)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054519" FT VARIANT 697 FT /note="C -> F (in LYNCH1; decreased mismatch repair FT activity; loss of protein expression; confers multiple FT biochemical defects; dbSNP:rs63750398)" FT /evidence="ECO:0000269|PubMed:10469597, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:9298827" FT /id="VAR_004486" FT VARIANT 697 FT /note="C -> R (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs63750961)" FT /evidence="ECO:0000269|PubMed:10612836, FT ECO:0000269|PubMed:18561205" FT /id="VAR_009251" FT VARIANT 714 FT /note="A -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63751224)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043780" FT VARIANT 722 FT /note="V -> I (in LYNCH1; dbSNP:rs587781996)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076355" FT VARIANT 723 FT /note="S -> F (in LYNCH1; decreased mismatch repair FT activity; has no effect on MSH2 splicing; FT dbSNP:rs63750794)" FT /evidence="ECO:0000269|PubMed:11920458, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:22102614" FT /id="VAR_043781" FT VARIANT 729 FT /note="M -> V (in LYNCH1; somatic mutation; FT dbSNP:rs1558520059)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043782" FT VARIANT 732 FT /note="T -> I (in LYNCH1; somatic mutation; FT dbSNP:rs730881765)" FT /evidence="ECO:0000269|PubMed:9419403" FT /id="VAR_043783" FT VARIANT 745..746 FT /note="Missing (in LYNCH1; decreased mismatch repair FT activity)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043784" FT VARIANT 748 FT /note="D -> Y (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608007)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054520" FT VARIANT 749 FT /note="E -> K (in LYNCH1; decreased mismatch repair FT activity; no loss of protein expression; dbSNP:rs63751477)" FT /evidence="ECO:0000269|PubMed:17101317, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944" FT /id="VAR_043785" FT VARIANT 759 FT /note="G -> E (in LYNCH1; uncertain significance; decreased FT mismatch repair activity; dbSNP:rs386833406)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067290" FT VARIANT 770 FT /note="I -> V (in dbSNP:rs63750684)" FT /evidence="ECO:0000269|PubMed:9718327" FT /id="VAR_004487" FT VARIANT 779 FT /note="M -> I (in dbSNP:rs41295292)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038028" FT VARIANT 805 FT /note="L -> V (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs779182536)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067291" FT VARIANT 807 FT /note="T -> S (in dbSNP:rs41295294)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038029" FT VARIANT 813 FT /note="M -> I (no effect on protein levels; FT dbSNP:rs587781678)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079825" FT VARIANT 813 FT /note="M -> V (in LYNCH1; uncertain significance; FT dbSNP:rs63749841)" FT /evidence="ECO:0000269|PubMed:12373605" FT /id="VAR_043786" FT VARIANT 824 FT /note="Q -> E (in gastric cancer; uncertain significance; FT dbSNP:rs63750623)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043787" FT VARIANT 834 FT /note="A -> T (in LYNCH1; likely benign; decreased mismatch FT repair activity; shows no functional defects in gel shift FT assay; dbSNP:rs63750757)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18822302, FT ECO:0000269|PubMed:18951462, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004488" FT VARIANT 835 FT /note="N -> H (in dbSNP:rs41295296)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038030" FT VARIANT 839 FT /note="H -> Q (in LYNCH1; has no effect on MSH2 splicing; FT dbSNP:rs267608016)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054521" FT VARIANT 839 FT /note="H -> R (in LYNCH1; decreases protein levels; FT dbSNP:rs63750027)" FT /evidence="ECO:0000269|PubMed:15613555, FT ECO:0000269|PubMed:28494185" FT /id="VAR_043788" FT VARIANT 843 FT /note="C -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs1667495338)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067292" FT VARIANT 845 FT /note="K -> E (in LYNCH1; dbSNP:rs63750571)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_013172" FT VARIANT 853 FT /note="E -> A (in LYNCH1; uncertain significance; FT dbSNP:rs63750797)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043789" FT VARIANT 860 FT /note="S -> L (in LYNCH1; likely benign; normal mismatch FT repair activity; dbSNP:rs63750849)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067293" FT VARIANT 868 FT /note="P -> A (in gastric cancer; uncertain significance; FT dbSNP:rs63751400)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043790" FT VARIANT 870 FT /note="A -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750709)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043791" FT VARIANT 873 FT /note="C -> G (in gastric cancer; uncertain significance; FT dbSNP:rs63750795)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043792" FT VARIANT 886 FT /note="E -> G (in LYNCH1; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750350)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614" FT /id="VAR_043793" FT VARIANT 905 FT /note="T -> R (in LYNCH1; likely benign; FT dbSNP:rs267608022)" FT /evidence="ECO:0000269|PubMed:12124176" FT /id="VAR_004489" FT VARIANT 909 FT /note="K -> I (found in a colorectal cancer sample; normal FT mismatch repair activity; dbSNP:rs34319539)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068709" FT VARIANT 911 FT /note="L -> R (in dbSNP:rs41295182)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038031" FT VARIANT 923 FT /note="V -> E (in LYNCH1; uncertain significance; FT dbSNP:rs146421227)" FT /evidence="ECO:0000269|PubMed:12112654, FT ECO:0000269|PubMed:17101317, ECO:0000269|PubMed:18951462, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043794" FT VARIANT 931 FT /note="K -> T (in LYNCH1; dbSNP:rs267608023)" FT /evidence="ECO:0000269|PubMed:15046096" FT /id="VAR_043795" FT MUTAGEN 675 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH6 mutant R- FT 1140." FT /evidence="ECO:0000269|PubMed:9564049" FT MUTAGEN 845 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-847, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 847 FT /note="K->R: Reduces interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-871 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 871 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-892." FT /evidence="ECO:0000269|PubMed:24882211" FT MUTAGEN 892 FT /note="K->R: Does not affect interaction with MSH6. Reduces FT acetylation; when associated with R-845, R-847 and R-871." FT /evidence="ECO:0000269|PubMed:24882211" FT CONFLICT 784 FT /note="F -> I (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT CONFLICT 836 FT /note="F -> S (in Ref. 7; BX649122)" FT /evidence="ECO:0000305" FT HELIX 14..24 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 33..38 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 40..46 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 48..56 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 59..61 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 65..71 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 75..81 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 82..94 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 117..124 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 129..131 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 137..139 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 160..167 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 168..171 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 172..179 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 185..194 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 197..204 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 208..220 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 223..227 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 229..232 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 234..236 FT /evidence="ECO:0007829|PDB:8OLX" FT HELIX 237..244 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:8OLX" FT TURN 252..254 FT /evidence="ECO:0007829|PDB:2O8E" FT HELIX 255..257 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 259..262 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 264..277 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 279..281 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 283..285 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 286..288 FT /evidence="ECO:0007829|PDB:8R7E" FT STRAND 289..293 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 296..298 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 304..309 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 321..323 FT /evidence="ECO:0007829|PDB:8OMA" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 336..347 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 353..367 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 370..377 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 378..380 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 387..395 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 401..411 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 414..423 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 432..435 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 437..455 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 472..474 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 476..502 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 507..509 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 512..515 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 517..519 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 521..525 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 527..530 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 531..535 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 536..538 FT /evidence="ECO:0007829|PDB:8OMO" FT STRAND 540..544 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 546..548 FT /evidence="ECO:0007829|PDB:8OMQ" FT STRAND 549..552 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 556..563 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 568..585 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 586..588 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 589..613 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 623..625 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 631..637 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 640..644 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:8R7C" FT STRAND 653..658 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 659..661 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 664..668 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 671..674 FT /evidence="ECO:0007829|PDB:8OMO" FT HELIX 675..691 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 695..703 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 706..711 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 718..721 FT /evidence="ECO:0007829|PDB:8OMQ" FT HELIX 724..738 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 744..749 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 750..753 FT /evidence="ECO:0007829|PDB:8R7E" FT HELIX 756..772 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 777..783 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 785..792 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 797..807 FT /evidence="ECO:0007829|PDB:3THX" FT STRAND 810..820 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 827..833 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 838..850 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 851..855 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 875..892 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 896..898 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 901..917 FT /evidence="ECO:0007829|PDB:3THX" FT HELIX 921..928 FT /evidence="ECO:0007829|PDB:3THX" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 934 AA; 104743 MW; 664A058C78242E05 CRC64; MAVQPKETLQ LESAAEVGFV RFFQGMPEKP TTTVRLFDRG DFYTAHGEDA LLAAREVFKT QGVIKYMGPA GAKNLQSVVL SKMNFESFVK DLLLVRQYRV EVYKNRAGNK ASKENDWYLA YKASPGNLSQ FEDILFGNND MSASIGVVGV KMSAVDGQRQ VGVGYVDSIQ RKLGLCEFPD NDQFSNLEAL LIQIGPKECV LPGGETAGDM GKLRQIIQRG GILITERKKA DFSTKDIYQD LNRLLKGKKG EQMNSAVLPE MENQVAVSSL SAVIKFLELL SDDSNFGQFE LTTFDFSQYM KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGQR LVNQWIKQPL MDKNRIEERL NLVEAFVEDA ELRQTLQEDL LRRFPDLNRL AKKFQRQAAN LQDCYRLYQG INQLPNVIQA LEKHEGKHQK LLLAVFVTPL TDLRSDFSKF QEMIETTLDM DQVENHEFLV KPSFDPNLSE LREIMNDLEK KMQSTLISAA RDLGLDPGKQ IKLDSSAQFG YYFRVTCKEE KVLRNNKNFS TVDIQKNGVK FTNSKLTSLN EEYTKNKTEY EEAQDAIVKE IVNISSGYVE PMQTLNDVLA QLDAVVSFAH VSNGAPVPYV RPAILEKGQG RIILKASRHA CVEVQDEIAF IPNDVYFEKD KQMFHIITGP NMGGKSTYIR QTGVIVLMAQ IGCFVPCESA EVSIVDCILA RVGAGDSQLK GVSTFMAEML ETASILRSAT KDSLIIIDEL GRGTSTYDGF GLAWAISEYI ATKIGAFCMF ATHFHELTAL ANQIPTVNNL HVTALTTEET LTMLYQVKKG VCDQSFGIHV AELANFPKHV IECAKQKALE LEEFQYIGES QGYDIMEPAA KKCYLEREQG EKIIQEFLSK VKQMPFTEMS EENITIKLKQ LKAEVIAKNN SFVNEIISRI KVTT // ID MSH6_HUMAN Reviewed; 1360 AA. AC P52701; B4DF41; B4E3I4; F5H2F9; O43706; O43917; Q8TCX4; Q9BTB5; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 21-JUN-2005, sequence version 2. DT 28-JAN-2026, entry version 259. DE RecName: Full=DNA mismatch repair protein Msh6 {ECO:0000250|UniProtKB:P54276}; DE Short=hMSH6 {ECO:0000303|PubMed:8942985}; DE AltName: Full=G/T mismatch-binding protein {ECO:0000303|PubMed:7604265}; DE Short=GTBP {ECO:0000303|PubMed:9455487}; DE Short=GTMBP {ECO:0000250|UniProtKB:P54276}; DE AltName: Full=MutS protein homolog 6 {ECO:0000312|HGNC:HGNC:7329}; DE AltName: Full=MutS-alpha 160 kDa subunit; DE Short=p160 {ECO:0000303|PubMed:7604264}; GN Name=MSH6 {ECO:0000312|HGNC:HGNC:7329}; Synonyms=GTBP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], VARIANT GLU-39, AND SUBUNIT. RX PubMed=8942985; DOI=10.1073/pnas.93.24.13629; RA Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., RA Kolodner R.D., Fishel R.; RT "hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6."; RL Proc. Natl. Acad. Sci. U.S.A. 93:13629-13634(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING. RX PubMed=9455487; DOI=10.1093/dnares/4.5.359; RA Shiwaku H.O., Wakatsuki S., Mori Y., Fukushige S., Horii A.; RT "Alternative splicing of GTBP in normal human tissues."; RL DNA Res. 4:359-362(1997). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-39; VAL-396; ALA-623 RP AND VAL-886. RG NIEHS SNPs program; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 69-1360, AND PARTIAL PROTEIN SEQUENCE. RX PubMed=7604265; DOI=10.1126/science.7604265; RA Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., RA D'Arrigo A., Truong O., Hsuan J.J., Jiricny J.; RT "GTBP, a 160-kilodalton protein essential for mismatch-binding activity in RT human cells."; RL Science 268:1912-1914(1995). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-116. RX PubMed=8838326; DOI=10.1006/geno.1996.0067; RA Nicolaides N.C., Palombo F., Kinzler K.W., Vogelstein B., Jiricny J.; RT "Molecular cloning of the N-terminus of GTBP."; RL Genomics 31:395-397(1996). RN [9] RP CHARACTERIZATION, PARTIAL PROTEIN SEQUENCE, AND SUBUNIT. RX PubMed=7604264; DOI=10.1126/science.7604264; RA Drummond J.T., Li G.-M., Longley M.J., Modrich P.; RT "Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair RT to tumor cells."; RL Science 268:1909-1912(1995). RN [10] RP FUNCTION. RX PubMed=9822680; DOI=10.1074/jbc.273.48.32055; RA Blackwell L.J., Martik D., Bjornson K.P., Bjornson E.S., Modrich P.; RT "Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is RT consistent with an ATP-dependent translocation mechanism."; RL J. Biol. Chem. 273:32055-32062(1998). RN [11] RP FUNCTION. RX PubMed=9822679; DOI=10.1074/jbc.273.48.32049; RA Blackwell L.J., Bjornson K.P., Modrich P.; RT "DNA-dependent activation of the hMutSalpha ATPase."; RL J. Biol. Chem. 273:32049-32054(1998). RN [12] RP FUNCTION, AND MUTAGENESIS OF LYS-1140. RX PubMed=9564049; DOI=10.1093/emboj/17.9.2677; RA Iaccarino I., Marra G., Palombo F., Jiricny J.; RT "hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute RT differently to the ATPase activity of hMutSalpha."; RL EMBO J. 17:2677-2686(1998). RN [13] RP MISMATCH-BINDING. RX PubMed=9889267; DOI=10.1093/nar/27.3.736; RA Clark A.B., Cook M.E., Tran H.T., Gordenin D.A., Resnick M.A., Kunkel T.A.; RT "Functional analysis of human MutSalpha and MutSbeta complexes in yeast."; RL Nucleic Acids Res. 27:736-742(1999). RN [14] RP FUNCTION. RX PubMed=10078208; DOI=10.1016/s1097-2765(00)80316-0; RA Gradia S., Subramanian D., Wilson T., Acharya S., Makhov A., Griffith J., RA Fishel R.; RT "hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched RT DNA."; RL Mol. Cell 3:255-261(1999). RN [15] RP FUNCTION. RX PubMed=10660545; DOI=10.1074/jbc.275.6.3922; RA Gradia S., Acharya S., Fishel R.; RT "The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular RT switch."; RL J. Biol. Chem. 275:3922-3930(2000). RN [16] RP FUNCTION. RX PubMed=15064730; DOI=10.1038/sj.onc.1207462; RA Yang Q., Zhang R., Wang X.W., Linke S.P., Sengupta S., Hickson I.D., RA Pedrazzi G., Perrera C., Stagljar I., Littman S.J., Modrich P., RA Harris C.C.; RT "The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase."; RL Oncogene 23:3749-3756(2004). RN [17] RP PHOSPHORYLATION BY PRKCZ. RX PubMed=15808853; DOI=10.1016/j.jmb.2005.02.001; RA Hernandez-Pigeon H., Quillet-Mary A., Louat T., Schambourg A., Humbert O., RA Selves J., Salles B., Laurent G., Lautier D.; RT "hMutS alpha is protected from ubiquitin-proteasome-dependent degradation RT by atypical protein kinase C zeta phosphorylation."; RL J. Mol. Biol. 348:63-74(2005). RN [18] RP IDENTIFICATION OF MSH6 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [19] RP INVOLVEMENT IN LYNCH5. RX PubMed=9354786; DOI=10.1038/ng1197-271; RA Miyaki M., Konishi M., Tanaka K., Kikuchi-Yanoshita R., Muraoka M., RA Yasuno M., Igari T., Koike M., Chiba M., Mori T.; RT "Germline mutation of MSH6 as the cause of hereditary nonpolyposis RT colorectal cancer."; RL Nat. Genet. 17:271-272(1997). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-219; SER-227 AND SER-261, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-41 AND SER-43, RP VARIANT [LARGE SCALE ANALYSIS] GLU-39, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [22] RP INVOLVEMENT IN MMRCS. RX PubMed=17557300; DOI=10.1002/humu.20569; RA Auclair J., Leroux D., Desseigne F., Lasset C., Saurin J.C., Joly M.O., RA Pinson S., Xu X.L., Montmain G., Ruano E., Navarro C., Puisieux A., RA Wang Q.; RT "Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a RT likely cause of PMS2 gene inactivation."; RL Hum. Mutat. 28:1084-1090(2007). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-309, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-79; SER-91; SER-137; RP SER-200; SER-227; SER-252; SER-254; SER-256 AND SER-261, AND IDENTIFICATION RP BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-70 AND LYS-504, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227 AND RP SER-830, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [29] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-219; RP SER-227; SER-252; SER-261; THR-269; SER-274; SER-275; SER-279; SER-280 AND RP SER-309, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-137; SER-227; RP SER-252; SER-309; THR-488; SER-830; SER-935 AND THR-1010, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [32] RP CHARACTERIZATION OF VARIANTS LYNCH5 LEU-128; ILE-144; ARG-566; LEU-623; RP THR-728; GLY-881 DELINS LYS-SER; THR-1087; HIS-1095; LYS-1193 AND GLN-1354, RP CHARACTERIZATION OF VARIANT ARG-1087, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [33] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL12 (MICROBIAL INFECTION). RX PubMed=21957315; DOI=10.1128/jvi.05487-11; RA Mohni K.N., Mastrocola A.S., Bai P., Weller S.K., Heinen C.D.; RT "DNA mismatch repair proteins are required for efficient herpes simplex RT virus 1 replication."; RL J. Virol. 85:12241-12253(2011). RN [34] RP FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-103 AND RP 105-TRP-TRP-106. RX PubMed=23622243; DOI=10.1016/j.cell.2013.03.025; RA Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M.; RT "The histone mark H3K36me3 regulates human DNA mismatch repair through its RT interaction with MutSalpha."; RL Cell 153:590-600(2013). RN [35] RP IDENTIFICATION IN THE MMR COMPLEX, AND INTERACTION WITH MCM9. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [36] RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS). RX PubMed=17531815; DOI=10.1016/j.molcel.2007.04.018; RA Warren J.J., Pohlhaus T.J., Changela A., Iyer R.R., Modrich P.L., RA Beese L.S.; RT "Structure of the human MutSalpha DNA lesion recognition complex."; RL Mol. Cell 26:579-592(2007). RN [37] RP VARIANTS VAL-1213 AND ILE-1260. RX PubMed=7604266; DOI=10.1126/science.7604266; RA Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., RA Palombo F., D'Arrigo A., Markowitz S., Willson J.K.V., Kinzler K.W., RA Jiricny J., Vogelstein B.; RT "Mutations of GTBP in genetically unstable cells."; RL Science 268:1915-1917(1995). RN [38] RP VARIANTS LYNCH5 ILE-144 AND CYS-850. RX PubMed=10521294; DOI=10.1086/302612; RA Wu Y., Berends M.J.W., Mensink R.G.J., Kempinga C., Sijmons R.H., RA van Der Zee A.G.J., Hollema H., Kleibeuker J.H., Buys C.H.C.M., RA Hofstra R.M.W.; RT "Association of hereditary nonpolyposis colorectal cancer-related tumors RT displaying low microsatellite instability with MSH6 germline mutations."; RL Am. J. Hum. Genet. 65:1291-1298(1999). RN [39] RP VARIANTS CRC ILE-285; ARG-566; GLY-803 AND THR-1087, AND VARIANTS GLU-39; RP ASP-220; VAL-396 AND LEU-800. RX PubMed=10537275; RA Kolodner R.D., Tytell J.D., Schmeits J.L., Kane M.F., Das Gupta R., RA Weger J., Wahlberg S., Fox E.A., Peel D., Ziogas A., Garber J.E., RA Syngal S., Anton-Culver H., Li F.P.; RT "Germ-line msh6 mutations in colorectal cancer families."; RL Cancer Res. 59:5068-5074(1999). RN [40] RP VARIANT LYNCH5 GLU-698. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [41] RP VARIANT CRC MET-1284. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [42] RP VARIANTS CRC VAL-20; ALA-878 AND HIS-901, AND VARIANTS ENDMC VAL-20; RP ALA-878 AND HIS-901. RX PubMed=11153917; DOI=10.1007/s004390000417; RA Charames G.S., Millar A.L., Pal T., Narod S., Bapat B.; RT "Do MSH6 mutations contribute to double primary cancers of the colorectum RT and endometrium?"; RL Hum. Genet. 107:623-629(2000). RN [43] RP VARIANTS GLU-39 AND SER-340. RX PubMed=10699937; RX DOI=10.1002/(sici)1097-0215(20000301)85:5<606::aid-ijc2>3.0.co;2-b; RA Plaschke J., Kruppa C., Tischler R., Bocker T., Pistorius S., Dralle H., RA Rueschoff J., Saeger H.D., Fishel R., Schackert H.K.; RT "Sequence analysis of the mismatch repair gene hMSH6 in the germline of RT patients with familial and sporadic colorectal cancer."; RL Int. J. Cancer 85:606-613(2000). RN [44] RP VARIANTS CRC ALA-685; GLN-772; ALA-800; MET-854; ALA-878; VAL-1031 AND RP ARG-1158. RX PubMed=11470537; DOI=10.1016/s0378-1119(01)00517-0; RA Ohmiya N., Matsumoto S., Yamamoto H., Baranovskaya S., Malkhosyan S.R., RA Perucho M.; RT "Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal RT cancers of the microsatellite mutator phenotype."; RL Gene 272:301-313(2001). RN [45] RP VARIANT LYNCH5 ALA-878. RX PubMed=11586295; DOI=10.1038/ng1001-137; RA Wu Y., Berends M.J.W., Sijmons R.H., Mensink R.G.J., Verlind E., Kooi K.A., RA van der Sluis T., Kempinga C., van der Zee A.G.J., Hollema H., RA Buys C.H.C.M., Kleibeuker J.H., Hofstra R.M.W.; RT "A role for MLH3 in hereditary nonpolyposis colorectal cancer."; RL Nat. Genet. 29:137-138(2001). RN [46] RP VARIANTS CRC ILE-144; ARG-522; MET-725; CYS-850; ALA-878; ASP-1021; RP MET-1100; ILE-1219 AND ASP-1248. RX PubMed=11709755; DOI=10.1086/337944; RA Berends M.J.W., Wu Y., Sijmons R.H., Mensink R.G.J., van der Sluis T., RA Hordijk-Hos J.M., de Vries E.G.E., Hollema H., Karrenbeld A., RA Buys C.H.C.M., van der Zee A.G.J., Hofstra R.M.W., Kleibeuker J.H.; RT "Molecular and clinical characteristics of MSH6 variants: an analysis of 25 RT index carriers of a germline variant."; RL Am. J. Hum. Genet. 70:26-37(2002). RN [47] RP VARIANT CRC HIS-976. RX PubMed=11807791; DOI=10.1002/ijc.10097; RA Plaschke J., Krueger S., Pistorius S., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Involvement of hMSH6 in the development of hereditary and sporadic RT colorectal cancer revealed by immunostaining is based on germline RT mutations, but rarely on somatic inactivation."; RL Int. J. Cancer 97:643-648(2002). RN [48] RP VARIANT LYNCH5 VAL-492. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [49] RP VARIANTS CRC HIS-1095 AND GLN-1354. RX PubMed=12522549; DOI=10.1007/s00439-002-0866-4; RA Kariola R., Otway R., Loennqvist K.E., Raevaara T.E., Macrae F., Vos Y.J., RA Kohonen-Corish M., Hofstra R.M.W., Nystroem-Lahti M.; RT "Two mismatch repair gene mutations found in a colon cancer patient - which RT one is pathogenic?"; RL Hum. Genet. 112:105-109(2003). RN [50] RP VARIANTS GLU-39; ALA-54; ALA-509; MET-854 AND ALA-878. RX PubMed=14520694; DOI=10.1002/ijc.11415; RA Peterlongo P., Nafa K., Lerman G.S., Glogowski E., Shia J., Ye T.Z., RA Markowitz A.J., Guillem J.G., Kolachana P., Boyd J.A., Offit K., RA Ellis N.A.; RT "MSH6 germline mutations are rare in colorectal cancer families."; RL Int. J. Cancer 107:571-579(2003). RN [51] RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193, AND CHARACTERIZATION OF RP VARIANTS LEU-128; LEU-623; THR-728 AND LYS-1193. RX PubMed=15354210; DOI=10.1038/sj.bjc.6602129; RA Kariola R., Hampel H., Frankel W.L., Raevaara T.E., de la Chapelle A., RA Nystroem-Lahti M.; RT "MSH6 missense mutations are often associated with no or low cancer RT susceptibility."; RL Br. J. Cancer 91:1287-1292(2004). RN [52] RP VARIANT LYNCH5 TRP-772. RX PubMed=14974087; DOI=10.1002/humu.9217; RG The German HNPCC consortium; RA Plaschke J., Krueger S., Dietmaier W., Gebert J., Sutter C., Mangold E., RA Pagenstecher C., Holinski-Feder E., Schulmann K., Moeslein G., RA Rueschoff J., Engel C., Evans G., Schackert H.K.; RT "Eight novel MSH6 germline mutations in patients with familial and RT nonfamilial colorectal cancer selected by loss of protein expression in RT tumor tissue."; RL Hum. Mutat. 23:285-285(2004). RN [53] RP VARIANT LYNCH5 VAL-1163. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [54] RP VARIANT CRC PRO-449, AND VARIANT ENDMC PRO-449. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [55] RP VARIANTS CRC ASN-99; ASP-619; VAL-787; ALA-878 AND CYS-1076. RX PubMed=15483016; DOI=10.1200/jco.2004.02.033; RA Plaschke J., Engel C., Krueger S., Holinski-Feder E., Pagenstecher C., RA Mangold E., Moeslein G., Schulmann K., Gebert J., von Knebel Doeberitz M., RA Rueschoff J., Loeffler M., Schackert H.K.; RT "Lower incidence of colorectal cancer and later age of disease onset in 27 RT families with pathogenic MSH6 germline mutations compared with families RT with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal RT cancer consortium."; RL J. Clin. Oncol. 22:4486-4494(2004). RN [56] RP VARIANTS [LARGE SCALE ANALYSIS] ASP-221 AND VAL-492. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [57] RP VARIANTS THR-13; LEU-65; ILE-144; HIS-468; CYS-503; LEU-580; ALA-878; RP LEU-1232 AND GLY-1321. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [58] RP CHARACTERIZATION OF VARIANT LYNCH5 VAL-20, CHARACTERIZATION OF VARIANTS CRC RP HIS-976 AND ASP-1021, AND CHARACTERIZATION OF VARIANTS SER-25; VAL-326; RP VAL-396; VAL-492; CYS-503; ARG-522; ASN-610; CYS-850; ALA-878; TYR-1026; RP SER-1087 AND MET-1225. RX PubMed=22102614; DOI=10.1002/humu.22000; RA Drost M., Zonneveld J.B., van Hees S., Rasmussen L.J., Hofstra R.M., RA de Wind N.; RT "A rapid and cell-free assay to test the activity of lynch syndrome- RT associated MSH2 and MSH6 missense variants."; RL Hum. Mutat. 33:488-494(2012). RN [59] RP CHARACTERIZATION OF VARIANTS PRO-435; PRO-585; THR-677; ALA-878; HIS-1095 RP AND GLN-1354. RX PubMed=22581703; DOI=10.1002/humu.22119; RA Kantelinen J., Kansikas M., Candelin S., Hampel H., Smith B., Holm L., RA Kariola R., Nystrom M.; RT "Mismatch repair analysis of inherited MSH2 and/or MSH6 variation pairs RT found in cancer patients."; RL Hum. Mutat. 33:1294-1301(2012). CC -!- FUNCTION: Component of the post-replicative DNA mismatch repair system CC (MMR). Heterodimerizes with MSH2 to form MutS alpha, which binds to DNA CC mismatches thereby initiating DNA repair. When bound, MutS alpha bends CC the DNA helix and shields approximately 20 base pairs, and recognizes CC single base mismatches and dinucleotide insertion-deletion loops (IDL) CC in the DNA. After mismatch binding, forms a ternary complex with the CC MutL alpha heterodimer, which is thought to be responsible for CC directing the downstream MMR events, including strand discrimination, CC excision, and resynthesis. ATP binding and hydrolysis play a pivotal CC role in mismatch repair functions. The ATPase activity associated with CC MutS alpha regulates binding similar to a molecular switch: mismatched CC DNA provokes ADP-->ATP exchange, resulting in a discernible CC conformational transition that converts MutS alpha into a sliding clamp CC capable of hydrolysis-independent diffusion along the DNA backbone. CC This transition is crucial for mismatch repair. MutS alpha may also CC play a role in DNA homologous recombination repair. Recruited on CC chromatin in G1 and early S phase via its PWWP domain that specifically CC binds trimethylated 'Lys-36' of histone H3 (H3K36me3): early CC recruitment to chromatin to be replicated allowing a quick CC identification of mismatch repair to initiate the DNA mismatch repair CC reaction. {ECO:0000269|PubMed:10078208, ECO:0000269|PubMed:10660545, CC ECO:0000269|PubMed:15064730, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:23622243, ECO:0000269|PubMed:9564049, CC ECO:0000269|PubMed:9822679, ECO:0000269|PubMed:9822680}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC consisting of MSH2-MSH6 (MutS alpha) (PubMed:7604264, PubMed:8942985). CC Forms a ternary complex with MutL alpha (MLH1-PMS1). Interacts with CC MCM9 (PubMed:26300262). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10783165). {ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:7604264, CC ECO:0000269|PubMed:8942985}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC protein UL12. {ECO:0000269|PubMed:21957315}. CC -!- INTERACTION: CC P52701; Q9NXL9: MCM9; NbExp=3; IntAct=EBI-395529, EBI-2804985; CC P52701; P43246: MSH2; NbExp=11; IntAct=EBI-395529, EBI-355888; CC P52701; P01106: MYC; NbExp=2; IntAct=EBI-395529, EBI-447544; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23622243}. Chromosome CC {ECO:0000269|PubMed:23622243}. Note=Associates with H3K36me3 via its CC PWWP domain. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=GTBP-N; CC IsoId=P52701-1; Sequence=Displayed; CC Name=GTBP-alt; CC IsoId=P52701-2; Sequence=VSP_003291, VSP_003292; CC Name=3; CC IsoId=P52701-3; Sequence=VSP_054419; CC Name=4; CC IsoId=P52701-4; Sequence=VSP_055020; CC -!- DOMAIN: The PWWP domain specifically recognizes and binds trimethylated CC 'Lys-36' of histone H3 (H3K36me3). {ECO:0000269|PubMed:23622243}. CC -!- PTM: The N-terminus is blocked. CC -!- PTM: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation CC by the ubiquitin-proteasome pathway. {ECO:0000269|PubMed:15808853}. CC -!- DISEASE: Lynch syndrome 5 (LYNCH5) [MIM:614350]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10521294, CC ECO:0000269|PubMed:11586295, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14974087, ECO:0000269|PubMed:15365995, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22102614, CC ECO:0000269|PubMed:9354786}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:11153917, CC ECO:0000269|PubMed:14961575}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 3 (MMRCS3) [MIM:619097]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:17557300}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10537275, ECO:0000269|PubMed:10699937, CC ECO:0000269|PubMed:11153917, ECO:0000269|PubMed:11470537, CC ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:11807791, CC ECO:0000269|PubMed:12522549, ECO:0000269|PubMed:14520694, CC ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:15483016, CC ECO:0000269|PubMed:22102614}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutS family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/344/MSH6"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U73737; AAB47425.1; -; Genomic_DNA. DR EMBL; U73732; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73733; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73734; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; U73736; AAB47425.1; JOINED; Genomic_DNA. DR EMBL; D89645; BAA23674.1; -; Genomic_DNA. DR EMBL; D89646; BAA23675.1; -; mRNA. DR EMBL; AK293921; BAG57302.1; -; mRNA. DR EMBL; AK304735; BAG65496.1; -; mRNA. DR EMBL; AY082894; AAL87401.1; -; Genomic_DNA. DR EMBL; AC006509; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004246; AAH04246.1; -; mRNA. DR EMBL; U54777; AAB39212.2; -; mRNA. DR EMBL; U28946; AAC50461.1; -; mRNA. DR CCDS; CCDS1836.1; -. [P52701-1] DR CCDS; CCDS62906.1; -. [P52701-3] DR PIR; JC5839; JC5839. DR RefSeq; NP_000170.1; NM_000179.3. [P52701-1] DR RefSeq; NP_001268421.1; NM_001281492.2. [P52701-3] DR RefSeq; NP_001268422.1; NM_001281493.2. [P52701-4] DR RefSeq; NP_001268423.1; NM_001281494.2. [P52701-4] DR RefSeq; NP_001393725.1; NM_001406796.1. [P52701-1] DR RefSeq; NP_001393738.1; NM_001406809.1. [P52701-1] DR RefSeq; NP_001393740.1; NM_001406811.1. [P52701-4] DR RefSeq; NP_001393741.1; NM_001406812.1. [P52701-4] DR RefSeq; NP_001393743.1; NM_001406814.1. [P52701-4] DR RefSeq; NP_001393744.1; NM_001406815.1. [P52701-4] DR RefSeq; NP_001393745.1; NM_001406816.1. [P52701-4] DR RefSeq; NP_001393752.1; NM_001406823.1. [P52701-4] DR RefSeq; NP_001393758.1; NM_001406829.1. [P52701-4] DR PDB; 2GFU; NMR; -; A=68-201. DR PDB; 2O8B; X-ray; 2.75 A; B=341-1360. DR PDB; 2O8C; X-ray; 3.37 A; B=341-1360. DR PDB; 2O8D; X-ray; 3.00 A; B=341-1360. DR PDB; 2O8E; X-ray; 3.30 A; B=341-1360. DR PDB; 2O8F; X-ray; 3.25 A; B=341-1360. DR PDB; 6OQM; X-ray; 2.20 A; A=87-198. DR PDB; 8AG6; EM; 2.80 A; B=2-1360. DR PDBsum; 2GFU; -. DR PDBsum; 2O8B; -. DR PDBsum; 2O8C; -. DR PDBsum; 2O8D; -. DR PDBsum; 2O8E; -. DR PDBsum; 2O8F; -. DR PDBsum; 6OQM; -. DR PDBsum; 8AG6; -. DR AlphaFoldDB; P52701; -. DR EMDB; EMD-15417; -. DR SMR; P52701; -. DR BioGRID; 109211; 288. DR ComplexPortal; CPX-80; DNA mismatch repair MutSalpha complex. DR CORUM; P52701; -. DR DIP; DIP-32972N; -. DR ELM; P52701; -. DR FunCoup; P52701; 3882. DR IntAct; P52701; 103. DR MINT; P52701; -. DR STRING; 9606.ENSP00000234420; -. DR ChEMBL; CHEMBL4739849; -. DR CarbonylDB; P52701; -. DR GlyCosmos; P52701; 1 site, 1 glycan. DR GlyGen; P52701; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P52701; -. DR MetOSite; P52701; -. DR PhosphoSitePlus; P52701; -. DR SwissPalm; P52701; -. DR BioMuta; MSH6; -. DR DMDM; 68067672; -. DR CPTAC; CPTAC-544; -. DR jPOST; P52701; -. DR MassIVE; P52701; -. DR PaxDb; 9606-ENSP00000234420; -. DR PeptideAtlas; P52701; -. DR ProteomicsDB; 25957; -. DR ProteomicsDB; 4004; -. DR ProteomicsDB; 56502; -. [P52701-1] DR ProteomicsDB; 56503; -. [P52701-2] DR Pumba; P52701; -. DR ABCD; P52701; 6 sequenced antibodies. DR Antibodypedia; 3963; 880 antibodies from 46 providers. DR CPTC; P52701; 2 antibodies. DR DNASU; 2956; -. DR Ensembl; ENST00000234420.11; ENSP00000234420.5; ENSG00000116062.20. [P52701-1] DR Ensembl; ENST00000540021.6; ENSP00000446475.1; ENSG00000116062.20. [P52701-3] DR GeneID; 2956; -. DR KEGG; hsa:2956; -. DR MANE-Select; ENST00000234420.11; ENSP00000234420.5; NM_000179.3; NP_000170.1. DR UCSC; uc002rwd.5; human. [P52701-1] DR AGR; HGNC:7329; -. DR CIViC; 2956; 7 evidence items across 7 molecular profiles. DR ClinPGx; PA184; -. DR CTD; 2956; -. DR DisGeNET; 2956; -. DR GeneCards; MSH6; -. DR GeneReviews; MSH6; -. DR HGNC; HGNC:7329; MSH6. DR HPA; ENSG00000116062; Low tissue specificity. DR MalaCards; MSH6; -. DR MIM; 114500; phenotype. DR MIM; 600678; gene. DR MIM; 608089; phenotype. DR MIM; 614350; phenotype. DR MIM; 619097; phenotype. DR OpenTargets; ENSG00000116062; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000116062; -. DR eggNOG; KOG0217; Eukaryota. DR GeneTree; ENSGT00550000075024; -. DR HOGENOM; CLU_002472_1_3_1; -. DR InParanoid; P52701; -. DR OMA; TPMMAQY; -. DR OrthoDB; 10252754at2759; -. DR PAN-GO; P52701; 4 GO annotations based on evolutionary models. DR PhylomeDB; P52701; -. DR PathwayCommons; P52701; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5632928; Defective Mismatch Repair Associated With MSH2. DR Reactome; R-HSA-5632968; Defective Mismatch Repair Associated With MSH6. DR SignaLink; P52701; -. DR SIGNOR; P52701; -. DR Agora; ENSG00000116062; -. DR BioGRID-ORCS; 2956; 15 hits in 1169 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MSH6; human. DR EvolutionaryTrace; P52701; -. DR GeneWiki; MSH6; -. DR GenomeRNAi; 2956; -. DR Pharos; P52701; Tbio. DR PRO; PR:P52701; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; P52701; protein. DR Bgee; ENSG00000116062; Expressed in ventricular zone and 219 other cell types or tissues. DR ExpressionAtlas; P52701; baseline and differential. DR GO; GO:0000785; C:chromatin; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0032301; C:MutSalpha complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008094; F:ATP-dependent activity, acting on DNA; IDA:HGNC-UCL. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0140003; F:histone H3K36me3 reader activity; IDA:UniProtKB. DR GO; GO:0030983; F:mismatched DNA binding; IDA:UniProtKB. DR GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL. DR GO; GO:0006281; P:DNA repair; IDA:BHF-UCL. DR GO; GO:0097193; P:intrinsic apoptotic signaling pathway; ISS:BHF-UCL. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISS:BHF-UCL. DR GO; GO:0045190; P:isotype switching; ISS:BHF-UCL. DR GO; GO:0000710; P:meiotic mismatch repair; ISS:BHF-UCL. DR GO; GO:0006298; P:mismatch repair; IDA:UniProtKB. DR GO; GO:0045910; P:negative regulation of DNA recombination; IDA:BHF-UCL. DR GO; GO:0009411; P:response to UV; ISS:BHF-UCL. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; ISS:BHF-UCL. DR GO; GO:0016447; P:somatic recombination of immunoglobulin gene segments; ISS:BHF-UCL. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd05837; PWWP_MSH6; 1. DR FunFam; 1.10.1420.10:FF:000005; DNA mismatch repair protein; 1. DR FunFam; 1.10.1420.10:FF:000006; DNA mismatch repair protein; 1. DR FunFam; 2.30.30.140:FF:000069; DNA mismatch repair protein; 1. DR FunFam; 3.30.420.110:FF:000004; DNA mismatch repair protein; 1. DR FunFam; 3.40.1170.10:FF:000002; DNA mismatch repair protein; 1. DR FunFam; 3.40.50.300:FF:000645; DNA mismatch repair protein; 1. DR Gene3D; 1.10.1420.10; -; 2. DR Gene3D; 2.30.30.140; -; 1. DR Gene3D; 3.40.1170.10; DNA repair protein MutS, domain I; 1. DR Gene3D; 3.30.420.110; MutS, connector domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR IDEAL; IID00054; -. DR InterPro; IPR007695; DNA_mismatch_repair_MutS-lik_N. DR InterPro; IPR017261; DNA_mismatch_repair_MutS/MSH. DR InterPro; IPR000432; DNA_mismatch_repair_MutS_C. DR InterPro; IPR007861; DNA_mismatch_repair_MutS_clamp. DR InterPro; IPR007696; DNA_mismatch_repair_MutS_core. DR InterPro; IPR016151; DNA_mismatch_repair_MutS_N. DR InterPro; IPR036187; DNA_mismatch_repair_MutS_sf. DR InterPro; IPR007860; DNA_mmatch_repair_MutS_con_dom. DR InterPro; IPR045076; MutS. DR InterPro; IPR036678; MutS_con_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR000313; PWWP_dom. DR NCBIfam; NF003810; PRK05399.1; 1. DR PANTHER; PTHR11361:SF148; DNA MISMATCH REPAIR PROTEIN MSH6; 1. DR PANTHER; PTHR11361; DNA MISMATCH REPAIR PROTEIN MUTS FAMILY MEMBER; 1. DR Pfam; PF01624; MutS_I; 1. DR Pfam; PF05188; MutS_II; 1. DR Pfam; PF05192; MutS_III; 1. DR Pfam; PF05190; MutS_IV; 1. DR Pfam; PF00488; MutS_V; 1. DR Pfam; PF00855; PWWP; 1. DR PIRSF; PIRSF037677; DNA_mis_repair_Msh6; 1. DR SMART; SM00534; MUTSac; 1. DR SMART; SM00533; MUTSd; 1. DR SMART; SM00293; PWWP; 1. DR SUPFAM; SSF55271; DNA repair protein MutS, domain I; 1. DR SUPFAM; SSF48334; DNA repair protein MutS, domain III; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF63748; Tudor/PWWP/MBT; 1. DR PROSITE; PS00486; DNA_MISMATCH_REPAIR_2; 1. DR PROSITE; PS50812; PWWP; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Hereditary nonpolyposis colorectal cancer; KW Host-virus interaction; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome. FT CHAIN 1..1360 FT /note="DNA mismatch repair protein Msh6" FT /id="PRO_0000115207" FT DOMAIN 92..154 FT /note="PWWP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00162" FT REGION 1..84 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 195..362 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33..51 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 198..209 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 219..230 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 240..249 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 263..273 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 320..351 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1134..1141 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 43 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243" FT MOD_RES 70 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 79 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 137 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 219 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:21406692" FT MOD_RES 227 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 254 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 256 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 261 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692" FT MOD_RES 269 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 274 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 275 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 279 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 280 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 309 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 488 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 504 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 830 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 935 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1010 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..302 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_055020" FT VAR_SEQ 80..209 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_054419" FT VAR_SEQ 1058..1068 FT /note="DVLLCLANYSR -> GKTLNKLVLRL (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003291" FT VAR_SEQ 1069..1360 FT /note="Missing (in isoform GTBP-alt)" FT /evidence="ECO:0000305" FT /id="VSP_003292" FT VARIANT 13 FT /note="K -> T (in dbSNP:rs41294988)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038032" FT VARIANT 20 FT /note="A -> V (in LYNCH5, CRC and ENDMC; likely benign; FT normal mismatch repair activity; dbSNP:rs63750664)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043943" FT VARIANT 25 FT /note="A -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608026)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067294" FT VARIANT 25 FT /note="A -> V (in dbSNP:rs35462442)" FT /id="VAR_038033" FT VARIANT 39 FT /note="G -> E (in dbSNP:rs1042821)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:10699937, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:8942985, ECO:0000269|Ref.4, FT ECO:0007744|PubMed:16964243" FT /id="VAR_004490" FT VARIANT 54 FT /note="G -> A (in dbSNP:rs63751098)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043944" FT VARIANT 65 FT /note="S -> L (in dbSNP:rs41294984)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038034" FT VARIANT 99 FT /note="K -> N (in CRC; uncertain significance; FT dbSNP:rs63751258)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043945" FT VARIANT 128 FT /note="R -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750143)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043946" FT VARIANT 144 FT /note="S -> I (in LYNCH5 and CRC; benign; normal mismatch FT repair activity; dbSNP:rs3211299)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012955" FT VARIANT 220 FT /note="E -> D (in dbSNP:rs1800938)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012956" FT VARIANT 221 FT /note="E -> D (in dbSNP:rs41557217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042274" FT VARIANT 285 FT /note="S -> I (in CRC; uncertain significance; FT dbSNP:rs63750878)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012957" FT VARIANT 295 FT /note="K -> R (in multiple colorectal adenoma; FT dbSNP:rs267608051)" FT /id="VAR_043947" FT VARIANT 326 FT /note="A -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs587779323)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067295" FT VARIANT 340 FT /note="F -> S (in dbSNP:rs61753793)" FT /evidence="ECO:0000269|PubMed:10699937" FT /id="VAR_043948" FT VARIANT 396 FT /note="L -> V (in LYNCH5; benign; normal mismatch repair FT activity; dbSNP:rs2020908)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:22102614, ECO:0000269|Ref.4" FT /id="VAR_012958" FT VARIANT 435 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs63751405)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068710" FT VARIANT 449 FT /note="L -> P (in CRC and ENDMC; dbSNP:rs63750741)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043949" FT VARIANT 468 FT /note="R -> H (in dbSNP:rs41295268)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038035" FT VARIANT 492 FT /note="M -> V (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs61754783)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:22102614" FT /id="VAR_042275" FT VARIANT 503 FT /note="S -> C (in LYNCH5; likely benign; normal mismatch FT repair activity; dbSNP:rs63750897)" FT /evidence="ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614" FT /id="VAR_038036" FT VARIANT 509 FT /note="V -> A (in dbSNP:rs63751005)" FT /evidence="ECO:0000269|PubMed:14520694" FT /id="VAR_043950" FT VARIANT 522 FT /note="Q -> R (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63751009)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043951" FT VARIANT 538 FT /note="Y -> S (in dbSNP:rs728619)" FT /id="VAR_038037" FT VARIANT 566 FT /note="G -> R (in CRC and LYNCH5; decreased mismatch repair FT activity; loss of protein expression; dbSNP:rs63749973)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012959" FT VARIANT 580 FT /note="S -> L (in dbSNP:rs41295270)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038038" FT VARIANT 585 FT /note="L -> P (decreased mismatch repair activity; FT dbSNP:rs587779220)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068711" FT VARIANT 610 FT /note="K -> N (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs201735525)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067296" FT VARIANT 619 FT /note="E -> D (in CRC; uncertain significance; FT dbSNP:rs63751121)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043952" FT VARIANT 623 FT /note="P -> A (in dbSNP:rs3136334)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_029244" FT VARIANT 623 FT /note="P -> L (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs63750462)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043953" FT VARIANT 677 FT /note="S -> T (normal mismatch repair activity; FT dbSNP:rs587779224)" FT /evidence="ECO:0000269|PubMed:22581703" FT /id="VAR_068712" FT VARIANT 685 FT /note="G -> A (in CRC; uncertain significance; FT dbSNP:rs63750358)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043954" FT VARIANT 698 FT /note="Q -> E (in HNPCC; uncertain significance; FT dbSNP:rs63750832)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012960" FT VARIANT 725 FT /note="I -> M (in CRC; uncertain significance; FT dbSNP:rs63750304)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043955" FT VARIANT 728 FT /note="K -> T (in LYNCH5; uncertain significance; no FT impairment of heterodimerization with MSH2; normal mismatch FT repair activity; dbSNP:rs35552856)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043956" FT VARIANT 772 FT /note="R -> Q (in CRC; uncertain significance; FT dbSNP:rs63750725)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043957" FT VARIANT 772 FT /note="R -> W (in LYNCH5; dbSNP:rs63750138)" FT /evidence="ECO:0000269|PubMed:14974087" FT /id="VAR_043958" FT VARIANT 787 FT /note="A -> V (in CRC; uncertain significance; FT dbSNP:rs63750637)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043959" FT VARIANT 800 FT /note="V -> A (in CRC; somatic mutation; dbSNP:rs63750895)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043960" FT VARIANT 800 FT /note="V -> L (in dbSNP:rs61748083)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012961" FT VARIANT 803 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63751450)" FT /evidence="ECO:0000269|PubMed:10537275" FT /id="VAR_012962" FT VARIANT 850 FT /note="Y -> C (in LYNCH5 and CRC; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750389)" FT /evidence="ECO:0000269|PubMed:10521294, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:22102614" FT /id="VAR_012963" FT VARIANT 854 FT /note="K -> M (in CRC; uncertain significance; FT dbSNP:rs34374438)" FT /evidence="ECO:0000269|PubMed:11470537, FT ECO:0000269|PubMed:14520694" FT /id="VAR_043961" FT VARIANT 878 FT /note="V -> A (in LYNCH5, CRC and ENDMC; benign; normal FT mismatch repair activity; dbSNP:rs2020912)" FT /evidence="ECO:0000269|PubMed:11153917, FT ECO:0000269|PubMed:11470537, ECO:0000269|PubMed:11586295, FT ECO:0000269|PubMed:11709755, ECO:0000269|PubMed:14520694, FT ECO:0000269|PubMed:15483016, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:22102614, ECO:0000269|PubMed:22581703" FT /id="VAR_012964" FT VARIANT 881 FT /note="G -> KS (in LYNCH5; uncertain significance; normal FT mismatch repair activity)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076356" FT VARIANT 886 FT /note="I -> V (in dbSNP:rs2020914)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014902" FT VARIANT 901 FT /note="R -> H (in CRC and ENDMC; uncertain significance; FT dbSNP:rs63749889)" FT /evidence="ECO:0000269|PubMed:11153917" FT /id="VAR_043962" FT VARIANT 976 FT /note="R -> H (in CRC; uncertain significance; sporadic; FT normal mismatch repair activity; dbSNP:rs63751113)" FT /evidence="ECO:0000269|PubMed:11807791, FT ECO:0000269|PubMed:22102614" FT /id="VAR_012965" FT VARIANT 1021 FT /note="A -> D (in CRC; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750287)" FT /evidence="ECO:0000269|PubMed:11709755, FT ECO:0000269|PubMed:22102614" FT /id="VAR_043963" FT VARIANT 1026 FT /note="D -> Y (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs267608054)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067297" FT VARIANT 1031 FT /note="D -> V (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750804)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043964" FT VARIANT 1076 FT /note="R -> C (in CRC; dbSNP:rs63750617)" FT /evidence="ECO:0000269|PubMed:15483016" FT /id="VAR_043965" FT VARIANT 1087 FT /note="P -> R (in dbSNP:rs63750753)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076357" FT VARIANT 1087 FT /note="P -> S (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067298" FT VARIANT 1087 FT /note="P -> T (in CRC and LYNCH5; uncertain significance; FT dbSNP:rs63750998)" FT /evidence="ECO:0000269|PubMed:10537275, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012966" FT VARIANT 1095 FT /note="R -> H (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs63750253)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043966" FT VARIANT 1100 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750442)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043967" FT VARIANT 1158 FT /note="C -> R (in CRC; uncertain significance; somatic FT mutation; dbSNP:rs63750157)" FT /evidence="ECO:0000269|PubMed:11470537" FT /id="VAR_043968" FT VARIANT 1163 FT /note="E -> V (in LYNCH5; dbSNP:rs63750252)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043969" FT VARIANT 1193 FT /note="E -> K (in LYNCH5; decreased mismatch repair FT activity; displays marked impairment of heterodimerization FT with MSH2; dbSNP:rs63751328)" FT /evidence="ECO:0000269|PubMed:15354210, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043970" FT VARIANT 1213 FT /note="D -> V (in dbSNP:rs2104526240)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004491" FT VARIANT 1219 FT /note="T -> I (in CRC; uncertain significance; FT dbSNP:rs63750949)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043971" FT VARIANT 1225 FT /note="T -> M (in LYNCH5; uncertain significance; normal FT mismatch repair activity; dbSNP:rs63750370)" FT /evidence="ECO:0000269|PubMed:22102614" FT /id="VAR_067299" FT VARIANT 1232 FT /note="V -> L (in dbSNP:rs41295276)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038039" FT VARIANT 1234 FT /note="E -> Q (in dbSNP:rs35717727)" FT /id="VAR_038040" FT VARIANT 1248 FT /note="H -> D (in CRC; uncertain significance; FT dbSNP:rs63750882)" FT /evidence="ECO:0000269|PubMed:11709755" FT /id="VAR_043972" FT VARIANT 1260 FT /note="V -> I (in dbSNP:rs63750673)" FT /evidence="ECO:0000269|PubMed:7604266" FT /id="VAR_004492" FT VARIANT 1284 FT /note="T -> M (in CRC; uncertain significance; FT dbSNP:rs63750836)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043973" FT VARIANT 1321 FT /note="R -> G (in dbSNP:rs41295278)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038041" FT VARIANT 1354 FT /note="L -> Q (in CRC and LYNCH5; uncertain significance; FT normal mismatch repair activity; dbSNP:rs267608140)" FT /evidence="ECO:0000269|PubMed:12522549, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22581703" FT /id="VAR_043974" FT MUTAGEN 103 FT /note="Y->A: Abolishes binding to H3K36me3 and DNA mismatch FT repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 105..106 FT /note="WW->AA: Abolishes binding to H3K36me3 and DNA FT mismatch repair activity." FT /evidence="ECO:0000269|PubMed:23622243" FT MUTAGEN 1140 FT /note="K->R: No effect on mismatch binding, complete loss FT of DNA repair function when associated with MSH2 mutant R- FT 675." FT /evidence="ECO:0000269|PubMed:9564049" FT CONFLICT 36..57 FT /note="AAPGASPSPGGDAAWSEAGPGP -> GCPRGLSFPRRGCGLERGWAWA (in FT Ref. 2; BAA23674/BAA23675)" FT /evidence="ECO:0000305" FT CONFLICT 868 FT /note="M -> V (in Ref. 3; BAG65496)" FT /evidence="ECO:0000305" FT CONFLICT 1358..1360 FT /note="KEL -> D (in Ref. 4; AAL87401)" FT /evidence="ECO:0000305" FT STRAND 74..79 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 106..110 FT /evidence="ECO:0007829|PDB:6OQM" FT TURN 114..116 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 117..120 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 128..133 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 139..144 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 145..147 FT /evidence="ECO:0007829|PDB:6OQM" FT STRAND 148..150 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 170..183 FT /evidence="ECO:0007829|PDB:6OQM" FT HELIX 187..191 FT /evidence="ECO:0007829|PDB:2GFU" FT TURN 192..195 FT /evidence="ECO:0007829|PDB:2GFU" FT STRAND 197..199 FT /evidence="ECO:0007829|PDB:2GFU" FT HELIX 366..369 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 371..373 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 375..377 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 400..403 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 408..419 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 420..422 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 423..429 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 432..436 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 453..456 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 458..462 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 463..465 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 466..475 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 480..485 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 489..497 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 499..501 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 505..507 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 511..517 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 519..521 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 526..528 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 538..546 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 554..561 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 563..565 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 568..575 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 591..597 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 603..609 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 610..615 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 616..621 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 624..626 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 630..639 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 640..643 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 644..647 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 657..661 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 671..673 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 675..677 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 678..693 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 697..701 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 706..708 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 712..715 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 737..742 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 758..762 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 768..779 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 785..799 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 802..812 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 818..829 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 831..836 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 838..841 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 847..879 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 885..890 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 894..896 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 897..900 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 906..913 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 918..923 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 931..933 FT /evidence="ECO:0007829|PDB:8AG6" FT HELIX 936..955 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 959..961 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 968..970 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 973..975 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 978..981 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 983..986 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 995..999 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1002..1005 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1008..1010 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1011..1041 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1044..1066 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1070..1072 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1082..1084 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1089..1094 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1111..1116 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1120..1122 FT /evidence="ECO:0007829|PDB:2O8F" FT STRAND 1129..1133 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1136..1138 FT /evidence="ECO:0007829|PDB:2O8F" FT HELIX 1140..1154 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1155..1157 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1160..1167 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1171..1176 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1189..1203 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1209..1213 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1215..1218 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1221..1237 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1242..1246 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1250..1255 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1256..1258 FT /evidence="ECO:0007829|PDB:8AG6" FT STRAND 1260..1269 FT /evidence="ECO:0007829|PDB:2O8B" FT STRAND 1285..1292 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1298..1305 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1310..1322 FT /evidence="ECO:0007829|PDB:2O8B" FT TURN 1323..1326 FT /evidence="ECO:0007829|PDB:2O8F" FT TURN 1330..1332 FT /evidence="ECO:0007829|PDB:2O8B" FT HELIX 1347..1359 FT /evidence="ECO:0007829|PDB:8AG6" SQ SEQUENCE 1360 AA; 152786 MW; 4A4AA9F8ECB8FFE9 CRC64; MSRQSTLYSF FPKSPALSDA NKASARASRE GGRAAAAPGA SPSPGGDAAW SEAGPGPRPL ARSASPPKAK NLNGGLRRSV APAAPTSCDF SPGDLVWAKM EGYPWWPCLV YNHPFDGTFI REKGKSVRVH VQFFDDSPTR GWVSKRLLKP YTGSKSKEAQ KGGHFYSAKP EILRAMQRAD EALNKDKIKR LELAVCDEPS EPEEEEEMEV GTTYVTDKSE EDNEIESEEE VQPKTQGSRR SSRQIKKRRV ISDSESDIGG SDVEFKPDTK EEGSSDEISS GVGDSESEGL NSPVKVARKR KRMVTGNGSL KRKSSRKETP SATKQATSIS SETKNTLRAF SAPQNSESQA HVSGGGDDSS RPTVWYHETL EWLKEEKRRD EHRRRPDHPD FDASTLYVPE DFLNSCTPGM RKWWQIKSQN FDLVICYKVG KFYELYHMDA LIGVSELGLV FMKGNWAHSG FPEIAFGRYS DSLVQKGYKV ARVEQTETPE MMEARCRKMA HISKYDRVVR REICRIITKG TQTYSVLEGD PSENYSKYLL SLKEKEEDSS GHTRAYGVCF VDTSLGKFFI GQFSDDRHCS RFRTLVAHYP PVQVLFEKGN LSKETKTILK SSLSCSLQEG LIPGSQFWDA SKTLRTLLEE EYFREKLSDG IGVMLPQVLK GMTSESDSIG LTPGEKSELA LSALGGCVFY LKKCLIDQEL LSMANFEEYI PLDSDTVSTT RSGAIFTKAY QRMVLDAVTL NNLEIFLNGT NGSTEGTLLE RVDTCHTPFG KRLLKQWLCA PLCNHYAIND RLDAIEDLMV VPDKISEVVE LLKKLPDLER LLSKIHNVGS PLKSQNHPDS RAIMYEETTY SKKKIIDFLS ALEGFKVMCK IIGIMEEVAD GFKSKILKQV ISLQTKNPEG RFPDLTVELN RWDTAFDHEK ARKTGLITPK AGFDSDYDQA LADIRENEQS LLEYLEKQRN RIGCRTIVYW GIGRNRYQLE IPENFTTRNL PEEYELKSTK KGCKRYWTKT IEKKLANLIN AEERRDVSLK DCMRRLFYNF DKNYKDWQSA VECIAVLDVL LCLANYSRGG DGPMCRPVIL LPEDTPPFLE LKGSRHPCIT KTFFGDDFIP NDILIGCEEE EQENGKAYCV LVTGPNMGGK STLMRQAGLL AVMAQMGCYV PAEVCRLTPI DRVFTRLGAS DRIMSGESTF FVELSETASI LMHATAHSLV LVDELGRGTA TFDGTAIANA VVKELAETIK CRTLFSTHYH SLVEDYSQNV AVRLGHMACM VENECEDPSQ ETITFLYKFI KGACPKSYGF NAARLANLPE EVIQKGHRKA REFEKMNQSL RLFREVCLAS ERSTVDAEAV HKLLTLIKEL // ID NTRK2_HUMAN Reviewed; 822 AA. AC Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 249. DE RecName: Full=BDNF/NT-3 growth factors receptor; DE EC=2.7.10.1 {ECO:0000269|PubMed:15494731}; DE AltName: Full=GP145-TrkB; DE Short=Trk-B; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 2; DE AltName: Full=TrkB tyrosine kinase; DE AltName: Full=Tropomyosin-related kinase B; DE Flags: Precursor; GN Name=NTRK2; Synonyms=TRKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB). RC TISSUE=Hippocampus; RX PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q; RA Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J., RA Nycum L.M., Biegel J.A., Brodeur G.M.; RT "Cloning and chromosomal localization of the human TRK-B tyrosine kinase RT receptor gene (NTRK2)."; RL Genomics 25:538-546(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1). RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Hippocampus; RX PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x; RA Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M., RA Colebrook S.M., Feeney R., Macgowan S.H.; RT "Cloning of a non-catalytic form of human trkB and distribution of RT messenger RNA for trkB in human brain."; RL Neuroscience 60:825-834(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5), RP ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11798182; DOI=10.1006/bbrc.2001.6301; RA Stoilov P., Castren E., Stamm S.; RT "Analysis of the human TrkB gene genomic organization reveals novel TrkB RT isoforms, unusual gene length, and splicing mechanism."; RL Biochem. Biophys. Res. Commun. 290:1054-1065(2002). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309. RA Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J., RA Methner A.; RT "Full length truncated TrkB sequence identified in a screen for genes RT regulated by ischemic preconditioning."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121; RP ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412. RX PubMed=7574684; DOI=10.1006/abbi.1995.1460; RA Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.; RT "Extracellular domain of neurotrophin receptor trkB: disulfide structure, RT N-glycosylation sites, and ligand binding."; RL Arch. Biochem. Biophys. 322:256-264(1995). RN [12] RP INTERACTION WITH FRS2. RX PubMed=10092678; DOI=10.1074/jbc.274.14.9861; RA Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.; RT "The signaling adapter FRS-2 competes with Shc for binding to the nerve RT growth factor receptor TrkA. A model for discriminating proliferation and RT differentiation."; RL J. Biol. Chem. 274:9861-9870(1999). RN [13] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [14] RP ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1). RX PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x; RA Luberg K., Wong J., Weickert C.S., Timmusk T.; RT "Human TrkB gene: novel alternative transcripts, protein isoforms and RT expression pattern in the prefrontal cerebral cortex during postnatal RT development."; RL J. Neurochem. 113:952-964(2010). RN [15] {ECO:0007744|PDB:1WWB} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [16] {ECO:0007744|PDB:1HCF} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND RP DISULFIDE BONDS. RX PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5; RA Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., RA Brady R.L.; RT "Specificity in Trk receptor:neurotrophin interactions: the crystal RT structure of TrkB-d5 in complex with neurotrophin-4/5."; RL Structure 9:1191-1199(2001). RN [17] RP INTERACTION WITH SLITRK2. RX PubMed=35840571; DOI=10.1038/s41467-022-31566-z; RA El Chehadeh S., Han K.A., Kim D., Jang G., Bakhtiari S., Lim D., Kim H.Y., RA Kim J., Kim H., Wynn J., Chung W.K., Vitiello G., Cutcutache I., Page M., RA Gecz J., Harper K., Han A.R., Kim H.M., Wessels M., Bayat A., Jaen A.F., RA Selicorni A., Maitz S., de Brouwer A.P.M., Silfhout A.V., Armstrong M., RA Symonds J., Kuery S., Isidor B., Cogne B., Nizon M., Feger C., Muller J., RA Torti E., Grange D.K., Willems M., Kruer M.C., Ko J., Piton A., Um J.W.; RT "SLITRK2 variants associated with neurodevelopmental disorders impair RT excitatory synaptic function and cognition in mice."; RL Nat. Commun. 13:4112-4112(2022). RN [18] RP VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS RP A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=15494731; DOI=10.1038/nn1336; RA Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., RA Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.; RT "A de novo mutation affecting human TrkB associated with severe obesity and RT developmental delay."; RL Nat. Neurosci. 7:1187-1189(2004). RN [19] RP VARIANT [LARGE SCALE ANALYSIS] PHE-138. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP VARIANTS ILE-697; GLY-699 AND CYS-718. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). RN [21] RP VARIANT OBHD 444-GLY--GLY-822 DEL. RX PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215; RA Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L., RA Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J., RA Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M., RA van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A., RA Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.; RT "Diagnostic value of exome and whole genome sequencing in RT craniosynostosis."; RL J. Med. Genet. 54:260-268(2017). RN [22] RP VARIANT DEE58 CYS-434, VARIANT OBHD ILE-704, AND INVOLVEMENT IN DEE58. RX PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008; RG Deciphering Developmental Disorders Study; RA Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D., RA Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M., RA Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W., RA Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C., RA Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N., RA Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A., RA Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q., RA Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N., RA Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K., RA Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C., RA Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S., RA Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G., RA O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C., RA Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R., RA Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M., RA Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G., RA Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z., RA Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C., RA Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E., RA Minassian B.A., Michaud J.L.; RT "High rate of recurrent de novo mutations in developmental and epileptic RT encephalopathies."; RL Am. J. Hum. Genet. 101:664-685(2017). CC -!- FUNCTION: Receptor tyrosine kinase involved in the development and the CC maturation of the central and the peripheral nervous systems through CC regulation of neuron survival, proliferation, migration, CC differentiation, and synapse formation and plasticity (By similarity). CC Receptor for BDNF/brain-derived neurotrophic factor and CC NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 CC which is less efficient in activating the receptor but regulates neuron CC survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand- CC binding, undergoes homodimerization, autophosphorylation and activation CC (PubMed:15494731). Recruits, phosphorylates and/or activates several CC downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that CC regulate distinct overlapping signaling cascades. Through SHC1, FRS2, CC SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for CC instance neuronal differentiation including neurite outgrowth. Through CC the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade CC that mainly regulates growth and survival. Through PLCG1 and the CC downstream protein kinase C-regulated pathways controls synaptic CC plasticity. Thereby, plays a role in learning and memory by regulating CC both short term synaptic function and long-term potentiation. PLCG1 CC also leads to NF-Kappa-B activation and the transcription of genes CC involved in cell survival. Hence, it is able to suppress anoikis, the CC apoptosis resulting from loss of cell-matrix interactions. May also CC play a role in neutrophin-dependent calcium signaling in glial cells CC and mediate communication between neurons and glia. CC {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:7574684}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15494731}; CC -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium CC positively regulate the kinase activity and the internalization of the CC receptor which are both important for active signaling. Regulated by CC NGFR that may control the internalization of the receptor. NGFR may CC also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A CC inhibits the autophosphorylation of the receptor, and alters the CC recruitment and activation of downstream effectors and signaling CC cascades. The formation of active receptors dimers able to fully CC transduce the ligand-mediated signal, may be negatively regulated by CC the formation of inactive heterodimers with the non-catalytic isoforms CC (By similarity). {ECO:0000250|UniProtKB:P15209, CC ECO:0000250|UniProtKB:Q63604}. CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures. Interacts CC (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 CC phosphorylation and activation. Interacts (phosphorylated upon CC activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 CC phosphorylation and activation. Interacts with SH2B1 and SH2B2. CC Interacts with NGFR; may regulate the ligand specificity of the CC receptor (By similarity). Interacts with SORCS2; this interaction is CC important for normal targeting to post-synaptic densities in response CC to high-frequency stimulation (By similarity). Interacts CC (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. CC Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC (phosphorylated upon ligand-binding) with FRS2; activates the MAPK CC signaling pathway (PubMed:10092678). Interacts with APPL1 (By CC similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with CC KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with CC SORL1; this interaction facilitates NTRK2 trafficking between synaptic CC plasma membranes, postsynaptic densities and cell soma, hence CC positively regulates BDNF signaling (By similarity). Interacts with CC SLITRK2 (PubMed:35840571). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604, CC ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045, CC ECO:0000269|PubMed:35840571}. CC -!- INTERACTION: CC Q16620; P00533: EGFR; NbExp=3; IntAct=EBI-3904881, EBI-297353; CC Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704; CC Q16620; Q13485: SMAD4; NbExp=4; IntAct=EBI-3904881, EBI-347263; CC Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731}; CC Single-pass type I membrane protein {ECO:0000305}. Endosome membrane CC {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein CC {ECO:0000250|UniProtKB:P15209}. Early endosome membrane CC {ECO:0000250|UniProtKB:P15209}. Cell projection, axon CC {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region CC {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density CC {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon CC ligand-binding. {ECO:0000250|UniProtKB:P15209}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Comment=Additional isoforms seem to exist.; CC Name=TrkB; Synonyms=gp145-TrkB; CC IsoId=Q16620-1; Sequence=Displayed; CC Name=TrkB-T1; CC IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902; CC Name=TrkB-T-Shc; CC IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904; CC Name=4; CC IsoId=Q16620-4; Sequence=VSP_041942; CC Name=5; CC IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904; CC Name=TrkB-T-TK; CC IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179; CC Name=TrkB-N-T1; CC IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902; CC -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and CC peripheral nervous system. In the central nervous system (CNS), CC expression is observed in the cerebral cortex, hippocampus, thalamus, CC choroid plexus, granular layer of the cerebellum, brain stem, and CC spinal cord. In the peripheral nervous system, it is expressed in many CC cranial ganglia, the ophthalmic nerve, the vestibular system, multiple CC facial structures, the submaxillary glands, and dorsal root ganglia. CC Isoform TrkB-T1 is mainly expressed in the brain but also detected in CC other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc CC is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182, CC ECO:0000269|PubMed:7936202}. CC -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain. CC {ECO:0000269|PubMed:7936202}. CC -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that CC is required for interaction with SHC1 and PLCG1 and other downstream CC effectors. Isoform TrkB-T-Shc is not phosphorylated. CC {ECO:0000269|PubMed:15494731}. CC -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation; CC regulated by NGFR. Ubiquitination regulates the internalization of the CC receptor (By similarity). {ECO:0000250}. CC -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58) CC [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE58 is an autosomal dominant condition characterized CC by onset of refractory seizures in the first days or months of life. CC {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD) CC [MIM:613886]: A disorder characterized by early-onset obesity, CC hyperphagia, and severe developmental delay in motor function, speech, CC and language. {ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the CC first Trk was isolated as an oncogenic protein which was the result of CC a fusion between the tropomyosin gene TPM3 and NTRK1. CC -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41589/NTRK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U12140; AAC51371.1; -; mRNA. DR EMBL; S76473; AAB33109.1; -; mRNA. DR EMBL; S76474; AAB33110.1; -; mRNA. DR EMBL; X75958; CAA53571.1; -; mRNA. DR EMBL; AF410899; AAL67965.1; -; mRNA. DR EMBL; AF410900; AAL67966.1; -; mRNA. DR EMBL; AF410901; AAL67967.1; -; mRNA. DR EMBL; AF508964; AAM77876.1; -; mRNA. DR EMBL; AB209118; BAD92355.1; -; mRNA. DR EMBL; AK294285; BAG57570.1; -; mRNA. DR EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62688.1; -; Genomic_DNA. DR EMBL; BC031835; AAH31835.1; -; mRNA. DR CCDS; CCDS35050.1; -. [Q16620-1] DR CCDS; CCDS35051.1; -. [Q16620-5] DR CCDS; CCDS35052.1; -. [Q16620-3] DR CCDS; CCDS35053.1; -. [Q16620-2] DR CCDS; CCDS6671.1; -. [Q16620-4] DR CCDS; CCDS94429.1; -. [Q16620-7] DR PIR; A56853; A56853. DR PIR; I73631; I73631. DR RefSeq; NP_001007098.1; NM_001007097.3. [Q16620-2] DR RefSeq; NP_001018074.1; NM_001018064.3. [Q16620-1] DR RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5] DR RefSeq; NP_001018076.1; NM_001018066.3. [Q16620-3] DR RefSeq; NP_001356461.1; NM_001369532.1. [Q16620-1] DR RefSeq; NP_001356462.1; NM_001369533.1. [Q16620-1] DR RefSeq; NP_001356466.1; NM_001369537.1. [Q16620-5] DR RefSeq; NP_001356467.1; NM_001369538.1. [Q16620-3] DR RefSeq; NP_001356468.1; NM_001369539.1. [Q16620-2] DR RefSeq; NP_001356469.1; NM_001369540.1. [Q16620-2] DR RefSeq; NP_001356470.1; NM_001369541.1. [Q16620-2] DR RefSeq; NP_001356471.1; NM_001369542.1. [Q16620-2] DR RefSeq; NP_001356472.1; NM_001369543.1. [Q16620-2] DR RefSeq; NP_001356473.1; NM_001369544.1. [Q16620-2] DR RefSeq; NP_001356474.1; NM_001369545.1. [Q16620-2] DR RefSeq; NP_001356477.1; NM_001369548.1. [Q16620-2] DR RefSeq; NP_001356478.1; NM_001369549.1. [Q16620-2] DR RefSeq; NP_001356479.1; NM_001369550.1. [Q16620-7] DR RefSeq; NP_001356480.1; NM_001369551.1. [Q16620-7] DR RefSeq; NP_001356481.1; NM_001369552.1. [Q16620-7] DR RefSeq; NP_006171.2; NM_006180.4. [Q16620-4] DR RefSeq; XP_005252058.1; XM_005252001.4. [Q16620-4] DR RefSeq; XP_005252060.1; XM_005252003.4. [Q16620-4] DR RefSeq; XP_005252061.1; XM_005252004.3. [Q16620-4] DR RefSeq; XP_011517020.1; XM_011518718.4. [Q16620-1] DR RefSeq; XP_016870240.1; XM_017014751.3. [Q16620-4] DR RefSeq; XP_016870241.1; XM_017014752.2. [Q16620-1] DR RefSeq; XP_016870242.1; XM_017014753.3. [Q16620-1] DR RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5] DR RefSeq; XP_016870249.1; XM_017014760.3. [Q16620-2] DR RefSeq; XP_047279388.1; XM_047423432.1. [Q16620-4] DR RefSeq; XP_047279389.1; XM_047423433.1. [Q16620-4] DR RefSeq; XP_054218993.1; XM_054363018.1. [Q16620-4] DR RefSeq; XP_054218994.1; XM_054363019.1. [Q16620-4] DR RefSeq; XP_054218995.1; XM_054363020.1. [Q16620-4] DR RefSeq; XP_054218996.1; XM_054363021.1. [Q16620-4] DR RefSeq; XP_054218997.1; XM_054363022.1. [Q16620-4] DR RefSeq; XP_054218998.1; XM_054363023.1. [Q16620-4] DR RefSeq; XP_054218999.1; XM_054363024.1. [Q16620-1] DR RefSeq; XP_054219000.1; XM_054363025.1. [Q16620-1] DR RefSeq; XP_054219001.1; XM_054363026.1. [Q16620-1] DR RefSeq; XP_054219002.1; XM_054363027.1. [Q16620-5] DR RefSeq; XP_054219003.1; XM_054363028.1. [Q16620-2] DR PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383. DR PDB; 1WWB; X-ray; 2.10 A; X=283-385. DR PDB; 2MFQ; NMR; -; B=497-519. DR PDB; 4ASZ; X-ray; 1.70 A; A=527-822. DR PDB; 4AT3; X-ray; 1.77 A; A=527-822. DR PDB; 4AT4; X-ray; 2.36 A; A=527-822. DR PDB; 4AT5; X-ray; 1.71 A; A=527-822. DR PDB; 5MO9; X-ray; 2.59 A; X=278-426. DR PDB; 8OYD; NMR; -; A/B=422-466. DR PDBsum; 1HCF; -. DR PDBsum; 1WWB; -. DR PDBsum; 2MFQ; -. DR PDBsum; 4ASZ; -. DR PDBsum; 4AT3; -. DR PDBsum; 4AT4; -. DR PDBsum; 4AT5; -. DR PDBsum; 5MO9; -. DR PDBsum; 8OYD; -. DR AlphaFoldDB; Q16620; -. DR SMR; Q16620; -. DR BioGRID; 110970; 137. DR DIP; DIP-5720N; -. DR FunCoup; Q16620; 1218. DR IntAct; Q16620; 116. DR MINT; Q16620; -. DR STRING; 9606.ENSP00000277120; -. DR BindingDB; Q16620; -. DR ChEMBL; CHEMBL4898; -. DR DrugBank; DB00321; Amitriptyline. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB11823; Esketamine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16620; -. DR GuidetoPHARMACOLOGY; 1818; -. DR TCDB; 8.A.23.1.38; the basigin (basigin) family. DR GlyConnect; 1029; 12 N-Linked glycans (7 sites). DR GlyCosmos; Q16620; 13 sites, 14 glycans. DR GlyGen; Q16620; 13 sites, 21 N-linked glycans (8 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q16620; -. DR PhosphoSitePlus; Q16620; -. DR SwissPalm; Q16620; -. DR BioMuta; NTRK2; -. DR DMDM; 2497560; -. DR jPOST; Q16620; -. DR MassIVE; Q16620; -. DR PaxDb; 9606-ENSP00000277120; -. DR PeptideAtlas; Q16620; -. DR ProteomicsDB; 60955; -. [Q16620-1] DR ProteomicsDB; 60956; -. [Q16620-2] DR ProteomicsDB; 60957; -. [Q16620-3] DR ProteomicsDB; 60958; -. [Q16620-4] DR ProteomicsDB; 60959; -. [Q16620-5] DR ProteomicsDB; 60960; -. [Q16620-6] DR ProteomicsDB; 60961; -. [Q16620-7] DR ABCD; Q16620; 146 sequenced antibodies. DR Antibodypedia; 2081; 1498 antibodies from 49 providers. DR DNASU; 4915; -. DR Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.19. [Q16620-7] DR Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.19. [Q16620-5] DR GeneID; 4915; -. DR KEGG; hsa:4915; -. DR MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4] DR UCSC; uc004anz.1; human. [Q16620-1] DR AGR; HGNC:8032; -. DR CIViC; 4915; 5 evidence items across 2 molecular profiles. DR ClinPGx; PA31818; -. DR CTD; 4915; -. DR DisGeNET; 4915; -. DR GeneCards; NTRK2; -. DR HGNC; HGNC:8032; NTRK2. DR HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland). DR MalaCards; NTRK2; -. DR MIM; 600456; gene. DR MIM; 613886; phenotype. DR MIM; 617830; phenotype. DR OpenTargets; ENSG00000148053; -. DR Orphanet; 99704; Early-onset obesity-hyperphagia-severe developmental delay syndrome. DR Orphanet; 697160; Infantile epileptic spasms syndrome. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000148053; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155181; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16620; -. DR OMA; HIAMQIA; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16620; 16 GO annotations based on evolutionary models. DR PhylomeDB; Q16620; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16620; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-187024; NGF-independant TRKA activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1. DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN. DR Reactome; R-HSA-9032759; NTRK2 activates RAC1. DR Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5. DR SignaLink; Q16620; -. DR SIGNOR; Q16620; -. DR Agora; ENSG00000148053; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4915; 10 hits in 1188 CRISPR screens. DR ChiTaRS; NTRK2; human. DR EvolutionaryTrace; Q16620; -. DR GeneWiki; TrkB_receptor; -. DR GenomeRNAi; 4915; -. DR Pharos; Q16620; Tclin. DR PRO; PR:Q16620; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q16620; protein. DR Bgee; ENSG00000148053; Expressed in cranial nerve II and 196 other cell types or tissues. DR ExpressionAtlas; Q16620; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; ISS:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0043195; C:terminal bouton; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB. DR GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB. DR GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:ARUK-UCL. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central. DR GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0007631; P:feeding behavior; IEA:Ensembl. DR GO; GO:0014047; P:glutamate secretion; IEA:Ensembl. DR GO; GO:0007612; P:learning; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl. DR GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd05855; IgI_TrkB_d5; 1. DR CDD; cd05093; PTKc_TrkB; 1. DR DisProt; DP03945; -. DR FunFam; 2.60.40.10:FF:000239; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 3.80.10.10:FF:000048; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 1.10.510.10:FF:000034; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000486; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00672; -. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020455; NTRK2. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF136; BDNF_NT-3 GROWTH FACTORS RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01941; NTKRECEPTOR2. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Cytoplasm; Developmental protein; Differentiation; KW Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Obesity; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Synapse; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..31 FT CHAIN 32..822 FT /note="BDNF/NT-3 growth factors receptor" FT /id="PRO_0000016727" FT TOPO_DOM 32..430 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 431..454 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 455..822 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..61 FT /note="LRRNT" FT REPEAT 92..113 FT /note="LRR 1" FT REPEAT 116..137 FT /note="LRR 2" FT DOMAIN 148..196 FT /note="LRRCT" FT DOMAIN 197..282 FT /note="Ig-like C2-type 1" FT DOMAIN 295..365 FT /note="Ig-like C2-type 2" FT DOMAIN 538..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 455..466 FT /note="Interaction with MAPK8IP3/JIP3" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT REGION 475..498 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 485..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 676 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 706 FT /note="Interaction with SH2D1A" FT /evidence="ECO:0000250" FT SITE 817 FT /note="Interaction with PLCG1" FT /evidence="ECO:0000250" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P15209" FT MOD_RES 702 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 706 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 707 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 817 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 95 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 254 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 325 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 338 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT DISULFID 32..38 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 36..45 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 152..176 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 154..194 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 218..266 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 302..345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045, FT ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF, FT ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9" FT VAR_SEQ 1..156 FT /note="Missing (in isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042177" FT VAR_SEQ 465 FT /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_041942" FT VAR_SEQ 467..477 FT /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and FT isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002901" FT VAR_SEQ 478..822 FT /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002902" FT VAR_SEQ 529..537 FT /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002903" FT VAR_SEQ 538..822 FT /note="Missing (in isoform TrkB-T-Shc and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002904" FT VAR_SEQ 710..735 FT /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL FT LRLS (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042178" FT VAR_SEQ 736..822 FT /note="Missing (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042179" FT VARIANT 138 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041470" FT VARIANT 309 FT /note="G -> R" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_016320" FT VARIANT 338 FT /note="N -> Y (in dbSNP:rs1047856)" FT /id="VAR_011973" FT VARIANT 434 FT /note="Y -> C (in DEE58; uncertain significance; FT dbSNP:rs886041091)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080659" FT VARIANT 444..822 FT /note="Missing (in OBHD)" FT /evidence="ECO:0000269|PubMed:27884935" FT /id="VAR_080660" FT VARIANT 545 FT /note="G -> V (in dbSNP:rs1075108)" FT /id="VAR_049715" FT VARIANT 697 FT /note="M -> I (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046518" FT VARIANT 699 FT /note="R -> G (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046519" FT VARIANT 704 FT /note="T -> I (in OBHD; uncertain significance; FT dbSNP:rs1554774973)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080661" FT VARIANT 706 FT /note="Y -> C (in OBHD; expressed normally on the cell FT surface; results in markedly impaired ligand-induced FT phosphorylation as well as impaired downstream MAPK1 FT phosphorylation; dbSNP:rs121434633)" FT /evidence="ECO:0000269|PubMed:15494731" FT /id="VAR_065890" FT VARIANT 718 FT /note="R -> C (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs1324578301)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046520" FT STRAND 285..292 FT /evidence="ECO:0007829|PDB:5MO9" FT STRAND 300..308 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 328..337 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 339..350 FT /evidence="ECO:0007829|PDB:1WWB" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 357..364 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 369..376 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 380..382 FT /evidence="ECO:0007829|PDB:5MO9" FT HELIX 428..460 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 462..464 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:2MFQ" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:2MFQ" FT TURN 515..517 FT /evidence="ECO:0007829|PDB:2MFQ" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 538..545 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 552..557 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 567..574 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 579..592 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 634..638 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:4AT5" FT HELIX 650..669 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 679..681 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 682..684 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 686..688 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 690..692 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 698..701 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 713..715 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 722..727 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 732..747 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 748..750 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 753..756 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 759..768 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 780..789 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 794..796 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 800..813 FT /evidence="ECO:0007829|PDB:4ASZ" SQ SEQUENCE 822 AA; 91999 MW; 2FEB9159948F0D13 CRC64; MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG // ID RIPK1_HUMAN Reviewed; 671 AA. AC Q13546; A0AV89; B2RAG1; B4E3F9; Q13180; Q59H33; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-2005, sequence version 3. DT 28-JAN-2026, entry version 243. DE RecName: Full=Receptor-interacting serine/threonine-protein kinase 1; DE EC=2.7.11.1 {ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; DE AltName: Full=Cell death protein RIP {ECO:0000303|PubMed:8612133}; DE AltName: Full=Receptor-interacting protein 1 {ECO:0000303|PubMed:16603398}; DE Short=RIP-1 {ECO:0000303|PubMed:16603398}; GN Name=RIPK1 {ECO:0000312|HGNC:HGNC:10019}; GN Synonyms=RIP {ECO:0000303|PubMed:8612133}, GN RIP1 {ECO:0000303|PubMed:16603398}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-45, INTERACTION WITH TRADD; TRAF1; RP TRAF2 AND TRAF3, AND VARIANT VAL-438. RC TISSUE=Umbilical vein endothelial cell; RX PubMed=8612133; DOI=10.1016/s1074-7613(00)80252-6; RA Hsu H., Huang J., Shu H.-B., Baichwal V.R., Goeddel D.V.; RT "TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 RT signaling complex."; RL Immunity 4:387-396(1996). RN [2] RP SEQUENCE REVISION TO 120. RA Huang J., Hsu H., Baichwal V.R., Goeddel D.V.; RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 15-671 (ISOFORM 2). RC TISSUE=Adrenal gland, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-234. RG SeattleSNPs variation discovery resource; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-438. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 153-671. RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 300-671, AND VARIANT VAL-438. RC TISSUE=Leukemic T-cell; RX PubMed=7538908; DOI=10.1016/0092-8674(95)90072-1; RA Stanger B.Z., Leder P., Lee T.-H., Kim E., Seed B.; RT "RIP: a novel protein containing a death domain that interacts with RT Fas/APO-1 (CD95) in yeast and causes cell death."; RL Cell 81:513-523(1995). RN [9] RP INTERACTION WITH CRADD, AND DOMAIN. RX PubMed=9044836; RA Ahmad M., Srinivasula S.M., Wang L., Talanian R.V., Litwack G., RA Fernandes-Alnemri T., Alnemri E.S.; RT "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and RT FasL/tumor necrosis factor receptor-interacting protein RIP."; RL Cancer Res. 57:615-619(1997). RN [10] RP CLEAVAGE BY CASP8, AND MUTAGENESIS OF ASP-324. RX PubMed=10521396; DOI=10.1101/gad.13.19.2514; RA Lin Y., Devin A., Rodriguez Y., Liu Z.-G.; RT "Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced RT apoptosis."; RL Genes Dev. 13:2514-2526(1999). RN [11] RP INTERACTION WITH SQSTM1 AND TRAF2, AND DOMAIN DEATH. RX PubMed=10356400; DOI=10.1093/emboj/18.11.3044; RA Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.; RT "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB RT activation."; RL EMBO J. 18:3044-3053(1999). RN [12] RP INTERACTION WITH RIPK3. RX PubMed=10358032; DOI=10.1074/jbc.274.24.16871; RA Sun X., Lee J., Navas T., Baldwin D.T., Stewart T.A., Dixit V.M.; RT "RIP3, a novel apoptosis-inducing kinase."; RL J. Biol. Chem. 274:16871-16875(1999). RN [13] RP INTERACTION WITH BNLF1. RX PubMed=10409763; DOI=10.1128/mcb.19.8.5759; RA Izumi K.M., Cahir McFarland E., Ting A.T., Riley E.A., Seed B., Kieff E.D.; RT "The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the RT tumor necrosis factor receptor-associated proteins TRADD and receptor- RT interacting protein (RIP) but does not induce apoptosis or require RIP for RT NF-kappaB activation."; RL Mol. Cell. Biol. 19:5759-5767(1999). RN [14] RP INTERACTION WITH IKBKG. RX PubMed=9927690; DOI=10.1073/pnas.96.3.1042; RA Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A., RA Wallach D., Horwitz M.S.; RT "Identification of a cell protein (FIP-3) as a modulator of NF-kappaB RT activity and as a target of an adenovirus inhibitor of tumor necrosis RT factor alpha-induced apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 96:1042-1047(1999). RN [15] RP FUNCTION. RX PubMed=11101870; DOI=10.1038/82732; RA Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., RA Bodmer J.L., Schneider P., Seed B., Tschopp J.; RT "Fas triggers an alternative, caspase-8-independent cell death pathway RT using the kinase RIP as effector molecule."; RL Nat. Immunol. 1:489-495(2000). RN [16] RP INTERACTION WITH EGFR. RX PubMed=11116146; DOI=10.1074/jbc.m008458200; RA Habib A.A., Chatterjee S., Park S.-K., Ratan R.R., Lefebvre S., RA Vartanian T.; RT "The epidermal growth factor receptor engages receptor interacting protein RT and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF- RT kappa B. Identification of a novel receptor-tyrosine kinase signalosome."; RL J. Biol. Chem. 276:8865-8874(2001). RN [17] RP INTERACTION WITH RNF216. RX PubMed=11854271; DOI=10.1074/jbc.m108675200; RA Chen D., Li X., Zhai Z., Shu H.-B.; RT "A novel zinc finger protein interacts with receptor-interacting protein RT (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B RT activation."; RL J. Biol. Chem. 277:15985-15991(2002). RN [18] RP RIP HOMOTYPIC INTERACTION MOTIF, AND INTERACTION WITH RIPK3. RX PubMed=11734559; DOI=10.1074/jbc.m109488200; RA Sun X., Yin J., Starovasnik M.A., Fairbrother W.J., Dixit V.M.; RT "Identification of a novel homotypic interaction motif required for the RT phosphorylation of receptor-interacting protein (RIP) by RIP3."; RL J. Biol. Chem. 277:9505-9511(2002). RN [19] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-384, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [20] RP INTERACTION WITH ZFAND5. RX PubMed=14754897; DOI=10.1074/jbc.m309491200; RA Huang J., Teng L., Li L., Liu T., Li L., Chen D., Xu L.-G., Zhai Z., RA Shu H.-B.; RT "ZNF216 is an A20-like and IkappaB kinase gamma-interacting inhibitor of RT NFkappaB activation."; RL J. Biol. Chem. 279:16847-16853(2004). RN [21] RP INTERACTION WITH DAB2IP. RX PubMed=15310755; DOI=10.1074/jbc.m407617200; RA Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.; RT "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2- RT induced ASK1-JNK activation."; RL J. Biol. Chem. 279:44955-44965(2004). RN [22] RP UBIQUITINATION BY TRAF2, AND DEUBIQUITINATION BY TNFAIP3. RX PubMed=15258597; DOI=10.1038/nature02794; RA Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., RA Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M.; RT "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF- RT kappaB signalling."; RL Nature 430:694-699(2004). RN [23] RP INTERACTION WITH MAVS. RX PubMed=16127453; DOI=10.1038/ni1243; RA Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., RA Takeuchi O., Akira S.; RT "IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon RT induction."; RL Nat. Immunol. 6:981-988(2005). RN [24] RP UBIQUITINATION AT LYS-377, AND MUTAGENESIS OF LYS-377. RX PubMed=16603398; DOI=10.1016/j.molcel.2006.03.026; RA Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J.; RT "Activation of IKK by TNFalpha requires site-specific ubiquitination of RT RIP1 and polyubiquitin binding by NEMO."; RL Mol. Cell 22:245-257(2006). RN [25] RP INTERACTION WITH TAX1BP1, FUNCTION, AND UBIQUITINATION. RX PubMed=17703191; DOI=10.1038/sj.emboj.7601823; RA Shembade N., Harhaj N.S., Liebl D.J., Harhaj E.W.; RT "Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and RT LPS-mediated NF-kappaB and JNK signaling."; RL EMBO J. 26:3910-3922(2007). RN [26] RP REVIEW. RX PubMed=17301840; DOI=10.1038/sj.cdd.4402085; RA Festjens N., Vanden Berghe T., Cornelis S., Vandenabeele P.; RT "RIP1, a kinase on the crossroads of a cell's decision to live or die."; RL Cell Death Differ. 14:400-410(2007). RN [27] RP FUNCTION IN PHOSPHORYLATION OF DAB2IP, AND INTERACTION WITH DAB2IP. RX PubMed=17389591; DOI=10.1074/jbc.m701148200; RA Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.; RT "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical RT for tumor necrosis factor-induced ASK1-JNK/p38 activation."; RL J. Biol. Chem. 282:14788-14796(2007). RN [28] RP INTERACTION WITH RBCK1. RX PubMed=17449468; DOI=10.1074/jbc.m701913200; RA Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M., RA Chen D.Y., Zhai Z.H., Shu H.B.; RT "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1- RT triggered NF-kappaB activation by targeting TAB2/3 for degradation."; RL J. Biol. Chem. 282:16776-16782(2007). RN [29] RP INTERACTION WITH RFFL, AND UBIQUITINATION BY RFFL. RX PubMed=18450452; DOI=10.1016/j.cub.2008.04.017; RA Liao W., Xiao Q., Tchikov V., Fujita K., Yang W., Wincovitch S., RA Garfield S., Conze D., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates RT TNF-induced NF-kappaB activation."; RL Curr. Biol. 18:641-649(2008). RN [30] RP MUTAGENESIS OF SER-161, INHIBITION BY NECROSTATIN-1, AND PHOSPHORYLATION AT RP SER-6; SER-20; SER-25; SER-161; SER-166; SER-303; SER-320 AND SER-333. RX PubMed=18408713; DOI=10.1038/nchembio.83; RA Degterev A., Hitomi J., Germscheid M., Ch'en I.L., Korkina O., Teng X., RA Abbott D., Cuny G.D., Yuan C., Wagner G., Hedrick S.M., Gerber S.A., RA Lugovskoy A., Yuan J.; RT "Identification of RIP1 kinase as a specific cellular target of RT necrostatins."; RL Nat. Chem. Biol. 4:313-321(2008). RN [31] RP INTERACTION WITH MURID HERPESVIRUS 1 PROTEIN RIR1. RX PubMed=18442983; DOI=10.1074/jbc.c800051200; RA Upton J.W., Kaiser W.J., Mocarski E.S.; RT "Cytomegalovirus M45 cell death suppression requires receptor-interacting RT protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RT RIP1."; RL J. Biol. Chem. 283:16966-16970(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, AND PHOSPHORYLATION. RX PubMed=19524513; DOI=10.1016/j.cell.2009.05.037; RA Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., RA Chan F.K.; RT "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates RT programmed necrosis and virus-induced inflammation."; RL Cell 137:1112-1123(2009). RN [34] RP FUNCTION, AND INTERACTION WITH RIPK3. RX PubMed=19524512; DOI=10.1016/j.cell.2009.05.021; RA He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X.; RT "Receptor interacting protein kinase-3 determines cellular necrotic RT response to TNF-alpha."; RL Cell 137:1100-1111(2009). RN [35] RP INTERACTION WITH RNF34, AND UBIQUITINATION BY RNF34. RX DOI=10.1016/j.cub.2008.11.041; RA Liao W., Fujita K., Xiao Q., Tchikov V., Yang W., Gunsor M., Garfield S., RA Goldsmith P., El-Deiry W.S., Schuetze S., Srinivasula S.M.; RT "Response: CARP1 regulates induction of NF-kappaB by TNFalpha."; RL Curr. Biol. 19:R17-R19(2009). RN [36] RP REVIEW. RX PubMed=20354226; DOI=10.1126/scisignal.3115re4; RA Vandenabeele P., Declercq W., Van Herreweghe F., Vanden Berghe T.; RT "The role of the kinases RIP1 and RIP3 in TNF-induced necrosis."; RL Sci. Signal. 3:RE4-RE4(2010). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP UBIQUITINATION BY THE LUBAC COMPLEX. RX PubMed=21455173; DOI=10.1038/nature09816; RA Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., RA Haas T.L., Webb A.I., Rickard J.A., Anderton H., Wong W.W., Nachbur U., RA Gangoda L., Warnken U., Purcell A.W., Silke J., Walczak H.; RT "Linear ubiquitination prevents inflammation and regulates immune RT signalling."; RL Nature 471:591-596(2011). RN [39] RP UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH RP BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4. RX PubMed=21931591; DOI=10.1371/journal.pone.0022356; RA Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J., RA Gevaert K., Declercq W., Vandenabeele P.; RT "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin RT chains to receptor interacting proteins kinases 1 to 4 (RIP1-4)."; RL PLoS ONE 6:E22356-E22356(2011). RN [40] RP IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK3 AND MLKL. RX PubMed=22265414; DOI=10.1016/j.cell.2011.11.030; RA Wang Z., Jiang H., Chen S., Du F., Wang X.; RT "The mitochondrial phosphatase PGAM5 functions at the convergence point of RT multiple necrotic death pathways."; RL Cell 148:228-243(2012). RN [41] RP INTERACTION WITH ARHGEF2. RX PubMed=21887730; DOI=10.1002/ibd.21851; RA Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B., RA Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.; RT "Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1."; RL Inflamm. Bowel Dis. 18:603-612(2012). RN [42] RP INTERACTION WITH DDX24. RX PubMed=24204270; DOI=10.1371/journal.ppat.1003721; RA Ma Z., Moore R., Xu X., Barber G.N.; RT "DDX24 negatively regulates cytosolic RNA-mediated innate immune RT signaling."; RL PLoS Pathog. 9:e1003721-e1003721(2013). RN [43] RP PROTEOLYTIC CLEAVAGE. RX PubMed=22858542; DOI=10.1038/cdd.2012.98; RA van Raam B.J., Ehrnhoefer D.E., Hayden M.R., Salvesen G.S.; RT "Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase- RT 6."; RL Cell Death Differ. 20:86-96(2013). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-320, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [45] RP FUNCTION, AND DEUBIQUITINATION BY USP7. RX PubMed=24144979; DOI=10.1128/mcb.00465-13; RA Zaman M.M., Nomura T., Takagi T., Okamura T., Jin W., Shinagawa T., RA Tanaka Y., Ishii S.; RT "Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor RT necrosis factor alpha-induced apoptosis."; RL Mol. Cell. Biol. 33:4971-4984(2013). RN [46] RP GLYCOSYLATION AT ARG-603 (MICROBIAL INFECTION). RX PubMed=23955153; DOI=10.1038/nature12436; RA Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L., RA Chen X., Chen S., Shao F.; RT "Pathogen blocks host death receptor signalling by arginine GlcNAcylation RT of death domains."; RL Nature 501:242-246(2013). RN [47] RP INTERACTION WITH TNFRSF1A. RX PubMed=24130170; DOI=10.1093/carcin/bgt338; RA Kim T.W., Kang Y.K., Park Z.Y., Kim Y.H., Hong S.W., Oh S.J., Sohn H.A., RA Yang S.J., Jang Y.J., Lee D.C., Kim S.Y., Yoo H.S., Kim E., Yeom Y.I., RA Park K.C.; RT "SH3RF2 functions as an oncogene by mediating PAK4 protein stability."; RL Carcinogenesis 35:624-634(2014). RN [48] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [49] RP REVIEW. RX PubMed=25459879; DOI=10.1016/j.molcel.2014.11.001; RA Weinlich R., Green D.R.; RT "The two faces of receptor interacting protein kinase-1."; RL Mol. Cell 56:469-480(2014). RN [50] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [51] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 AND 2 PROTEIN RIR1 (MICROBIAL RP INFECTION). RX PubMed=25674983; DOI=10.1016/j.chom.2015.01.003; RA Guo H., Omoto S., Harris P.A., Finger J.N., Bertin J., Gough P.J., RA Kaiser W.J., Mocarski E.S.; RT "Herpes simplex virus suppresses necroptosis in human cells."; RL Cell Host Microbe 17:243-251(2015). RN [52] RP INTERACTION WITH MUMPS VIRUS PROTEIN SH (MICROBIAL INFECTION). RX PubMed=28659487; DOI=10.1128/jvi.01037-17; RA Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M., RA Finsterbusch T., Geyer H., Mankertz A., Friedrich N.; RT "Mumps virus SH protein inhibits NF-kappaB activation by interacting with RT tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like RT receptor 3 complexes."; RL J. Virol. 91:0-0(2017). RN [53] RP INTERACTION WITH PELI1 AND RIPK3, AND UBIQUITINATION BY PELI1. RX PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016; RA Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K., RA Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.; RT "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent RT proteasomal degradation."; RL Mol. Cell 70:920-935(2018). RN [54] RP FUNCTION, SUBUNIT, MUTAGENESIS OF LYS-599, AND PHOSPHORYLATION AT SER-166. RX PubMed=29440439; DOI=10.1073/pnas.1722013115; RA Meng H., Liu Z., Li X., Wang H., Jin T., Wu G., Shan B., RA Christofferson D.E., Qi C., Yu Q., Li Y., Yuan J.; RT "Death-domain dimerization-mediated activation of RIPK1 controls RT necroptosis and RIPK1-dependent apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 115:E2001-E2009(2018). RN [55] RP INVOLVEMENT IN IMD57. RX PubMed=30026316; DOI=10.1126/science.aar2641; RA Cuchet-Lourenco D., Eletto D., Wu C., Plagnol V., Papapietro O., Curtis J., RA Ceron-Gutierrez L., Bacon C.M., Hackett S., Alsaleem B., Maes M., RA Gaspar M., Alisaac A., Goss E., AlIdrissi E., Siegmund D., Wajant H., RA Kumararatne D., AlZahrani M.S., Arkwright P.D., Abinun M., Doffinger R., RA Nejentsev S.; RT "Biallelic RIPK1 mutations in humans cause severe immunodeficiency, RT arthritis, and intestinal inflammation."; RL Science 361:810-813(2018). RN [56] RP REVIEW. RX PubMed=31457011; DOI=10.3389/fcell.2019.00163; RA Ang R.L., Chan M., Ting A.T.; RT "Ripoptocide - A Spark for Inflammation."; RL Front. Cell Dev. Biol. 7:163-163(2019). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-25, AND MUTAGENESIS OF RP SER-25 AND LYS-45. RX PubMed=30988283; DOI=10.1038/s41467-019-09690-0; RA Dondelinger Y., Delanghe T., Priem D., Wynosky-Dolfi M.A., Sorobetea D., RA Rojas-Rivera D., Giansanti P., Roelandt R., Gropengiesser J., RA Ruckdeschel K., Savvides S.N., Heck A.J.R., Vandenabeele P., Brodsky I.E., RA Bertrand M.J.M.; RT "Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in RT models of infection and inflammation."; RL Nat. Commun. 10:1729-1729(2019). RN [58] RP FUNCTION, PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION), AND MUTAGENESIS OF RP 539-ILE--GLY-542. RX PubMed=32657447; DOI=10.15252/embj.2020104469; RA Ashida H., Sasakawa C., Suzuki T.; RT "A unique bacterial tactic to circumvent the cell death crosstalk induced RT by blockade of caspase-8."; RL EMBO J. 39:e104469-e104469(2020). RN [59] RP FUNCTION, AND INTERACTION WITH GRB2. RX PubMed=35831301; DOI=10.1038/s41420-022-01106-1; RA Hou B., Huang H., Li Y., Liang J., Xi Z., Jiang X., Liu L., Li E.; RT "Grb2 interacts with necrosome components and is involved in rasfonin- RT induced necroptosis."; RL Cell. Death. Discov. 8:319-319(2022). RN [60] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-294 IN COMPLEXES WITH RP NECROSTATIN-TYPE INHIBITORS, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP AUTOPHOSPHORYLATION. RX PubMed=23473668; DOI=10.1016/j.str.2013.01.016; RA Xie T., Peng W., Liu Y., Yan C., Maki J., Degterev A., Yuan J., Shi Y.; RT "Structural basis of RIP1 inhibition by necrostatins."; RL Structure 21:493-499(2013). RN [61] {ECO:0007744|PDB:5V7Z} RP STRUCTURE BY NMR OF 532-549 IN COMPLEX WITH RIPK3, SUBUNIT, INTERACTION RP WITH RIPK3, DOMAIN, AND MUTAGENESIS OF SER-536. RX PubMed=29681455; DOI=10.1016/j.cell.2018.03.032; RA Mompean M., Li W., Li J., Laage S., Siemer A.B., Bozkurt G., Wu H., RA McDermott A.E.; RT "The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid RT signaling complex."; RL Cell 173:1244-1253(2018). RN [62] {ECO:0007744|PDB:6AC5} RP X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 561-671, GLYCOSYLATION AT ARG-603 RP (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-603. RX PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028; RA Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.; RT "Structural and functional insights into host death domains inactivation by RT the bacterial arginine GlcNAcyltransferase effector."; RL Mol. Cell 74:922-935(2019). RN [63] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-64; ILE-81; VAL-220; SER-404; VAL-443 RP AND VAL-569. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [64] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, RP CHARACTERIZATION OF VARIANTS AIEFL ASN-324; HIS-324 AND TYR-324, CLEAVAGE RP BY CASP8, AND FUNCTION. RX PubMed=31827281; DOI=10.1038/s41586-019-1828-5; RA Lalaoui N., Boyden S.E., Oda H., Wood G.M., Stone D.L., Chau D., Liu L., RA Stoffels M., Kratina T., Lawlor K.E., Zaal K.J.M., Hoffmann P.M., RA Etemadi N., Shield-Artin K., Biben C., Tsai W.L., Blake M.D., Kuehn H.S., RA Yang D., Anderton H., Silke N., Wachsmuth L., Zheng L., Moura N.S., RA Beck D.B., Gutierrez-Cruz G., Ombrello A.K., Pinto-Patarroyo G.P., RA Kueh A.J., Herold M.J., Hall C., Wang H., Chae J.J., Dmitrieva N.I., RA McKenzie M., Light A., Barham B.K., Jones A., Romeo T.M., Zhou Q., RA Aksentijevich I., Mullikin J.C., Gross A.J., Shum A.K., Hawkins E.D., RA Masters S.L., Lenardo M.J., Boehm M., Rosenzweig S.D., Pasparakis M., RA Voss A.K., Gadina M., Kastner D.L., Silke J.; RT "Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory RT disease."; RL Nature 577:103-108(2020). RN [65] RP INVOLVEMENT IN AIEFL, VARIANTS AIEFL HIS-324 AND VAL-324, CHARACTERIZATION RP OF VARIANTS AIEFL HIS-324 AND VAL-324, FUNCTION, CATALYTIC ACTIVITY, RP AUTOPHOSPHORYLATION, PHOSPHORYLATION AT SER-166, AND CLEAVAGE BY CASP8. RX PubMed=31827280; DOI=10.1038/s41586-019-1830-y; RA Tao P., Sun J., Wu Z., Wang S., Wang J., Li W., Pan H., Bai R., Zhang J., RA Wang Y., Lee P.Y., Ying W., Zhou Q., Hou J., Wang W., Sun B., Yang M., RA Liu D., Fang R., Han H., Yang Z., Huang X., Li H., Deuitch N., Zhang Y., RA Dissanayake D., Haude K., McWalter K., Roadhouse C., MacKenzie J.J., RA Laxer R.M., Aksentijevich I., Yu X., Wang X., Yuan J., Zhou Q.; RT "A dominant autoinflammatory disease caused by non-cleavable variants of RT RIPK1."; RL Nature 577:109-114(2020). CC -!- FUNCTION: Serine-threonine kinase which is a key regulator of TNF- CC mediated apoptosis, necroptosis and inflammatory pathways CC (PubMed:17703191, PubMed:24144979, PubMed:31827280, PubMed:31827281, CC PubMed:32657447, PubMed:35831301). Exhibits kinase activity-dependent CC functions that regulate cell death and kinase-independent scaffold CC functions regulating inflammatory signaling and cell survival CC (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, CC PubMed:30988283). Has kinase-independent scaffold functions: upon CC binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling CC complex (TNF-RSC also known as complex I) where it acts as a scaffold CC protein promoting cell survival, in part, by activating the canonical CC NF-kappa-B pathway (By similarity). Kinase activity is essential to CC regulate necroptosis and apoptosis, two parallel forms of cell death: CC upon activation of its protein kinase activity, regulates assembly of CC two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), CC which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which CC drives necroptosis (By similarity). RIPK1 is required to limit CASP8- CC dependent TNFR1-induced apoptosis (By similarity). In normal CC conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, CC a process mediated by RIPK3 component of complex IIb, which catalyzes CC phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3- CC mediated necroptosis via FADD-mediated recruitment of CASP8, which CC cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, CC PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit CC apoptosis and necroptosis during embryonic development: acts by CC preventing the interaction of TRADD with FADD thereby limiting aberrant CC activation of CASP8 (By similarity). In addition to apoptosis and CC necroptosis, also involved in inflammatory response by promoting CC transcriptional production of pro-inflammatory cytokines, such as CC interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates CC RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans- CC phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' CC in a TNF-dependent manner, and thereby activates the MAP3K5-JNK CC apoptotic cascade (PubMed:15310755, PubMed:17389591). Required for CC ZBP1-induced NF-kappa-B activation in response to DNA damage (By CC similarity). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:15310755, CC ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513, CC ECO:0000269|PubMed:24144979, ECO:0000269|PubMed:29440439, CC ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281, ECO:0000269|PubMed:32657447, CC ECO:0000269|PubMed:35831301}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:23473668, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:8612133}; CC -!- ACTIVITY REGULATION: Serine-threonine kinase activity is inhibited by CC linear polyubiquitination ('Met-1'-linked) by the LUBAC complex (By CC similarity). Inhibited by necrostatins, including necrostatin-1, CC necrostatin-3 and necrostatin-4 (PubMed:23473668). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:23473668}. CC -!- SUBUNIT: Homodimer (PubMed:29440439, PubMed:29681455). Interacts (via CC RIP homotypic interaction motif) with RIPK3 (via RIP homotypic CC interaction motif); this interaction induces RIPK1 phosphorylation and CC formation of a RIPK1-RIPK3 necroptosis-inducing complex CC (PubMed:10358032, PubMed:11734559, PubMed:19524512, PubMed:29681455, CC PubMed:29883609). Upon TNF-induced necrosis, the RIPK1-RIPK3 dimer CC further interacts with PGAM5 and MLKL; the formation of this complex CC leads to PGAM5 phosphorylation and increase in PGAM5 phosphatase CC activity (PubMed:22265414). Interacts (via the death domain) with CC TNFRSF6 (via the death domain) and TRADD (via the death domain) CC (PubMed:8612133). Is recruited by TRADD to TNFRSF1A in a TNF-dependent CC process (PubMed:24130170). Binds RNF216, EGFR, IKBKG, TRAF1, TRAF2 and CC TRAF3 (PubMed:11116146, PubMed:11854271, PubMed:8612133, CC PubMed:9927690). Interacts with BNLF1 (PubMed:10409763). Interacts with CC SQSTM1 upon TNF stimulation (PubMed:10356400). May interact with CC MAVS/IPS1 (PubMed:16127453). Interacts with ZFAND5 (PubMed:14754897). CC Interacts with RBCK1 (PubMed:17449468). Interacts with ZBP1 (By CC similarity). Interacts with BIRC2/c-IAP1, BIRC3/c-IAP2 and XIAP/BIRC4 CC (PubMed:21931591). Interacts (via kinase domain) with DAB2IP (via Ras- CC GAP domain); the interaction occurs in a TNF-dependent manner CC (PubMed:15310755, PubMed:17389591). Interacts with ARHGEF2 CC (PubMed:21887730). Interacts (via protein kinase domain) with RFFL; CC involved in RIPK1 ubiquitination (PubMed:18450452). Interacts with CC RNF34; involved in RIPK1 ubiquitination (Ref.35). Interacts with TICAM1 CC and this interaction is enhanced in the presence of WDFY1 CC (PubMed:25736436). Interacts with PELI1 (PubMed:29883609). Interacts CC (via death domain) with CRADD (via death domain); the interaction is CC direct (PubMed:9044836). Component of complex IIa composed of at least CC RIPK1, FADD and CASP8 (By similarity). Component of the AIM2 CC PANoptosome complex, a multiprotein complex that drives inflammatory CC cell death (PANoptosis) (By similarity). Interacts with MAP3K7, CFLAR, CC CASP8, FADD and NEMO (By similarity). Interacts with TAX1BP1; this CC interaction negatively regulates RIPK1 ubiquitination CC (PubMed:17703191). Interacts with GRB2 (PubMed:35831301). Interacts CC with DDX24; this interaction disrupts RLR signaling activation of IFN- CC dependent transcription factor IRF7 (PubMed:24204270). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:10358032, ECO:0000269|PubMed:10409763, CC ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11734559, CC ECO:0000269|PubMed:11854271, ECO:0000269|PubMed:14754897, CC ECO:0000269|PubMed:16127453, ECO:0000269|PubMed:17389591, CC ECO:0000269|PubMed:17449468, ECO:0000269|PubMed:17703191, CC ECO:0000269|PubMed:18450452, ECO:0000269|PubMed:19524512, CC ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:24130170, CC ECO:0000269|PubMed:24204270, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:29440439, ECO:0000269|PubMed:29681455, CC ECO:0000269|PubMed:29883609, ECO:0000269|PubMed:35831301, CC ECO:0000269|PubMed:8612133, ECO:0000269|PubMed:9044836, CC ECO:0000269|PubMed:9927690, ECO:0000269|Ref.35}. CC -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH; CC this interaction inhibits downstream NF-kappa-B pathway activation. CC {ECO:0000269|PubMed:28659487}. CC -!- SUBUNIT: (Microbial infection) Interacts with Murid herpesvirus 1 CC protein RIR1. {ECO:0000269|PubMed:18442983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 1/HHV-1 protein RIR1/ICP6 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- SUBUNIT: (Microbial infection) Interacts (via RIP homotypic interaction CC motif) with herpes simplex virus 2/HHV-2 protein RIR1/ICP10 (via RIP CC homotypic interaction motif); this interaction prevents necroptosis CC activation. {ECO:0000269|PubMed:25674983}. CC -!- INTERACTION: CC Q13546; P04083: ANXA1; NbExp=5; IntAct=EBI-358507, EBI-354007; CC Q13546; Q13490: BIRC2; NbExp=10; IntAct=EBI-358507, EBI-514538; CC Q13546; Q13489: BIRC3; NbExp=3; IntAct=EBI-358507, EBI-517709; CC Q13546; Q92851: CASP10; NbExp=2; IntAct=EBI-358507, EBI-495095; CC Q13546; Q14790: CASP8; NbExp=30; IntAct=EBI-358507, EBI-78060; CC Q13546; Q8IVM0: CCDC50; NbExp=2; IntAct=EBI-358507, EBI-723996; CC Q13546; P48729: CSNK1A1; NbExp=5; IntAct=EBI-358507, EBI-1383726; CC Q13546; Q13158: FADD; NbExp=12; IntAct=EBI-358507, EBI-494804; CC Q13546; P08238: HSP90AB1; NbExp=2; IntAct=EBI-358507, EBI-352572; CC Q13546; Q9Y6K9: IKBKG; NbExp=9; IntAct=EBI-358507, EBI-81279; CC Q13546; Q96AB6: NTAN1; NbExp=2; IntAct=EBI-358507, EBI-12401218; CC Q13546; Q9ULZ3: PYCARD; NbExp=2; IntAct=EBI-358507, EBI-751215; CC Q13546; Q13546: RIPK1; NbExp=11; IntAct=EBI-358507, EBI-358507; CC Q13546; Q9Y572: RIPK3; NbExp=27; IntAct=EBI-358507, EBI-298250; CC Q13546; P19438: TNFRSF1A; NbExp=7; IntAct=EBI-358507, EBI-299451; CC Q13546; Q15628: TRADD; NbExp=3; IntAct=EBI-358507, EBI-359215; CC Q13546; Q13077: TRAF1; NbExp=8; IntAct=EBI-358507, EBI-359224; CC Q13546; Q12933: TRAF2; NbExp=10; IntAct=EBI-358507, EBI-355744; CC Q13546; Q13114: TRAF3; NbExp=5; IntAct=EBI-358507, EBI-357631; CC Q13546; O00635: TRIM38; NbExp=2; IntAct=EBI-358507, EBI-2130415; CC Q13546; Q13107: USP4; NbExp=4; IntAct=EBI-358507, EBI-723290; CC Q13546; B7UI21: nleB1; Xeno; NbExp=4; IntAct=EBI-358507, EBI-16070376; CC Q13546; PRO_0000449629 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-358507, EBI-25475885; CC Q13546; U5TQE9: UL39; Xeno; NbExp=3; IntAct=EBI-358507, EBI-11894787; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q60855}. Cell CC membrane {ECO:0000250|UniProtKB:Q9ZUF4}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q13546-1; Sequence=Displayed; CC Name=2; CC IsoId=Q13546-2; Sequence=VSP_037690; CC -!- DOMAIN: The RIP homotypic interaction motif (RHIM) mediates interaction CC with the RHIM motif of RIPK1. Both motifs form a hetero-amyloid CC serpentine fold, stabilized by hydrophobic packing and featuring an CC unusual Cys-Ser ladder of alternating Ser (from RIPK1) and Cys (from CC RIPK3). {ECO:0000269|PubMed:29681455}. CC -!- DOMAIN: The death domain mediates dimerization and activation of its CC kinase activity during necroptosis and apoptosis (PubMed:29440439). It CC engages other DD-containing proteins as well as a central CC (intermediate) region important for NF-kB activation and RHIM-dependent CC signaling (PubMed:10356400). {ECO:0000269|PubMed:10356400, CC ECO:0000269|PubMed:29440439}. CC -!- PTM: (Microbial infection) Proteolytically cleaved by S.flexneri OspD3 CC within the RIP homotypic interaction motif (RHIM), leading to its CC degradation and inhibition of necroptosis. CC {ECO:0000269|PubMed:32657447}. CC -!- PTM: Proteolytically cleaved by CASP8 at Asp-324 (PubMed:10521396, CC PubMed:31827280, PubMed:31827281). Cleavage is crucial for limiting CC TNF-induced apoptosis, necroptosis and inflammatory response CC (PubMed:31827280, PubMed:31827281). Cleavage abolishes NF-kappa-B CC activation and enhances the interaction of TRADD with FADD CC (PubMed:10521396). Proteolytically cleaved by CASP6 during intrinsic CC apoptosis (PubMed:22858542). {ECO:0000250|UniProtKB:Q60855, CC ECO:0000269|PubMed:10521396, ECO:0000269|PubMed:31827280, CC ECO:0000269|PubMed:31827281}. CC -!- PTM: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation CC (PubMed:18408713, PubMed:19524513, PubMed:31827280). Phosphorylation of CC Ser-161 by RIPK3 is necessary for the formation of the necroptosis- CC inducing complex (PubMed:18408713). Phosphorylation at Ser-25 represses CC its kinase activity and consequently prevents TNF-mediated RIPK1- CC dependent cell death (PubMed:30988283). Phosphorylated at Ser-320 by CC MAP3K7 which requires prior ubiquitination with 'Lys-63'-linked chains CC by BIRC2/c-IAP1 and BIRC3/c-IAP2 (By similarity). This phosphorylation CC positively regulates RIPK1 interaction with RIPK3 to promote CC necroptosis but negatively regulates RIPK1 kinase activity and its CC interaction with FADD to mediate apoptosis (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:18408713, CC ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:30988283, CC ECO:0000269|PubMed:31827280}. CC -!- PTM: Deubiquitinated by USP7; this modification is required for TNF- CC induced apoptosis. {ECO:0000269|PubMed:24144979}. CC -!- PTM: Ubiquitinated with 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear- CC linked type ubiquitin (PubMed:15258597, PubMed:16603398, CC PubMed:17703191, PubMed:18450452, PubMed:21455173, PubMed:21931591, CC PubMed:29883609, Ref.35). Polyubiquitination with 'Lys-63'-linked CC chains by TRAF2 induces association with the IKK complex CC (PubMed:15258597). Deubiquitination of 'Lys-63'-linked chains and CC polyubiquitination with 'Lys-48'-linked chains by TNFAIP3 leads to CC RIPK1 proteasomal degradation and consequently down-regulates TNF- CC induced NF-kappa-B signaling (PubMed:15258597). 'Lys-48'-linked CC polyubiquitination by RFFL or RNF34 also promotes proteasomal CC degradation and negatively regulates TNF-induced NF-kappa-B signaling CC (PubMed:18450452, Ref.35). Linear polyubiquitinated; the head-to-tail CC linear polyubiquitination ('Met-1'-linked) is mediated by the LUBAC CC complex and decreases protein kinase activity (PubMed:21455173). CC Deubiquitination of linear polyubiquitin by CYLD promotes the kinase CC activity (By similarity). Polyubiquitinated with 'Lys-48' and 'Lys-63'- CC linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation CC of NF-kappa-B (PubMed:21931591). Ubiquitinated with 'Lys-63'-linked CC chains by PELI1 (PubMed:29883609). Ubiquitination at Lys-377 with 'Lys- CC 63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2 is essential for its CC phosphorylation at Ser-320 mediated by MAP3K7 (By similarity). This CC ubiquitination is required for NF-kB activation, suppresses RIPK1 CC kinase activity and plays a critical role in preventing cell death CC during embryonic development (By similarity). CC {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:15258597, CC ECO:0000269|PubMed:16603398, ECO:0000269|PubMed:18450452, CC ECO:0000269|PubMed:21455173, ECO:0000269|PubMed:21931591, CC ECO:0000269|PubMed:29883609, ECO:0000269|Ref.35}. CC -!- PTM: (Microbial infection) Glycosylated at Arg-603 by enteropathogenic CC E.coli protein NleB1: arginine GlcNAcylation prevents CC homotypic/heterotypic death domain interactions. CC {ECO:0000305|PubMed:23955153}. CC -!- DISEASE: Immunodeficiency 57 with autoinflammation (IMD57) CC [MIM:618108]: An autosomal recessive primary immunodeficiency CC characterized by lymphopenia and recurrent viral, bacterial, and fungal CC infections. Patients exhibit early-onset inflammatory bowel disease CC involving the upper and lower gastrointestinal tract, and develop CC progressive polyarthritis. {ECO:0000269|PubMed:30026316}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. RIPK1-deficient immune cells from IMD57 patients have impaired CC proinflammatory signaling leading to dysregulated cytokine secretion CC and are prone to necroptosis. {ECO:0000269|PubMed:30026316}. CC -!- DISEASE: Autoinflammation with episodic fever and lymphadenopathy CC (AIEFL) [MIM:618852]: An autosomal dominant immunologic disorder CC characterized by early onset of recurrent episodes of unexplained CC fever, lymphadenopathy, hepatosplenomegaly, and increased levels of CC inflammatory cytokines and chemokines in patient serum. CC {ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAG65471.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U50062; AAC32232.1; -; mRNA. DR EMBL; AK314176; BAG36858.1; -; mRNA. DR EMBL; AK304701; BAG65471.1; ALT_INIT; mRNA. DR EMBL; AY682848; AAT74626.1; -; Genomic_DNA. DR EMBL; AL031963; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC126254; AAI26255.1; -; mRNA. DR EMBL; BC126256; AAI26257.1; -; mRNA. DR EMBL; AB208926; BAD92163.1; -; mRNA. DR EMBL; U25994; AAC50137.1; -; mRNA. DR CCDS; CCDS4482.1; -. [Q13546-1] DR CCDS; CCDS93851.1; -. [Q13546-2] DR PIR; T09479; T09479. DR RefSeq; NP_001341859.1; NM_001354930.2. [Q13546-1] DR RefSeq; NP_001341860.1; NM_001354931.2. [Q13546-2] DR RefSeq; NP_003795.2; NM_003804.6. [Q13546-1] DR RefSeq; XP_047275403.1; XM_047419447.1. [Q13546-1] DR RefSeq; XP_047275404.1; XM_047419448.1. [Q13546-1] DR RefSeq; XP_054212622.1; XM_054356647.1. [Q13546-1] DR PDB; 4ITH; X-ray; 2.25 A; A/B=1-294. DR PDB; 4ITI; X-ray; 2.86 A; A/B=1-294. DR PDB; 4ITJ; X-ray; 1.80 A; A/B=1-294. DR PDB; 4NEU; X-ray; 2.57 A; A/B=1-324. DR PDB; 5HX6; X-ray; 2.23 A; A/B=1-294. DR PDB; 5TX5; X-ray; 2.56 A; A/B=1-294. DR PDB; 5V7Z; NMR; -; B/D/F/H=532-549. DR PDB; 6AC5; X-ray; 1.45 A; A=561-671. DR PDB; 6C3E; X-ray; 2.60 A; A/B=2-294. DR PDB; 6C4D; X-ray; 2.52 A; A/B/C/D=2-294. DR PDB; 6HHO; X-ray; 3.49 A; A/B=1-294. DR PDB; 6NW2; X-ray; 2.00 A; A/B=1-294. DR PDB; 6NYH; X-ray; 2.10 A; A/B=1-294. DR PDB; 6OCQ; X-ray; 2.79 A; A/B=1-294. DR PDB; 6R5F; X-ray; 3.25 A; A/B/C/D=1-294. DR PDB; 6RLN; X-ray; 2.87 A; A/B=1-294. DR PDB; 7CJB; X-ray; 2.80 A; D/H/L/P=189-203. DR PDB; 7FCZ; X-ray; 2.21 A; A/B=1-294. DR PDB; 7FD0; X-ray; 2.00 A; A/B=1-294. DR PDB; 7XMK; X-ray; 2.38 A; A/B=1-294. DR PDB; 7YDX; X-ray; 2.64 A; A/B=1-294. DR PDB; 8I2N; X-ray; 2.29 A; A/B=1-294. DR PDB; 8Z93; EM; 4.65 A; A/B/C=496-583. DR PDB; 9MZX; X-ray; 2.53 A; A/B=6-294. DR PDB; 9MZY; X-ray; 2.32 A; A/B=8-294. DR PDB; 9MZZ; X-ray; 2.68 A; A/B=7-294. DR PDBsum; 4ITH; -. DR PDBsum; 4ITI; -. DR PDBsum; 4ITJ; -. DR PDBsum; 4NEU; -. DR PDBsum; 5HX6; -. DR PDBsum; 5TX5; -. DR PDBsum; 5V7Z; -. DR PDBsum; 6AC5; -. DR PDBsum; 6C3E; -. DR PDBsum; 6C4D; -. DR PDBsum; 6HHO; -. DR PDBsum; 6NW2; -. DR PDBsum; 6NYH; -. DR PDBsum; 6OCQ; -. DR PDBsum; 6R5F; -. DR PDBsum; 6RLN; -. DR PDBsum; 7CJB; -. DR PDBsum; 7FCZ; -. DR PDBsum; 7FD0; -. DR PDBsum; 7XMK; -. DR PDBsum; 7YDX; -. DR PDBsum; 8I2N; -. DR PDBsum; 8Z93; -. DR PDBsum; 9MZX; -. DR PDBsum; 9MZY; -. DR PDBsum; 9MZZ; -. DR AlphaFoldDB; Q13546; -. DR BMRB; Q13546; -. DR EMDB; EMD-39853; -. DR SMR; Q13546; -. DR BioGRID; 114274; 207. DR ComplexPortal; CPX-1907; Ripoptosome. DR ComplexPortal; CPX-25723; sTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-25726; mTNF-TNR1A receptor-ligand core complex, BIRC3 variant. DR ComplexPortal; CPX-8828; sTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR ComplexPortal; CPX-8932; mTNF-TNR1A receptor-ligand core complex, BIRC2 variant. DR CORUM; Q13546; -. DR DIP; DIP-433N; -. DR FunCoup; Q13546; 1287. DR IntAct; Q13546; 138. DR MINT; Q13546; -. DR STRING; 9606.ENSP00000259808; -. DR BindingDB; Q13546; -. DR ChEMBL; CHEMBL5464; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16875; GSK-2982772. DR DrugBank; DB16492; SAR443122. DR DrugCentral; Q13546; -. DR GuidetoPHARMACOLOGY; 2189; -. DR GlyCosmos; Q13546; 3 sites, 1 glycan. DR GlyGen; Q13546; 6 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q13546; -. DR MetOSite; Q13546; -. DR PhosphoSitePlus; Q13546; -. DR BioMuta; RIPK1; -. DR DMDM; 60393639; -. DR CPTAC; CPTAC-1053; -. DR CPTAC; CPTAC-900; -. DR CPTAC; CPTAC-901; -. DR CPTAC; CPTAC-902; -. DR jPOST; Q13546; -. DR MassIVE; Q13546; -. DR PaxDb; 9606-ENSP00000259808; -. DR PeptideAtlas; Q13546; -. DR ProteomicsDB; 59527; -. [Q13546-1] DR ProteomicsDB; 59528; -. [Q13546-2] DR Pumba; Q13546; -. DR Antibodypedia; 4145; 668 antibodies from 45 providers. DR DNASU; 8737; -. DR Ensembl; ENST00000259808.9; ENSP00000259808.3; ENSG00000137275.17. [Q13546-1] DR Ensembl; ENST00000380409.3; ENSP00000369773.3; ENSG00000137275.17. [Q13546-2] DR GeneID; 8737; -. DR KEGG; hsa:8737; -. DR MANE-Select; ENST00000259808.9; ENSP00000259808.3; NM_001354930.2; NP_001341859.1. DR UCSC; uc003mux.4; human. [Q13546-1] DR AGR; HGNC:10019; -. DR ClinPGx; PA34394; -. DR CTD; 8737; -. DR DisGeNET; 8737; -. DR GeneCards; RIPK1; -. DR HGNC; HGNC:10019; RIPK1. DR HPA; ENSG00000137275; Low tissue specificity. DR MalaCards; RIPK1; -. DR MIM; 603453; gene. DR MIM; 618108; phenotype. DR MIM; 618852; phenotype. DR OpenTargets; ENSG00000137275; -. DR Orphanet; 529977; Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome. DR VEuPathDB; HostDB:ENSG00000137275; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000159347; -. DR HOGENOM; CLU_017229_0_0_1; -. DR InParanoid; Q13546; -. DR OrthoDB; 535509at2759; -. DR PAN-GO; Q13546; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q13546; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; Q13546; -. DR Reactome; R-HSA-140534; Caspase activation via Death Receptors in the presence of ligand. DR Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment. DR Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1. DR Reactome; R-HSA-2562578; TRIF-mediated programmed cell death. DR Reactome; R-HSA-3295583; TRP channels. DR Reactome; R-HSA-3371378; Regulation by c-FLIP. DR Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-5218900; CASP8 activity is inhibited. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway. DR Reactome; R-HSA-5675482; Regulation of necroptotic cell death. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-69416; Dimerization of procaspase-8. DR Reactome; R-HSA-75893; TNF signaling. DR Reactome; R-HSA-9013957; TLR3-mediated TICAM1-dependent programmed cell death. DR Reactome; R-HSA-933543; NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10. DR Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1. DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis. DR Reactome; R-HSA-9692913; SARS-CoV-1-mediated effects on programmed cell death. DR Reactome; R-HSA-9693928; Defective RIPK1-mediated regulated necrosis. DR SignaLink; Q13546; -. DR SIGNOR; Q13546; -. DR Agora; ENSG00000137275; -. DR BioGRID-ORCS; 8737; 38 hits in 1199 CRISPR screens. DR ChiTaRS; RIPK1; human. DR EvolutionaryTrace; Q13546; -. DR GeneWiki; RIPK1; -. DR GenomeRNAi; 8737; -. DR Pharos; Q13546; Tchem. DR PRO; PR:Q13546; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q13546; protein. DR Bgee; ENSG00000137275; Expressed in granulocyte and 154 other cell types or tissues. DR ExpressionAtlas; Q13546; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0031264; C:death-inducing signaling complex; IDA:BHF-UCL. DR GO; GO:0010008; C:endosome membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0097342; C:ripoptosome; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0070513; F:death domain binding; IPI:BHF-UCL. DR GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:DisProt. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0035591; F:signaling adaptor activity; IEA:Ensembl. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB. DR GO; GO:1990000; P:amyloid fibril formation; IDA:DisProt. DR GO; GO:0006915; P:apoptotic process; IMP:UniProtKB. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl. DR GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:ARUK-UCL. DR GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IDA:BHF-UCL. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL. DR GO; GO:0070266; P:necroptotic process; IMP:UniProtKB. DR GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB. DR GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IMP:UniProtKB. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0060546; P:negative regulation of necroptotic process; ISS:UniProtKB. DR GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:UniProtKB. DR GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB. DR GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL. DR GO; GO:0050729; P:positive regulation of inflammatory response; IMP:UniProtKB. DR GO; GO:0070105; P:positive regulation of interleukin-6-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:BHF-UCL. DR GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; IMP:UniProtKB. DR GO; GO:1903800; P:positive regulation of miRNA processing; IDA:ARUK-UCL. DR GO; GO:0060545; P:positive regulation of necroptotic process; IMP:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB. DR GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; IEA:Ensembl. DR GO; GO:0043068; P:positive regulation of programmed cell death; IMP:UniProtKB. DR GO; GO:0062100; P:positive regulation of programmed necrotic cell death; IMP:BHF-UCL. DR GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:BHF-UCL. DR GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0097300; P:programmed necrotic cell death; ISS:ARUK-UCL. DR GO; GO:0046777; P:protein autophosphorylation; IMP:UniProtKB. DR GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB. DR GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL. DR GO; GO:0034612; P:response to tumor necrosis factor; IMP:BHF-UCL. DR GO; GO:0097343; P:ripoptosome assembly; IMP:UniProtKB. DR GO; GO:1901026; P:ripoptosome assembly involved in necroptotic process; IMP:DisProt. DR GO; GO:0070231; P:T cell apoptotic process; ISS:UniProtKB. DR GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IC:BHF-UCL. DR CDD; cd08777; Death_RIP1; 1. DR CDD; cd14027; STKc_RIP1; 1. DR DisProt; DP04298; -. DR FunFam; 1.10.533.10:FF:000052; Putative receptor-interacting serine/threonine-protein kinase 1; 1. DR FunFam; 1.10.510.10:FF:000472; Receptor interacting serine/threonine kinase 1; 1. DR Gene3D; 1.10.533.10; Death Domain, Fas; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011029; DEATH-like_dom_sf. DR InterPro; IPR000488; Death_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR037934; RIP1_Death. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329:SF6; RECEPTOR-INTERACTING SERINE_THREONINE-PROTEIN KINASE 1; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00531; Death; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00005; DEATH; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF47986; DEATH domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50017; DEATH_DOMAIN; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Cytoplasm; Disease variant; Glycoprotein; Host-virus interaction; KW Inflammatory response; Isopeptide bond; Kinase; Membrane; Necrosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Reference proteome; Serine/threonine-protein kinase; Transferase; KW Ubl conjugation. FT CHAIN 1..671 FT /note="Receptor-interacting serine/threonine-protein kinase FT 1" FT /id="PRO_0000086606" FT DOMAIN 17..289 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 583..669 FT /note="Death" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00064" FT REGION 290..582 FT /note="Interaction with SQSTM1" FT /evidence="ECO:0000269|PubMed:10356400" FT REGION 331..354 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 389..455 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 531..547 FT /note="RIP homotypic interaction motif (RHIM)" FT /evidence="ECO:0000269|PubMed:11734559, FT ECO:0000269|PubMed:29681455" FT COMPBIAS 331..348 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 428..444 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 138 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 23..31 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 45 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 324..325 FT /note="Cleavage; by CASP8" FT /evidence="ECO:0000269|PubMed:10521396, FT ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281" FT MOD_RES 6 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 20 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 25 FT /note="Phosphoserine; by IKKA and IKKB" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0000269|PubMed:30988283" FT MOD_RES 161 FT /note="Phosphoserine; by RIPK3 and autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 166 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000255, ECO:0000269|PubMed:29440439, FT ECO:0000269|PubMed:31827280" FT MOD_RES 303 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 320 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 331 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000250|UniProtKB:Q60855" FT MOD_RES 333 FT /note="Phosphoserine; by MAP3K7" FT /evidence="ECO:0000269|PubMed:18408713" FT MOD_RES 384 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:15144186" FT CARBOHYD 603 FT /note="(Microbial infection) N-beta-linked (GlcNAc) FT arginine" FT /evidence="ECO:0000269|PubMed:30979585, FT ECO:0000305|PubMed:23955153, ECO:0007744|PDB:6AC5" FT CROSSLNK 377 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:16603398" FT VAR_SEQ 108..153 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_037690" FT VARIANT 64 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs774996232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041039" FT VARIANT 81 FT /note="V -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs758268804)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041040" FT VARIANT 220 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs759012409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041041" FT VARIANT 234 FT /note="E -> K (in dbSNP:rs17548383)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_021109" FT VARIANT 324 FT /note="D -> H (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827280, FT ECO:0000269|PubMed:31827281" FT /id="VAR_083518" FT VARIANT 324 FT /note="D -> N (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083519" FT VARIANT 324 FT /note="D -> V (in AIEFL; prevents cleavage by CASP8; FT increased kinase activity; increased inflammatory response; FT dbSNP:rs1760720924)" FT /evidence="ECO:0000269|PubMed:31827280" FT /id="VAR_084135" FT VARIANT 324 FT /note="D -> Y (in AIEFL; prevents cleavage by CASP8; FT changed inflammatory response; dbSNP:rs1760720617)" FT /evidence="ECO:0000269|PubMed:31827281" FT /id="VAR_083520" FT VARIANT 404 FT /note="A -> S (in dbSNP:rs34872409)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041042" FT VARIANT 438 FT /note="A -> V (in dbSNP:rs3173519)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:7538908, ECO:0000269|PubMed:8612133" FT /id="VAR_058285" FT VARIANT 443 FT /note="A -> V (in dbSNP:rs35722193)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041043" FT VARIANT 569 FT /note="A -> V (in dbSNP:rs55861377)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041044" FT MUTAGEN 25 FT /note="S->D: Phophomimetic mutant. Significant loss of FT kinase activity." FT /evidence="ECO:0000269|PubMed:30988283" FT MUTAGEN 45 FT /note="K->A: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:30988283, FT ECO:0000269|PubMed:8612133" FT MUTAGEN 161 FT /note="S->A: Decreases RIPK1 kinase activity." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 161 FT /note="S->E: No effect on RIPK1 autophosphorylation." FT /evidence="ECO:0000269|PubMed:18408713" FT MUTAGEN 324 FT /note="D->K: Abolishes cleavage by caspase-8." FT /evidence="ECO:0000269|PubMed:10521396" FT MUTAGEN 377 FT /note="K->R: Abolishes RIP-mediated NF-Kappa-B activation." FT /evidence="ECO:0000269|PubMed:16603398" FT MUTAGEN 536 FT /note="S->C: Strongly reduced homodimerization and FT interaction with RIPK3." FT /evidence="ECO:0000269|PubMed:29681455" FT MUTAGEN 539..542 FT /note="IQIG->AAAA: Abolished cleavage by S.flexneri OspD3." FT /evidence="ECO:0000269|PubMed:32657447" FT MUTAGEN 599 FT /note="K->R: Blocks homodimerization, necroptosis and FT apoptosis." FT /evidence="ECO:0000269|PubMed:29440439" FT MUTAGEN 603 FT /note="R->A: Abolished GlcNAcylation by E.coli NleB1." FT /evidence="ECO:0000269|PubMed:30979585" FT CONFLICT 258 FT /note="R -> I (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 286 FT /note="R -> S (in Ref. 3; BAG36858)" FT /evidence="ECO:0000305" FT CONFLICT 514 FT /note="T -> S (in Ref. 8; AAC50137)" FT /evidence="ECO:0000305" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:7FD0" FT HELIX 14..16 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 17..19 FT /evidence="ECO:0007829|PDB:5HX6" FT STRAND 20..22 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 26..28 FT /evidence="ECO:0007829|PDB:7FD0" FT STRAND 30..36 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 37..39 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 40..51 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 54..56 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 57..68 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 87..93 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 100..104 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 106..108 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 112..131 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 141..143 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 144..146 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 152..154 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 163..168 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 171..173 FT /evidence="ECO:0007829|PDB:4ITH" FT HELIX 190..192 FT /evidence="ECO:0007829|PDB:6NW2" FT HELIX 195..197 FT /evidence="ECO:0007829|PDB:4ITJ" FT STRAND 201..203 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 207..223 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 228..230 FT /evidence="ECO:0007829|PDB:6C4D" FT HELIX 234..242 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 249..251 FT /evidence="ECO:0007829|PDB:4ITJ" FT TURN 252..255 FT /evidence="ECO:0007829|PDB:6C3E" FT HELIX 258..267 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 272..274 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 278..292 FT /evidence="ECO:0007829|PDB:4ITJ" FT HELIX 294..296 FT /evidence="ECO:0007829|PDB:4NEU" FT HELIX 297..309 FT /evidence="ECO:0007829|PDB:4NEU" FT TURN 310..312 FT /evidence="ECO:0007829|PDB:4NEU" FT STRAND 533..542 FT /evidence="ECO:0007829|PDB:5V7Z" FT HELIX 575..577 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 584..593 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 599..604 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 609..618 FT /evidence="ECO:0007829|PDB:6AC5" FT TURN 619..622 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 624..643 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 646..655 FT /evidence="ECO:0007829|PDB:6AC5" FT HELIX 659..668 FT /evidence="ECO:0007829|PDB:6AC5" SQ SEQUENCE 671 AA; 75931 MW; 976E2428D525A9B2 CRC64; MQPDMSLNVI KMKSSDFLES AELDSGGFGK VSLCFHRTQG LMIMKTVYKG PNCIEHNEAL LEEAKMMNRL RHSRVVKLLG VIIEEGKYSL VMEYMEKGNL MHVLKAEMST PLSVKGRIIL EIIEGMCYLH GKGVIHKDLK PENILVDNDF HIKIADLGLA SFKMWSKLNN EEHNELREVD GTAKKNGGTL YYMAPEHLND VNAKPTEKSD VYSFAVVLWA IFANKEPYEN AICEQQLIMC IKSGNRPDVD DITEYCPREI ISLMKLCWEA NPEARPTFPG IEEKFRPFYL SQLEESVEED VKSLKKEYSN ENAVVKRMQS LQLDCVAVPS SRSNSATEQP GSLHSSQGLG MGPVEESWFA PSLEHPQEEN EPSLQSKLQD EANYHLYGSR MDRQTKQQPR QNVAYNREEE RRRRVSHDPF AQQRPYENFQ NTEGKGTAYS SAASHGNAVH QPSGLTSQPQ VLYQNNGLYS SHGFGTRPLD PGTAGPRVWY RPIPSHMPSL HNIPVPETNY LGNTPTMPFS SLPPTDESIK YTIYNSTGIQ IGAYNYMEIG GTSSSLLDST NTNFKEEPAA KYQAIFDNTT SLTDKHLDPI RENLGKHWKN CARKLGFTQS QIDEIDHDYE RDGLKEKVYQ MLQKWVMREG IKGATVGKLA QALHQCSRID LLSSLIYVSQ N // ID SMAD3_HUMAN Reviewed; 425 AA. AC P84022; A8K4B6; B7Z4Z5; B7Z6M9; B7Z9Q2; F5H383; O09064; O09144; O14510; AC O35273; Q92940; Q93002; Q9GKR4; DT 05-JUL-2004, integrated into UniProtKB/Swiss-Prot. DT 05-JUL-2004, sequence version 1. DT 28-JAN-2026, entry version 216. DE RecName: Full=SMAD family member 3 {ECO:0000312|HGNC:HGNC:6769}; DE Short=SMAD 3 {ECO:0000305}; DE Short=hSMAD3; DE AltName: Full=JV15-2; DE AltName: Full=Mothers against decapentaplegic homolog 3; DE Short=MAD homolog 3; DE Short=Mad3; DE Short=Mothers against DPP homolog 3; DE Short=hMAD-3; GN Name=SMAD3 {ECO:0000312|HGNC:HGNC:6769}; Synonyms=MADH3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION. RC TISSUE=Placenta; RX PubMed=8774881; DOI=10.1038/383168a0; RA Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.; RT "Receptor-associated Mad homologues synergize as effectors of the TGF-beta RT response."; RL Nature 383:168-172(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8673135; DOI=10.1038/ng0796-347; RA Riggins G.J., Thiagalingam S., Rosenblum E., Weinstein C.L., Kern S.E., RA Hamilton S.R., Willson J.K.V., Markowitz S.D., Kinzler K.W., RA Vogelstein B.V.; RT "Mad-related genes in the human."; RL Nat. Genet. 13:347-349(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Colon carcinoma; RX PubMed=9464505; DOI=10.1016/s0304-3835(97)00384-4; RA Arai T., Akiyama Y., Okabe S., Ando M., Endo M., Yuasa Y.; RT "Genomic structure of the human Smad3 gene and its infrequent alterations RT in colorectal cancers."; RL Cancer Lett. 122:157-163(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Hagiwara K., Yang K., McMenamin M.G., Freeman A.H., Bennett W.P., RA Nagashima M., Minter A.R., Miyazono K., Takenoshita S., Harris C.C.; RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4). RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16572171; DOI=10.1038/nature04601; RA Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K., RA Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K., RA FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N., RA Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S., RA Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K., RA DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J., RA Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E., RA Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B., RA Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R., RA O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B., RA Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S., RA Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.; RT "Analysis of the DNA sequence and duplication history of human chromosome RT 15."; RL Nature 440:671-675(2006). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP INTERACTION WITH TGFBR1. RX PubMed=9311995; DOI=10.1093/emboj/16.17.5353; RA Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., RA Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.; RT "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4."; RL EMBO J. 16:5353-5362(1997). RN [10] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [11] RP SUBUNIT. RX PubMed=9670020; DOI=10.1093/emboj/17.14.4056; RA Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.; RT "Smad proteins exist as monomers in vivo and undergo homo- and hetero- RT oligomerization upon activation by serine/threonine kinase receptors."; RL EMBO J. 17:4056-4065(1998). RN [12] RP PHOSPHORYLATION, AND INTERACTION WITH EP300. RX PubMed=9843571; DOI=10.1091/mbc.9.12.3309; RA Shen X., Hu P.P., Liberati N.T., Datto M.B., Frederick J.P., Wang X.F.; RT "TGF-beta-induced phosphorylation of Smad3 regulates its interaction with RT coactivator p300/CREB-binding protein."; RL Mol. Biol. Cell 9:3309-3319(1998). RN [13] RP INTERACTION WITH MECOM. RX PubMed=9665135; DOI=10.1038/27945; RA Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S., RA Yazaki Y., Matsumoto K., Hirai H.; RT "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3."; RL Nature 394:92-96(1998). RN [14] RP IDENTIFICATION AS A COMPONENT OF THE SMAD3/SMAD4/JUN/FOS COMPLEX, RP INTERACTION WITH JUN AND FOS, DNA-BINDING, AND FUNCTION. RX PubMed=9732876; DOI=10.1038/29814; RA Zhang Y., Feng X.H., Derynck R.; RT "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced RT transcription."; RL Nature 394:909-913(1998). RN [15] RP INTERACTION WITH ACVR1B, AND FUNCTION. RX PubMed=9892009; DOI=10.1210/mend.13.1.0218; RA Lebrun J.J., Takabe K., Chen Y., Vale W.; RT "Roles of pathway-specific and inhibitory Smads in activin receptor RT signaling."; RL Mol. Endocrinol. 13:15-23(1999). RN [16] RP INTERACTION WITH JUN IN THE SMAD3/SMAD4/JUN/FOS COMPLEX, DNA-BINDING, RP FUNCTION, AND MUTAGENESIS OF LYS-40; LYS-41; LYS-43; LYS-44 AND ARG-74. RX PubMed=10995748; DOI=10.1074/jbc.m004731200; RA Qing J., Zhang Y., Derynck R.; RT "Structural and functional characterization of the transforming growth RT factor-beta -induced Smad3/c-Jun transcriptional cooperativity."; RL J. Biol. Chem. 275:38802-38812(2000). RN [17] RP INTERACTION WITH DAB2. RX PubMed=11387212; DOI=10.1093/emboj/20.11.2789; RA Hocevar B.A., Smine A., Xu X.X., Howe P.H.; RT "The adaptor molecule Disabled-2 links the transforming growth factor beta RT receptors to the Smad pathway."; RL EMBO J. 20:2789-2801(2001). RN [18] RP INTERACTION WITH SNW1. RX PubMed=11278756; DOI=10.1074/jbc.m010815200; RA Leong G.M., Subramaniam N., Figueroa J., Flanagan J.L., Hayman M.J., RA Eisman J.A., Kouzmenko A.P.; RT "Ski-interacting protein interacts with Smad proteins to augment RT transforming growth factor-beta-dependent transcription."; RL J. Biol. Chem. 276:18243-18248(2001). RN [19] RP INTERACTION WITH TGIF2. RX PubMed=11427533; DOI=10.1074/jbc.m103377200; RA Melhuish T.A., Gallo C.M., Wotton D.; RT "TGIF2 interacts with histone deacetylase 1 and represses transcription."; RL J. Biol. Chem. 276:32109-32114(2001). RN [20] RP SUBUNIT, PHOSPHORYLATION, AND MUTAGENESIS OF 422-SER--SER-425. RX PubMed=11224571; DOI=10.1038/84995; RA Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.; RT "The L3 loop and C-terminal phosphorylation jointly define Smad protein RT trimerization."; RL Nat. Struct. Biol. 8:248-253(2001). RN [21] RP INTERACTION WITH MEN1. RX PubMed=11274402; DOI=10.1073/pnas.061358098; RA Kaji H., Canaff L., Lebrun J.J., Goltzman D., Hendy G.N.; RT "Inactivation of menin, a Smad3-interacting protein, blocks transforming RT growth factor type beta signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 98:3837-3842(2001). RN [22] RP INTERACTION WITH ZNF8. RX PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002; RA Jiao K., Zhou Y., Hogan B.L.M.; RT "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, RT as a novel nuclear interaction partner of Smad1."; RL Mol. Cell. Biol. 22:7633-7644(2002). RN [23] RP INTERACTION WITH DACH1. RX PubMed=14525983; DOI=10.1074/jbc.m310021200; RA Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K., RA Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.; RT "DACH1 inhibits transforming growth factor-beta signaling through binding RT Smad4."; RL J. Biol. Chem. 278:51673-51684(2003). RN [24] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND ITCH, AND INTERACTION WITH RP NEDD9. RX PubMed=15051726; DOI=10.1074/jbc.m403221200; RA Feng L., Guedes S., Wang T.; RT "Atrophin-1-interacting protein 4/human Itch is a ubiquitin E3 ligase for RT human enhancer of filamentation 1 in transforming growth factor-beta RT signaling pathways."; RL J. Biol. Chem. 279:29681-29690(2004). RN [25] RP PHOSPHORYLATION AT THR-8; THR-179; SER-204; SER-208 AND SER-213, FUNCTION, RP AND MUTAGENESIS OF THR-8; THR-179; SER-204; SER-208 AND SER-213. RX PubMed=15241418; DOI=10.1038/nature02650; RA Matsuura I., Denissova N.G., Wang G., He D., Long J., Liu F.; RT "Cyclin-dependent kinases regulate the antiproliferative function of RT Smads."; RL Nature 430:226-231(2004). RN [26] RP TRANSCRIPTIONAL ACTIVATION DOMAIN, FUNCTION, PHOSPHORYLATION, SUBUNIT, AND RP INTERACTION WITH EP300. RX PubMed=15588252; DOI=10.1042/bj20041820; RA Wang G., Long J., Matsuura I., He D., Liu F.; RT "The Smad3 linker region contains a transcriptional activation domain."; RL Biochem. J. 386:29-34(2005). RN [27] RP PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION, RP FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208. RX PubMed=16156666; DOI=10.1021/bi050560g; RA Matsuura I., Wang G., He D., Liu F.; RT "Identification and characterization of ERK MAP kinase phosphorylation RT sites in Smad3."; RL Biochemistry 44:12546-12553(2005). RN [28] RP SUBCELLULAR LOCATION, AND INTERACTION WITH LEMD3. RX PubMed=15601644; DOI=10.1093/hmg/ddi040; RA Lin F., Morrison J.M., Wu W., Worman H.J.; RT "MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and RT Smad3 and antagonizes transforming growth factor-beta signaling."; RL Hum. Mol. Genet. 14:437-445(2005). RN [29] RP INTERACTION WITH TGFB1I1. RX PubMed=15561701; DOI=10.1074/jbc.m411575200; RA Wang H., Song K., Sponseller T.L., Danielpour D.; RT "Novel function of androgen receptor-associated protein 55/Hic-5 as a RT negative regulator of Smad3 signaling."; RL J. Biol. Chem. 280:5154-5162(2005). RN [30] RP INTERACTION WITH LEMD3. RX PubMed=15647271; DOI=10.1074/jbc.m411234200; RA Pan D., Estevez-Salmeron L.D., Stroschein S.L., Zhu X., He J., Zhou S., RA Luo K.; RT "The integral inner nuclear membrane protein MAN1 physically interacts with RT the R-Smad proteins to repress signaling by the transforming growth RT factor-{beta} superfamily of cytokines."; RL J. Biol. Chem. 280:15992-16001(2005). RN [31] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=15799969; DOI=10.1074/jbc.m500362200; RA Chen H.B., Rud J.G., Lin K., Xu L.; RT "Nuclear targeting of transforming growth factor-beta-activated Smad RT complexes."; RL J. Biol. Chem. 280:21329-21336(2005). RN [32] RP INTERACTION WITH SKOR2. RX PubMed=16200078; DOI=10.1038/labinvest.3700344; RA Arndt S., Poser I., Schubert T., Moser M., Bosserhoff A.-K.; RT "Cloning and functional characterization of a new Ski homolog, Fussel-18, RT specifically expressed in neuronal tissues."; RL Lab. Invest. 85:1330-1341(2005). RN [33] RP INTERACTION WITH MECOM. RX PubMed=15897867; DOI=10.1038/sj.onc.1208754; RA Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S., RA Kurokawa M., Hirai H.; RT "Oligomerization of Evi-1 regulated by the PR domain contributes to RT recruitment of corepressor CtBP."; RL Oncogene 24:6165-6173(2005). RN [34] RP INTERACTION WITH PPM1A, DEPHOSPHORYLATION, FUNCTION, AND SUBCELLULAR RP LOCATION. RX PubMed=16751101; DOI=10.1016/j.cell.2006.03.044; RA Lin X., Duan X., Liang Y.Y., Su Y., Wrighton K.H., Long J., Hu M., RA Davis C.M., Wang J., Brunicardi F.C., Shi Y., Chen Y.G., Meng A., RA Feng X.H.; RT "PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling."; RL Cell 125:915-928(2006). RN [35] RP IDENTIFICATION IN A COMPLEX WITH SMAD2 AND TRIM33, AND INTERACTION WITH RP SMAD2 AND TRIM33. RX PubMed=16751102; DOI=10.1016/j.cell.2006.03.045; RA He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A., Massague J.; RT "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the RT TGFbeta pathway."; RL Cell 125:929-941(2006). RN [36] RP INTERACTION WITH ZMIZ1. RX PubMed=16777850; DOI=10.1074/jbc.m508365200; RA Li X., Thyssen G., Beliakoff J., Sun Z.; RT "The novel PIAS-like protein hZimp10 enhances Smad transcriptional RT activity."; RL J. Biol. Chem. 281:23748-23756(2006). RN [37] RP IDENTIFICATION IN A COMPLEX WITH RAN AND XPO4, INTERACTION WITH XPO4, AND RP MUTAGENESIS OF 422-SER--SER-425. RX PubMed=16449645; DOI=10.1128/mcb.26.4.1318-1332.2006; RA Kurisaki A., Kurisaki K., Kowanetz M., Sugino H., Yoneda Y., Heldin C.-H., RA Moustakas A.; RT "The mechanism of nuclear export of Smad3 involves exportin 4 and Ran."; RL Mol. Cell. Biol. 26:1318-1332(2006). RN [38] RP INTERACTION WITH RBPMS. RX PubMed=17099224; DOI=10.1093/nar/gkl914; RA Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H., RA Ye Q.; RT "Potentiation of Smad-mediated transcriptional activation by the RNA- RT binding protein RBPMS."; RL Nucleic Acids Res. 34:6314-6326(2006). RN [39] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [40] RP INTERACTION WITH SKOR1. RX PubMed=17292623; DOI=10.1016/j.mcn.2007.01.002; RA Arndt S., Poser I., Moser M., Bosserhoff A.-K.; RT "Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling."; RL Mol. Cell. Neurosci. 34:603-611(2007). RN [41] RP ACETYLATION AT LYS-378, FUNCTION, AND MUTAGENESIS OF LYS-333; LYS-341; RP LYS-378; LYS-409 AND 422-SER--SER-425. RX PubMed=16862174; DOI=10.1038/sj.onc.1209826; RA Inoue Y., Itoh Y., Abe K., Okamoto T., Daitoku H., Fukamizu A., Onozaki K., RA Hayashi H.; RT "Smad3 is acetylated by p300/CBP to regulate its transactivation RT activity."; RL Oncogene 26:500-508(2007). RN [42] RP INTERACTION WITH WWTR1. RX PubMed=18568018; DOI=10.1038/ncb1748; RA Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., RA Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.; RT "TAZ controls Smad nucleocytoplasmic shuttling and regulates human RT embryonic stem-cell self-renewal."; RL Nat. Cell Biol. 10:837-848(2008). RN [43] RP INTERACTION WITH SARS-COV NUCLEOPROTEIN (MICROBIAL INFECTION). RX PubMed=18055455; DOI=10.1074/jbc.m708033200; RA Zhao X., Nicholls J.M., Chen Y.G.; RT "Severe acute respiratory syndrome-associated coronavirus nucleocapsid RT protein interacts with Smad3 and modulates transforming growth factor-beta RT signaling."; RL J. Biol. Chem. 283:3272-3280(2008). RN [44] RP INTERACTION WITH CSNK1G2, UBIQUITINATION, PHOSPHORYLATION AT SER-418 BY RP CSNK1G2/CK1, AND MUTAGENESIS OF SER-418. RX PubMed=18794808; DOI=10.1038/onc.2008.337; RA Guo X., Waddell D.S., Wang W., Wang Z., Liberati N.T., Yong S., Liu X., RA Wang X.-F.; RT "Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 RT gamma 2, an inhibitor of TGF-beta signaling."; RL Oncogene 27:7235-7247(2008). RN [45] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [46] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [47] RP INTERACTION WITH RANBP3, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=19289081; DOI=10.1016/j.devcel.2009.01.022; RA Dai F., Lin X., Chang C., Feng X.H.; RT "Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of RT TGF-beta signaling."; RL Dev. Cell 16:345-357(2009). RN [48] RP INTERACTION WITH PRDM16; SKI AND HDAC1. RX PubMed=19049980; DOI=10.1074/jbc.m808989200; RA Takahata M., Inoue Y., Tsuda H., Imoto I., Koinuma D., Hayashi M., RA Ichikura T., Yamori T., Nagasaki K., Yoshida M., Matsuoka M., Morishita K., RA Yuki K., Hanyu A., Miyazawa K., Inazawa J., Miyazono K., Imamura T.; RT "SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal RT in gastric cancer cells."; RL J. Biol. Chem. 284:3334-3344(2009). RN [49] RP PHOSPHORYLATION AT THR-179; SER-204 AND SER-208, SUBCELLULAR LOCATION, RP FUNCTION, AND MUTAGENESIS OF THR-179; SER-204 AND SER-208. RX PubMed=19218245; DOI=10.1074/jbc.m809281200; RA Wang G., Matsuura I., He D., Liu F.; RT "Transforming growth factor-{beta}-inducible phosphorylation of Smad3."; RL J. Biol. Chem. 284:9663-9673(2009). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=21145499; DOI=10.1016/j.devcel.2010.11.012; RA Varelas X., Samavarchi-Tehrani P., Narimatsu M., Weiss A., Cockburn K., RA Larsen B.G., Rossant J., Wrana J.L.; RT "The Crumbs complex couples cell density sensing to Hippo-dependent control RT of the TGF-beta-SMAD pathway."; RL Dev. Cell 19:831-844(2010). RN [51] RP INTERACTION WITH MTMR4. RX PubMed=20061380; DOI=10.1074/jbc.m109.075036; RA Yu J., Pan L., Qin X., Chen H., Xu Y., Chen Y., Tang H.; RT "MTMR4 attenuates transforming growth factor beta (TGFbeta) signaling by RT dephosphorylating R-Smads in endosomes."; RL J. Biol. Chem. 285:8454-8462(2010). RN [52] RP INTERACTION WITH PMEPA1. RX PubMed=20129061; DOI=10.1016/j.molcel.2009.10.028; RA Watanabe Y., Itoh S., Goto T., Ohnishi E., Inamitsu M., Itoh F., Satoh K., RA Wiercinska E., Yang W., Shi L., Tanaka A., Nakano N., Mommaas A.M., RA Shibuya H., Ten Dijke P., Kato M.; RT "TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad RT proteins from active participation in TGF-beta signaling."; RL Mol. Cell 37:123-134(2010). RN [53] RP INTERACTION WITH IL1F7. RX PubMed=20935647; DOI=10.1038/ni.1944; RA Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., RA Dinarello C.A.; RT "IL-37 is a fundamental inhibitor of innate immunity."; RL Nat. Immunol. 11:1014-1022(2010). RN [54] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [55] RP UBIQUITINATION, DEUBIQUITINATION BY USP15, DNA-BINDING, INTERACTION WITH RP USP15, UBIQUITINATION AT LYS-33 AND LYS-81, AND MUTAGENESIS OF LYS-33; RP LYS-53 AND LYS-81. RX PubMed=21947082; DOI=10.1038/ncb2346; RA Inui M., Manfrin A., Mamidi A., Martello G., Morsut L., Soligo S., Enzo E., RA Moro S., Polo S., Dupont S., Cordenonsi M., Piccolo S.; RT "USP15 is a deubiquitylating enzyme for receptor-activated SMADs."; RL Nat. Cell Biol. 13:1368-1375(2011). RN [56] RP INTERACTION WITH PPP5C, AND SUBCELLULAR LOCATION. RX PubMed=22781750; DOI=10.1016/j.cellsig.2012.07.003; RA Bruce D.L., Macartney T., Yong W., Shou W., Sapkota G.P.; RT "Protein phosphatase 5 modulates SMAD3 function in the transforming growth RT factor-beta pathway."; RL Cell. Signal. 24:1999-2006(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-416, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [59] RP INTERACTION WITH STUB1; HSPA1A; HSPA1B; HSP90AA1 AND HSP90AB1, RP UBIQUITINATION, AND PROTEASOMAL DEGRADATION. RX PubMed=24613385; DOI=10.1016/j.bbrc.2014.02.124; RA Shang Y., Xu X., Duan X., Guo J., Wang Y., Ren F., He D., Chang Z.; RT "Hsp70 and Hsp90 oppositely regulate TGF-beta signaling through RT CHIP/Stub1."; RL Biochem. Biophys. Res. Commun. 446:387-392(2014). RN [60] RP INTERACTION WITH ZNF451, AND IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD2 RP AND SMAD4. RX PubMed=24324267; DOI=10.1074/jbc.m113.526905; RA Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.; RT "Zinc finger protein 451 is a novel Smad corepressor in transforming growth RT factor-beta signaling."; RL J. Biol. Chem. 289:2072-2083(2014). RN [61] RP INTERACTION WITH LDLRAD4. RX PubMed=24627487; DOI=10.1074/jbc.m114.558981; RA Nakano N., Maeyama K., Sakata N., Itoh F., Akatsu R., Nakata M., Katsu Y., RA Ikeno S., Togawa Y., Vo Nguyen T.T., Watanabe Y., Kato M., Itoh S.; RT "C18 ORF1, a novel negative regulator of transforming growth factor-beta RT signaling."; RL J. Biol. Chem. 289:12680-12692(2014). RN [62] RP INTERACTION WITH ZFHX3. RX PubMed=25105025; DOI=10.1155/2014/970346; RA Sakata N., Kaneko S., Ikeno S., Miura Y., Nakabayashi H., Dong X.Y., RA Dong J.T., Tamaoki T., Nakano N., Itoh S.; RT "TGF-beta signaling cooperates with AT motif-binding factor-1 for RT repression of the alpha -fetoprotein promoter."; RL J. Signal Transduct. 2014:970346-970346(2014). RN [63] RP ADP-RIBOSYLATION. RX PubMed=25133494; DOI=10.1371/journal.pone.0103651; RA Dahl M., Maturi V., Lonn P., Papoutsoglou P., Zieba A., Vanlandewijck M., RA van der Heide L.P., Watanabe Y., Soderberg O., Hottiger M.O., Heldin C.H., RA Moustakas A.; RT "Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and RT poly(ADP-ribose) glycohydrolase during transforming growth factor beta RT Signaling."; RL PLoS ONE 9:E103651-E103651(2014). RN [64] RP INTERACTION WITH NEDD9. RX PubMed=29899023; DOI=10.1126/scitranslmed.aap7294; RA Samokhin A.O., Stephens T., Wertheim B.M., Wang R.S., Vargas S.O., RA Yung L.M., Cao M., Brown M., Arons E., Dieffenbach P.B., Fewell J.G., RA Matar M., Bowman F.P., Haley K.J., Alba G.A., Marino S.M., Kumar R., RA Rosas I.O., Waxman A.B., Oldham W.M., Khanna D., Graham B.B., Seo S., RA Gladyshev V.N., Yu P.B., Fredenburgh L.E., Loscalzo J., Leopold J.A., RA Maron B.A.; RT "NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary RT arterial hypertension."; RL Sci. Transl. Med. 10:0-0(2018). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-144. RX PubMed=9741623; DOI=10.1016/s0092-8674(00)81600-1; RA Shi Y., Wang Y.-F., Jayaraman L., Yang H., Massague J., Pavletich N.P.; RT "Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA RT binding in TGF-beta signaling."; RL Cell 94:585-594(1998). RN [66] RP X-RAY CRYSTALLOGRAPHY (2.74 ANGSTROMS) OF 220-425 IN COMPLEX WITH ZFYVE9. RX PubMed=12154125; DOI=10.1101/gad.1002002; RA Qin B.Y., Lam S.S., Correia J.J., Lin K.; RT "Smad3 allostery links TGF-beta receptor kinase activation to RT transcriptional control."; RL Genes Dev. 16:1950-1963(2002). RN [67] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-144 IN COMPLEX WITH DNA, AND RP ZINC. RX PubMed=12686552; DOI=10.1074/jbc.c300134200; RA Chai J., Wu J.W., Yan N., Massague J., Pavletich N.P., Shi Y.; RT "Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA RT binding."; RL J. Biol. Chem. 278:20327-20331(2003). RN [68] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 228-424 IN COMPLEX WITH SMAD4, AND RP SUBUNIT. RX PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016; RA Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., RA De Caestecker M., Lin K.; RT "Structural basis of heteromeric smad protein assembly in TGF-beta RT signaling."; RL Mol. Cell 15:813-823(2004). RN [69] RP VARIANT [LARGE SCALE ANALYSIS] LEU-393, AND INVOLVEMENT IN COLORECTAL RP CANCER. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [70] RP VARIANTS LDS3 VAL-112; LYS-239 AND LYS-279. RX PubMed=21778426; DOI=10.1161/circresaha.111.248161; RA Regalado E.S., Guo D.C., Villamizar C., Avidan N., Gilchrist D., RA McGillivray B., Clarke L., Bernier F., Santos-Cortez R.L., Leal S.M., RA Bertoli-Avella A.M., Shendure J., Rieder M.J., Nickerson D.A., RA Milewicz D.M.; RT "Exome sequencing identifies SMAD3 mutations as a cause of familial RT thoracic aortic aneurysm and dissection with intracranial and other RT arterial aneurysms."; RL Circ. Res. 109:680-686(2011). RN [71] RP VARIANTS LDS3 ILE-261 AND TRP-287. RX PubMed=21217753; DOI=10.1038/ng.744; RA van de Laar I.M., Oldenburg R.A., Pals G., Roos-Hesselink J.W., RA de Graaf B.M., Verhagen J.M., Hoedemaekers Y.M., Willemsen R., RA Severijnen L.A., Venselaar H., Vriend G., Pattynama P.M., Collee M., RA Majoor-Krakauer D., Poldermans D., Frohn-Mulder I.M., Micha D., RA Timmermans J., Hilhorst-Hofstee Y., Bierma-Zeinstra S.M., Willems P.J., RA Kros J.M., Oei E.H., Oostra B.A., Wessels M.W., Bertoli-Avella A.M.; RT "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and RT dissections with early-onset osteoarthritis."; RL Nat. Genet. 43:121-126(2011). CC -!- FUNCTION: Receptor-regulated SMAD (R-SMAD) that is an intracellular CC signal transducer and transcriptional modulator activated by TGF-beta CC (transforming growth factor) and activin type 1 receptor kinases. Binds CC the TRE element in the promoter region of many genes that are regulated CC by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates CC transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP- CC 1/SMAD site to regulate TGF-beta-mediated transcription. Has an CC inhibitory effect on wound healing probably by modulating both growth CC and migration of primary keratinocytes and by altering the TGF-mediated CC chemotaxis of monocytes. This effect on wound healing appears to be CC hormone-sensitive. Regulator of chondrogenesis and osteogenesis and CC inhibits early healing of bone fractures. Positively regulates PDPK1 CC kinase activity by stimulating its dissociation from the 14-3-3 protein CC YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748, CC ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, CC ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}. CC -!- SUBUNIT: Monomer; in the absence of TGF-beta (PubMed:9670020). CC Homooligomer; in the presence of TGF-beta (PubMed:9670020). CC Heterotrimer; forms a heterotrimer in the presence of TGF-beta CC consisting of two molecules of C-terminally phosphorylated SMAD2 or CC SMAD3 and one of SMAD4 to form the transcriptionally active CC SMAD2/SMAD3-SMAD4 complex (PubMed:11224571, PubMed:15350224, CC PubMed:15799969, PubMed:9670020). Part of a complex consisting of CC MAGI2/ARIP1, ACVR2A, ACVR1B and SMAD3 (PubMed:9892009). Forms a complex CC with SMAD2 and TRIM33 upon addition of TGF-beta (PubMed:16751102). CC Found in a complex composed of SMAD3, RAN and XPO4; within the complex CC interacts directly with XPO4 (PubMed:16449645). Component of the CC multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1 promoter CC site; required for synergistic transcriptional activity in response to CC TGF-beta (PubMed:10995748, PubMed:9732876). Part of a ternary complex CC composed of SMAD3, ITCH/AIP4 and NEDD9/HEF1; within the complex CC NEDD9/HEF1 interacts (via N-terminus) with ITCH/AIP4; the complex CC mediates ubiquitination and proteasomal degradation of NEDD9/HEF1 CC (PubMed:15051726). Interacts with NEDD9; the interaction promotes NEDD9 CC ubiquitination and proteasomal degradation (PubMed:15051726). Interacts CC (via an N-terminal domain) with JUN (via its basic DNA binding and CC leucine zipper domains); this interaction is essential for DNA binding CC and cooperative transcriptional activity in response to TGF-beta CC (PubMed:10995748, PubMed:9732876). Identified in a complex that CC contains at least ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). CC Interacts with PPM1A; the interaction dephosphorylates SMAD3 in the C- CC terminal SXS motif leading to disruption of the SMAD2/3-SMAD4 complex, CC nuclear export and termination of TGF-beta signaling (PubMed:16751101). CC Interacts (via MH2 domain) with ZMIZ1 (via SP-RING-type domain); in the CC TGF-beta signaling pathway increases the activity of the SMAD3/SMAD4 CC transcriptional complex (PubMed:16777850). Interacts (when CC phosphorylated) with RNF111; RNF111 acts as an enhancer of the CC transcriptional responses by mediating ubiquitination and degradation CC of SMAD3 inhibitors (PubMed:9311995). Interacts (dephosphorylated form CC via the MH1 and MH2 domains) with RANBP3 (via its C-terminal R domain); CC the interaction results in the export of dephosphorylated SMAD3 out of CC the nucleus and termination of the TGF-beta signaling CC (PubMed:19289081). Interacts (via MH2 domain) with LEMD3; the CC interaction represses SMAD3 transcriptional activity through preventing CC the formation of the heteromeric complex with SMAD4 and translocation CC to the nucleus (PubMed:15601644, PubMed:15647271). Interacts (via the CC linker region) with EP300 (C-terminal); the interaction promotes SMAD3 CC acetylation and is enhanced by TGF-beta phosphorylation in the C- CC terminal of SMAD3 (PubMed:15588252, PubMed:9843571). This interaction CC can be blocked by competitive binding of adenovirus oncoprotein E1A to CC the same C-terminal site on EP300, which then results in partially CC inhibited SMAD3/SMAD4 transcriptional activity (PubMed:15588252, CC PubMed:9843571). Interacts with TGFBR1 (PubMed:9311995). Interacts with CC TGFB1I1 (PubMed:15561701). Interacts with PRDM16 (PubMed:19049980). CC Interacts with SNW1 (PubMed:11278756). Interacts (via MH2 domain) with CC ZFYVE9 (PubMed:12154125, PubMed:9865696). Interacts with HDAC1 CC (PubMed:19049980). Interacts with TGIF2 (PubMed:11427533). Interacts CC with SKOR1 (PubMed:17292623). Interacts with SKOR2 (PubMed:16200078). CC Interacts with DACH1; the interaction inhibits the TGF-beta signaling CC (PubMed:14525983). Interacts with RBPMS (PubMed:17099224). Interacts CC (via MH2 domain) with MECOM (PubMed:15897867, PubMed:9665135). CC Interacts with WWTR1 (via its coiled-coil domain) (PubMed:18568018). CC Interacts with SKI; the interaction represses SMAD3 transcriptional CC activity (PubMed:19049980). Interacts with MEN1 (PubMed:11274402). CC Interacts with IL1F7 (PubMed:20935647). Interaction with CSNK1G2 CC (PubMed:18794808). Interacts with PDPK1 (via PH domain) CC (PubMed:17327236). Interacts with DAB2; the interactions are enhanced CC upon TGF-beta stimulation (PubMed:11387212). Interacts with USP15 CC (PubMed:21947082). Interacts with PPP5C; the interaction decreases CC SMAD3 phosphorylation and protein levels (PubMed:22781750). Interacts CC with LDLRAD4 (via the SMAD interaction motif) (PubMed:24627487). CC Interacts with PMEPA1 (PubMed:20129061). Interacts with ZNF451 CC (PubMed:24324267). Interacts with ZFHX3 (PubMed:25105025). Interacts CC weakly with ZNF8 (PubMed:12370310). Interacts with STUB1, HSPA1A, CC HSPA1B, HSP90AA1 and HSP90AB1 (PubMed:24613385). Interacts with YAP1 CC (when phosphorylated at 'Ser-127') (By similarity). Interacts with CC MAGI2/ARIP1 (By similarity). Interacts (via MH2 domain) with CITED2 CC (via C-terminus) (By similarity). Interacts with HGS (By similarity). CC Interacts with WWP1 (By similarity). Interacts with TTRAP (By CC similarity). Interacts with FOXL2 (By similarity). Interacts with PML CC (By similarity). Interacts with NEDD4L; the interaction requires TGF- CC beta stimulation (By similarity). Interacts with ZC3H3 (By similarity). CC Interacts with TGIF. Interacts with CREBBP. Interacts with ATF2. CC Interacts with NEDD9; the interaction is inhibited by oxidation of CC NEDD9 (PubMed:29899023). Interacts with MTMR4; negatively regulates CC TGF-beta signaling through SMAD3 dephosphorylation and retention in CC endosomes (PubMed:20061380). {ECO:0000250|UniProtKB:P84025, CC ECO:0000250|UniProtKB:Q8BUN5, ECO:0000269|PubMed:10995748, CC ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11274402, CC ECO:0000269|PubMed:11278756, ECO:0000269|PubMed:11387212, CC ECO:0000269|PubMed:11427533, ECO:0000269|PubMed:12154125, CC ECO:0000269|PubMed:12370310, ECO:0000269|PubMed:14525983, CC ECO:0000269|PubMed:15051726, ECO:0000269|PubMed:15350224, CC ECO:0000269|PubMed:15561701, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15647271, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:15897867, CC ECO:0000269|PubMed:16200078, ECO:0000269|PubMed:16449645, CC ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16751102, CC ECO:0000269|PubMed:16777850, ECO:0000269|PubMed:17099224, CC ECO:0000269|PubMed:17292623, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:18568018, ECO:0000269|PubMed:18794808, CC ECO:0000269|PubMed:19049980, ECO:0000269|PubMed:19289081, CC ECO:0000269|PubMed:20061380, ECO:0000269|PubMed:20129061, CC ECO:0000269|PubMed:20935647, ECO:0000269|PubMed:21947082, CC ECO:0000269|PubMed:22781750, ECO:0000269|PubMed:24324267, CC ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:24627487, CC ECO:0000269|PubMed:25105025, ECO:0000269|PubMed:29899023, CC ECO:0000269|PubMed:9311995, ECO:0000269|PubMed:9665135, CC ECO:0000269|PubMed:9670020, ECO:0000269|PubMed:9732876, CC ECO:0000269|PubMed:9843571, ECO:0000269|PubMed:9865696, CC ECO:0000269|PubMed:9892009}. CC -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV nucleoprotein. CC {ECO:0000269|PubMed:18055455}. CC -!- INTERACTION: CC P84022; P60709: ACTB; NbExp=3; IntAct=EBI-347161, EBI-353944; CC P84022; Q06481-5: APLP2; NbExp=3; IntAct=EBI-347161, EBI-25646567; CC P84022; P05067: APP; NbExp=3; IntAct=EBI-347161, EBI-77613; CC P84022; Q9H2G9: BLZF1; NbExp=9; IntAct=EBI-347161, EBI-2548012; CC P84022; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-347161, EBI-1383687; CC P84022; P29466-3: CASP1; NbExp=3; IntAct=EBI-347161, EBI-12248206; CC P84022; E9PSE9: CCDC198; NbExp=3; IntAct=EBI-347161, EBI-11748295; CC P84022; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-347161, EBI-740841; CC P84022; Q9H2X0: CHRD; NbExp=2; IntAct=EBI-347161, EBI-947551; CC P84022; Q8N684: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-746909; CC P84022; Q8N684-3: CPSF7; NbExp=3; IntAct=EBI-347161, EBI-11523759; CC P84022; O43186: CRX; NbExp=3; IntAct=EBI-347161, EBI-748171; CC P84022; Q96PZ7: CSMD1; NbExp=3; IntAct=EBI-347161, EBI-766158; CC P84022; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-347161, EBI-9087876; CC P84022; P98082: DAB2; NbExp=3; IntAct=EBI-347161, EBI-1171238; CC P84022; P17844: DDX5; NbExp=2; IntAct=EBI-347161, EBI-351962; CC P84022; Q9BZ29: DOCK9; NbExp=3; IntAct=EBI-347161, EBI-2695893; CC P84022; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-347161, EBI-6658203; CC P84022; Q01543: FLI1; NbExp=3; IntAct=EBI-347161, EBI-2271018; CC P84022; O75593: FOXH1; NbExp=4; IntAct=EBI-347161, EBI-1759806; CC P84022; O43524: FOXO3; NbExp=5; IntAct=EBI-347161, EBI-1644164; CC P84022; P10070: GLI2; NbExp=4; IntAct=EBI-347161, EBI-10821567; CC P84022; Q16665: HIF1A; NbExp=6; IntAct=EBI-347161, EBI-447269; CC P84022; O15397: IPO8; NbExp=2; IntAct=EBI-347161, EBI-358808; CC P84022; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-347161, EBI-1055254; CC P84022; P50222: MEOX2; NbExp=6; IntAct=EBI-347161, EBI-748397; CC P84022; Q9NYA4: MTMR4; NbExp=2; IntAct=EBI-347161, EBI-1052346; CC P84022; Q99836: MYD88; NbExp=3; IntAct=EBI-347161, EBI-447677; CC P84022; P46934-3: NEDD4; NbExp=3; IntAct=EBI-347161, EBI-11980721; CC P84022; Q16822: PCK2; NbExp=2; IntAct=EBI-347161, EBI-2825219; CC P84022; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-347161, EBI-713786; CC P84022; Q8IXK0-5: PHC2; NbExp=3; IntAct=EBI-347161, EBI-11527347; CC P84022; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-347161, EBI-9090282; CC P84022; Q9BZL4: PPP1R12C; NbExp=2; IntAct=EBI-347161, EBI-721802; CC P84022; P17612: PRKACA; NbExp=3; IntAct=EBI-347161, EBI-476586; CC P84022; P24158: PRTN3; NbExp=2; IntAct=EBI-347161, EBI-465028; CC P84022; P20618: PSMB1; NbExp=3; IntAct=EBI-347161, EBI-372273; CC P84022; Q96EP0: RNF31; NbExp=2; IntAct=EBI-347161, EBI-948111; CC P84022; P0C264: SBK3; NbExp=3; IntAct=EBI-347161, EBI-17181801; CC P84022; Q9BYW2: SETD2; NbExp=2; IntAct=EBI-347161, EBI-945869; CC P84022; P12755: SKI; NbExp=11; IntAct=EBI-347161, EBI-347281; CC P84022; Q15796: SMAD2; NbExp=3; IntAct=EBI-347161, EBI-1040141; CC P84022; P84022: SMAD3; NbExp=3; IntAct=EBI-347161, EBI-347161; CC P84022; Q13485: SMAD4; NbExp=43; IntAct=EBI-347161, EBI-347263; CC P84022; Q9HAU4: SMURF2; NbExp=8; IntAct=EBI-347161, EBI-396727; CC P84022; Q13573: SNW1; NbExp=5; IntAct=EBI-347161, EBI-632715; CC P84022; Q13501: SQSTM1; NbExp=3; IntAct=EBI-347161, EBI-307104; CC P84022; Q12772: SREBF2; NbExp=3; IntAct=EBI-347161, EBI-465059; CC P84022; Q05066: SRY; NbExp=3; IntAct=EBI-347161, EBI-464987; CC P84022; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-347161, EBI-750487; CC P84022; Q15583: TGIF1; NbExp=3; IntAct=EBI-347161, EBI-714215; CC P84022; Q08117: TLE5; NbExp=4; IntAct=EBI-347161, EBI-717810; CC P84022; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347161, EBI-11741437; CC P84022; Q9Y3Q8: TSC22D4; NbExp=2; IntAct=EBI-347161, EBI-739485; CC P84022; Q93009: USP7; NbExp=2; IntAct=EBI-347161, EBI-302474; CC P84022; Q9H0M0: WWP1; NbExp=9; IntAct=EBI-347161, EBI-742157; CC P84022; O00308: WWP2; NbExp=7; IntAct=EBI-347161, EBI-743923; CC P84022; Q5D1E8: ZC3H12A; NbExp=2; IntAct=EBI-347161, EBI-747793; CC P84022; O95405: ZFYVE9; NbExp=7; IntAct=EBI-347161, EBI-296817; CC P84022; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-347161, EBI-10251462; CC P84022; P51141: Dvl1; Xeno; NbExp=2; IntAct=EBI-347161, EBI-1538407; CC P84022; Q64729: Tgfbr1; Xeno; NbExp=6; IntAct=EBI-347161, EBI-2899393; CC P84022; PRO_0000278742 [O92972]; Xeno; NbExp=6; IntAct=EBI-347161, EBI-9213553; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499, CC ECO:0000269|PubMed:22781750}. Nucleus {ECO:0000269|PubMed:15601644, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:16156666, CC ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499, CC ECO:0000269|PubMed:22781750}. Note=Cytoplasmic and nuclear in the CC absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus CC when complexed with SMAD4 (PubMed:15799969, PubMed:21145499). Through CC the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 CC complex, and exported out of the nucleus by interaction with RANBP1 CC (PubMed:16751101, PubMed:19289081). Co-localizes with LEMD3 at the CC nucleus inner membrane (PubMed:15601644). MAPK-mediated phosphorylation CC appears to have no effect on nuclear import (PubMed:19218245). PDPK1 CC prevents its nuclear translocation in response to TGF-beta CC (PubMed:17327236). Localized mainly to the nucleus in the early stages CC of embryo development with expression becoming evident in the cytoplasm CC of the inner cell mass at the blastocyst stage (By similarity). CC {ECO:0000250|UniProtKB:Q8BUN5, ECO:0000269|PubMed:15601644, CC ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:16751101, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:21145499}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P84022-1; Sequence=Displayed; CC Name=2; CC IsoId=P84022-2; Sequence=VSP_042900; CC Name=3; CC IsoId=P84022-3; Sequence=VSP_043793; CC Name=4; CC IsoId=P84022-4; Sequence=VSP_045348; CC -!- DOMAIN: The MH1 domain is required for DNA binding. Also binds zinc CC ions which are necessary for the DNA binding. CC -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric CC interactions and for transcriptional regulation. Sufficient for nuclear CC import. CC -!- DOMAIN: The linker region is required for the TGFbeta-mediated CC transcriptional activity and acts synergistically with the MH2 domain. CC -!- PTM: Phosphorylated on serine and threonine residues. Enhanced CC phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on CC EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated CC phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle CC dependent manner and inhibits both the transcriptional activity and CC antiproliferative functions of SMAD3. This phosphorylation is inhibited CC by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also CC phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 CC and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is CC required for interaction with SMAD4, nuclear location and CC transactivational activity, and appears to be a prerequisite for the CC TGF-beta mediated phosphorylation in the linker region. CC Dephosphorylated in the C-terminal SXS motif by PPM1A. This CC dephosphorylation disrupts the interaction with SMAD4, promotes nuclear CC export and terminates TGF-beta-mediated signaling. Phosphorylation at CC Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and CC subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF- CC beta responses. Phosphorylated by PDPK1. {ECO:0000269|PubMed:11224571, CC ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, CC ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:17327236, CC ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19218245, CC ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:8774881, CC ECO:0000269|PubMed:9843571}. CC -!- PTM: Acetylation in the nucleus by EP300 in the MH2 domain regulates CC positively its transcriptional activity and is enhanced by TGF-beta. CC {ECO:0000269|PubMed:16862174}. CC -!- PTM: Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation CC negatively regulates SMAD3 transcriptional responses during the course CC of TGF-beta signaling. {ECO:0000269|PubMed:25133494}. CC -!- PTM: Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding CC (PubMed:21947082). Deubiquitination by USP15 alleviates inhibition and CC promotes activation of TGF-beta target genes (PubMed:21947082). CC Ubiquitinated by RNF111, leading to its degradation: only SMAD3 CC proteins that are 'in use' are targeted by RNF111, RNF111 playing a key CC role in activating SMAD3 and regulating its turnover (By similarity). CC Undergoes STUB1-mediated ubiquitination and degradation CC (PubMed:24613385). {ECO:0000250|UniProtKB:Q8BUN5, CC ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:24613385}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Loeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm CC syndrome with widespread systemic involvement. The disorder is CC characterized by the triad of arterial tortuosity and aneurysms, CC hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also CC manifest early-onset osteoarthritis. They lack craniosynostosis and CC intellectual disability. {ECO:0000269|PubMed:21217753, CC ECO:0000269|PubMed:21778426}. Note=The disease is caused by variants CC affecting the gene represented in this entry. SMAD3 mutations have been CC reported to be also associated with thoracic aortic aneurysms and CC dissection (TAAD) (PubMed:21778426). This phenotype is distinguised CC from LDS3 by having aneurysms restricted to thoracic aorta. As CC individuals carrying these mutations also exhibit aneurysms of other CC arteries, including abdominal aorta, iliac, and/or intracranial CC arteries (PubMed:21778426), they have been classified as LDS3 by the CC OMIM resource. {ECO:0000269|PubMed:21778426}. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U68019; AAB80960.1; -; mRNA. DR EMBL; U76622; AAB18967.1; -; mRNA. DR EMBL; AB004930; BAA22032.1; -; Genomic_DNA. DR EMBL; AF025300; AAL68976.1; -; Genomic_DNA. DR EMBL; AF025293; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025294; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025295; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025296; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025297; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025298; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AF025299; AAL68976.1; JOINED; Genomic_DNA. DR EMBL; AK290881; BAF83570.1; -; mRNA. DR EMBL; AK298139; BAH12731.1; -; mRNA. DR EMBL; AK300614; BAH13315.1; -; mRNA. DR EMBL; AK316017; BAH14388.1; -; mRNA. DR EMBL; AC012568; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC087482; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471082; EAW77788.1; -; Genomic_DNA. DR EMBL; BC050743; AAH50743.1; -; mRNA. DR CCDS; CCDS10222.1; -. [P84022-1] DR CCDS; CCDS45288.1; -. [P84022-2] DR CCDS; CCDS53950.1; -. [P84022-3] DR CCDS; CCDS53951.1; -. [P84022-4] DR PIR; S71798; S71798. DR RefSeq; NP_001138574.1; NM_001145102.2. [P84022-3] DR RefSeq; NP_001138575.1; NM_001145103.2. [P84022-2] DR RefSeq; NP_001138576.1; NM_001145104.2. [P84022-4] DR RefSeq; NP_001393945.1; NM_001407016.1. [P84022-3] DR RefSeq; NP_001393946.1; NM_001407017.1. [P84022-4] DR RefSeq; NP_005893.1; NM_005902.4. [P84022-1] DR RefSeq; XP_054233890.1; XM_054377915.1. [P84022-3] DR PDB; 1MHD; X-ray; 2.80 A; A/B=1-132. DR PDB; 1MJS; X-ray; 1.91 A; A=229-425. DR PDB; 1MK2; X-ray; 2.74 A; A=220-425. DR PDB; 1OZJ; X-ray; 2.40 A; A/B=1-144. DR PDB; 1U7F; X-ray; 2.60 A; A/C=228-425. DR PDB; 2LAJ; NMR; -; B=202-211. DR PDB; 2LB2; NMR; -; B=178-189. DR PDB; 5OD6; X-ray; 2.00 A; A/B=11-135. DR PDB; 5ODG; X-ray; 2.12 A; A/B=11-135. DR PDB; 5XOC; X-ray; 2.40 A; A=220-416. DR PDB; 6YIB; X-ray; 1.70 A; P=417-425. DR PDB; 6ZMN; X-ray; 2.33 A; A/B=10-136. DR PDBsum; 1MHD; -. DR PDBsum; 1MJS; -. DR PDBsum; 1MK2; -. DR PDBsum; 1OZJ; -. DR PDBsum; 1U7F; -. DR PDBsum; 2LAJ; -. DR PDBsum; 2LB2; -. DR PDBsum; 5OD6; -. DR PDBsum; 5ODG; -. DR PDBsum; 5XOC; -. DR PDBsum; 6YIB; -. DR PDBsum; 6ZMN; -. DR AlphaFoldDB; P84022; -. DR SMR; P84022; -. DR BioGRID; 110263; 430. DR ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex. DR ComplexPortal; CPX-10345; IL37-SMAD3 transcriptional repressor complex. DR ComplexPortal; CPX-12; SMAD3 homotrimer. DR ComplexPortal; CPX-3252; SMAD3-SMAD4 complex. DR ComplexPortal; CPX-6062; SMAD3-TTF-1 complex. DR CORUM; P84022; -. DR DIP; DIP-29720N; -. DR FunCoup; P84022; 2136. DR IntAct; P84022; 245. DR MINT; P84022; -. DR STRING; 9606.ENSP00000332973; -. DR BindingDB; P84022; -. DR ChEMBL; CHEMBL1293258; -. DR MoonDB; P84022; Predicted. DR GlyGen; P84022; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P84022; -. DR PhosphoSitePlus; P84022; -. DR SwissPalm; P84022; -. DR BioMuta; SMAD3; -. DR DMDM; 51338669; -. DR jPOST; P84022; -. DR MassIVE; P84022; -. DR PaxDb; 9606-ENSP00000332973; -. DR PeptideAtlas; P84022; -. DR ProteomicsDB; 26192; -. DR ProteomicsDB; 57743; -. [P84022-1] DR ProteomicsDB; 57744; -. [P84022-2] DR ProteomicsDB; 57745; -. [P84022-3] DR Pumba; P84022; -. DR ABCD; P84022; 2 sequenced antibodies. DR Antibodypedia; 26224; 2325 antibodies from 46 providers. DR DNASU; 4088; -. DR Ensembl; ENST00000327367.9; ENSP00000332973.4; ENSG00000166949.18. [P84022-1] DR Ensembl; ENST00000439724.7; ENSP00000401133.3; ENSG00000166949.18. [P84022-2] DR Ensembl; ENST00000537194.6; ENSP00000445348.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000540846.6; ENSP00000437757.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000558428.6; ENSP00000454165.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000558739.2; ENSP00000453684.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000558827.2; ENSP00000452767.2; ENSG00000166949.18. [P84022-4] DR Ensembl; ENST00000559460.6; ENSP00000453082.2; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000679624.1; ENSP00000505445.1; ENSG00000166949.18. [P84022-3] DR Ensembl; ENST00000681239.1; ENSP00000505641.1; ENSG00000166949.18. [P84022-3] DR GeneID; 4088; -. DR KEGG; hsa:4088; -. DR MANE-Select; ENST00000327367.9; ENSP00000332973.4; NM_005902.4; NP_005893.1. DR UCSC; uc002aqj.4; human. [P84022-1] DR AGR; HGNC:6769; -. DR CIViC; 4088; 1 evidence item across 1 molecular profile. DR ClinPGx; PA30526; -. DR CTD; 4088; -. DR DisGeNET; 4088; -. DR GeneCards; SMAD3; -. DR GeneReviews; SMAD3; -. DR HGNC; HGNC:6769; SMAD3. DR HPA; ENSG00000166949; Low tissue specificity. DR MalaCards; SMAD3; -. DR MIM; 114500; phenotype. DR MIM; 603109; gene. DR MIM; 613795; phenotype. DR OpenTargets; ENSG00000166949; -. DR Orphanet; 284984; Aneurysm-osteoarthritis syndrome. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR VEuPathDB; HostDB:ENSG00000166949; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000153499; -. DR HOGENOM; CLU_026736_0_0_1; -. DR InParanoid; P84022; -. DR OMA; VENCRYS; -. DR OrthoDB; 5794312at2759; -. DR PAN-GO; P84022; 10 GO annotations based on evolutionary models. DR PhylomeDB; P84022; -. DR PathwayCommons; P84022; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription. DR Reactome; R-HSA-9008059; Interleukin-37 signaling. DR Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription. DR Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes. DR Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9796292; Formation of axial mesoderm. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR SignaLink; P84022; -. DR SIGNOR; P84022; -. DR Agora; ENSG00000166949; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4088; 18 hits in 1191 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR CD-CODE; 804901D1; Nuclear speckle. DR ChiTaRS; SMAD3; human. DR EvolutionaryTrace; P84022; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_3; -. DR GenomeRNAi; 4088; -. DR Pharos; P84022; Tchem. DR PRO; PR:P84022; -. DR Proteomes; UP000005640; Chromosome 15. DR RNAct; P84022; protein. DR Bgee; ENSG00000166949; Expressed in tendon of biceps brachii and 204 other cell types or tissues. DR ExpressionAtlas; P84022; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0035869; C:ciliary transition zone; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IGI:ARUK-UCL. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IDA:BHF-UCL. DR GO; GO:0005637; C:nuclear inner membrane; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:Ensembl. DR GO; GO:0043235; C:receptor complex; IMP:BHF-UCL. DR GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:UniProtKB. DR GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl. DR GO; GO:0043425; F:bHLH transcription factor binding; IPI:BHF-UCL. DR GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl. DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0017151; F:DEAD/H-box RNA helicase binding; IPI:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IDA:ARUK-UCL. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:NTNU_SB. DR GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0001217; F:DNA-binding transcription repressor activity; IDA:ARUK-UCL. DR GO; GO:0070411; F:I-SMAD binding; IBA:GO_Central. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:CAFA. DR GO; GO:0031962; F:nuclear mineralocorticoid receptor binding; IPI:CAFA. DR GO; GO:0016922; F:nuclear receptor binding; IPI:BHF-UCL. DR GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB. DR GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0070412; F:R-SMAD binding; IPI:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0032810; F:sterol response element binding; IGI:ARUK-UCL. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB. DR GO; GO:0001222; F:transcription corepressor binding; IPI:HGNC-UCL. DR GO; GO:0005160; F:transforming growth factor beta receptor binding; IPI:BHF-UCL. DR GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB. DR GO; GO:0032924; P:activin receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0097190; P:apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0008283; P:cell population proliferation; IEA:Ensembl. DR GO; GO:0045216; P:cell-cell junction organization; IMP:BHF-UCL. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:CAFA. DR GO; GO:0098586; P:cellular response to virus; IEA:Ensembl. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl. DR GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl. DR GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl. DR GO; GO:0007492; P:endoderm development; IEA:Ensembl. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0001947; P:heart looping; IEA:Ensembl. DR GO; GO:0006955; P:immune response; IMP:BHF-UCL. DR GO; GO:0002520; P:immune system development; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0007254; P:JNK cascade; IEA:Ensembl. DR GO; GO:0070306; P:lens fiber cell differentiation; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0001707; P:mesoderm formation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0045596; P:negative regulation of cell differentiation; ISS:UniProt. DR GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:BHF-UCL. DR GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IDA:BHF-UCL. DR GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl. DR GO; GO:0061767; P:negative regulation of lung blood pressure; IEA:Ensembl. DR GO; GO:1902894; P:negative regulation of miRNA transcription; IMP:BHF-UCL. DR GO; GO:0030279; P:negative regulation of ossification; IDA:UniProt. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IEA:Ensembl. DR GO; GO:0033689; P:negative regulation of osteoblast proliferation; IEA:Ensembl. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ARUK-UCL. DR GO; GO:0061045; P:negative regulation of wound healing; IEA:Ensembl. DR GO; GO:0038092; P:nodal signaling pathway; IMP:BHF-UCL. DR GO; GO:0002076; P:osteoblast development; IEA:Ensembl. DR GO; GO:0048340; P:paraxial mesoderm morphogenesis; IEA:Ensembl. DR GO; GO:0060039; P:pericardium development; IEA:Ensembl. DR GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl. DR GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl. DR GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IDA:BHF-UCL. DR GO; GO:0051894; P:positive regulation of focal adhesion assembly; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL. DR GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL. DR GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:BHF-UCL. DR GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl. DR GO; GO:0042307; P:positive regulation of protein import into nucleus; NAS:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IMP:BHF-UCL. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0032916; P:positive regulation of transforming growth factor beta3 production; IEA:Ensembl. DR GO; GO:0031053; P:primary miRNA processing; TAS:BHF-UCL. DR GO; GO:0050821; P:protein stabilization; IEA:Ensembl. DR GO; GO:0061001; P:regulation of dendritic spine morphogenesis; IEA:Ensembl. DR GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0050678; P:regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0050776; P:regulation of immune response; IEA:Ensembl. DR GO; GO:1902893; P:regulation of miRNA transcription; IC:ARUK-UCL. DR GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl. DR GO; GO:0016202; P:regulation of striated muscle tissue development; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:NTNU_SB. DR GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl. DR GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL. DR GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Ensembl. DR GO; GO:0097305; P:response to alcohol; IEA:Ensembl. DR GO; GO:1990776; P:response to angiotensin; IMP:BHF-UCL. DR GO; GO:0042220; P:response to cocaine; IEA:Ensembl. DR GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL. DR GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0042110; P:T cell activation; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0060290; P:transdifferentiation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0061450; P:trophoblast cell migration; IDA:UniProt. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR GO; GO:0042060; P:wound healing; TAS:BHF-UCL. DR CDD; cd10491; MH1_SMAD_2_3; 1. DR CDD; cd10985; MH2_SMAD_2_3; 1. DR DisProt; DP01648; -. DR FunFam; 2.60.200.10:FF:000001; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000001; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00113; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF53; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 3; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ADP-ribosylation; Alternative splicing; KW Aortic aneurysm; Cytoplasm; Disease variant; DNA-binding; KW Host-virus interaction; Isopeptide bond; Metal-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Transcription; Transcription regulation; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..425 FT /note="SMAD family member 3" FT /id="PRO_0000090856" FT DOMAIN 10..136 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 232..425 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 137..231 FT /note="Linker" FT REGION 165..208 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 271..324 FT /note="Sufficient for interaction with XPO4" FT /evidence="ECO:0000269|PubMed:16449645" FT COMPBIAS 165..177 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 64 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 109 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 121 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT BINDING 126 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT SITE 40 FT /note="Required for trimerization" FT SITE 41 FT /note="Required for interaction with DNA and JUN and for FT functional cooperation with JUN" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 8 FT /note="Phosphothreonine; by CDK2 and CDK4" FT /evidence="ECO:0000269|PubMed:15241418" FT MOD_RES 179 FT /note="Phosphothreonine; by CDK2, CDK4 and MAPK" FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MOD_RES 204 FT /note="Phosphoserine; by GSK3 and MAPK" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666, FT ECO:0000269|PubMed:19218245" FT MOD_RES 208 FT /note="Phosphoserine; by MAPK" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:16156666, FT ECO:0000269|PubMed:19218245" FT MOD_RES 213 FT /note="Phosphoserine; by CDK2 and CDK4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:15241418" FT MOD_RES 378 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:16862174" FT MOD_RES 416 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 418 FT /note="Phosphoserine; by CK1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439, FT ECO:0000269|PubMed:18794808" FT MOD_RES 422 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT MOD_RES 423 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT MOD_RES 425 FT /note="Phosphoserine; by TGFBR1" FT /evidence="ECO:0000250|UniProtKB:Q8BUN5, FT ECO:0000255|PROSITE-ProRule:PRU00439" FT CROSSLNK 33 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:21947082" FT CROSSLNK 81 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:21947082" FT VAR_SEQ 1..195 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045348" FT VAR_SEQ 1..105 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_043793" FT VAR_SEQ 1..68 FT /note="MSSILPFTPPIVKRLLGWKKGEQNGQEEKWCEKAVKSLVKKLKKTGQLDELE FT KAITTQNVNTKCITIP -> MSCLHPRQTWKGAALVHRKAWWMG (in isoform FT 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042900" FT VARIANT 112 FT /note="A -> V (in LDS3; dbSNP:rs387906854)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067051" FT VARIANT 170 FT /note="I -> V (in dbSNP:rs35874463)" FT /id="VAR_052021" FT VARIANT 239 FT /note="E -> K (in LDS3; dbSNP:rs387906853)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067047" FT VARIANT 261 FT /note="T -> I (in LDS3; dbSNP:rs387906851)" FT /evidence="ECO:0000269|PubMed:21217753" FT /id="VAR_065578" FT VARIANT 279 FT /note="R -> K (in LDS3; dbSNP:rs387906852)" FT /evidence="ECO:0000269|PubMed:21778426" FT /id="VAR_067048" FT VARIANT 287 FT /note="R -> W (in LDS3; dbSNP:rs387906850)" FT /evidence="ECO:0000269|PubMed:21217753" FT /id="VAR_065579" FT VARIANT 393 FT /note="P -> L (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036474" FT MUTAGEN 8 FT /note="T->V: Reduced phosphorylation, increased FT transcriptional and antiproliferative activities. Further FT increase in transcriptional and antiproliferative FT activities; when associated with V-179 and A-213." FT /evidence="ECO:0000269|PubMed:15241418" FT MUTAGEN 33 FT /note="K->R: Slightly decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 40 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-41; A-43 and A-44." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 41 FT /note="K->A: Greatly reduced interaction with DNA and JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-40; A-44 and A-43." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 43 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with DNA and JUN; when associated FT with A-40; A-41 and A-44." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 44 FT /note="K->A: Little effect on interaction with DNA or JUN. FT Abolishes interaction with JUN; when associated with A-40; FT A-41 and A-43." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 53 FT /note="K->R: Slightly decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 74 FT /note="R->D: Reduced interaction with JUN. Loss of FT transcriptional activity and cooperation with JUN." FT /evidence="ECO:0000269|PubMed:10995748" FT MUTAGEN 81 FT /note="K->R: Decreased monoubiquitination." FT /evidence="ECO:0000269|PubMed:21947082" FT MUTAGEN 179 FT /note="T->V: Reduced phosphorylation, increased FT transcriptional and increased antiproliferative activities. FT Further increase in transcriptional and antiproliferative FT activities; when associated with V-8 and A-213." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 204 FT /note="S->A: Increased transcriptional activity. Further FT increased transcriptional activity; when associated with S- FT 208." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 208 FT /note="S->A: Increased transcriptional activity. Further FT increased transcriptional activity; when associated with S- FT 208." FT /evidence="ECO:0000269|PubMed:15241418, FT ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:19218245" FT MUTAGEN 213 FT /note="S->A: Reduced phosphorylation. Increased FT transcriptional and antiproliferative activities. Further FT increase in transcriptional and antiproliferative FT activities; when associated with V-8 and V-179." FT /evidence="ECO:0000269|PubMed:15241418" FT MUTAGEN 333 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-341; R-378 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 341 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-378 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 378 FT /note="K->Q: Increased transcriptional activity. No further FT increase in transcriptional activity with EP300." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 378 FT /note="K->R: Greatly reduced acetylation and 85% reduction FT in transcriptional activity. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-341 and R-409." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 409 FT /note="K->R: No effect on acetylation. Completely abolishes FT acetylation and 97% reduction in transcriptional activity; FT when associated with R-333; R-341 and R-378." FT /evidence="ECO:0000269|PubMed:16862174" FT MUTAGEN 418 FT /note="S->A: Increased constitutive activity." FT /evidence="ECO:0000269|PubMed:18794808" FT MUTAGEN 418 FT /note="S->D: Decreased activity." FT /evidence="ECO:0000269|PubMed:18794808" FT MUTAGEN 422..425 FT /note="SSVS->AAVA: Does not abolish protein nuclear export. FT Abolishes almost completely acetylation." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT MUTAGEN 422..425 FT /note="SSVS->EEVE: Forms heterotrimers." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT MUTAGEN 422..425 FT /note="SSVS->RRVR: Diminishes cargo protein export." FT /evidence="ECO:0000269|PubMed:11224571, FT ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16862174" FT CONFLICT 178 FT /note="E -> EVGTWAAQAGL (in Ref. 3; BAA22032)" FT /evidence="ECO:0000305" FT CONFLICT 360 FT /note="F -> L (in Ref. 5; BAH13315)" FT /evidence="ECO:0000305" FT HELIX 11..17 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 25..44 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 48..57 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 60..62 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 66..68 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 71..73 FT /evidence="ECO:0007829|PDB:6ZMN" FT STRAND 75..77 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 80..82 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 84..92 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 100..102 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 103..105 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 113..115 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 118..121 FT /evidence="ECO:0007829|PDB:5OD6" FT HELIX 124..126 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 127..129 FT /evidence="ECO:0007829|PDB:5OD6" FT STRAND 221..225 FT /evidence="ECO:0007829|PDB:1MK2" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 242..250 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 252..258 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 268..270 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 271..273 FT /evidence="ECO:0007829|PDB:1U7F" FT HELIX 281..290 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 294..299 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 302..307 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 309..311 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 313..316 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 318..321 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 323..325 FT /evidence="ECO:0007829|PDB:1MK2" FT STRAND 332..334 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 339..343 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 345..358 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 360..364 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 365..370 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 371..377 FT /evidence="ECO:0007829|PDB:1MJS" FT STRAND 384..386 FT /evidence="ECO:0007829|PDB:1MK2" FT HELIX 389..391 FT /evidence="ECO:0007829|PDB:5XOC" FT STRAND 392..400 FT /evidence="ECO:0007829|PDB:1MJS" FT HELIX 401..413 FT /evidence="ECO:0007829|PDB:1MJS" SQ SEQUENCE 425 AA; 48081 MW; 46DF5E8B371321AC CRC64; MSSILPFTPP IVKRLLGWKK GEQNGQEEKW CEKAVKSLVK KLKKTGQLDE LEKAITTQNV NTKCITIPRS LDGRLQVSHR KGLPHVIYCR LWRWPDLHSH HELRAMELCE FAFNMKKDEV CVNPYHYQRV ETPVLPPVLV PRHTEIPAEF PPLDDYSHSI PENTNFPAGI EPQSNIPETP PPGYLSEDGE TSDHQMNHSM DAGSPNLSPN PMSPAHNNLD LQPVTYCEPA FWCSISYYEL NQRVGETFHA SQPSMTVDGF TDPSNSERFC LGLLSNVNRN AAVELTRRHI GRGVRLYYIG GEVFAECLSD SAIFVQSPNC NQRYGWHPAT VCKIPPGCNL KIFNNQEFAA LLAQSVNQGF EAVYQLTRMC TIRMSFVKGW GAEYRRQTVT STPCWIELHL NGPLQWLDKV LTQMGSPSIR CSSVS // ID TGFR2_HUMAN Reviewed; 567 AA. AC P37173; B4DTV5; Q15580; Q6DKT6; Q99474; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 2. DT 28-JAN-2026, entry version 258. DE RecName: Full=TGF-beta receptor type-2; DE Short=TGFR-2; DE EC=2.7.11.30; DE AltName: Full=TGF-beta type II receptor; DE AltName: Full=Transforming growth factor-beta receptor type II; DE Short=TGF-beta receptor type II; DE Short=TbetaR-II; DE Flags: Precursor; GN Name=TGFBR2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT ALA-439, AND SUBCELLULAR RP LOCATION. RC TISSUE=Liver; RX PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RT "Expression cloning of the TGF-beta type II receptor, a functional RT transmembrane serine/threonine kinase."; RL Cell 68:775-785(1992). RN [2] RP ERRATUM OF PUBMED:1310899. RX PubMed=1525823; RA Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.; RL Cell 70:1069-1069(1992). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RC TISSUE=Glial cell; RX PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3; RA Nikawa J.; RT "A cDNA encoding the human transforming growth factor beta receptor RT suppresses the growth defect of a yeast mutant."; RL Gene 149:367-372(1994). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8812462; DOI=10.1006/geno.1996.0471; RA Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P., RA Harris C.C.; RT "The genomic structure of the gene encoding the human transforming growth RT factor beta type II receptor (TGF-beta RII)."; RL Genomics 36:341-344(1996). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439. RX PubMed=8840968; RA Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.; RT "Genomic structure of the transforming growth factor beta type II receptor RT gene and its mutations in hereditary nonpolyposis colorectal cancers."; RL Cancer Res. 56:4595-4598(1996). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439. RC TISSUE=Liver; RX PubMed=8973329; DOI=10.1016/s0378-1119(96)00501-x; RA Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.; RT "Cloning of a cDNA encoding the human transforming growth factor-beta type RT II receptor: heterogeneity of the mRNA."; RL Gene 181:185-190(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION (ISOFORM 3), SUBUNIT RP (ISOFORM 3), AND SUBCELLULAR LOCATION (ISOFORM 3). RC TISSUE=Peripheral blood T-cell {ECO:0000303|PubMed:34568316}; RX PubMed=34568316; DOI=10.3389/fcell.2021.690397; RA Bertolio M.S., La Colla A., Carrea A., Romo A., Canziani G., Echarte S.M., RA Campisano S., Barletta G.P., Monzon A.M., Rodriguez T.M., Chisari A.N., RA Dewey R.A.; RT "A Novel Splice Variant of Human TGF-beta Type II Receptor Encodes a RT Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in RT vivo."; RL Front. Cell Dev. Biol. 9:690397-690397(2021). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36. RG NIEHS SNPs program; RL Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP PROTEIN SEQUENCE OF 23-37. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [12] RP FUNCTION IN PHOSPHORYLATION OF TGFBR1. RX PubMed=7774578; DOI=10.1002/j.1460-2075.1995.tb07214.x; RA Wieser R., Wrana J.L., Massague J.; RT "GS domain mutations that constitutively activate T beta R-I, the RT downstream signaling component in the TGF-beta receptor complex."; RL EMBO J. 14:2199-2208(1995). RN [13] RP INTERACTION WITH CLU. RX PubMed=8555189; DOI=10.1021/bi951880a; RA Reddy K.B., Karode M.C., Harmony A.K., Howe P.H.; RT "Interaction of transforming growth factor beta receptors with RT apolipoprotein J/clusterin."; RL Biochemistry 35:309-314(1996). RN [14] RP ALTERNATIVE SPLICING (ISOFORM 2), AND FUNCTION (ISOFORMS 1 AND 2). RX PubMed=8635485; DOI=10.1006/excr.1996.0066; RA Hirai R., Fijita T.; RT "A human transforming growth factor-beta type II receptor that contains an RT insertion in the extracellular domain."; RL Exp. Cell Res. 223:135-141(1996). RN [15] RP INTERACTION WITH ZFYVE9. RX PubMed=9865696; DOI=10.1016/s0092-8674(00)81701-8; RA Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.; RT "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."; RL Cell 95:779-791(1998). RN [16] RP HOMODIMERIZATION. RX PubMed=9472030; DOI=10.1083/jcb.140.4.767; RA Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.; RT "Oligomeric structure of type I and type II transforming growth factor beta RT receptors: homodimers form in the ER and persist at the plasma membrane."; RL J. Cell Biol. 140:767-777(1998). RN [17] RP INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277. RX PubMed=11483955; DOI=10.1038/35087019; RA Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.; RT "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that RT facilitates JNK activation."; RL Nat. Cell Biol. 3:708-714(2001). RN [18] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [19] RP INTERACTION WITH DYNLT4. RX PubMed=16982625; DOI=10.1074/jbc.m608614200; RA Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T., RA McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.; RT "Identification of Tctex2beta, a novel dynein light chain family member RT that interacts with different transforming growth factor-beta receptors."; RL J. Biol. Chem. 281:37069-37080(2006). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [22] RP IDENTIFICATION IN A COMPLEX WITH TSC22D1 AND TGFBR1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [23] RP INTERACTION WITH SCUBE3. RX PubMed=21441952; DOI=10.1038/onc.2011.85; RA Wu Y.Y., Peck K., Chang Y.L., Pan S.H., Cheng Y.F., Lin J.C., Yang R.B., RA Hong T.M., Yang P.C.; RT "SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the RT epithelial-mesenchymal transition in lung cancer."; RL Oncogene 30:3682-3693(2011). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION. RX PubMed=25893292; DOI=10.1038/onc.2015.100; RA Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H., Lee J.H.; RT "Syntenin regulates TGF-beta1-induced Smad activation and the epithelial- RT to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I RT receptor internalization."; RL Oncogene 35:389-401(2016). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH TGF-BETA3, RP AND DISULFIDE BONDS. RX PubMed=11850637; DOI=10.1038/nsb766; RA Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.; RT "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex."; RL Nat. Struct. Biol. 9:203-208(2002). RN [28] RP X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159, AND DISULFIDE BONDS. RX PubMed=12121646; DOI=10.1016/s0969-2126(02)00780-3; RA Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.; RT "The 1.1 A crystal structure of human TGF-beta type II receptor ligand RT binding domain."; RL Structure 10:913-919(2002). RN [29] RP STRUCTURE BY NMR OF 38-159, AND DISULFIDE BONDS. RX PubMed=12939140; DOI=10.1021/bi034366a; RA Deep S., Walker K.P. III, Shu Z., Hinck A.P.; RT "Solution structure and backbone dynamics of the TGFbeta type II receptor RT extracellular domain."; RL Biochemistry 42:10126-10139(2003). RN [30] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 43-149 IN COMPLEX WITH TGFBR1 AND RP TGFB3, AND DISULFIDE BONDS. RX PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039; RA Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., RA Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.; RT "Cooperative assembly of TGF-beta superfamily signaling complexes is RT mediated by two disparate mechanisms and distinct modes of receptor RT binding."; RL Mol. Cell 29:157-168(2008). RN [31] RP X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 38-153 IN COMPLEX WITH TGFBR1 AND RP TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS. RX PubMed=20207738; DOI=10.1074/jbc.m109.079921; RA Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.; RT "Ternary complex of transforming growth factor-beta1 reveals isoform- RT specific ligand recognition and receptor recruitment in the superfamily."; RL J. Biol. Chem. 285:14806-14814(2010). RN [32] RP VARIANT HNPCC6 MET-315. RX PubMed=9590282; DOI=10.1038/ng0598-17; RA Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K., RA Yuasa Y.; RT "HNPCC associated with germline mutation in the TGF-beta type II receptor RT gene."; RL Nat. Genet. 19:17-18(1998). RN [33] RP VARIANT ESOPHAGEAL CANCER GLN-526. RX PubMed=10789724; DOI=10.1054/bjoc.1999.1178; RA Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.; RT "A dominant negative mutation of transforming growth factor-beta receptor RT type II gene in microsatellite stable oesophageal carcinoma."; RL Br. J. Cancer 82:1557-1560(2000). RN [34] RP VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND RP CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND MET-452. RX PubMed=11212236; RA Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M., Hughes-Davies L., RA Kemp P.R., Hesketh R.; RT "Inhibiting mutations in the transforming growth factor beta type 2 RT receptor in recurrent human breast cancer."; RL Cancer Res. 61:482-485(2001). RN [35] RP VARIANT ILE-191. RX PubMed=12202987; DOI=10.1007/s100380200069; RA Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T., Matsumoto N., RA Ishikawa M., Niikawa N., Yoshiura K.; RT "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types RT of variations in genes for transforming growth factor-beta1 (TGF-beta1) and RT its signaling pathway."; RL J. Hum. Genet. 47:478-483(2002). RN [36] RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF RP VARIANTS LDS2 PRO-308; PHE-449 AND CYS-537. RX PubMed=15235604; DOI=10.1038/ng1392; RA Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., RA Morisaki T., Allard D., Varret M., Claustres M., Morisaki H., Ihara M., RA Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G., Ohta T., RA Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C., Matsumoto N.; RT "Heterozygous TGFBR2 mutations in Marfan syndrome."; RL Nat. Genet. 36:855-860(2004). RN [37] RP VARIANTS LDS2 CYS-460 AND HIS-460. RX PubMed=16027248; DOI=10.1161/circulationaha.105.537340; RA Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E., RA Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S., RA Willing M.C., Raman C.S., Milewicz D.M.; RT "Mutations in transforming growth factor-beta receptor type II cause RT familial thoracic aortic aneurysms and dissections."; RL Circulation 112:513-520(2005). RN [38] RP VARIANTS LDS2 ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528. RX PubMed=15731757; DOI=10.1038/ng1511; RA Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., RA Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A., RA Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y., RA Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B., De Paepe A.M., RA Dietz H.C.; RT "A syndrome of altered cardiovascular, craniofacial, neurocognitive and RT skeletal development caused by mutations in TGFBR1 or TGFBR2."; RL Nat. Genet. 37:275-281(2005). RN [39] RP VARIANT LDS2 ASN-446. RX PubMed=16251899; DOI=10.1038/sj.ejhg.5201502; RA Disabella E., Grasso M., Marziliano N., Ansaldi S., Lucchelli C., Porcu E., RA Tagliani M., Pilotto A., Diegoli M., Lanzarini L., Malattia C., RA Pelliccia A., Ficcadenti A., Gabrielli O., Arbustini E.; RT "Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not RT associated with FBN1 gene defects."; RL Eur. J. Hum. Genet. 14:34-38(2006). RN [40] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328; ILE-373; RP MET-387 AND SER-490. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [42] RP VARIANTS LDS2 HIS-190; VAL-247; PRO-325; ARG-357 AND ILE-530. RX PubMed=19533785; DOI=10.1002/ajmg.a.32918; RA Chung B.H., Lam S.T., Tong T.M., Li S.Y., Lun K.S., Chan D.H., Fok S.F., RA Or J.S., Smith D.K., Yang W., Lau Y.L.; RT "Identification of novel FBN1 and TGFBR2 mutations in 65 probands with RT Marfan syndrome or Marfan-like phenotypes."; RL Am. J. Med. Genet. A 149A:1452-1459(2009). RN [43] RP VARIANT LDS2 SER-510. RX PubMed=19883511; DOI=10.1186/1750-1172-4-24; RA Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R., RA Calzavara-Pinton P.G., Barlati S., Colombi M.; RT "Loeys-Dietz syndrome type I and type II: clinical findings and novel RT mutations in two Italian patients."; RL Orphanet J. Rare Dis. 4:24-24(2009). RN [44] RP VARIANT LDS2 LYS-457. RX PubMed=20101701; DOI=10.1002/ajmg.a.33263; RA Muramatsu Y., Kosho T., Magota M., Yokotsuka T., Ito M., Yasuda A., RA Kito O., Suzuki C., Nagata Y., Kawai S., Ikoma M., Hatano T., Nakayama M., RA Kawamura R., Wakui K., Morisaki H., Morisaki T., Fukushima Y.; RT "Progressive aortic root and pulmonary artery aneurysms in a neonate with RT Loeys-Dietz syndrome type 1B."; RL Am. J. Med. Genet. A 152:417-421(2010). RN [45] RP VARIANTS LDS2 PRO-308 AND ARG-521. RX PubMed=20358619; DOI=10.1002/ajmg.a.33356; RA Kirmani S., Tebben P.J., Lteif A.N., Gordon D., Clarke B.L., Hefferan T.E., RA Yaszemski M.J., McGrann P.S., Lindor N.M., Ellison J.W.; RT "Germline TGF-beta receptor mutations and skeletal fragility: a report on RT two patients with Loeys-Dietz syndrome."; RL Am. J. Med. Genet. A 152:1016-1019(2010). RN [46] RP VARIANTS LDS2 GLN-306 DELINS HIS-GLU; ARG-377; PHE-449 AND ARG-514. RX PubMed=22113417; DOI=10.1038/jhg.2011.130; RA Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K., RA Lee H.J., Kim D.K.; RT "Clinical features and genetic analysis of Korean patients with Loeys-Dietz RT syndrome."; RL J. Hum. Genet. 57:52-56(2012). RN [47] RP VARIANTS LDS2 VAL-509 AND PHE-510. RX PubMed=21949523; DOI=10.3345/kjp.2011.54.6.272; RA Ha J.S., Kim Y.H.; RT "A sporadic case of Loeys-Dietz syndrome type I with two novel mutations of RT the TGFBR2 gene."; RL Korean J. Pediatr. 54:272-275(2011). CC -!- FUNCTION: Transmembrane serine/threonine kinase forming with the TGF- CC beta type I serine/threonine kinase receptor, TGFBR1, the non- CC promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. CC Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to CC the cytoplasm and thus regulates a plethora of physiological and CC pathological processes including cell cycle arrest in epithelial and CC hematopoietic cells, control of mesenchymal cell proliferation and CC differentiation, wound healing, extracellular matrix production, CC immunosuppression and carcinogenesis. The formation of the receptor CC complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound CC to the cytokine dimer results in the phosphorylation and activation of CC TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 CC phosphorylates SMAD2 which dissociates from the receptor and interacts CC with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the CC nucleus where it modulates the transcription of the TGF-beta-regulated CC genes. This constitutes the canonical SMAD-dependent TGF-beta signaling CC cascade. Also involved in non-canonical, SMAD-independent TGF-beta CC signaling pathways. {ECO:0000269|PubMed:7774578}. CC -!- FUNCTION: [Isoform 1]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 2]: Has transforming growth factor beta-activated CC receptor activity. {ECO:0000269|PubMed:8635485}. CC -!- FUNCTION: [Isoform 3]: Binds TGFB1, TGFB2 and TGFB3 in the picomolar CC affinity range without the participation of additional receptors. CC Blocks activation of SMAD2 and SMAD3 by TGFB1. CC {ECO:0000269|PubMed:34568316}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric CC ligands assemble a functional receptor composed of two TGFBR1 and CC TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The CC respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate CC the kinetics of assembly of the receptor and may explain the different CC biological activities of TGFB1, TGFB2 and TGFB3. Component of a complex CC composed of TSC22D1 (via N-terminus), TGFBR1 and TGFBR2; the CC interaction between TSC22D1 and TGFBR1 is inhibited by SMAD7 and CC promoted by TGFB1 (PubMed:21791611). Interacts with DAXX. Interacts CC with DYNLT4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to CC the TGF-beta receptor. Interacts with and is activated by SCUBE3; this CC interaction does not affect TGFB1-binding to TGFBR2. Interacts with CC VPS39; this interaction is independent of the receptor kinase activity CC and of the presence of TGF-beta. Interacts with CLU (PubMed:8555189). CC {ECO:0000269|PubMed:11483955, ECO:0000269|PubMed:11850637, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:16982625, CC ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738, CC ECO:0000269|PubMed:21441952, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:8555189, ECO:0000269|PubMed:9865696}. CC -!- SUBUNIT: [Isoform 3]: Homodimer; disulfide-linked. CC {ECO:0000269|PubMed:34568316}. CC -!- INTERACTION: CC P37173; P54819: AK2; NbExp=3; IntAct=EBI-296151, EBI-1056291; CC P37173; P61966-2: AP1S1; NbExp=3; IntAct=EBI-296151, EBI-12067760; CC P37173; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-296151, EBI-2875816; CC P37173; O75143-2: ATG13; NbExp=3; IntAct=EBI-296151, EBI-20151086; CC P37173; Q93084-2: ATP2A3; NbExp=3; IntAct=EBI-296151, EBI-21505448; CC P37173; P54253: ATXN1; NbExp=3; IntAct=EBI-296151, EBI-930964; CC P37173; P54252: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-946046; CC P37173; Q4VBR4: ATXN3; NbExp=3; IntAct=EBI-296151, EBI-12928880; CC P37173; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-296151, EBI-742750; CC P37173; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-296151, EBI-747505; CC P37173; P40227: CCT6A; NbExp=3; IntAct=EBI-296151, EBI-356687; CC P37173; P12830: CDH1; NbExp=3; IntAct=EBI-296151, EBI-727477; CC P37173; Q8NE08: COL25A1; NbExp=3; IntAct=EBI-296151, EBI-25836642; CC P37173; P48730-2: CSNK1D; NbExp=3; IntAct=EBI-296151, EBI-9087876; CC P37173; Q9UER7: DAXX; NbExp=2; IntAct=EBI-296151, EBI-77321; CC P37173; Q9UMR2: DDX19B; NbExp=3; IntAct=EBI-296151, EBI-719232; CC P37173; P49184: DNASE1L1; NbExp=3; IntAct=EBI-296151, EBI-20894690; CC P37173; O14531: DPYSL4; NbExp=3; IntAct=EBI-296151, EBI-719542; CC P37173; P26378-2: ELAVL4; NbExp=3; IntAct=EBI-296151, EBI-21603100; CC P37173; P15036: ETS2; NbExp=3; IntAct=EBI-296151, EBI-1646991; CC P37173; P09471: GNAO1; NbExp=3; IntAct=EBI-296151, EBI-715087; CC P37173; P51674: GPM6A; NbExp=3; IntAct=EBI-296151, EBI-7187133; CC P37173; P42858: HTT; NbExp=3; IntAct=EBI-296151, EBI-466029; CC P37173; O75874: IDH1; NbExp=3; IntAct=EBI-296151, EBI-715695; CC P37173; Q6PI98: INO80C; NbExp=3; IntAct=EBI-296151, EBI-722540; CC P37173; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-296151, EBI-2557660; CC P37173; P06756: ITGAV; NbExp=3; IntAct=EBI-296151, EBI-298282; CC P37173; P23276: KEL; NbExp=3; IntAct=EBI-296151, EBI-746662; CC P37173; O60259: KLK8; NbExp=3; IntAct=EBI-296151, EBI-3915857; CC P37173; Q96E93: KLRG1; NbExp=3; IntAct=EBI-296151, EBI-750770; CC P37173; Q8N448: LNX2; NbExp=3; IntAct=EBI-296151, EBI-2340947; CC P37173; Q7Z434: MAVS; NbExp=3; IntAct=EBI-296151, EBI-995373; CC P37173; Q93074: MED12; NbExp=3; IntAct=EBI-296151, EBI-394357; CC P37173; Q14728: MFSD10; NbExp=3; IntAct=EBI-296151, EBI-11337904; CC P37173; P01106: MYC; NbExp=3; IntAct=EBI-296151, EBI-447544; CC P37173; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-296151, EBI-3446748; CC P37173; Q99435-2: NELL2; NbExp=3; IntAct=EBI-296151, EBI-17754404; CC P37173; Q8TAT6: NPLOC4; NbExp=3; IntAct=EBI-296151, EBI-1994109; CC P37173; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-296151, EBI-22002759; CC P37173; Q96IY1: NSL1; NbExp=3; IntAct=EBI-296151, EBI-2554690; CC P37173; Q16549: PCSK7; NbExp=3; IntAct=EBI-296151, EBI-8059854; CC P37173; Q9NUD9: PIGV; NbExp=3; IntAct=EBI-296151, EBI-25836582; CC P37173; Q8TBJ4: PLPPR1; NbExp=3; IntAct=EBI-296151, EBI-18063495; CC P37173; Q07869: PPARA; NbExp=3; IntAct=EBI-296151, EBI-78615; CC P37173; Q13200: PSMD2; NbExp=3; IntAct=EBI-296151, EBI-357648; CC P37173; P21246: PTN; NbExp=3; IntAct=EBI-296151, EBI-473725; CC P37173; Q13702-2: RAPSN; NbExp=3; IntAct=EBI-296151, EBI-22012855; CC P37173; P52756: RBM5; NbExp=3; IntAct=EBI-296151, EBI-714003; CC P37173; Q6NTF9-3: RHBDD2; NbExp=3; IntAct=EBI-296151, EBI-17589229; CC P37173; Q96NA2: RILP; NbExp=3; IntAct=EBI-296151, EBI-2856119; CC P37173; P61513: RPL37A; NbExp=3; IntAct=EBI-296151, EBI-356793; CC P37173; Q8IX30: SCUBE3; NbExp=6; IntAct=EBI-296151, EBI-4479975; CC P37173; Q8NC51: SERBP1; NbExp=3; IntAct=EBI-296151, EBI-523558; CC P37173; Q16586: SGCA; NbExp=3; IntAct=EBI-296151, EBI-5663553; CC P37173; Q99720-4: SIGMAR1; NbExp=3; IntAct=EBI-296151, EBI-25831036; CC P37173; Q8NCS7: SLC44A5; NbExp=3; IntAct=EBI-296151, EBI-21504521; CC P37173; Q16560-2: SNRNP35; NbExp=3; IntAct=EBI-296151, EBI-12938570; CC P37173; Q7Z614-3: SNX20; NbExp=3; IntAct=EBI-296151, EBI-12336127; CC P37173; Q3SY56: SP6; NbExp=3; IntAct=EBI-296151, EBI-11175533; CC P37173; P46977: STT3A; NbExp=3; IntAct=EBI-296151, EBI-719212; CC P37173; O43463: SUV39H1; NbExp=3; IntAct=EBI-296151, EBI-349968; CC P37173; Q13428-5: TCOF1; NbExp=3; IntAct=EBI-296151, EBI-25832010; CC P37173; P01137: TGFB1; NbExp=11; IntAct=EBI-296151, EBI-779636; CC P37173; P10600: TGFB3; NbExp=8; IntAct=EBI-296151, EBI-1033020; CC P37173; Q9Y228: TRAF3IP3; NbExp=3; IntAct=EBI-296151, EBI-765817; CC P37173; Q96BQ3: TRIM43; NbExp=3; IntAct=EBI-296151, EBI-2129899; CC P37173; Q9UHP3: USP25; NbExp=3; IntAct=EBI-296151, EBI-2513462; CC P37173; Q969W3: VCF1; NbExp=3; IntAct=EBI-296151, EBI-10281506; CC P37173; P19544-6: WT1; NbExp=3; IntAct=EBI-296151, EBI-11745701; CC P37173; P25490: YY1; NbExp=3; IntAct=EBI-296151, EBI-765538; CC P37173; A2AGH6: Med12; Xeno; NbExp=3; IntAct=EBI-296151, EBI-5744969; CC P37173; P07200: TGFB1; Xeno; NbExp=2; IntAct=EBI-296151, EBI-907660; CC P37173-2; P02750: LRG1; NbExp=3; IntAct=EBI-16065370, EBI-9083443; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1310899, CC ECO:0000269|PubMed:25893292}; Single-pass type I membrane protein CC {ECO:0000269|PubMed:1310899}. Membrane raft CC {ECO:0000269|PubMed:25893292}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted CC {ECO:0000269|PubMed:34568316}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=betaR-II {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-1; Sequence=Displayed; CC Name=2; Synonyms=betaR-IIB {ECO:0000303|PubMed:8635485}; CC IsoId=P37173-2; Sequence=VSP_012157; CC Name=3; Synonyms=TbetaRII-SE {ECO:0000303|PubMed:34568316}; CC IsoId=P37173-3; Sequence=VSP_061513, VSP_061514; CC -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic domain. CC -!- DISEASE: Hereditary non-polyposis colorectal cancer 6 (HNPCC6) CC [MIM:614331]: An autosomal dominant disease associated with marked CC increase in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. HNPCC is reported to be the most common form of CC inherited colorectal cancer in the Western world. Clinically, HNPCC is CC often divided into two subgroups. Type I is characterized by hereditary CC predisposition to colorectal cancer, a young age of onset, and CC carcinoma observed in the proximal colon. Type II is characterized by CC increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical HNPCC is based on the Amsterdam CC criteria: 3 or more relatives affected by colorectal cancer, one a CC first degree relative of the other two; 2 or more generation affected; CC 1 or more colorectal cancers presenting before 50 years of age; CC exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' CC or 'incomplete HNPCC' can be used to describe families who do not or CC only partially fulfill the Amsterdam criteria, but in whom a genetic CC basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:9590282}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:10789724}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic aneurysm CC syndrome with widespread systemic involvement, characterized by CC arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or CC cleft palate. Physical findings include prominent joint laxity, easy CC bruising, wide and atrophic scars, velvety and translucent skin with CC easily visible veins, spontaneous rupture of the spleen or bowel, and CC catastrophic complications of pregnancy, including rupture of the CC gravid uterus and the arteries, either during pregnancy or in the CC immediate postpartum period. Some patients have craniosynostosis, CC exotropy, micrognathia and retrognathia, structural brain CC abnormalities, and intellectual deficit. {ECO:0000269|PubMed:15235604, CC ECO:0000269|PubMed:15731757, ECO:0000269|PubMed:16027248, CC ECO:0000269|PubMed:16251899, ECO:0000269|PubMed:19533785, CC ECO:0000269|PubMed:19883511, ECO:0000269|PubMed:20101701, CC ECO:0000269|PubMed:20358619, ECO:0000269|PubMed:21949523, CC ECO:0000269|PubMed:22113417}. Note=The disease is caused by variants CC affecting the gene represented in this entry. TGFBR2 mutations Cys-460 CC and His-460 have been reported to be associated with thoracic aortic CC aneurysms and dissection (TAAD). This phenotype, also known as thoracic CC aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by having CC aneurysms restricted to thoracic aorta. As individuals carrying these CC mutations also exhibit descending aortic disease and aneurysms of other CC arteries (PubMed:16027248), they have been considered as LDS2 by the CC OMIM resource. {ECO:0000269|PubMed:16027248}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M85079; AAA61164.1; -; mRNA. DR EMBL; D28131; BAA05673.1; -; mRNA. DR EMBL; U52246; AAB17553.1; -; Genomic_DNA. DR EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA. DR EMBL; U69152; AAB40916.1; -; Genomic_DNA. DR EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA. DR EMBL; D50683; BAA09332.1; -; mRNA. DR EMBL; MW881156; UDE22710.1; -; mRNA. DR EMBL; AY675319; AAT70724.1; -; Genomic_DNA. DR EMBL; AK300383; BAG62117.1; -; mRNA. DR EMBL; CH471055; EAW64412.1; -; Genomic_DNA. DR CCDS; CCDS2648.1; -. [P37173-1] DR CCDS; CCDS33727.1; -. [P37173-2] DR PIR; A42100; A42100. DR RefSeq; NP_001020018.1; NM_001024847.3. [P37173-2] DR RefSeq; NP_003233.4; NM_003242.5. [P37173-1] DR PDB; 1KTZ; X-ray; 2.15 A; B=38-159. DR PDB; 1M9Z; X-ray; 1.05 A; A=49-159. DR PDB; 1PLO; NMR; -; A=38-159. DR PDB; 2PJY; X-ray; 3.00 A; B=42-149. DR PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153. DR PDB; 4P7U; X-ray; 1.50 A; A=49-159. DR PDB; 4XJJ; X-ray; 1.40 A; A=50-159. DR PDB; 5E8V; X-ray; 1.69 A; A=237-549. DR PDB; 5E8Y; X-ray; 2.05 A; A=237-549. DR PDB; 5E91; X-ray; 2.42 A; A=237-549. DR PDB; 5E92; X-ray; 2.08 A; A=237-549. DR PDB; 5QIN; X-ray; 1.57 A; A=237-549. DR PDB; 5TX4; X-ray; 1.88 A; A=38-153. DR PDB; 5TY4; EM; 2.90 A; A=47-149. DR PDB; 7DV6; X-ray; 2.39 A; A=237-549. DR PDB; 8G4K; X-ray; 1.24 A; B=45-155. DR PDB; 8YGZ; X-ray; 2.10 A; A=237-549. DR PDB; 9B9F; X-ray; 3.00 A; D/I=42-153. DR PDB; 9E9G; X-ray; 1.40 A; A=38-154. DR PDB; 9FDY; EM; 3.40 A; D/E=42-153. DR PDB; 9FK5; EM; 4.10 A; D=42-153. DR PDB; 9FKP; EM; 3.72 A; D/E=42-153. DR PDBsum; 1KTZ; -. DR PDBsum; 1M9Z; -. DR PDBsum; 1PLO; -. DR PDBsum; 2PJY; -. DR PDBsum; 3KFD; -. DR PDBsum; 4P7U; -. DR PDBsum; 4XJJ; -. DR PDBsum; 5E8V; -. DR PDBsum; 5E8Y; -. DR PDBsum; 5E91; -. DR PDBsum; 5E92; -. DR PDBsum; 5QIN; -. DR PDBsum; 5TX4; -. DR PDBsum; 5TY4; -. DR PDBsum; 7DV6; -. DR PDBsum; 8G4K; -. DR PDBsum; 8YGZ; -. DR PDBsum; 9B9F; -. DR PDBsum; 9E9G; -. DR PDBsum; 9FDY; -. DR PDBsum; 9FK5; -. DR PDBsum; 9FKP; -. DR AlphaFoldDB; P37173; -. DR BMRB; P37173; -. DR EMDB; EMD-50333; -. DR EMDB; EMD-50519; -. DR EMDB; EMD-50524; -. DR EMDB; EMD-8472; -. DR SMR; P37173; -. DR BioGRID; 112906; 202. DR ComplexPortal; CPX-2544; TGF-beta-3-TGFR complex. DR ComplexPortal; CPX-529; TGF-beta-1-TGFR complex. DR ComplexPortal; CPX-834; TGF-beta-2-TGFR complex. DR CORUM; P37173; -. DR DIP; DIP-5939N; -. DR FunCoup; P37173; 1304. DR IntAct; P37173; 185. DR MINT; P37173; -. DR STRING; 9606.ENSP00000351905; -. DR BindingDB; P37173; -. DR ChEMBL; CHEMBL4267; -. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB10772; Foreskin keratinocyte (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P37173; -. DR GuidetoPHARMACOLOGY; 1795; -. DR GlyConnect; 1979; 9 N-Linked glycans (3 sites). DR GlyCosmos; P37173; 5 sites, 9 glycans. DR GlyGen; P37173; 7 sites, 11 N-linked glycans (3 sites), 1 O-linked glycan (2 sites). DR iPTMnet; P37173; -. DR PhosphoSitePlus; P37173; -. DR SwissPalm; P37173; -. DR BioMuta; TGFBR2; -. DR DMDM; 116242818; -. DR jPOST; P37173; -. DR MassIVE; P37173; -. DR PaxDb; 9606-ENSP00000351905; -. DR PeptideAtlas; P37173; -. DR ProteomicsDB; 55264; -. [P37173-1] DR ProteomicsDB; 55265; -. [P37173-2] DR Pumba; P37173; -. DR Antibodypedia; 11570; 809 antibodies from 42 providers. DR DNASU; 7048; -. DR Ensembl; ENST00000295754.10; ENSP00000295754.5; ENSG00000163513.21. [P37173-1] DR Ensembl; ENST00000359013.4; ENSP00000351905.4; ENSG00000163513.21. [P37173-2] DR GeneID; 7048; -. DR KEGG; hsa:7048; -. DR MANE-Select; ENST00000295754.10; ENSP00000295754.5; NM_003242.6; NP_003233.4. DR UCSC; uc003cen.4; human. [P37173-1] DR AGR; HGNC:11773; -. DR ClinPGx; PA36486; -. DR CTD; 7048; -. DR DisGeNET; 7048; -. DR GeneCards; TGFBR2; -. DR GeneReviews; TGFBR2; -. DR HGNC; HGNC:11773; TGFBR2. DR HPA; ENSG00000163513; Low tissue specificity. DR MalaCards; TGFBR2; -. DR MIM; 133239; phenotype. DR MIM; 190182; gene. DR MIM; 610168; phenotype. DR MIM; 614331; phenotype. DR OpenTargets; ENSG00000163513; -. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 60030; Loeys-Dietz syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 284973; Marfan syndrome type 2. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000163513; -. DR eggNOG; KOG3653; Eukaryota. DR GeneTree; ENSGT00940000157527; -. DR HOGENOM; CLU_000288_8_3_1; -. DR InParanoid; P37173; -. DR OMA; QMPNLCK; -. DR OrthoDB; 547665at2759; -. DR PAN-GO; P37173; 12 GO annotations based on evolutionary models. DR PhylomeDB; P37173; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P37173; -. DR Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition). DR Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer. DR Reactome; R-HSA-3642279; TGFBR2 MSI Frameshift Mutants in Cancer. DR Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer. DR Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer. DR Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer. DR Reactome; R-HSA-5689603; UCH proteinases. DR Reactome; R-HSA-9839389; TGFBR3 regulates TGF-beta signaling. DR SignaLink; P37173; -. DR SIGNOR; P37173; -. DR Agora; ENSG00000163513; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 7048; 45 hits in 1213 CRISPR screens. DR ChiTaRS; TGFBR2; human. DR EvolutionaryTrace; P37173; -. DR GeneWiki; TGF_beta_receptor_2; -. DR GenomeRNAi; 7048; -. DR Pharos; P37173; Tchem. DR PRO; PR:P37173; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P37173; protein. DR Bgee; ENSG00000163513; Expressed in pericardium and 211 other cell types or tissues. DR ExpressionAtlas; P37173; baseline and differential. DR GO; GO:0048179; C:activin receptor complex; IBA:GO_Central. DR GO; GO:0005901; C:caveola; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005615; C:extracellular space; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0045121; C:membrane raft; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0043235; C:receptor complex; IDA:BHF-UCL. DR GO; GO:0070021; C:transforming growth factor beta ligand-receptor complex; IPI:ComplexPortal. DR GO; GO:0048185; F:activin binding; IBA:GO_Central. DR GO; GO:0016361; F:activin receptor activity, type I; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL. DR GO; GO:0019209; F:kinase activator activity; IEA:Ensembl. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0060090; F:molecular adaptor activity; EXP:DisProt. DR GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL. DR GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL. DR GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:BHF-UCL. DR GO; GO:0005026; F:transforming growth factor beta receptor activity, type II; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; IDA:BHF-UCL. DR GO; GO:0034713; F:type I transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0034714; F:type III transforming growth factor beta receptor binding; IDA:BHF-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; IMP:BHF-UCL. DR GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IDA:UniProtKB. DR GO; GO:0048844; P:artery morphogenesis; IMP:BHF-UCL. DR GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001568; P:blood vessel development; TAS:BHF-UCL. DR GO; GO:0007420; P:brain development; ISS:BHF-UCL. DR GO; GO:0001569; P:branching involved in blood vessel morphogenesis; ISS:BHF-UCL. DR GO; GO:0060434; P:bronchus morphogenesis; IEA:Ensembl. DR GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL. DR GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL. DR GO; GO:0003274; P:endocardial cushion fusion; ISS:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0007369; P:gastrulation; IEA:Ensembl. DR GO; GO:0003430; P:growth plate cartilage chondrocyte growth; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:BHF-UCL. DR GO; GO:0001947; P:heart looping; ISS:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:1905317; P:inferior endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0061520; P:Langerhans cell differentiation; IEA:Ensembl. DR GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl. DR GO; GO:1990086; P:lens fiber cell apoptotic process; IEA:Ensembl. DR GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl. DR GO; GO:0060443; P:mammary gland morphogenesis; IEA:Ensembl. DR GO; GO:0003149; P:membranous septum morphogenesis; ISS:BHF-UCL. DR GO; GO:1990428; P:miRNA transport; ISS:BHF-UCL. DR GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL. DR GO; GO:0007399; P:nervous system development; IBA:GO_Central. DR GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0002663; P:positive regulation of B cell tolerance induction; ISS:BHF-UCL. DR GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc. DR GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:BHF-UCL. DR GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; ISS:BHF-UCL. DR GO; GO:0051138; P:positive regulation of NK T cell differentiation; ISS:BHF-UCL. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0002666; P:positive regulation of T cell tolerance induction; ISS:BHF-UCL. DR GO; GO:0002651; P:positive regulation of tolerance induction to self antigen; ISS:BHF-UCL. DR GO; GO:0042127; P:regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:2000736; P:regulation of stem cell differentiation; IMP:BHF-UCL. DR GO; GO:0072091; P:regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL. DR GO; GO:0009410; P:response to xenobiotic stimulus; IDA:BHF-UCL. DR GO; GO:0060021; P:roof of mouth development; IMP:BHF-UCL. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl. DR GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl. DR GO; GO:0060440; P:trachea formation; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd14055; STKc_TGFbR2_like; 1. DR CDD; cd23538; TFP_LU_ECD_TGFR2; 1. DR DisProt; DP01760; -. DR FunFam; 1.10.510.10:FF:000260; TGF-beta receptor type-2; 1. DR FunFam; 2.10.60.10:FF:000009; TGF-beta receptor type-2; 1. DR FunFam; 3.30.200.20:FF:000213; TGF-beta receptor type-2; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00414; -. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR InterPro; IPR017194; Transform_growth_fac-b_typ-2. DR InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto. DR PANTHER; PTHR23255:SF55; TGF-BETA RECEPTOR TYPE-2; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF08917; ecTbetaR2; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF037393; TGFRII; 1. DR PRINTS; PR00653; ACTIVIN2R. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis; KW ATP-binding; Cell membrane; Craniosynostosis; Differentiation; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Growth regulation; Hereditary nonpolyposis colorectal cancer; Kinase; KW Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Secreted; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..22 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 23..567 FT /note="TGF-beta receptor type-2" FT /id="PRO_0000024426" FT TOPO_DOM 23..166 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 167..187 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 188..567 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 244..544 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 439..567 FT /note="Sufficient for interaction with CLU" FT /evidence="ECO:0000269|PubMed:8555189" FT ACT_SITE 379 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 250..258 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 277 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 409 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT MOD_RES 548 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 553 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62312" FT CARBOHYD 70 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 94 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 154 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 51..84 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 54..71 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 61..67 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 77..101 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 121..136 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT DISULFID 138..143 FT /evidence="ECO:0000269|PubMed:11850637, FT ECO:0000269|PubMed:12121646, ECO:0000269|PubMed:12939140, FT ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:20207738" FT VAR_SEQ 31..32 FT /note="SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:7959019" FT /id="VSP_012157" FT VAR_SEQ 68..80 FT /note="MSNCSITSICEKP -> FSKVHYEGKKKAW (in isoform 3)" FT /id="VSP_061513" FT VAR_SEQ 81..567 FT /note="Missing (in isoform 3)" FT /id="VSP_061514" FT VARIANT 36 FT /note="M -> V (in dbSNP:rs17025864)" FT /evidence="ECO:0000269|Ref.8" FT /id="VAR_020510" FT VARIANT 61 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041414" FT VARIANT 73 FT /note="I -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036070" FT VARIANT 190 FT /note="R -> H (in LDS2; dbSNP:rs780542125)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076167" FT VARIANT 191 FT /note="V -> I (in dbSNP:rs56105708)" FT /evidence="ECO:0000269|PubMed:12202987, FT ECO:0000269|PubMed:17344846" FT /id="VAR_017606" FT VARIANT 247 FT /note="D -> V (in LDS2; dbSNP:rs761231369)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076168" FT VARIANT 306 FT /note="Q -> HE (in LDS2)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066723" FT VARIANT 308 FT /note="L -> P (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs28934568)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:20358619" FT /id="VAR_022351" FT VARIANT 315 FT /note="T -> M (in HNPCC6; dbSNP:rs34833812)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:9590282" FT /id="VAR_008156" FT VARIANT 325 FT /note="T -> P (in LDS2; dbSNP:rs2125435431)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076169" FT VARIANT 328 FT /note="H -> Y (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2125435491)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041415" FT VARIANT 336 FT /note="Y -> N (in LDS2; dbSNP:rs104893812)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022352" FT VARIANT 355 FT /note="A -> P (in LDS2; dbSNP:rs104893813)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022353" FT VARIANT 357 FT /note="G -> R (in LDS2)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076170" FT VARIANT 357 FT /note="G -> W (in LDS2; dbSNP:rs104893814)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022354" FT VARIANT 373 FT /note="M -> I (in dbSNP:rs35719192)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041416" FT VARIANT 377 FT /note="H -> R (in LDS2; dbSNP:rs1553630274)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066724" FT VARIANT 387 FT /note="V -> M (in a breast tumor; dbSNP:rs35766612)" FT /evidence="ECO:0000269|PubMed:11212236, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022355" FT VARIANT 435 FT /note="N -> S (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022356" FT VARIANT 439 FT /note="V -> A (in dbSNP:rs1050833)" FT /evidence="ECO:0000269|PubMed:1310899, FT ECO:0000269|PubMed:8812462, ECO:0000269|PubMed:8840968, FT ECO:0000269|PubMed:8973329" FT /id="VAR_028063" FT VARIANT 446 FT /note="D -> N (in LDS2; dbSNP:rs886039551)" FT /evidence="ECO:0000269|PubMed:16251899" FT /id="VAR_066725" FT VARIANT 447 FT /note="V -> A (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022357" FT VARIANT 449 FT /note="S -> F (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893807)" FT /evidence="ECO:0000269|PubMed:15235604, FT ECO:0000269|PubMed:22113417" FT /id="VAR_022358" FT VARIANT 452 FT /note="L -> M (in a breast tumor; signaling of TGF-beta FT significantly inhibited)" FT /evidence="ECO:0000269|PubMed:11212236" FT /id="VAR_022359" FT VARIANT 457 FT /note="M -> K (in LDS2)" FT /evidence="ECO:0000269|PubMed:20101701" FT /id="VAR_066726" FT VARIANT 460 FT /note="R -> C (in LDS2; dbSNP:rs104893811)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029760" FT VARIANT 460 FT /note="R -> H (in LDS2; dbSNP:rs104893816)" FT /evidence="ECO:0000269|PubMed:16027248" FT /id="VAR_029761" FT VARIANT 490 FT /note="N -> S (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1699660823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041417" FT VARIANT 509 FT /note="G -> V (in LDS2; dbSNP:rs863223853)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066727" FT VARIANT 510 FT /note="I -> F (in LDS2; dbSNP:rs2125455070)" FT /evidence="ECO:0000269|PubMed:21949523" FT /id="VAR_066728" FT VARIANT 510 FT /note="I -> S (in LDS2)" FT /evidence="ECO:0000269|PubMed:19883511" FT /id="VAR_066729" FT VARIANT 514 FT /note="C -> R (in LDS2; dbSNP:rs193922664)" FT /evidence="ECO:0000269|PubMed:22113417" FT /id="VAR_066730" FT VARIANT 521 FT /note="W -> R (in LDS2; dbSNP:rs1575166666)" FT /evidence="ECO:0000269|PubMed:20358619" FT /id="VAR_066731" FT VARIANT 526 FT /note="E -> Q (in esophageal cancer; dbSNP:rs121918714)" FT /evidence="ECO:0000269|PubMed:10789724" FT /id="VAR_015816" FT VARIANT 528 FT /note="R -> C (in LDS2; dbSNP:rs104893810)" FT /evidence="ECO:0000269|PubMed:15731757" FT /id="VAR_022360" FT VARIANT 528 FT /note="R -> H (in LDS2; dbSNP:rs104893815)" FT /evidence="ECO:0000269|PubMed:15731757, FT ECO:0000269|PubMed:16959974" FT /id="VAR_022361" FT VARIANT 530 FT /note="T -> I (in LDS2; dbSNP:rs1699708963)" FT /evidence="ECO:0000269|PubMed:19533785" FT /id="VAR_076171" FT VARIANT 537 FT /note="R -> C (in LDS2; has a negative effect on TGF-beta FT signaling; dbSNP:rs104893809)" FT /evidence="ECO:0000269|PubMed:15235604" FT /id="VAR_022362" FT MUTAGEN 277 FT /note="K->R: Abolishes kinase activity, TGF-beta signaling FT and interaction with DAXX." FT /evidence="ECO:0000269|PubMed:11483955" FT CONFLICT 381 FT /note="K -> N (in Ref. 6; BAA09332)" FT /evidence="ECO:0000305" FT STRAND 40..45 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 55..58 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 65..68 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 74..76 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 78..81 FT /evidence="ECO:0007829|PDB:1PLO" FT STRAND 83..90 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 95..102 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 104..106 FT /evidence="ECO:0007829|PDB:5TY4" FT STRAND 108..110 FT /evidence="ECO:0007829|PDB:2PJY" FT TURN 114..117 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 119..122 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 124..126 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 131..138 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:1PLO" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:1M9Z" FT STRAND 146..148 FT /evidence="ECO:0007829|PDB:1M9Z" FT HELIX 151..153 FT /evidence="ECO:0007829|PDB:9E9G" FT STRAND 244..252 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 257..263 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 267..269 FT /evidence="ECO:0007829|PDB:7DV6" FT STRAND 272..280 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 281..283 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 284..294 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 297..299 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 307..315 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 318..326 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 333..339 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 344..362 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 382..384 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 385..387 FT /evidence="ECO:0007829|PDB:5QIN" FT STRAND 393..395 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 410..413 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 422..424 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 427..430 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 440..459 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 462..464 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 473..477 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 484..491 FT /evidence="ECO:0007829|PDB:5QIN" FT TURN 492..494 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 502..506 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 508..520 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 525..527 FT /evidence="ECO:0007829|PDB:5QIN" FT HELIX 531..539 FT /evidence="ECO:0007829|PDB:5QIN" SQ SEQUENCE 567 AA; 64568 MW; C541DA751FFBDBEB CRC64; MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE LEHLDRLSGR SCSEEKIPED GSLNTTK // ID TITIN_HUMAN Reviewed; 34350 AA. AC Q8WZ42; A0A0A0MTS7; A6NKB1; C9JQJ2; E7EQE6; E7ET18; K7ENY1; Q10465; Q10466; AC Q15598; Q2XUS3; Q32Q60; Q4U1Z6; Q4ZG20; Q6NSG0; Q6PDB1; Q6PJP0; Q7KYM2; AC Q7KYN4; Q7KYN5; Q7LDM3; Q7Z2X3; Q8TCG8; Q8WZ51; Q8WZ52; Q8WZ53; Q8WZB3; AC Q92761; Q92762; Q9UD97; Q9UP84; Q9Y6L9; DT 13-JUN-2006, integrated into UniProtKB/Swiss-Prot. DT 18-APR-2012, sequence version 4. DT 28-JAN-2026, entry version 220. DE RecName: Full=Titin; DE EC=2.7.11.1; DE AltName: Full=Connectin; DE AltName: Full=Rhabdomyosarcoma antigen MU-RMS-40.14; GN Name=TTN; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF RP 3336-12202 (ISOFORM 4), AND VARIANTS ILE-498; GLU-1201; MET-3261; ASN-3419; RP SER-3491; GLU-12679; ILE-19762; ILE-20718; ASN-23807; MET-24980 AND RP THR-27755. RC TISSUE=Skeletal muscle; RX PubMed=7569978; DOI=10.1126/science.270.5234.293; RA Labeit S., Kolmerer B.; RT "Titins, giant proteins in charge of muscle ultrastructure and RT elasticity."; RL Science 270:293-296(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS RP LEU-1295; GLN-1572; ILE-2610; ASN-2831; SER-3491; PRO-4215; PHE-4283 AND RP ARG-12383. RX PubMed=10850961; DOI=10.1161/01.res.86.11.1114; RA Freiburg A., Trombitas K., Hell W., Cazorla O., Fougerousse F., Centner T., RA Kolmerer B., Witt C., Beckmann J.S., Gregorio C.C., Granzier H., Labeit S.; RT "Series of exon-skipping events in the elastic spring region of titin as RT the structural basis for myofibrillar elastic diversity."; RL Circ. Res. 86:1114-1121(2000). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, TISSUE RP SPECIFICITY, INTERACTION WITH OBSCN, AND VARIANTS LEU-1295; GLN-1572; RP ILE-2610; ASN-2831; SER-3491; PRO-4215 AND PHE-4283. RX PubMed=11717165; DOI=10.1161/hh2301.100981; RA Bang M.-L., Centner T., Fornoff F., Geach A.J., Gotthardt M., McNabb M., RA Witt C.C., Labeit D., Gregorio C.C., Granzier H., Labeit S.; RT "The complete gene sequence of titin, expression of an unusual ~700 kDa RT titin isoform and its interaction with obscurin identify a novel Z-line to RT I-band linking system."; RL Circ. Res. 89:1065-1072(2001). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-626 AND 34071-34350 (ISOFORM RP 3). RC TISSUE=Muscle, and Skeletal muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 405-709 (ISOFORMS 1 AND 2). RC TISSUE=Heart muscle; RX PubMed=8937992; DOI=10.1242/jcs.109.11.2747; RA Gautel M., Goulding D., Bullard B., Weber K., Furst D.O.; RT "The central Z-disk region of titin is assembled from a novel repeat in RT variable copy numbers."; RL J. Cell Sci. 109:2747-2754(1996). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 2023-2060, AND TISSUE SPECIFICITY. RC TISSUE=Heart muscle; RX PubMed=7819249; DOI=10.1021/bi00002a021; RA Musco G., Tziatzos C., Schuck P., Pastore A.; RT "Dissecting titin into its structural motifs: identification of an alpha RT helix near the N-terminus."; RL Biochemistry 34:553-561(1995). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3455-4473, AND VARIANTS PRO-4215 AND RP PHE-4283. RX PubMed=10051295; DOI=10.1161/01.cir.99.8.1022; RA Siu B.L., Niimura H., Osborne J.A., Fatkin D., MacRae C., Solomon S., RA Benson D.W., Seidman J.G., Seidman C.E.; RT "Familial dilated cardiomyopathy locus maps to chromosome 2q31."; RL Circulation 99:1022-1026(1999). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 9806-12017 (ISOFORM 5). RC TISSUE=Heart ventricle; RX PubMed=12785098; DOI=10.1023/a:1023410523184; RA Greaser M.L., Berri M., Warren C.M., Mozdziak P.E.; RT "Species variations in cDNA sequence and exon splicing patterns in the RT extensible I-band region of cardiac titin: relation to passive tension."; RL J. Muscle Res. Cell Motil. 23:473-482(2002). RN [10] RP PROTEIN SEQUENCE OF 11773-11783; 17908-17931; 18656-18669; 26545-26553; RP 28758-28774 AND 32920-32928, AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Fetal brain cortex; RA Lubec G., Chen W.-Q., Sun Y.; RL Submitted (DEC-2008) to UniProtKB. RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12947-13797. RC TISSUE=Embryonic rhabdomyosarcoma; RA Behrends U., Gotz C., Mautner J.; RT "Serological identification of rhabdomyosarcoma antigens."; RL Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE OF 14257-14543. RX PubMed=8351016; DOI=10.1212/wnl.43.8.1581; RA Gautel M., Lakey A., Barlow D.P., Holmes Z., Scales S., Leonard K., RA Labeit S., Mygland A., Gilhus N.E., Aarli J.A.; RT "Titin antibodies in myasthenia gravis: identification of a major RT immunogenic region of titin."; RL Neurology 43:1581-1585(1993). RN [13] RP NUCLEOTIDE SEQUENCE [MRNA] OF 21021-22120, AND NUCLEOTIDE SEQUENCE [GENOMIC RP DNA] OF 23754-24284. RX PubMed=1582406; DOI=10.1002/j.1460-2075.1992.tb05222.x; RA Labeit S., Gautel M., Lakey A., Trinick J.; RT "Towards a molecular understanding of titin."; RL EMBO J. 11:1711-1716(1992). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 29701-34350, AND PHOSPHORYLATION. RX PubMed=8404852; DOI=10.1002/j.1460-2075.1993.tb06061.x; RA Gautel M., Leonard K., Labeit S.; RT "Phosphorylation of KSF motifs in the C-terminal region of titin in RT differentiating myoblasts."; RL EMBO J. 12:3827-3834(1993). RN [15] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33119-34350. RC TISSUE=Skeletal muscle; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [16] RP INTERACTION WITH TCAP. RX PubMed=9645487; DOI=10.1016/s0014-5793(98)00501-8; RA Mues A., van der Ven P.F.M., Young P., Furst D.O., Gautel M.; RT "Two immunoglobulin-like domains of the Z-disc portion of titin interact in RT a conformation-dependent way with telethonin."; RL FEBS Lett. 428:111-114(1998). RN [17] RP INTERACTION WITH NEB. RX PubMed=12482578; DOI=10.1016/s0014-5793(02)03655-4; RA Ma K., Wang K.; RT "Interaction of nebulin SH3 domain with titin PEVK and myopalladin: RT implications for the signaling and assembly role of titin and nebulin."; RL FEBS Lett. 532:273-278(2002). RN [18] RP INTERACTION WITH FHL2. RX PubMed=12432079; DOI=10.1242/jcs.00181; RA Lange S., Auerbach D., McLoughlin P., Perriard E., Schafer B.W., RA Perriard J.-C., Ehler E.; RT "Subcellular targeting of metabolic enzymes to titin in heart muscle may be RT mediated by DRAL/FHL-2."; RL J. Cell Sci. 115:4925-4936(2002). RN [19] RP INTERACTION WITH ANK1. RX PubMed=12444090; DOI=10.1074/jbc.m209012200; RA Kontrogianni-Konstantopoulos A., Bloch R.J.; RT "The hydrophilic domain of small ankyrin-1 interacts with the two N- RT terminal immunoglobulin domains of titin."; RL J. Biol. Chem. 278:3985-3991(2003). RN [20] RP INTERACTION WITH ANKRD1; ANKRD2; ANKRD23 AND CAPN3. RX PubMed=14583192; DOI=10.1016/j.jmb.2003.09.012; RA Miller M.K., Bang M.-L., Witt C.C., Labeit D., Trombitas C., Watanabe K., RA Granzier H., McElhinny A.S., Gregorio C.C., Labeit S.; RT "The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family RT of titin filament-based stress response molecules."; RL J. Mol. Biol. 333:951-964(2003). RN [21] RP INTERACTION WITH CRYAB. RX PubMed=14676215; DOI=10.1074/jbc.m307473200; RA Bullard B., Ferguson C., Minajeva A., Leake M.C., Gautel M., Labeit D., RA Ding L., Labeit S., Horwitz J., Leonard K.R., Linke W.A.; RT "Association of the chaperone alphaB-crystallin with titin in heart RT muscle."; RL J. Biol. Chem. 279:7917-7924(2004). RN [22] RP INTERACTION WITH TRIM63 AND TRIM55. RX PubMed=15967462; DOI=10.1016/j.jmb.2005.05.021; RA Witt S.H., Granzier H., Witt C.C., Labeit S.; RT "MURF-1 and MURF-2 target a specific subset of myofibrillar proteins RT redundantly: towards understanding MURF-dependent muscle ubiquitination."; RL J. Mol. Biol. 350:713-722(2005). RN [23] RP INTERACTION WITH LAMIN, AND SUBCELLULAR LOCATION. RX PubMed=16410549; DOI=10.1242/jcs.02728; RA Zastrow M.S., Flaherty D.B., Benian G.M., Wilson K.L.; RT "Nuclear titin interacts with A- and B-type lamins in vitro and in vivo."; RL J. Cell Sci. 119:239-249(2006). RN [24] RP REVIEW. RX PubMed=16537787; DOI=10.1152/ajpheart.00816.2005; RA Hoshijima M.; RT "Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, RT titin, and associated structures."; RL Am. J. Physiol. 290:H1313-H1325(2006). RN [25] RP INTERACTION WITH CMYA5. RX PubMed=20634290; DOI=10.1074/jbc.m110.108720; RA Sarparanta J., Blandin G., Charton K., Vihola A., Marchand S., Milic A., RA Hackman P., Ehler E., Richard I., Udd B.; RT "Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to RT tibial and limb-girdle muscular dystrophies."; RL J. Biol. Chem. 285:30304-30315(2010). RN [26] RP STRUCTURE BY NMR OF 33483-33579. RX PubMed=7613868; DOI=10.1016/s0969-2126(01)00170-8; RA Pfuhl M., Pastore A.; RT "Tertiary structure of an immunoglobulin-like domain from the giant muscle RT protein titin: a new member of the I set."; RL Structure 3:391-401(1995). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 32172-32489, FUNCTION, ACTIVITY RP REGULATION, INTERACTION WITH CALM, PHOSPHORYLATION AT TYR-32341, AND RP MUTAGENESIS OF LYS-32207 AND TYR-32341. RX PubMed=9804419; DOI=10.1038/27603; RA Mayans O., van der Ven P.F.M., Wilm M., Mues A., Young P., Furst D.O., RA Wilmanns M., Gautel M.; RT "Structural basis for activation of the titin kinase domain during RT myofibrillogenesis."; RL Nature 395:863-869(1998). RN [28] RP STRUCTURE BY NMR OF 22283-22385. RX PubMed=9782056; DOI=10.1016/s0969-2126(98)00129-4; RA Goll C.M., Pastore A., Nilges M.; RT "The three-dimensional structure of a type I module from titin: a prototype RT of intracellular fibronectin type III domains."; RL Structure 6:1291-1302(1998). RN [29] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 2073-2171, AND DISULFIDE BOND. RX PubMed=11525170; DOI=10.1016/s0969-2126(01)00591-3; RA Mayans O., Wuerges J., Canela S., Gautel M., Wilmanns M.; RT "Structural evidence for a possible role of reversible disulphide bridge RT formation in the elasticity of the muscle protein titin."; RL Structure 9:331-340(2001). RN [30] RP X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 1-196 IN COMPLEX WITH TCAP. RX PubMed=16407954; DOI=10.1038/nature04343; RA Zou P., Pinotsis N., Lange S., Song Y.-H., Popov A., Mavridis I., RA Mayans O.M., Gautel M., Wilmanns M.; RT "Palindromic assembly of the giant muscle protein titin in the sarcomeric RT Z-disk."; RL Nature 439:229-233(2006). RN [31] RP VARIANT CMH9 LEU-740. RX PubMed=10462489; DOI=10.1006/bbrc.1999.1221; RA Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., Kimura A.; RT "Structural analysis of the titin gene in hypertrophic cardiomyopathy: RT identification of a novel disease gene."; RL Biochem. Biophys. Res. Commun. 262:411-417(1999). RN [32] RP INVOLVEMENT IN LGMDR10, AND VARIANT TMD PRO-34315. RX PubMed=12145747; DOI=10.1086/342380; RA Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., RA De Seze J., Labeit S., Witt C., Peltonen L., Richard I., Udd B.; RT "Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the RT gene encoding the giant skeletal-muscle protein titin."; RL Am. J. Hum. Genet. 71:492-500(2002). RN [33] RP VARIANTS CMD1G MET-54; VAL-743; TYR-3799 AND ASN-4465, VARIANTS CYS-328; RP GLN-4084 AND PRO-4215, CHARACTERIZATION OF VARIANTS CMD1G MET-54 AND RP VAL-743, AND FUNCTION. RX PubMed=11846417; DOI=10.1006/bbrc.2002.6448; RA Itoh-Satoh M., Hayashi T., Nishi H., Koga Y., Arimura T., Koyanagi T., RA Takahashi M., Hohda S., Ueda K., Nouchi T., Hiroe M., Marumo F., RA Imaizumi T., Yasunami M., Kimura A.; RT "Titin mutations as the molecular basis for dilated cardiomyopathy."; RL Biochem. Biophys. Res. Commun. 291:385-393(2002). RN [34] RP VARIANT CMD1G ARG-976. RX PubMed=11788824; DOI=10.1038/ng815; RA Gerull B., Gramlich M., Atherton J., McNabb M., Trombitas K., RA Sasse-Klaassen S., Seidman J.G., Seidman C., Granzier H., Labeit S., RA Frenneaux M., Thierfelder L.; RT "Mutations of TTN, encoding the giant muscle filament titin, cause familial RT dilated cardiomyopathy."; RL Nat. Genet. 30:201-204(2002). RN [35] RP VARIANT TMD ASN-34306. RX PubMed=12891679; DOI=10.1002/ana.10647; RA Van den Bergh P.Y.K., Bouquiaux O., Verellen C., Marchand S., Richard I., RA Hackman P., Udd B.; RT "Tibial muscular dystrophy in a Belgian family."; RL Ann. Neurol. 54:248-251(2003). RN [36] RP VARIANT CMD1G GLN-32996. RX PubMed=16465475; DOI=10.1007/s10974-005-9018-5; RA Matsumoto Y., Hayashi T., Inagaki N., Takahashi M., Hiroi S., Nakamura T., RA Arimura T., Nakamura K., Ashizawa N., Yasunami M., Ohe T., Yano K., RA Kimura A.; RT "Functional analysis of titin/connectin N2-B mutations found in RT cardiomyopathy."; RL J. Muscle Res. Cell Motil. 26:367-374(2005). RN [37] RP VARIANT MFM9 TRP-279, CHARACTERIZATION OF VARIANT MFM9 TRP-279, AND RP INTERACTION WITH NBR1. RX PubMed=15802564; DOI=10.1126/science.1110463; RA Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., RA Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G., RA Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E., RA Udd B., Gautel M.; RT "The kinase domain of titin controls muscle gene expression and protein RT turnover."; RL Science 308:1599-1603(2005). RN [38] RP INVOLVEMENT IN CMYO5. RX PubMed=17444505; DOI=10.1002/ana.21089; RA Carmignac V., Salih M.A.M., Quijano-Roy S., Marchand S., Al Rayess M.M., RA Mukhtar M.M., Urtizberea J.A., Labeit S., Guicheney P., Leturcq F., RA Gautel M., Fardeau M., Campbell K.P., Richard I., Estournet B., RA Ferreiro A.; RT "C-terminal titin deletions cause a novel early-onset myopathy with fatal RT cardiomyopathy."; RL Ann. Neurol. 61:340-351(2007). RN [39] RP VARIANTS [LARGE SCALE ANALYSIS] TYR-60; MET-115; CYS-328; THR-360; ILE-498; RP MET-799; ILE-811; HIS-922; ASP-937; THR-1081; ARG-1137; GLU-1201; ALA-1202; RP LEU-1295; ASP-1345; THR-1347; HIS-1350; LEU-1353; VAL-1393; CYS-1416; RP PRO-1441; VAL-1544; GLN-1572; GLY-1658; GLN-1664; ASP-1692; LEU-1744; RP GLY-1772; ILE-1907; HIS-1998; LEU-2107; THR-2118; THR-2164; TYR-2240; RP SER-2392; PHE-2432; ILE-2610; MET-2771; PHE-2823; ASN-2831; ILE-2930; RP ARG-3154; GLU-3191; LEU-3238; GLY-3250; MET-3261; GLN-3367; LYS-3482; RP LYS-3570; VAL-3590; VAL-3762; PHE-3877; LEU-3965; PRO-4215; TRP-4238; RP PHE-4283; THR-4291; ASP-4303; GLU-4427; GLU-12310; ALA-12469; CYS-12642; RP LYS-12657; GLU-12679; PHE-12720; CYS-12798; GLY-13049; LYS-13083; RP LEU-13096; ARG-13099; ALA-13297; MET-13399; THR-13418; VAL-13428; RP THR-13430; LYS-13434; ASN-13469; ASN-13495; SER-13785; HIS-13870; RP ILE-14109; GLN-14131; THR-14208; VAL-14728; THR-14999; THR-15021; RP VAL-15520; ILE-15555; GLN-15620; ILE-15629; CYS-15635; GLN-15700; RP PRO-15705; MET-15837; HIS-16058; ILE-16067; THR-16090; HIS-16195; RP CYS-16409; PRO-16424; MET-16629; ARG-16877; ASP-17060; VAL-17637; RP HIS-17838; ASN-17866; GLU-17906; ALA-18094; SER-18109; THR-18164; RP LEU-18221; THR-18222; GLN-18726; ALA-18835; LYS-18881; SER-18939; RP GLN-19000; GLN-19060; LYS-19091; SER-19224; ILE-19367; LYS-19392; RP SER-19480; GLY-19495; HIS-19665; ILE-19762; ARG-19947; MET-19956; RP GLN-19992; CYS-20057; LEU-20075; LYS-20179; THR-20198; VAL-20198; RP HIS-20331; THR-20408; LYS-20564; ILE-20718; PRO-20726; ASN-20892; RP ARG-20894; GLU-21125; SER-21403; CYS-21730; GLN-21747; ARG-21851; RP ARG-21851; ARG-21925; HIS-21995; VAL-22045; HIS-22149; ILE-22160; RP THR-22261; ASN-22306; HIS-22357; PRO-22408; HIS-22537; LEU-22584; RP PRO-22646; ALA-22670; ASP-22770; THR-22801; TRP-22823; GLN-22968; RP LEU-23074; PHE-23079; ASN-23282; TYR-23303; CYS-23306; SER-23515; RP GLN-23551; ASN-23807; ASN-23872; ALA-23891; HIS-23933; MET-23939; RP LEU-23952; GLY-24098; SER-24119; ILE-24133; ALA-24159; ALA-24239; RP LYS-24265; THR-24584; THR-24781; HIS-24799; HIS-24954; MET-24980; RP HIS-25659; THR-25679; ALA-25720; LYS-25821; LYS-25859; LYS-25879; RP VAL-25923; ILE-26045; GLU-26059; VAL-26134; CYS-26477; TYR-26843; RP ARG-27346; CYS-27652; VAL-27728; LEU-27754; THR-27755; VAL-27929; RP LEU-28132; GLN-28168; HIS-28538; THR-28572; THR-28948; VAL-28986; RP GLU-28993; VAL-28998; MET-29070; VAL-29090; CYS-29419; PRO-29479; RP LEU-29880; GLU-29976; GLY-30042; CYS-30107; PHE-30125; PRO-30211; RP THR-30412; SER-30617; ILE-30674; ILE-30809; ILE-30818; LYS-30825; RP THR-30856; ASP-30887; SER-30887; HIS-30897; HIS-30907; HIS-30946; RP PHE-31081; CYS-31107; GLY-31124; SER-31156; THR-31246; HIS-31330; RP ARG-31690; GLN-31724; ILE-31725; SER-31732; ILE-31886; CYS-32097; RP ASN-32171; ILE-32248; HIS-32281; HIS-32323; TRP-32411; VAL-32558; RP VAL-32610; VAL-32637; ALA-32922; ARG-32943; HIS-32953; LEU-33213; RP CYS-33242; MET-33387; ASP-33419; MET-33536; GLN-33568; LYS-33616; RP LEU-33620; VAL-33886; THR-33899; PRO-33904; ILE-33955 AND ALA-34115. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [40] RP VARIANTS VAL-16046 AND GLN-32742. RX PubMed=23033978; DOI=10.1056/nejmoa1206524; RA de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G., RA Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C., RA del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G., RA Veltman J.A., Vissers L.E.; RT "Diagnostic exome sequencing in persons with severe intellectual RT disability."; RL N. Engl. J. Med. 367:1921-1929(2012). RN [41] RP VARIANTS PRO-2963 AND GLN-14750. RX PubMed=25173926; DOI=10.1161/circgenetics.113.000486; RA Girolami F., Iascone M., Tomberli B., Bardi S., Benelli M., Marseglia G., RA Pescucci C., Pezzoli L., Sana M.E., Basso C., Marziliano N., Merlini P.A., RA Fornaro A., Cecchi F., Torricelli F., Olivotto I.; RT "Novel alpha-actinin 2 variant associated with familial hypertrophic RT cardiomyopathy and juvenile atrial arrhythmias: a massively parallel RT sequencing study."; RL Circ. Cardiovasc. Genet. 7:741-750(2014). CC -!- FUNCTION: Key component in the assembly and functioning of vertebrate CC striated muscles. By providing connections at the level of individual CC microfilaments, it contributes to the fine balance of forces between CC the two halves of the sarcomere. The size and extensibility of the CC cross-links are the main determinants of sarcomere extensibility CC properties of muscle. In non-muscle cells, seems to play a role in CC chromosome condensation and chromosome segregation during mitosis. CC Might link the lamina network to chromatin or nuclear actin, or both CC during interphase. {ECO:0000269|PubMed:11846417, CC ECO:0000269|PubMed:9804419}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Full activation of the protein kinase domain CC requires both phosphorylation of Tyr-32341, preventing it from blocking CC the catalytic aspartate residue, and binding of Ca/CALM to the C- CC terminal regulatory tail of the molecule which results in ATP binding CC to the kinase. {ECO:0000269|PubMed:9804419}. CC -!- SUBUNIT: Interacts with MYOM1, MYOM2, tropomyosin and myosin. Interacts CC with actin, primarily via the PEVK domains and with MYPN (By CC similarity). Interacts with FHL2, NEB, CRYAB, LMNA/lamin-A and CC LMNB/lamin-B. Interacts with TCAP/telethonin and/or ANK1 isoform CC Mu17/ank1.5, via the first two N-terminal immunoglobulin domains. CC Interacts with TRIM63 and TRIM55, through several domains including CC immunoglobulin domains 141 and 142. Interacts with ANKRD1, ANKRD2 and CC ANKRD23, via the region between immunoglobulin domains 77 and 78 and CC interacts with CAPN3, via immunoglobulin domain 79. Interacts with NBR1 CC through the protein kinase domain. Interacts with CALM/calmodulin. CC Isoform 6 interacts with OBSCN isoform 3. Interacts with CMYA5. CC {ECO:0000250, ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:12432079, CC ECO:0000269|PubMed:12444090, ECO:0000269|PubMed:12482578, CC ECO:0000269|PubMed:14583192, ECO:0000269|PubMed:14676215, CC ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:15967462, CC ECO:0000269|PubMed:16407954, ECO:0000269|PubMed:16410549, CC ECO:0000269|PubMed:20634290, ECO:0000269|PubMed:9645487, CC ECO:0000269|PubMed:9804419}. CC -!- INTERACTION: CC Q8WZ42; P12814: ACTN1; NbExp=2; IntAct=EBI-681210, EBI-351710; CC Q8WZ42; P35609: ACTN2; NbExp=16; IntAct=EBI-681210, EBI-77797; CC Q8WZ42; P62158: CALM3; NbExp=2; IntAct=EBI-681210, EBI-397435; CC Q8WZ42; P20807: CAPN3; NbExp=4; IntAct=EBI-681210, EBI-5655000; CC Q8WZ42; O75953: DNAJB5; NbExp=4; IntAct=EBI-681210, EBI-5655937; CC Q8WZ42; O75923: DYSF; NbExp=17; IntAct=EBI-681210, EBI-2799016; CC Q8WZ42; P06733: ENO1; NbExp=3; IntAct=EBI-681210, EBI-353877; CC Q8WZ42; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-681210, EBI-373144; CC Q8WZ42; Q14324: MYBPC2; NbExp=14; IntAct=EBI-681210, EBI-5653200; CC Q8WZ42; Q13203: MYBPH; NbExp=3; IntAct=EBI-681210, EBI-5655165; CC Q8WZ42; P20929: NEB; NbExp=6; IntAct=EBI-681210, EBI-1049657; CC Q8WZ42; Q5VST9: OBSCN; NbExp=15; IntAct=EBI-681210, EBI-941850; CC Q8WZ42; O75147: OBSL1; NbExp=13; IntAct=EBI-681210, EBI-1223896; CC Q8WZ42; O15061: SYNM; NbExp=3; IntAct=EBI-681210, EBI-7843148; CC Q8WZ42; O15273: TCAP; NbExp=9; IntAct=EBI-681210, EBI-954089; CC Q8WZ42; Q969Q1: TRIM63; NbExp=3; IntAct=EBI-681210, EBI-5661333; CC Q8WZ42; Q8WZ42: TTN; NbExp=16; IntAct=EBI-681210, EBI-681210; CC Q8WZ42-3; O15273: TCAP; NbExp=2; IntAct=EBI-15564183, EBI-954089; CC Q8WZ42-3; Q8WZ42-3: TTN; NbExp=9; IntAct=EBI-15564183, EBI-15564183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305|PubMed:16410549}. Nucleus CC {ECO:0000269|PubMed:16410549}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=13; CC Comment=A number of isoforms may be produced, ranging from 27000 to CC 33000 residues in different striated muscle tissues, the size of the CC full-length protein may be up to 38138 residues.; CC Name=1; CC IsoId=Q8WZ42-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8WZ42-2; Sequence=VSP_019138; CC Name=3; Synonyms=Small cardiac N2-B; CC IsoId=Q8WZ42-3; Sequence=VSP_019139, VSP_019145; CC Name=4; Synonyms=Soleus; CC IsoId=Q8WZ42-4; Sequence=VSP_019142, VSP_019151; CC Name=5; CC IsoId=Q8WZ42-5; Sequence=VSP_019147, VSP_019148, VSP_019149, CC VSP_019150, VSP_019152; CC Name=6; Synonyms=Small cardiac novex-3; CC IsoId=Q8WZ42-6; Sequence=VSP_019143, VSP_019146; CC Name=7; Synonyms=Cardiac novex-2; CC IsoId=Q8WZ42-7; Sequence=VSP_019141, VSP_019144; CC Name=8; Synonyms=Cardiac novex-1; CC IsoId=Q8WZ42-8; Sequence=VSP_019140; CC Name=9; CC IsoId=Q8WZ42-9; Sequence=VSP_019139, VSP_042903, VSP_019145; CC Name=10; CC IsoId=Q8WZ42-10; Sequence=VSP_019139, VSP_019140, VSP_019145; CC Name=11; CC IsoId=Q8WZ42-11; Sequence=VSP_019142; CC Name=12; CC IsoId=Q8WZ42-12; Sequence=VSP_045935, VSP_045929, VSP_045930, CC VSP_045931, VSP_045932, VSP_045933, CC VSP_045934; CC Name=13; CC IsoId=Q8WZ42-13; Sequence=VSP_047142; CC -!- TISSUE SPECIFICITY: Isoforms 3, 7 and 8 are expressed in cardiac CC muscle. Isoform 4 is expressed in vertebrate skeletal muscle. Isoform 6 CC is expressed in skeletal muscle (at protein level). CC {ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7819249}. CC -!- DOMAIN: ZIS1 and ZIS5 regions contain multiple SPXR consensus sites for CC ERK- and CDK-like protein kinases as well as multiple SP motifs. ZIS1 CC could adopt a closed conformation which would block the TCAP-binding CC site. CC -!- DOMAIN: The PEVK region may serve as an entropic spring of a chain of CC structural folds and may also be an interaction site to other CC myofilament proteins to form interfilament connectivity in the CC sarcomere. CC -!- PTM: Autophosphorylated. {ECO:0000250}. CC -!- DISEASE: Myopathy, myofibrillar, 9, with early respiratory failure CC (MFM9) [MIM:603689]: An autosomal dominant myopathy characterized by CC adulthood onset of weakness in proximal, distal, axial and respiratory CC muscles. Pelvic girdle weakness, foot drop and neck weakness are the CC main symptoms at onset, but ultimately the weakness usually involves CC the proximal compartment of both upper and lower limbs. Additional CC features include variable degrees of Achilles tendon contractures, CC spinal rigidity and muscle hypertrophy. Respiratory involvement often CC leads to requirement for non-invasive ventilation support. CC {ECO:0000269|PubMed:15802564}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, familial hypertrophic, 9 (CMH9) [MIM:613765]: CC A hereditary heart disorder characterized by ventricular hypertrophy, CC which is usually asymmetric and often involves the interventricular CC septum. The symptoms include dyspnea, syncope, collapse, palpitations, CC and chest pain. They can be readily provoked by exercise. The disorder CC has inter- and intrafamilial variability ranging from benign to CC malignant forms with high risk of cardiac failure and sudden cardiac CC death. {ECO:0000269|PubMed:10462489}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1G (CMD1G) [MIM:604145]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:11788824, CC ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:16465475}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Tardive tibial muscular dystrophy (TMD) [MIM:600334]: CC Autosomal dominant, late-onset distal myopathy. Muscle weakness and CC atrophy are usually confined to the anterior compartment of the lower CC leg, in particular the tibialis anterior muscle. Clinical symptoms CC usually occur at age 35-45 years or much later. CC {ECO:0000269|PubMed:12145747, ECO:0000269|PubMed:12891679}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muscular dystrophy, limb-girdle, autosomal recessive 10 CC (LGMDR10) [MIM:608807]: An autosomal recessive degenerative myopathy CC characterized by progressive weakness of the pelvic and shoulder girdle CC muscles. Severe disability is observed within 20 years of onset. CC {ECO:0000269|PubMed:12145747}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Congenital myopathy 5 with cardiomyopathy (CMYO5) CC [MIM:611705]: An autosomal recessive, early-onset muscular disorder CC characterized by dilated cardiomyopathy, delayed motor development with CC generalized muscle weakness predominantly affecting proximal and distal CC lower limbs. Skeletal muscle biopsies show minicore-like lesions with CC mitochondrial depletion and sarcomere disorganization, centralized CC nuclei, and type 1 fiber predominance. Dystrophic changes become CC apparent in the second decade. Cardiac muscle biopsies show disruption CC of myocardial architecture, nuclear hypertrophy, and endomysial CC fibrosis. Sudden death may occurr due to cardiomyopathy. CC {ECO:0000269|PubMed:17444505}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In some isoforms, after the PEVK repeat region there is CC a long PEVK duplicated region. On account of this region, it has been CC very difficult to sequence the whole protein. The length of this region CC (ranging from 183 to 2174 residues), may be a key elastic element of CC titin. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH58824.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 553.; Evidence={ECO:0000305}; CC Sequence=AAH70170.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence starting in position 627.; Evidence={ECO:0000305}; CC Sequence=CAA62188.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=CAD12455.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Titin entry; CC URL="https://en.wikipedia.org/wiki/Titin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X90568; CAA62188.1; ALT_FRAME; mRNA. DR EMBL; X90569; CAA62189.1; -; mRNA. DR EMBL; AJ277892; CAD12455.1; ALT_FRAME; Genomic_DNA. DR EMBL; AJ277892; CAD12456.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12457.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12458.1; -; Genomic_DNA. DR EMBL; AJ277892; CAD12459.1; -; Genomic_DNA. DR EMBL; AC009948; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC010680; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC023270; AAX88844.1; -; Genomic_DNA. DR EMBL; FJ695199; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; KF459616; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC013396; AAH13396.1; -; mRNA. DR EMBL; BC058824; AAH58824.1; ALT_SEQ; mRNA. DR EMBL; BC070170; AAH70170.1; ALT_SEQ; mRNA. DR EMBL; BC107797; AAI07798.1; -; mRNA. DR EMBL; X98114; CAA66795.1; -; mRNA. DR EMBL; X98115; CAA66796.1; -; mRNA. DR EMBL; X83270; CAA58243.1; -; mRNA. DR EMBL; AF058332; AAD22603.1; -; Genomic_DNA. DR EMBL; AF058332; AAD22604.1; -; Genomic_DNA. DR EMBL; AF525413; AAP80791.1; -; mRNA. DR EMBL; DQ248309; ABB55264.1; -; mRNA. DR EMBL; X64698; CAA45939.1; -; mRNA. DR EMBL; X64699; CAA45940.1; -; Genomic_DNA. DR EMBL; X64697; CAA45938.1; -; mRNA. DR EMBL; X69490; CAA49245.1; -; mRNA. DR EMBL; AL713647; CAD28458.1; -; mRNA. DR CCDS; CCDS33337.1; -. [Q8WZ42-6] DR CCDS; CCDS54421.1; -. [Q8WZ42-3] DR CCDS; CCDS54422.1; -. [Q8WZ42-9] DR CCDS; CCDS54423.1; -. [Q8WZ42-10] DR CCDS; CCDS54424.1; -. [Q8WZ42-11] DR CCDS; CCDS59435.1; -. [Q8WZ42-12] DR PIR; I38344; I38344. DR PIR; I38346; I38346. DR RefSeq; NP_001243779.1; NM_001256850.1. [Q8WZ42-1] DR RefSeq; NP_001254479.2; NM_001267550.2. [Q8WZ42-12] DR RefSeq; NP_003310.4; NM_003319.4. [Q8WZ42-3] DR RefSeq; NP_596869.4; NM_133378.4. [Q8WZ42-11] DR RefSeq; NP_596870.2; NM_133379.5. [Q8WZ42-6] DR RefSeq; NP_597676.3; NM_133432.3. [Q8WZ42-10] DR PDB; 1BPV; NMR; -; A=22283-22385. DR PDB; 1G1C; X-ray; 2.10 A; A/B=2073-2171. DR PDB; 1NCT; NMR; -; A=33483-33579. DR PDB; 1NCU; NMR; -; A=33483-33579. DR PDB; 1TIT; NMR; -; A=12680-12765. DR PDB; 1TIU; NMR; -; A=12680-12765. DR PDB; 1TKI; X-ray; 2.00 A; A/B=32172-32492. DR PDB; 1TNM; NMR; -; A=33489-33579. DR PDB; 1TNN; NMR; -; A=33489-33579. DR PDB; 1WAA; X-ray; 1.80 A; A/B/C/D/E/F=12677-12765. DR PDB; 1YA5; X-ray; 2.44 A; A/B=1-196. DR PDB; 2A38; X-ray; 2.00 A; A/B/C=1-194. DR PDB; 2BK8; X-ray; 1.69 A; A=32497-32590. DR PDB; 2F8V; X-ray; 2.75 A; A/B/C/D=1-196. DR PDB; 2ILL; X-ray; 2.20 A; A=31854-32047. DR PDB; 2J8H; X-ray; 1.99 A; A=31854-32047. DR PDB; 2J8O; X-ray; 2.49 A; A/B=31854-32047. DR PDB; 2NZI; X-ray; 2.90 A; A/B=31854-32155. DR PDB; 2RQ8; NMR; -; A=12677-12765. DR PDB; 2WP3; X-ray; 1.48 A; T=34252-34350. DR PDB; 2WWK; X-ray; 1.70 A; T=34252-34350. DR PDB; 2WWM; X-ray; 2.30 A; D/T=34252-34350. DR PDB; 2Y9R; X-ray; 1.90 A; T=34252-34350. DR PDB; 3B43; X-ray; 3.30 A; A=7945-8511. DR PDB; 3KNB; X-ray; 1.40 A; A=34253-34350. DR PDB; 3LCY; X-ray; 2.50 A; A/B/C/D=31456-31649. DR PDB; 3LPW; X-ray; 1.65 A; A/B=22877-23070. DR PDB; 3PUC; X-ray; 0.96 A; A=33774-33871. DR PDB; 3Q5O; X-ray; 2.05 A; A/B=34253-34350. DR PDB; 3QP3; X-ray; 2.00 A; A/B/C=33294-33395. DR PDB; 4C4K; X-ray; 1.95 A; T=34252-34350. DR PDB; 4JNW; X-ray; 2.06 A; A/B=32172-32492. DR PDB; 4O00; X-ray; 1.85 A; A/B=14217-14319. DR PDB; 4QEG; X-ray; 2.00 A; A=2880-2967. DR PDB; 4UOW; X-ray; 3.30 A; 1/3/5/7/9/B/D/F/H/J/L/N/P/R/T/V/X/Z=7-99. DR PDB; 5BS0; X-ray; 2.40 A; C=24337-24345. DR PDB; 5JDD; X-ray; 1.53 A; A=2795-3053. DR PDB; 5JDE; X-ray; 1.90 A; A/B=2795-3053. DR PDB; 5JDJ; X-ray; 1.74 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2880-2967. DR PDB; 5JOE; X-ray; 2.00 A; A=9582-9671. DR PDB; 6DL4; NMR; -; A=1821-1931. DR PDB; 6FWX; X-ray; 3.00 A; A/B=1-243. DR PDB; 6H4L; X-ray; 1.60 A; A=33294-33395. DR PDB; 6HCI; X-ray; 2.12 A; A/B/C/D=32712-32816. DR PDB; 6I0Y; EM; 3.20 A; z=12677-12765. DR PDB; 6SDB; X-ray; 2.80 A; A/B/C/D/E=3-196. DR PDB; 6YGN; X-ray; 2.40 A; A/B=32046-32594. DR PDB; 7AHS; X-ray; 2.05 A; A/B/C/D=9582-9851. DR PDB; 7NIP; NMR; -; A=9504-9544. DR PDB; 8BNQ; X-ray; 2.30 A; A/B=23562-23862. DR PDB; 8BVO; X-ray; 2.55 A; A=14415-14609. DR PDB; 8BW6; X-ray; 1.95 A; A=14415-14509. DR PDB; 8BXR; X-ray; 2.70 A; A=14319-14615. DR PDB; 8G4L; EM; 6.40 A; am/an/bm/bn/m/n=22784-23867. DR PDB; 8OIY; X-ray; 2.10 A; A/B/C/D/E/F=14217-14319. DR PDB; 8OMW; X-ray; 1.05 A; A=16525-16630. DR PDB; 8OQ9; X-ray; 1.65 A; A/B/C=21497-21598. DR PDB; 8ORL; X-ray; 1.43 A; A/B/C=21497-21598. DR PDB; 8OS3; X-ray; 1.68 A; A=15210-15313. DR PDB; 8OSD; X-ray; 1.70 A; A/B=20511-20616. DR PDB; 8OT5; X-ray; 1.56 A; A/B/C/D/E/F=25430-25531. DR PDB; 8OTY; X-ray; 1.90 A; A/B/C/D=26124-26224. DR PDB; 8OVU; X-ray; 1.95 A; A/B=3500-3598. DR PDB; 8P35; X-ray; 2.20 A; A/B/C/D/E/F=3500-3598. DR PDBsum; 1BPV; -. DR PDBsum; 1G1C; -. DR PDBsum; 1NCT; -. DR PDBsum; 1NCU; -. DR PDBsum; 1TIT; -. DR PDBsum; 1TIU; -. DR PDBsum; 1TKI; -. DR PDBsum; 1TNM; -. DR PDBsum; 1TNN; -. DR PDBsum; 1WAA; -. DR PDBsum; 1YA5; -. DR PDBsum; 2A38; -. DR PDBsum; 2BK8; -. DR PDBsum; 2F8V; -. DR PDBsum; 2ILL; -. DR PDBsum; 2J8H; -. DR PDBsum; 2J8O; -. DR PDBsum; 2NZI; -. DR PDBsum; 2RQ8; -. DR PDBsum; 2WP3; -. DR PDBsum; 2WWK; -. DR PDBsum; 2WWM; -. DR PDBsum; 2Y9R; -. DR PDBsum; 3B43; -. DR PDBsum; 3KNB; -. DR PDBsum; 3LCY; -. DR PDBsum; 3LPW; -. DR PDBsum; 3PUC; -. DR PDBsum; 3Q5O; -. DR PDBsum; 3QP3; -. DR PDBsum; 4C4K; -. DR PDBsum; 4JNW; -. DR PDBsum; 4O00; -. DR PDBsum; 4QEG; -. DR PDBsum; 4UOW; -. DR PDBsum; 5BS0; -. DR PDBsum; 5JDD; -. DR PDBsum; 5JDE; -. DR PDBsum; 5JDJ; -. DR PDBsum; 5JOE; -. DR PDBsum; 6DL4; -. DR PDBsum; 6FWX; -. DR PDBsum; 6H4L; -. DR PDBsum; 6HCI; -. DR PDBsum; 6I0Y; -. DR PDBsum; 6SDB; -. DR PDBsum; 6YGN; -. DR PDBsum; 7AHS; -. DR PDBsum; 7NIP; -. DR PDBsum; 8BNQ; -. DR PDBsum; 8BVO; -. DR PDBsum; 8BW6; -. DR PDBsum; 8BXR; -. DR PDBsum; 8G4L; -. DR PDBsum; 8OIY; -. DR PDBsum; 8OMW; -. DR PDBsum; 8OQ9; -. DR PDBsum; 8ORL; -. DR PDBsum; 8OS3; -. DR PDBsum; 8OSD; -. DR PDBsum; 8OT5; -. DR PDBsum; 8OTY; -. DR PDBsum; 8OVU; -. DR PDBsum; 8P35; -. DR EMDB; EMD-0322; -. DR EMDB; EMD-29722; -. DR SASBDB; Q8WZ42; -. DR SMR; Q8WZ42; -. DR BioGRID; 113124; 328. DR ComplexPortal; CPX-101; Titin-Telethonin complex. DR CORUM; Q8WZ42; -. DR DIP; DIP-33449N; -. DR FunCoup; Q8WZ42; 665. DR IntAct; Q8WZ42; 167. DR MINT; Q8WZ42; -. DR STRING; 9606.ENSP00000467141; -. DR MoonDB; Q8WZ42; Predicted. DR CarbonylDB; Q8WZ42; -. DR GlyCosmos; Q8WZ42; 11 sites, 2 glycans. DR GlyGen; Q8WZ42; 39 sites, 3 O-linked glycans (22 sites). DR iPTMnet; Q8WZ42; -. DR MetOSite; Q8WZ42; -. DR PhosphoSitePlus; Q8WZ42; -. DR SwissPalm; Q8WZ42; -. DR BioMuta; TTN; -. DR jPOST; Q8WZ42; -. DR MassIVE; Q8WZ42; -. DR PaxDb; 9606-ENSP00000467141; -. DR PeptideAtlas; Q8WZ42; -. DR ProteomicsDB; 75209; -. [Q8WZ42-1] DR ProteomicsDB; 75210; -. [Q8WZ42-10] DR ProteomicsDB; 75211; -. [Q8WZ42-11] DR ProteomicsDB; 75212; -. [Q8WZ42-2] DR ProteomicsDB; 75213; -. [Q8WZ42-3] DR ProteomicsDB; 75214; -. [Q8WZ42-4] DR ProteomicsDB; 75215; -. [Q8WZ42-5] DR ProteomicsDB; 75216; -. [Q8WZ42-6] DR ProteomicsDB; 75217; -. [Q8WZ42-7] DR ProteomicsDB; 75218; -. [Q8WZ42-8] DR ProteomicsDB; 75219; -. [Q8WZ42-9] DR Pumba; Q8WZ42; -. DR ABCD; Q8WZ42; 2 sequenced antibodies. DR Antibodypedia; 2056; 211 antibodies from 28 providers. DR DNASU; 7273; -. DR Ensembl; ENST00000342992.11; ENSP00000343764.6; ENSG00000155657.29. [Q8WZ42-11] DR Ensembl; ENST00000359218.11; ENSP00000352154.5; ENSG00000155657.29. [Q8WZ42-10] DR Ensembl; ENST00000360870.10; ENSP00000354117.4; ENSG00000155657.29. [Q8WZ42-6] DR Ensembl; ENST00000412264.2; ENSP00000394672.2; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000460472.6; ENSP00000434586.1; ENSG00000155657.29. [Q8WZ42-3] DR Ensembl; ENST00000589042.5; ENSP00000467141.1; ENSG00000155657.29. [Q8WZ42-12] DR Ensembl; ENST00000591111.5; ENSP00000465570.1; ENSG00000155657.29. [Q8WZ42-1] DR GeneID; 7273; -. DR KEGG; hsa:7273; -. DR MANE-Select; ENST00000589042.5; ENSP00000467141.1; NM_001267550.2; NP_001254479.2. [Q8WZ42-12] DR UCSC; uc002unb.4; human. [Q8WZ42-1] DR UCSC; uc031rqc.3; human. DR AGR; HGNC:12403; -. DR ClinPGx; PA37067; -. DR CTD; 7273; -. DR DisGeNET; 7273; -. DR GeneCards; TTN; -. DR GeneReviews; TTN; -. DR HGNC; HGNC:12403; TTN. DR HPA; ENSG00000155657; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TTN; -. DR MIM; 188840; gene. DR MIM; 600334; phenotype. DR MIM; 603689; phenotype. DR MIM; 604145; phenotype. DR MIM; 608807; phenotype. DR MIM; 611705; phenotype. DR MIM; 613765; phenotype. DR OpenTargets; ENSG00000155657; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR Orphanet; 466921; Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome. DR Orphanet; 324604; Classic multiminicore myopathy. DR Orphanet; 707983; Early-onset autosomal recessive TTN-related distal myopathy. DR Orphanet; 289377; Early-onset myopathy with fatal cardiomyopathy. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 334; Hereditary atrial fibrillation. DR Orphanet; 178464; Hereditary myopathy with early respiratory failure. DR Orphanet; 293888; Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant. DR Orphanet; 293910; Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant. DR Orphanet; 293899; Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant. DR Orphanet; 609; Tibial muscular dystrophy. DR Orphanet; 140922; Titin-related limb-girdle muscular dystrophy R10. DR VEuPathDB; HostDB:ENSG00000155657; -. DR eggNOG; KOG0613; Eukaryota. DR eggNOG; KOG4475; Eukaryota. DR GeneTree; ENSGT01150000286978; -. DR HOGENOM; CLU_000001_1_0_1; -. DR InParanoid; Q8WZ42; -. DR OMA; TSSWPEY; -. DR OrthoDB; 5969272at2759; -. DR PAN-GO; Q8WZ42; 0 GO annotations based on evolutionary models. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; Q8WZ42; -. DR Reactome; R-HSA-114608; Platelet degranulation. DR Reactome; R-HSA-390522; Striated Muscle Contraction. DR SignaLink; Q8WZ42; -. DR SIGNOR; Q8WZ42; -. DR Agora; ENSG00000155657; -. DR BioGRID-ORCS; 7273; 10 hits in 1181 CRISPR screens. DR CD-CODE; 232F8A39; P-body. DR ChiTaRS; TTN; human. DR EvolutionaryTrace; Q8WZ42; -. DR GeneWiki; Titin; -. DR GenomeRNAi; 7273; -. DR Pharos; Q8WZ42; Tbio. DR PRO; PR:Q8WZ42; -. DR Proteomes; UP000005640; Chromosome 2. DR Bgee; ENSG00000155657; Expressed in gluteal muscle and 163 other cell types or tissues. DR ExpressionAtlas; Q8WZ42; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; IEA:UniProtKB-ARBA. DR GO; GO:0000794; C:condensed nuclear chromosome; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0031674; C:I band; IDA:BHF-UCL. DR GO; GO:0031430; C:M band; IDA:BHF-UCL. DR GO; GO:0005865; C:striated muscle thin filament; IDA:BHF-UCL. DR GO; GO:1990733; C:titin-telethonin complex; IPI:ComplexPortal. DR GO; GO:0030018; C:Z disc; IDA:BHF-UCL. DR GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL. DR GO; GO:0042805; F:actinin binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0051371; F:muscle alpha-actinin binding; IPI:BHF-UCL. DR GO; GO:0002020; F:protease binding; IPI:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0019887; F:protein kinase regulator activity; IMP:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI. DR GO; GO:0008307; F:structural constituent of muscle; IMP:BHF-UCL. DR GO; GO:0097493; F:structural molecule activity conferring elasticity; IDA:BHF-UCL. DR GO; GO:0031433; F:telethonin binding; IPI:BHF-UCL. DR GO; GO:0055013; P:cardiac muscle cell development; IMP:BHF-UCL. DR GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL. DR GO; GO:0003300; P:cardiac muscle hypertrophy; IMP:BHF-UCL. DR GO; GO:0055008; P:cardiac muscle tissue morphogenesis; IMP:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; IMP:BHF-UCL. DR GO; GO:0035995; P:detection of muscle stretch; IDA:MGI. DR GO; GO:0007076; P:mitotic chromosome condensation; IEP:BHF-UCL. DR GO; GO:0006936; P:muscle contraction; TAS:UniProtKB. DR GO; GO:0030049; P:muscle filament sliding; NAS:ComplexPortal. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA. DR GO; GO:0050714; P:positive regulation of protein secretion; IMP:CAFA. DR GO; GO:0010737; P:protein kinase A signaling; IMP:CAFA. DR GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL. DR GO; GO:0045214; P:sarcomere organization; IMP:BHF-UCL. DR GO; GO:0048769; P:sarcomerogenesis; IMP:BHF-UCL. DR GO; GO:0003009; P:skeletal muscle contraction; NAS:ComplexPortal. DR GO; GO:0030241; P:skeletal muscle myosin thick filament assembly; IMP:BHF-UCL. DR GO; GO:0030240; P:skeletal muscle thin filament assembly; IMP:BHF-UCL. DR GO; GO:0006941; P:striated muscle contraction; TAS:UniProtKB. DR CDD; cd00063; FN3; 132. DR CDD; cd00096; Ig; 31. DR CDD; cd05748; Ig_Titin_like; 28. DR CDD; cd20974; IgI_1_Titin_Z1z2-like; 2. DR CDD; cd20972; IgI_2_Titin_Z1z2-like; 1. DR CDD; cd20951; IgI_titin_I1-like; 1. DR CDD; cd05747; IgI_Titin_like; 1. DR CDD; cd20927; IgI_Titin_M1-like; 1. DR CDD; cd14104; STKc_Titin; 1. DR DisProt; DP00072; -. DR FunFam; 2.60.40.10:FF:000022; Cardiac titin; 44. DR FunFam; 2.60.40.10:FF:000800; Cardiac titin; 1. DR FunFam; 2.60.40.10:FF:000345; Muscle M-line assembly protein unc-89; 1. DR FunFam; 2.60.40.10:FF:001284; Myomesin 2; 1. DR FunFam; 2.60.40.10:FF:000147; Myosin light chain kinase; 2. DR FunFam; 2.60.40.10:FF:000107; Myosin, light chain kinase a; 2. DR FunFam; 2.60.40.10:FF:000031; Myosin-binding protein C, slow type; 7. DR FunFam; 2.60.40.10:FF:001867; Titin; 1. DR FunFam; 2.60.40.10:FF:001911; Titin; 1. DR FunFam; 1.10.510.10:FF:000329; Titin a; 1. DR FunFam; 2.60.40.10:FF:000002; Titin a; 32. DR FunFam; 2.60.40.10:FF:000112; Titin a; 8. DR FunFam; 2.60.40.10:FF:000135; Titin a; 7. DR FunFam; 2.60.40.10:FF:000160; Titin a; 1. DR FunFam; 2.60.40.10:FF:000547; Titin a; 2. DR FunFam; 2.60.40.10:FF:000672; Titin a; 1. DR FunFam; 2.60.40.10:FF:000673; Titin a; 1. DR FunFam; 2.60.40.10:FF:000811; Titin a; 1. DR FunFam; 2.60.40.10:FF:000867; Titin a; 1. DR FunFam; 2.60.40.10:FF:000891; Titin a; 1. DR FunFam; 2.60.40.10:FF:000900; Titin a; 1. DR FunFam; 2.60.40.10:FF:000981; Titin a; 1. DR FunFam; 2.60.40.10:FF:001200; Titin a; 1. DR FunFam; 2.60.40.10:FF:001399; Titin a; 1. DR FunFam; 2.60.40.10:FF:001400; Titin a; 1. DR FunFam; 2.60.40.10:FF:001459; Titin a; 1. DR FunFam; 2.60.40.10:FF:001500; Titin a; 1. DR FunFam; 2.60.40.10:FF:001579; Titin a; 1. DR FunFam; 2.60.40.10:FF:001697; Titin a; 1. DR FunFam; 3.30.200.20:FF:000286; Titin a; 1. DR FunFam; 2.60.40.10:FF:000011; Titin b; 11. DR FunFam; 2.60.40.10:FF:000629; Titin b; 1. DR FunFam; 2.60.40.10:FF:000635; Titin b; 1. DR FunFam; 2.60.40.10:FF:000779; Titin b; 1. DR FunFam; 2.60.40.10:FF:000833; Titin b; 1. DR FunFam; 2.60.40.10:FF:000859; Titin b; 1. DR FunFam; 2.60.40.10:FF:000864; Titin b; 1. DR FunFam; 2.60.40.10:FF:000901; Titin b; 1. DR FunFam; 2.60.40.10:FF:000980; Titin b; 1. DR FunFam; 2.60.40.10:FF:000986; Titin b; 1. DR FunFam; 2.60.40.10:FF:001115; Titin b; 1. DR FunFam; 2.60.40.10:FF:001190; Titin b; 1. DR FunFam; 2.60.40.10:FF:001477; Titin b; 1. DR FunFam; 2.60.40.10:FF:000034; Titin isoform A; 26. DR FunFam; 2.60.40.10:FF:000050; Titin isoform B; 8. DR FunFam; 2.60.40.10:FF:000003; Titin isoform E; 22. DR FunFam; 2.60.40.10:FF:000012; titin isoform X1; 26. DR FunFam; 2.60.40.10:FF:000073; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000127; titin isoform X1; 4. DR FunFam; 2.60.40.10:FF:000148; titin isoform X1; 5. DR FunFam; 2.60.40.10:FF:000214; titin isoform X1; 7. DR FunFam; 2.60.40.10:FF:000218; titin isoform X1; 6. DR FunFam; 2.60.40.10:FF:000659; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000697; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000770; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000792; titin isoform X1; 2. DR FunFam; 2.60.40.10:FF:000983; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001003; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001213; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001229; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001272; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001327; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001328; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001342; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001343; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001344; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001345; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001350; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001365; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001367; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001382; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001385; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001408; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001430; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001434; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001454; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001476; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001544; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001581; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001610; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001612; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:001663; titin isoform X1; 1. DR FunFam; 2.60.40.10:FF:000714; Titin novex-3; 3. DR FunFam; 2.60.40.10:FF:001082; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001089; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001098; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001116; Titin novex-3; 1. DR FunFam; 2.60.40.10:FF:001804; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:001844; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002231; Titin, isoform CRA_a; 1. DR FunFam; 2.60.40.10:FF:002123; Titin, tandem duplicate 1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 299. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013106; Ig_V-set. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR040849; MyBP-C_THB. DR InterPro; IPR004168; PPAK_motif. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR015129; Titin_Z_rpt. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR14340; MICROFIBRIL-ASSOCIATED GLYCOPROTEIN 3; 1. DR PANTHER; PTHR14340:SF13; TITIN; 1. DR Pfam; PF00041; fn3; 132. DR Pfam; PF07679; I-set; 162. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF02818; PPAK; 9. DR Pfam; PF18362; THB; 1. DR Pfam; PF09042; Titin_Z; 2. DR SMART; SM00060; FN3; 132. DR SMART; SM00409; IG; 167. DR SMART; SM00408; IGc2; 148. DR SMART; SM00406; IGv; 23. DR SUPFAM; SSF49265; Fibronectin type III; 74. DR SUPFAM; SSF48726; Immunoglobulin; 167. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50853; FN3; 132. DR PROSITE; PS50835; IG_LIKE; 143. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Calcium; KW Calmodulin-binding; Cardiomyopathy; Coiled coil; Cytoplasm; KW Direct protein sequencing; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Limb-girdle muscular dystrophy; Magnesium; KW Metal-binding; Myofibrillar myopathy; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..34350 FT /note="Titin" FT /id="PRO_0000239311" FT DOMAIN 6..96 FT /note="Ig-like 1" FT DOMAIN 104..192 FT /note="Ig-like 2" FT REPEAT 417..462 FT /note="Z-repeat 1" FT REPEAT 466..511 FT /note="Z-repeat 2" FT REPEAT 512..554 FT /note="Z-repeat 3" FT REPEAT 555..600 FT /note="Z-repeat 4" FT REPEAT 601..646 FT /note="Z-repeat 5" FT REPEAT 647..691 FT /note="Z-repeat 6" FT REPEAT 692..740 FT /note="Z-repeat 7" FT DOMAIN 943..1031 FT /note="Ig-like 3" FT DOMAIN 1082..1172 FT /note="Ig-like 4" FT DOMAIN 1291..1382 FT /note="Ig-like 5" FT DOMAIN 1457..1546 FT /note="Ig-like 6" FT DOMAIN 1556..1646 FT /note="Ig-like 7" FT DOMAIN 1703..1793 FT /note="Ig-like 8" FT DOMAIN 1841..1928 FT /note="Ig-like 9" FT DOMAIN 2078..2167 FT /note="Ig-like 10" FT DOMAIN 2171..2262 FT /note="Ig-like 11" FT DOMAIN 2264..2354 FT /note="Ig-like 12" FT DOMAIN 2353..2443 FT /note="Ig-like 13" FT DOMAIN 2430..2529 FT /note="Ig-like 14" FT DOMAIN 2620..2703 FT /note="Ig-like 15" FT DOMAIN 2880..2965 FT /note="Ig-like 16" FT DOMAIN 2968..3050 FT /note="Ig-like 17" FT DOMAIN 3058..3141 FT /note="Ig-like 18" FT DOMAIN 3239..3327 FT /note="Ig-like 19" FT DOMAIN 3344..3432 FT /note="Ig-like 20" FT DOMAIN 3503..3586 FT /note="Ig-like 21" FT DOMAIN 3621..3712 FT /note="Ig-like 22" FT DOMAIN 4289..4376 FT /note="Ig-like 23" FT DOMAIN 4383..4471 FT /note="Ig-like 24" FT DOMAIN 4478..4566 FT /note="Ig-like 25" FT DOMAIN 4571..4659 FT /note="Ig-like 26" FT DOMAIN 4664..4753 FT /note="Ig-like 27" FT DOMAIN 4758..4846 FT /note="Ig-like 28" FT DOMAIN 4851..4936 FT /note="Ig-like 29" FT DOMAIN 4943..5032 FT /note="Ig-like 30" FT DOMAIN 5040..5128 FT /note="Ig-like 31" FT DOMAIN 5133..5221 FT /note="Ig-like 32" FT DOMAIN 5225..5314 FT /note="Ig-like 33" FT DOMAIN 5320..5408 FT /note="Ig-like 34" FT DOMAIN 5413..5501 FT /note="Ig-like 35" FT DOMAIN 5505..5594 FT /note="Ig-like 36" FT DOMAIN 5602..5690 FT /note="Ig-like 37" FT DOMAIN 5695..5783 FT /note="Ig-like 38" FT DOMAIN 5788..5877 FT /note="Ig-like 39" FT DOMAIN 5882..5970 FT /note="Ig-like 40" FT DOMAIN 5975..6063 FT /note="Ig-like 41" FT DOMAIN 6067..6156 FT /note="Ig-like 42" FT DOMAIN 6164..6252 FT /note="Ig-like 43" FT DOMAIN 6257..6347 FT /note="Ig-like 44" FT DOMAIN 6350..6440 FT /note="Ig-like 45" FT DOMAIN 6444..6534 FT /note="Ig-like 46" FT DOMAIN 6537..6626 FT /note="Ig-like 47" FT DOMAIN 6630..6721 FT /note="Ig-like 48" FT DOMAIN 6727..6815 FT /note="Ig-like 49" FT DOMAIN 6820..6908 FT /note="Ig-like 50" FT DOMAIN 6912..7001 FT /note="Ig-like 51" FT DOMAIN 7005..7093 FT /note="Ig-like 52" FT DOMAIN 7102..7190 FT /note="Ig-like 53" FT DOMAIN 7198..7286 FT /note="Ig-like 54" FT DOMAIN 7291..7380 FT /note="Ig-like 55" FT DOMAIN 7385..7473 FT /note="Ig-like 56" FT DOMAIN 7478..7567 FT /note="Ig-like 57" FT DOMAIN 7571..7662 FT /note="Ig-like 58" FT DOMAIN 7668..7756 FT /note="Ig-like 59" FT DOMAIN 7761..7849 FT /note="Ig-like 60" FT DOMAIN 7853..7942 FT /note="Ig-like 61" FT DOMAIN 7946..8035 FT /note="Ig-like 62" FT DOMAIN 8042..8133 FT /note="Ig-like 63" FT DOMAIN 8138..8229 FT /note="Ig-like 64" FT DOMAIN 8232..8321 FT /note="Ig-like 65" FT DOMAIN 8326..8414 FT /note="Ig-like 66" FT DOMAIN 8419..8508 FT /note="Ig-like 67" FT DOMAIN 8512..8603 FT /note="Ig-like 68" FT DOMAIN 8609..8697 FT /note="Ig-like 69" FT DOMAIN 8702..8790 FT /note="Ig-like 70" FT DOMAIN 8794..8883 FT /note="Ig-like 71" FT DOMAIN 8888..8976 FT /note="Ig-like 72" FT DOMAIN 8984..9074 FT /note="Ig-like 73" FT DOMAIN 9079..9168 FT /note="Ig-like 74" FT DOMAIN 9176..9265 FT /note="Ig-like 75" FT DOMAIN 9272..9361 FT /note="Ig-like 76" FT DOMAIN 9366..9470 FT /note="Ig-like 77" FT DOMAIN 9660..9755 FT /note="Ig-like 78" FT DOMAIN 9760..9851 FT /note="Ig-like 79" FT REPEAT 10216..10242 FT /note="PEVK 1" FT REPEAT 10244..10270 FT /note="PEVK 2" FT REPEAT 10272..10298 FT /note="PEVK 3" FT REPEAT 10300..10326 FT /note="PEVK 4" FT REPEAT 10327..10353 FT /note="PEVK 5" FT REPEAT 10355..10381 FT /note="PEVK 6" FT REPEAT 10508..10534 FT /note="PEVK 7" FT REPEAT 10536..10562 FT /note="PEVK 8" FT REPEAT 10592..10618 FT /note="PEVK 9" FT REPEAT 10878..10904 FT /note="PEVK 10" FT REPEAT 10906..10930 FT /note="PEVK 11" FT REPEAT 10932..10958 FT /note="PEVK 12" FT REPEAT 10960..10986 FT /note="PEVK 13" FT REPEAT 10987..11014 FT /note="PEVK 14" FT REPEAT 11363..11396 FT /note="PEVK 15" FT REPEAT 11397..11421 FT /note="PEVK 16" FT REPEAT 11453..11479 FT /note="PEVK 17" FT REPEAT 11481..11507 FT /note="PEVK 18" FT REPEAT 11509..11535 FT /note="PEVK 19" FT REPEAT 11537..11563 FT /note="PEVK 20" FT REPEAT 11565..11591 FT /note="PEVK 21" FT REPEAT 11657..11683 FT /note="PEVK 22" FT REPEAT 11703..11729 FT /note="PEVK 23" FT REPEAT 11745..11771 FT /note="PEVK 24" FT REPEAT 11775..11801 FT /note="PEVK 25" FT REPEAT 11836..11862 FT /note="PEVK 26" FT REPEAT 11864..11890 FT /note="PEVK 27" FT REPEAT 11893..11919 FT /note="PEVK 28" FT REPEAT 11929..11955 FT /note="PEVK 29" FT REPEAT 11966..11992 FT /note="PEVK 30" FT REPEAT 11996..12022 FT /note="PEVK 31" FT DOMAIN 12041..12133 FT /note="Ig-like 80" FT DOMAIN 12138..12222 FT /note="Ig-like 81" FT DOMAIN 12233..12318 FT /note="Ig-like 82" FT DOMAIN 12499..12584 FT /note="Ig-like 83" FT DOMAIN 12590..12672 FT /note="Ig-like 84" FT DOMAIN 12766..12850 FT /note="Ig-like 85" FT DOMAIN 12945..13032 FT /note="Ig-like 86" FT DOMAIN 13120..13206 FT /note="Ig-like 87" FT DOMAIN 13210..13295 FT /note="Ig-like 88" FT DOMAIN 13299..13384 FT /note="Ig-like 89" FT DOMAIN 13388..13478 FT /note="Ig-like 90" FT DOMAIN 13479..13562 FT /note="Ig-like 91" FT DOMAIN 13565..13655 FT /note="Ig-like 92" FT DOMAIN 13659..13748 FT /note="Ig-like 93" FT DOMAIN 13749..13833 FT /note="Ig-like 94" FT DOMAIN 13927..14012 FT /note="Ig-like 95" FT DOMAIN 14019..14114 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14120..14215 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14221..14316 FT /note="Fibronectin type-III 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14417..14513 FT /note="Fibronectin type-III 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14517..14614 FT /note="Fibronectin type-III 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14615..14708 FT /note="Ig-like 96" FT DOMAIN 14713..14806 FT /note="Fibronectin type-III 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14812..14907 FT /note="Fibronectin type-III 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 14913..15007 FT /note="Fibronectin type-III 8" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15010..15107 FT /note="Fibronectin type-III 9" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15113..15207 FT /note="Fibronectin type-III 10" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15214..15310 FT /note="Fibronectin type-III 11" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15314..15402 FT /note="Ig-like 97" FT DOMAIN 15409..15503 FT /note="Fibronectin type-III 12" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15509..15604 FT /note="Fibronectin type-III 13" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15608..15724 FT /note="Ig-like 98" FT DOMAIN 15731..15826 FT /note="Fibronectin type-III 14" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15832..15926 FT /note="Fibronectin type-III 15" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 15929..16025 FT /note="Fibronectin type-III 16" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16029..16119 FT /note="Ig-like 99" FT DOMAIN 16126..16218 FT /note="Fibronectin type-III 17" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16224..16318 FT /note="Fibronectin type-III 18" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16322..16420 FT /note="Ig-like 100" FT DOMAIN 16427..16522 FT /note="Fibronectin type-III 19" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16528..16628 FT /note="Fibronectin type-III 20" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16634..16734 FT /note="Fibronectin type-III 21" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16727..16834 FT /note="Ig-like 101" FT DOMAIN 16841..16934 FT /note="Fibronectin type-III 22" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 16941..17041 FT /note="Fibronectin type-III 23" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17044..17139 FT /note="Ig-like 102" FT DOMAIN 17147..17240 FT /note="Fibronectin type-III 24" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17246..17345 FT /note="Fibronectin type-III 25" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17348..17445 FT /note="Fibronectin type-III 26" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17449..17536 FT /note="Ig-like 103" FT DOMAIN 17545..17640 FT /note="Fibronectin type-III 27" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17646..17741 FT /note="Fibronectin type-III 28" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17745..17834 FT /note="Ig-like 104" FT DOMAIN 17842..17935 FT /note="Fibronectin type-III 29" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 17941..18036 FT /note="Fibronectin type-III 30" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18042..18139 FT /note="Fibronectin type-III 31" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18143..18228 FT /note="Ig-like 105" FT DOMAIN 18239..18333 FT /note="Fibronectin type-III 32" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18339..18431 FT /note="Fibronectin type-III 33" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18435..18526 FT /note="Ig-like 106" FT DOMAIN 18533..18632 FT /note="Fibronectin type-III 34" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18633..18727 FT /note="Fibronectin type-III 35" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18733..18829 FT /note="Fibronectin type-III 36" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 18833..18924 FT /note="Ig-like 107" FT DOMAIN 18931..19025 FT /note="Fibronectin type-III 37" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19030..19124 FT /note="Fibronectin type-III 38" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19128..19219 FT /note="Ig-like 108" FT DOMAIN 19226..19321 FT /note="Fibronectin type-III 39" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19325..19420 FT /note="Fibronectin type-III 40" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19426..19527 FT /note="Fibronectin type-III 41" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19531..19617 FT /note="Ig-like 109" FT DOMAIN 19628..19722 FT /note="Fibronectin type-III 42" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19728..19823 FT /note="Fibronectin type-III 43" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 19826..19914 FT /note="Ig-like 110" FT DOMAIN 19921..20017 FT /note="Fibronectin type-III 44" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20018..20116 FT /note="Fibronectin type-III 45" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20119..20217 FT /note="Fibronectin type-III 46" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20220..20311 FT /note="Ig-like 111" FT DOMAIN 20318..20411 FT /note="Fibronectin type-III 47" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20417..20512 FT /note="Fibronectin type-III 48" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20518..20613 FT /note="Fibronectin type-III 49" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20716..20813 FT /note="Fibronectin type-III 50" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20814..20908 FT /note="Fibronectin type-III 51" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 20893..20996 FT /note="Ig-like 112" FT DOMAIN 21006..21101 FT /note="Fibronectin type-III 52" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21105..21200 FT /note="Fibronectin type-III 53" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21203..21299 FT /note="Fibronectin type-III 54" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21303..21395 FT /note="Ig-like 113" FT DOMAIN 21402..21495 FT /note="Fibronectin type-III 55" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21501..21596 FT /note="Fibronectin type-III 56" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21602..21697 FT /note="Fibronectin type-III 57" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21701..21793 FT /note="Ig-like 114" FT DOMAIN 21797..21891 FT /note="Fibronectin type-III 58" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21894..21986 FT /note="Fibronectin type-III 59" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 21990..22083 FT /note="Ig-like 115" FT DOMAIN 22088..22182 FT /note="Fibronectin type-III 60" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22188..22283 FT /note="Fibronectin type-III 61" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22286..22382 FT /note="Fibronectin type-III 62" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22386..22477 FT /note="Ig-like 116" FT DOMAIN 22484..22578 FT /note="Fibronectin type-III 63" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22584..22679 FT /note="Fibronectin type-III 64" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22685..22781 FT /note="Fibronectin type-III 65" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22785..22874 FT /note="Ig-like 117" FT DOMAIN 22881..22976 FT /note="Fibronectin type-III 66" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 22978..23071 FT /note="Fibronectin type-III 67" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23075..23163 FT /note="Ig-like 118" FT DOMAIN 23170..23264 FT /note="Fibronectin type-III 68" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23270..23364 FT /note="Fibronectin type-III 69" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23368..23463 FT /note="Fibronectin type-III 70" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23468..23555 FT /note="Ig-like 119" FT DOMAIN 23566..23660 FT /note="Fibronectin type-III 71" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23666..23761 FT /note="Fibronectin type-III 72" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23767..23863 FT /note="Fibronectin type-III 73" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 23867..23954 FT /note="Ig-like 120" FT DOMAIN 23963..24057 FT /note="Fibronectin type-III 74" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24060..24153 FT /note="Fibronectin type-III 75" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24157..24241 FT /note="Ig-like 121" FT DOMAIN 24252..24346 FT /note="Fibronectin type-III 76" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24352..24446 FT /note="Fibronectin type-III 77" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24450..24546 FT /note="Fibronectin type-III 78" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24550..24641 FT /note="Ig-like 122" FT DOMAIN 24648..24742 FT /note="Fibronectin type-III 79" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24748..24843 FT /note="Fibronectin type-III 80" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24849..24945 FT /note="Fibronectin type-III 81" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 24949..25038 FT /note="Ig-like 123" FT DOMAIN 25045..25139 FT /note="Fibronectin type-III 82" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25142..25235 FT /note="Fibronectin type-III 83" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25239..25325 FT /note="Ig-like 124" FT DOMAIN 25335..25428 FT /note="Fibronectin type-III 84" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25434..25529 FT /note="Fibronectin type-III 85" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25532..25627 FT /note="Fibronectin type-III 86" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25632..25722 FT /note="Ig-like 125" FT DOMAIN 25731..25825 FT /note="Fibronectin type-III 87" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25831..25926 FT /note="Fibronectin type-III 88" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 25932..26028 FT /note="Fibronectin type-III 89" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26032..26121 FT /note="Ig-like 126" FT DOMAIN 26128..26222 FT /note="Fibronectin type-III 90" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26225..26318 FT /note="Fibronectin type-III 91" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26322..26410 FT /note="Ig-like 127" FT DOMAIN 26417..26510 FT /note="Fibronectin type-III 92" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26516..26611 FT /note="Fibronectin type-III 93" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26614..26710 FT /note="Fibronectin type-III 94" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26714..26801 FT /note="Ig-like 128" FT DOMAIN 26812..26906 FT /note="Fibronectin type-III 95" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 26912..27007 FT /note="Fibronectin type-III 96" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27013..27107 FT /note="Fibronectin type-III 97" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27101..27196 FT /note="Ig-like 129" FT DOMAIN 27205..27296 FT /note="Fibronectin type-III 98" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27302..27392 FT /note="Fibronectin type-III 99" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27499..27593 FT /note="Fibronectin type-III 100" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27599..27694 FT /note="Fibronectin type-III 101" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27697..27793 FT /note="Fibronectin type-III 102" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27797..27888 FT /note="Ig-like 130" FT DOMAIN 27895..27989 FT /note="Fibronectin type-III 103" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 27995..28090 FT /note="Fibronectin type-III 104" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28096..28192 FT /note="Fibronectin type-III 105" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28196..28286 FT /note="Ig-like 131" FT DOMAIN 28295..28389 FT /note="Fibronectin type-III 106" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28392..28484 FT /note="Fibronectin type-III 107" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28488..28577 FT /note="Ig-like 132" FT DOMAIN 28583..28680 FT /note="Fibronectin type-III 108" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28686..28781 FT /note="Fibronectin type-III 109" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28784..28879 FT /note="Fibronectin type-III 110" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 28882..28974 FT /note="Ig-like 133" FT DOMAIN 28979..29071 FT /note="Fibronectin type-III 111" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29081..29177 FT /note="Fibronectin type-III 112" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29180..29278 FT /note="Fibronectin type-III 113" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29282..29367 FT /note="Ig-like 134" FT DOMAIN 29378..29473 FT /note="Fibronectin type-III 114" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29475..29568 FT /note="Fibronectin type-III 115" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29568..29663 FT /note="Ig-like 135" FT DOMAIN 29670..29764 FT /note="Fibronectin type-III 116" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29770..29865 FT /note="Fibronectin type-III 117" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29868..29967 FT /note="Fibronectin type-III 118" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 29971..30059 FT /note="Ig-like 136" FT DOMAIN 30070..30163 FT /note="Fibronectin type-III 119" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30169..30265 FT /note="Fibronectin type-III 120" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30271..30367 FT /note="Fibronectin type-III 121" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30371..30460 FT /note="Ig-like 137" FT DOMAIN 30467..30561 FT /note="Fibronectin type-III 122" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30564..30658 FT /note="Fibronectin type-III 123" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30663..30754 FT /note="Ig-like 138" FT DOMAIN 30761..30855 FT /note="Fibronectin type-III 124" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30861..30956 FT /note="Fibronectin type-III 125" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 30962..31058 FT /note="Fibronectin type-III 126" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31061..31150 FT /note="Ig-like 139" FT DOMAIN 31158..31254 FT /note="Fibronectin type-III 127" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31258..31354 FT /note="Fibronectin type-III 128" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31360..31455 FT /note="Fibronectin type-III 129" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31460..31548 FT /note="Ig-like 140" FT DOMAIN 31653..31748 FT /note="Fibronectin type-III 130" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31754..31849 FT /note="Fibronectin type-III 131" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 31855..31945 FT /note="Ig-like 141" FT DOMAIN 31955..32046 FT /note="Ig-like 142" FT DOMAIN 32051..32144 FT /note="Fibronectin type-III 132" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 32178..32432 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 32496..32584 FT /note="Ig-like 143" FT DOMAIN 32617..32710 FT /note="Ig-like 144" FT DOMAIN 32722..32811 FT /note="Ig-like 145" FT DOMAIN 33301..33391 FT /note="Ig-like 146" FT DOMAIN 33488..33576 FT /note="Ig-like 147" FT DOMAIN 33645..33732 FT /note="Ig-like 148" FT DOMAIN 33779..33867 FT /note="Ig-like 149" FT DOMAIN 33963..34052 FT /note="Ig-like 150" FT DOMAIN 34061..34149 FT /note="Ig-like 151" FT DOMAIN 34256..34344 FT /note="Ig-like 152" FT REGION 244..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 253..341 FT /note="ZIS1" FT REGION 333..356 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 859..886 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1408..1443 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1410..1440 FT /note="ZIS5" FT REGION 4241..4272 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 9920..9945 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10039..10070 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10087..10109 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10207..10280 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10314..10361 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10412..10457 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10499..10566 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10583..10617 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10661..10743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 10882..11102 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11158..11193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11362..11636 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 11666..12032 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14216..14236 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 14891..14921 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 15911..15939 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 16614..16654 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18614..18637 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 18716..18743 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 19304..19331 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 27090..27110 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 31238..31267 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33213..33256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33432..33463 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33584..33638 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 33749..33777 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 529..561 FT /evidence="ECO:0000255" FT COILED 2025..2052 FT /evidence="ECO:0000255" FT COILED 3462..3487 FT /evidence="ECO:0000255" FT COILED 9534..9577 FT /evidence="ECO:0000255" FT COMPBIAS 1408..1419 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 4245..4257 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 9920..9938 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10041..10052 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10058..10070 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10087..10101 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10207..10224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10245..10265 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10329..10347 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10349..10360 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10418..10430 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10440..10457 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10684..10701 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10702..10720 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10721..10737 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10882..10944 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10961..10972 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 10989..11009 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11030..11101 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11164..11190 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11388..11416 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11438..11453 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11454..11465 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11466..11479 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11496..11509 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11510..11521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11538..11549 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11550..11563 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11580..11591 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11592..11613 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11614..11626 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11678..11696 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11704..11715 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11730..11745 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11768..11803 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11816..11825 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11834..11846 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11854..11875 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11882..11900 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11927..11936 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11948..11958 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11960..11971 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11972..11981 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11982..11995 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 11996..12008 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 14223..14236 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 19318..19331 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 31252..31262 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33231..33242 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33439..33450 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33594..33604 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33625..33634 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 33749..33771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 32298 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32184..32192 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 32207 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 267 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 6920 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 9122 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 11503 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12007 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 12009 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 12022 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 30443 FT /note="Phosphothreonine" FT /evidence="ECO:0000250" FT MOD_RES 32341 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:9804419" FT MOD_RES 33245 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33247 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33602 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT MOD_RES 33614 FT /note="Phosphoserine" FT /evidence="ECO:0000250" FT DISULFID 964..1015 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 1724..1777 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2109..2134 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:11525170" FT DISULFID 2196..2246 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 3259..3311 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4404..4455 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4499..4550 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4592..4643 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4686..4737 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 4779..4830 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5061..5112 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5248..5299 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5623..5674 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5810..5861 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 5903..5954 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6185..6236 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6372..6423 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6465..6516 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 6748..6799 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7027..7078 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7123..7174 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7219..7270 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7313..7364 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7406..7457 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7689..7740 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 7968..8019 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8064..8115 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8160..8211 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8254..8305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8347..8398 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8630..8681 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 8909..8960 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9005..9056 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9101..9152 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9294..9345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 9693..9743 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12067..12117 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12611..12660 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 12966..13016 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13233..13283 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13322..13372 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13411..13461 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 13771..13821 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 31481..31532 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 32516..32568 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 33664..33718 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 555..646 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8937992" FT /id="VSP_019138" FT VAR_SEQ 556..601 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019139" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPKVQALDRQSSGKDVRESTKSQAVADSSFTKEESKISQKEI FT KSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTG FT EAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQF FT LTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045935" FT VAR_SEQ 3434 FT /note="E -> EGFSKFEENTSNSQWHVSLSVSFKKEPLGQKPSFIQPLSSLRVHNGE FT TVRFHARVSGIPKPEIQWFHNQQLILPTKDVVFHFEESTGMALMLIVDAYSEHAGQYSC FT KAANSAGEATCAATLTVTPK (in isoform 8 and isoform 10)" FT /evidence="ECO:0000305" FT /id="VSP_019140" FT VAR_SEQ 3434 FT /note="E -> EVQALDRQSSGKDVRESAKSQAVADSSFTKEESKISQKEIKSFQGSS FT YEYEVQVFESVSQSSIHTAASVQDTQLCHTASLSQIAESTELSKECAKESTGEAPKIFL FT HLQDVTVKCGDTAQFLCVLKDDSFIDVTWTHEGAKIEESERLKQSQNGNIQFLTICNVQ FT LVDQGLYSCIVHNDCGERTTSAVLSVEG (in isoform 9)" FT /evidence="ECO:0000305" FT /id="VSP_042903" FT VAR_SEQ 3435..3645 FT /note="APESILHERIEQEIEMEMKEFSSSFLSAEEEGLHSAELQLSKINETLELLSE FT SPVYPTKFDSEKEGTGPIFIKEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTP FT SADYKFVFDGDDHSLIILFTKLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTET FT ESAVAKSLEKLGGPCPPHFLKELKPIRCAQGLPAIFEYTVV -> VQALDRQSSGKDVR FT ESTKSQAVADSSFTKEESKISQKEIKSFQGSSYEYEVQVFESVSQSSIHTAASVQDTQL FT CHTASLSQIAESTELSKECAKESTGEAPKIFLHLQDVTVKCGDTAQFLCVLKDDSFIDV FT TWTHEGAKIEESERLKQSQNGNIQFLTICNVQLVDQGLYSCIVHNDCGERTTSAVLSVE FT GAPESILHERIEQEIEMEMK (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019141" FT VAR_SEQ 3454..4380 FT /note="Missing (in isoform 4 and isoform 11)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019142" FT VAR_SEQ 3455..5604 FT /note="FSSSFLSAEEEGLHSAELQLSKINETLELLSESPVYPTKFDSEKEGTGPIFI FT KEVSNADISMGDVATLSVTVIGIPKPKIQWFFNGVLLTPSADYKFVFDGDDHSLIILFT FT KLEDEGEYTCMASNDYGKTICSAYLKINSKGEGHKDTETESAVAKSLEKLGGPCPPHFL FT KELKPIRCAQGLPAIFEYTVVGEPAPTVTWFKENKQLCTSVYYTIIHNPNGSGTFIVND FT PQREDSGLYICKAENMLGESTCAAELLVLLEDTDMTDTPCKAKSTPEAPEDFPQTPLKG FT PAVEALDSEQEIATFVKDTILKAALITEENQQLSYEHIAKANELSSQLPLGAQELQSIL FT EQDKLTPESTREFLCINGSIHFQPLKEPSPNLQLQIVQSQKTFSKEGILMPEEPETQAV FT LSDTEKIFPSAMSIEQINSLTVEPLKTLLAEPEGNYPQSSIEPPMHSYLTSVAEEVLSP FT KEKTVSDTNREQRVTLQKQEAQSALILSQSLAEGHVESLQSPDVMISQVNYEPLVPSEH FT SCTEGGKILIESANPLENAGQDSAVRIEEGKSLRFPLALEEKQVLLKEEHSDNVVMPPD FT QIIESKREPVAIKKVQEVQGRDLLSKESLLSGIPEEQRLNLKIQICRALQAAVASEQPG FT LFSEWLRNIEKVEVEAVNITQEPRHIMCMYLVTSAKSVTEEVTIIIEDVDPQMANLKME FT LRDALCAIIYEEIDILTAEGPRIQQGAKTSLQEEMDSFSGSQKVEPITEPEVESKYLIS FT TEEVSYFNVQSRVKYLDATPVTKGVASAVVSDEKQDESLKPSEEKEESSSESGTEEVAT FT VKIQEAEGGLIKEDGPMIHTPLVDTVSEEGDIVHLTTSITNAKEVNWYFENKLVPSDEK FT FKCLQDQNTYTLVIDKVNTEDHQGEYVCEALNDSGKTATSAKLTVVKRAAPVIKRKIEP FT LEVALGHLAKFTCEIQSAPNVRFQWFKAGREIYESDKCSIRSSKYISSLEILRTQVVDC FT GEYTCKASNEYGSVSCTATLTVTEAYPPTFLSRPKSLTTFVGKAAKFICTVTGTPVIET FT IWQKDGAALSPSPNWRISDAENKHILELSNLTIQDRGVYSCKASNKFGADICQAELIII FT DKPHFIKELEPVQSAINKKVHLECQVDEDRKVTVTWSKDGQKLPPGKDYKICFEDKIAT FT LEIPLAKLKDSGTYVCTASNEAGSSSCSATVTVREPPSFVKKVDPSYLMLPGESARLHC FT KLKGSPVIQVTWFKNNKELSESNTVRMYFVNSEAILDITDVKVEDSGSYSCEAVNDVGS FT DSCSTEIVIKEPPSFIKTLEPADIVRGTNALLQCEVSGTGPFEISWFKDKKQIRSSKKY FT RLFSQKSLVCLEIFSFNSADVGEYECVVANEVGKCGCMATHLLKEPPTFVKKVDDLIAL FT GGQTVTLQAAVRGSEPISVTWMKGQEVIREDGKIKMSFSNGVAVLIIPDVQISFGGKYT FT CLAENEAGSQTSVGELIVKEPAKIIERAELIQVTAGDPATLEYTVAGTPELKPKWYKDG FT RPLVASKKYRISFKNNVAQLKFYSAELHDSGQYTFEISNEVGSSSCETTFTVLDRDIAP FT FFTKPLRNVDSVVNGTCRLDCKIAGSLPMRVSWFKDGKEIAASDRYRIAFVEGTASLEI FT IRVDMNDAGNFTCRATNSVGSKDSSGALIVQEPPSFVTKPGSKDVLPGSAVCLKSTFQG FT STPLTIRWFKGNKELVSGGSCYITKEALESSLELYLVKTSDSGTYTCKVSNVAGGVECS FT ANLFVKEPATFVEKLEPSQLLKKGDATQLACKVTGTPPIKITWFANDREIKESSKHRMS FT FVESTAVLRLTDVGIEDSGEYMCEAQNEAGSDHCSSIVIVKESPYFTKEFKPIEVLKEY FT DVMLLAEVAGTPPFEITWFKDNTILRSGRKYKTFIQDHLVSLQILKFVAADAGEYQCRV FT TNEVGSSICSARVTLREPPSFIKKIESTSSLRGGTAAFQATLKGSLPITVTWLKDSDEI FT TEDDNIRMTFENNVASLYLSGIEVKHDGKYVCQAKNDAGIQRCSALLSVKEPATITEEA FT VSIDVTQGDPATLQVKFSGTKEITAKWFKDGQELTLGSKYKISVTDTVSILKIISTEKK FT DSGEYTFEVQNDVGRSSCKARINVLDLIIPPSF -> LFSEGESEHSERDTRDAFSDSE FT DIDHKSMAAKRYASRISSTSSWPEYFKPSFTQKLTFKYVLEGEPVVFTCRLIACPTPEM FT TWFHNNRPIPTGLRRIIKAESDLHHHSSSLEIKRVQDRDSGSYRLLAINSEGSAESTAS FT LLVIQKGQDEKYLEFLKRAERTHENVEALVERGEDRIKVDLRFTGSPFNKKQDVEQKGM FT MRTIHFKTMSSAKKTDYMYDEEYLESKSDIRGWLNVGESFLDKETKVKLQRLREARKTL FT MEKKKLSLLDTSSEISSRTLRSEASDKDILFSREDMKIRSMSDLAESYKVDHSAESIVQ FT NPHALSNQMDQNIESEELPTSFQTIVDEEIFQTEIRMSQEALVKESLPKDHLYGEILVN FT ENTQARGQLEEIMANTTIGESSTYITNVCEKEEVYETPENVSQAITPHASESFGTLVNV FT EESEEIASERIKKDDLRELQLSASTRIDEFKTEQKEENMRFFENSFRKRPQRCPPSFLQ FT EIESQEVYEGDSCNFVCHFQGYPQPIVTWYNNDMPIPRNQNFIIHSLENYSILTLSSVH FT HQNEGSITCVLFNQYGTVKTTSMLKVKAKQKHDVKAHKVPVFHDYLDEEEELALVFDQA FT KGAHPSMSQEGQTNLHLLKTNPPVPPSGDTELLSFPVEIQVTAATPIPEQDKESKEVFQ FT TEELEPKAMPQDQVTQSPKHRFVFLSDITNEPPKMLQEMPKHARCREGDSIILECLISG FT EPQPVVTWFQNGVLLKQNQKFQFEEVNCSHQLYIKDVNSQDSGKYKCVAENNSGAVESV FT SDLTVEPVTYRENSQFENIGEIYGKYSRDQQLQDQGESVRAHFYDYPAGPFTPWTNVKE FT YSVRDYFQSLETIEQIDQKEQVRCIPSREKIPRFVHGASRTIKISKPIRAEFIQCQAEG FT KERHVSEKSKLHQAEGTVYPFVDDFSDVTIKKEIRNNFGKLGRSEKENVQECAQSDYLP FT NIHSERISDSYNTKDSSAIVYEESLGEEIHYPGKKVKHRIIEFEKLHVEKGVLEKRPTR FT TSIVNPPQKKIDDKAFSLKQRESRSSNLNANMYQAEKMSPNTESDSSNIAINLKLLSSQ FT THKEFDAQEREQQEKISLIDKPAISKRAEHESPITFDLKQFHTQIKHTDVKFQELDSGQ FT PEEAYFKIQHPADTENIVFDLKQMYSHIGDPALEFQGQETREQQEIHYKEKIPSPETLQ FT PDTHNISKSVQNNVFASQEISSSQELSNRTMVEKSSIDENSISLEKEVRHVQEQNLDIL FT KTDLSLKSFSEEIYSESCALLPTSSADIEETDLSEKSCPLENGGRSSISHLKKAASEEK FT PLGVGEMEEECTLEPELAAFPKQDGGTQEYTDATLEDHRGDVQEADTLHRQLSLSQCFP FT LLMTEEQQNPGEQISTNIHASGEEKCYEEVQVQNEASFSTLEGEMIETSFSQNIPKLDE FT AHTTEAAESETSLTQYLLAAGKREVPETKDTRDQAKLVQSESITSMEVEEVTFNTVYEY FT YNQKQESLGRPLSPESDISIGVGSTTSEEISELDQFYTPPSSVEYFESPKSPDLYFNPS FT DITKQSSIHSGGETVERYSTPLGEVAERYSTPSEGEVGERYSTPPGETLERYSTPPGET FT LERYSTPPGETLERYSTPPGETLERYSTPPGETLERYSTPPGEALERYSIPTGGPNPTG FT TFKTYPSKIEREDGTPNEHFYTPTEERGSAYEIWRSDSFGTPNEAIEPKDNEMPPSFIE FT PLTKRKVYENTTLGFIVEVEGLPVPGVKWYRNKSLLEPDERIKMERVGNVCSLEISNIQ FT KGEGGEYMCHAVNIIGEAKSFANVDIMPQEERVVALPPPVTHQHVMEFDLEHTTSSRTP FT SPQEIVLEVELSEKDVKEFEKQVKIVTVPEFTPDHKSMIVSLDVLPFNFVDPNMDSREG FT EDKELKIDLEVFEMPPRFIMPICDFKIPENSDAVFKCSVIGIPTPEVKWYKEYMCIEPD FT NIKYVISEEKGSHTLKIRNVCLSDSATYRCRAVNCVGEAICRGFLTMGDSEIFAVIAKK FT SKVTLSSLMEELVLKSNYTDSFFEFQVVEGPPRFIKGISDCYAPIGTAAYFQCLVRGSP FT RPTVYWYKDGKLVQGRRFTVEESGTGFHNLFITSLVKSDEGEYRCVATNKSGMAESFAA FT LTLT (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019143" FT VAR_SEQ 3646..4380 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_019144" FT VAR_SEQ 4474..11851 FT /note="Missing (in isoform 3, isoform 9 and isoform 10)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7569978" FT /id="VSP_019145" FT VAR_SEQ 5605..34350 FT /note="Missing (in isoform 6)" FT /evidence="ECO:0000305" FT /id="VSP_019146" FT VAR_SEQ 10382..10645 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019147" FT VAR_SEQ 10742..10931 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019148" FT VAR_SEQ 11015..11163 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019149" FT VAR_SEQ 11117 FT /note="I -> VPKKPVPEKKVPVPAPKKVEPPPPPKVPEI (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045929" FT VAR_SEQ 11133 FT /note="E -> EAPPAKVSVVPKKPEPEKKVPPPGLKKAV (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045930" FT VAR_SEQ 11223..11852 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019150" FT VAR_SEQ 11421 FT /note="K -> KAPEVPKKIVPEEKVREAVLKKPEVPPAKVPGMPKKSVQEEKSPIVI FT SEDTEMYIYEASEEAVLEEKVLVTQPQKTKPKLAKVPEPPKKVVPEDKIYVTIPKKRET FT PATKEPDTTRGIFPEVEPPEAIPEIPEHPPTEEFEVFKEVIPEGETPIVKRRKTPSPTV FT PESPREIVPVKETPMAAPLEIEIPPTKAPEAMKEVVPEMKIFEDVPEEPETPRMKTPEA FT PQEIIPAKTVPSKKREPPSVKVPEALQEIVPEKKTLVVPLRKPEVLPDEVPEALREVVP FT EKKVHPPQRAEVVPVKVHEAPKEIIPEKKVSVVPPKKPEVPPVKVPEASKEVIREEKVP FT LAPPKEPEVPPVKVPEPPKEVVPEKKAPVAPPKEPEVPPVKVPEAPKEVVPEKKVPVPP FT PKKPEVPPTKVPEVPKAAVPEKKLPEAIPPKPESPPPE (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045931" FT VAR_SEQ 11450 FT /note="P -> PKVPEAPKEVVLEKKASVAVPKKPEAPRAKVPEAAQEVVPEKKIPKA FT PIKKPEAPAVTVPEVPQEATEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKP FT EAPPATVPEVPQEIVPEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPSAPPKKPEVPP FT V (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045932" FT VAR_SEQ 11507 FT /note="E -> EVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKVPEAPKEVVLEKKASV FT AVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEVPQEAAEKEIPVAPPK FT KPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIVPEKKTLVLPKKPEVP FT PVTVPEAPKEVVLEKKVPSTPPKKPEVPPVKVPEAPKEVVPEKKVPVPPPKKPEVPPTK FT VPEVPKAAVPEKKVPEAIPPKPESPPPEVPEVLPPKEVVPEKKVPVPPAKKPEAPPPKV FT PEAPKEVVLEKKVSVAVPKKPEAPRAKVPEAAQEVVPEKKIPKAPIKKPEAPAVTVPEV FT PQEAAEKEIPVAPPKKPEAPIVPVPEAQEVVPEKKVPKAPPTKPEAPPATVPEVPQEIV FT PEKKTLVLPKKPEVPPVTVPEAPKEVVLEKKVPLAPPKKPEVPPVKVPEAPKEVVPEKK FT VPVTPPKKPEVPPVKVPEAPIEVVPEKKMPLAPPKKPEVPPVKVPEAPKEVVPEKKVPS FT APPKKPEVPPVK (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045933" FT VAR_SEQ 11507 FT /note="E -> EVFEEPEESPSAPPKKPEVPPVR (in isoform 4)" FT /evidence="ECO:0000303|PubMed:7569978" FT /id="VSP_019151" FT VAR_SEQ 11790 FT /note="P -> PKEPEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVT FT KKPEVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKE FT TPPVEEREIEKYIKPEEPEPEPQPEEIPV (in isoform 13)" FT /evidence="ECO:0000305" FT /id="VSP_047142" FT VAR_SEQ 11793 FT /note="P -> PEMPKKVVPVKKVPTVKKPETPAAKVPEVPKKLVPVKKEPVPVTKKP FT EVLPEKVPKVPEKIIPEKEVSVPIPAEPEVPPAEVEETPEEIIYEEKASITIGRKETPP FT VEEREIEKYIKPEEPEPEPQPEEIPVKEP (in isoform 12)" FT /evidence="ECO:0000305" FT /id="VSP_045934" FT VAR_SEQ 11985..12201 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:12785098" FT /id="VSP_019152" FT VARIANT 54 FT /note="V -> M (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs139517732)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026685" FT VARIANT 60 FT /note="D -> Y (in dbSNP:rs35683768)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040078" FT VARIANT 115 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs564777385)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040079" FT VARIANT 279 FT /note="R -> W (in MFM9; disrupts NBR1-binding; FT dbSNP:rs138060032)" FT /evidence="ECO:0000269|PubMed:15802564" FT /id="VAR_026634" FT VARIANT 328 FT /note="R -> C (in dbSNP:rs16866538)" FT /evidence="ECO:0000269|PubMed:11846417, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026686" FT VARIANT 360 FT /note="R -> T (in dbSNP:rs56128843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040080" FT VARIANT 498 FT /note="V -> I (in dbSNP:rs72647851)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040081" FT VARIANT 740 FT /note="R -> L (in CMH9; dbSNP:rs28933405)" FT /evidence="ECO:0000269|PubMed:10462489" FT /id="VAR_026687" FT VARIANT 743 FT /note="A -> V (in CMD1G; affects interaction with TCAP/ FT telethonin; dbSNP:rs267607157)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026688" FT VARIANT 799 FT /note="T -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149061352)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040082" FT VARIANT 811 FT /note="T -> I (in dbSNP:rs35813871)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040083" FT VARIANT 922 FT /note="R -> H (in dbSNP:rs56046320)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040084" FT VARIANT 937 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040085" FT VARIANT 976 FT /note="W -> R (in CMD1G; dbSNP:rs267607155)" FT /evidence="ECO:0000269|PubMed:11788824" FT /id="VAR_026689" FT VARIANT 1081 FT /note="A -> T (in dbSNP:rs55914517)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040086" FT VARIANT 1137 FT /note="G -> R (in dbSNP:rs72647870)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040087" FT VARIANT 1201 FT /note="K -> E (in dbSNP:rs10497520)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040088" FT VARIANT 1202 FT /note="V -> A (in dbSNP:rs150667217)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040089" FT VARIANT 1249 FT /note="S -> L (in dbSNP:rs1552280)" FT /id="VAR_056081" FT VARIANT 1295 FT /note="S -> L (in dbSNP:rs1552280)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040090" FT VARIANT 1345 FT /note="G -> D (in dbSNP:rs36021856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040091" FT VARIANT 1347 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267599092)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040092" FT VARIANT 1350 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs539470256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040093" FT VARIANT 1353 FT /note="V -> L (in dbSNP:rs36062108)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040094" FT VARIANT 1393 FT /note="I -> V (in dbSNP:rs16866531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040095" FT VARIANT 1416 FT /note="R -> C (in dbSNP:rs72647875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040096" FT VARIANT 1441 FT /note="R -> P (in dbSNP:rs72647876)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040097" FT VARIANT 1544 FT /note="I -> V (in dbSNP:rs72647877)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040098" FT VARIANT 1572 FT /note="R -> Q (in dbSNP:rs12476289)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040099" FT VARIANT 1658 FT /note="R -> G (in dbSNP:rs56270960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040100" FT VARIANT 1664 FT /note="R -> Q (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs375029799)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040101" FT VARIANT 1692 FT /note="G -> D (in a lung squamous cell carcinoma sample; FT somatic mutation; dbSNP:rs370004591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040102" FT VARIANT 1744 FT /note="P -> L (in dbSNP:rs75686037)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040103" FT VARIANT 1772 FT /note="S -> G (in dbSNP:rs150725992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040104" FT VARIANT 1907 FT /note="T -> I (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040105" FT VARIANT 1998 FT /note="R -> H (in dbSNP:rs144135510)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040106" FT VARIANT 2107 FT /note="P -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040107" FT VARIANT 2118 FT /note="I -> T (in dbSNP:rs56404770)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040108" FT VARIANT 2164 FT /note="A -> T (in dbSNP:rs56285559)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040109" FT VARIANT 2240 FT /note="D -> Y" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040110" FT VARIANT 2392 FT /note="G -> S (in dbSNP:rs4894048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040111" FT VARIANT 2432 FT /note="L -> F (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs571572592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040112" FT VARIANT 2610 FT /note="M -> I (in dbSNP:rs56142888)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040113" FT VARIANT 2771 FT /note="I -> M (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs576644663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040114" FT VARIANT 2823 FT /note="V -> F (in dbSNP:rs33917087)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040115" FT VARIANT 2831 FT /note="S -> N (in dbSNP:rs2306636)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:17344846" FT /id="VAR_040116" FT VARIANT 2930 FT /note="V -> I (in dbSNP:rs56373393)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040117" FT VARIANT 2963 FT /note="T -> P (in dbSNP:rs200875815)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074293" FT VARIANT 3026 FT /note="N -> I (in dbSNP:rs11900987)" FT /id="VAR_056082" FT VARIANT 3154 FT /note="K -> R (in dbSNP:rs4893853)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040118" FT VARIANT 3191 FT /note="Q -> E (in dbSNP:rs33997263)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040119" FT VARIANT 3238 FT /note="P -> L (in a bladder carcinoma sample; somatic FT mutation; dbSNP:rs397517792)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040120" FT VARIANT 3250 FT /note="V -> G (in dbSNP:rs55634230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040121" FT VARIANT 3261 FT /note="V -> M (in dbSNP:rs2291311)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040122" FT VARIANT 3367 FT /note="R -> Q (in dbSNP:rs34819099)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040123" FT VARIANT 3419 FT /note="S -> N (in dbSNP:rs2291310)" FT /evidence="ECO:0000269|PubMed:7569978" FT /id="VAR_056083" FT VARIANT 3482 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040124" FT VARIANT 3491 FT /note="P -> S (in dbSNP:rs2627037)" FT /evidence="ECO:0000269|PubMed:10850961, FT ECO:0000269|PubMed:11717165, ECO:0000269|PubMed:7569978" FT /id="VAR_040125" FT VARIANT 3570 FT /note="E -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040126" FT VARIANT 3590 FT /note="L -> V (in dbSNP:rs55853696)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040127" FT VARIANT 3637 FT /note="P -> S (in dbSNP:rs757223770)" FT /id="VAR_056084" FT VARIANT 3762 FT /note="I -> V (in dbSNP:rs34070843)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040128" FT VARIANT 3799 FT /note="S -> Y (in CMD1G)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026690" FT VARIANT 3877 FT /note="I -> F (in dbSNP:rs34618570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040129" FT VARIANT 3965 FT /note="I -> L (in dbSNP:rs56244420)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040130" FT VARIANT 4084 FT /note="R -> Q (in dbSNP:rs200431386)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026691" FT VARIANT 4215 FT /note="T -> P (in dbSNP:rs2562829)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:11846417, ECO:0000269|PubMed:17344846" FT /id="VAR_026635" FT VARIANT 4238 FT /note="G -> W (in dbSNP:rs56030296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040131" FT VARIANT 4283 FT /note="L -> F (in dbSNP:rs1883085)" FT /evidence="ECO:0000269|PubMed:10051295, FT ECO:0000269|PubMed:10850961, ECO:0000269|PubMed:11717165, FT ECO:0000269|PubMed:17344846" FT /id="VAR_026636" FT VARIANT 4291 FT /note="I -> T (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040132" FT VARIANT 4303 FT /note="G -> D (in dbSNP:rs55857742)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040133" FT VARIANT 4427 FT /note="D -> E (in dbSNP:rs55906845)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040134" FT VARIANT 4465 FT /note="S -> N (in CMD1G; dbSNP:rs281864908)" FT /evidence="ECO:0000269|PubMed:11846417" FT /id="VAR_026692" FT VARIANT 8288 FT /note="A -> V (in dbSNP:rs16866412)" FT /id="VAR_056085" FT VARIANT 8474 FT /note="I -> T (in dbSNP:rs4893852)" FT /id="VAR_056086" FT VARIANT 12310 FT /note="G -> E (in dbSNP:rs55723264)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040135" FT VARIANT 12383 FT /note="H -> R (in dbSNP:rs2288563)" FT /evidence="ECO:0000269|PubMed:10850961" FT /id="VAR_040136" FT VARIANT 12469 FT /note="V -> A (in dbSNP:rs34706299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040137" FT VARIANT 12642 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs199684560)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040138" FT VARIANT 12657 FT /note="E -> K (in a Wilms tumor; somatic mutation; FT dbSNP:rs778634417)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040139" FT VARIANT 12679 FT /note="K -> E (in dbSNP:rs6723526)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040140" FT VARIANT 12720 FT /note="S -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040141" FT VARIANT 12798 FT /note="R -> C (in dbSNP:rs200914097)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040142" FT VARIANT 13049 FT /note="E -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040143" FT VARIANT 13083 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1458591077)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040144" FT VARIANT 13096 FT /note="R -> L (in dbSNP:rs373298007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040145" FT VARIANT 13099 FT /note="Q -> R (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040146" FT VARIANT 13297 FT /note="V -> A (in dbSNP:rs571522834)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040147" FT VARIANT 13399 FT /note="I -> M (in dbSNP:rs74580375)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040148" FT VARIANT 13418 FT /note="A -> T (in dbSNP:rs144668626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040149" FT VARIANT 13428 FT /note="E -> V (in dbSNP:rs114331773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040150" FT VARIANT 13430 FT /note="I -> T (in dbSNP:rs184078045)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040151" FT VARIANT 13434 FT /note="R -> K (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040152" FT VARIANT 13469 FT /note="D -> N (in dbSNP:rs17354992)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040153" FT VARIANT 13495 FT /note="K -> N (in dbSNP:rs72677225)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040154" FT VARIANT 13785 FT /note="N -> S (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040155" FT VARIANT 13870 FT /note="Q -> H (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040156" FT VARIANT 14109 FT /note="V -> I (in dbSNP:rs72677232)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040157" FT VARIANT 14131 FT /note="R -> Q (in dbSNP:rs72677233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040158" FT VARIANT 14208 FT /note="P -> T (in dbSNP:rs146181477)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040159" FT VARIANT 14728 FT /note="L -> V (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040160" FT VARIANT 14750 FT /note="R -> Q (in dbSNP:rs200944827)" FT /evidence="ECO:0000269|PubMed:25173926" FT /id="VAR_074294" FT VARIANT 14999 FT /note="S -> T (in dbSNP:rs55663050)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040161" FT VARIANT 15021 FT /note="N -> T (in dbSNP:rs36043230)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040162" FT VARIANT 15520 FT /note="A -> V (in dbSNP:rs16866412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040163" FT VARIANT 15555 FT /note="R -> I (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs751398376)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040164" FT VARIANT 15620 FT /note="R -> Q (in dbSNP:rs201825412)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040165" FT VARIANT 15629 FT /note="S -> I (in dbSNP:rs200650668)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040166" FT VARIANT 15635 FT /note="Y -> C (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040167" FT VARIANT 15700 FT /note="R -> Q (in dbSNP:rs370390570)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040168" FT VARIANT 15705 FT /note="L -> P (in dbSNP:rs755155531)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040169" FT VARIANT 15837 FT /note="I -> M (in dbSNP:rs554368924)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040170" FT VARIANT 16046 FT /note="G -> V (in dbSNP:rs780672348)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069432" FT VARIANT 16058 FT /note="R -> H (in dbSNP:rs72646808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040171" FT VARIANT 16067 FT /note="K -> I (in dbSNP:rs2303832)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040172" FT VARIANT 16090 FT /note="I -> T (in dbSNP:rs72646809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040173" FT VARIANT 16195 FT /note="R -> H (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs373526624)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040174" FT VARIANT 16409 FT /note="R -> C (in dbSNP:rs55734111)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040175" FT VARIANT 16424 FT /note="R -> P (in dbSNP:rs375895183)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040176" FT VARIANT 16575 FT /note="V -> M (in dbSNP:rs3813243)" FT /id="VAR_056087" FT VARIANT 16629 FT /note="I -> M (in dbSNP:rs55809450)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040177" FT VARIANT 16877 FT /note="K -> R (in dbSNP:rs72646823)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040178" FT VARIANT 17060 FT /note="N -> D (in dbSNP:rs1001238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040179" FT VARIANT 17637 FT /note="I -> V (in dbSNP:rs56025724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040180" FT VARIANT 17838 FT /note="R -> H (in dbSNP:rs2288569)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040181" FT VARIANT 17866 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040182" FT VARIANT 17906 FT /note="G -> E (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs374713701)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040183" FT VARIANT 18094 FT /note="E -> A (in dbSNP:rs769852851)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040184" FT VARIANT 18109 FT /note="G -> S (in dbSNP:rs200732032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040185" FT VARIANT 18164 FT /note="R -> T (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040186" FT VARIANT 18221 FT /note="P -> L (in dbSNP:rs16866406)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040187" FT VARIANT 18222 FT /note="A -> T" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040188" FT VARIANT 18726 FT /note="R -> Q (in dbSNP:rs141973925)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040189" FT VARIANT 18835 FT /note="V -> A (in a breast infiltrating ductal carcinoma FT sample; somatic mutation; dbSNP:rs1336054298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040190" FT VARIANT 18881 FT /note="R -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs1204056923)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040191" FT VARIANT 18939 FT /note="N -> S (in dbSNP:rs1470758075)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040192" FT VARIANT 19000 FT /note="R -> Q (in dbSNP:rs199895260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040193" FT VARIANT 19060 FT /note="L -> Q (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs1383995916)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040194" FT VARIANT 19091 FT /note="R -> K (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040195" FT VARIANT 19224 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040196" FT VARIANT 19367 FT /note="T -> I (in dbSNP:rs72646850)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040197" FT VARIANT 19392 FT /note="E -> K (in a lung neuroendocrine carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040198" FT VARIANT 19480 FT /note="A -> S (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040199" FT VARIANT 19495 FT /note="D -> G (in dbSNP:rs773075736)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040200" FT VARIANT 19665 FT /note="R -> H (in dbSNP:rs202240487)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040201" FT VARIANT 19762 FT /note="T -> I (in dbSNP:rs2042996)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040202" FT VARIANT 19947 FT /note="G -> R (in dbSNP:rs181717727)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040203" FT VARIANT 19956 FT /note="V -> M (in dbSNP:rs150661999)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040204" FT VARIANT 19992 FT /note="R -> Q (in dbSNP:rs141965360)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040205" FT VARIANT 20057 FT /note="R -> C (in dbSNP:rs72646861)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040206" FT VARIANT 20075 FT /note="S -> L (in dbSNP:rs13021201)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040207" FT VARIANT 20179 FT /note="T -> K" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040208" FT VARIANT 20198 FT /note="A -> T (in dbSNP:rs56378177)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040209" FT VARIANT 20198 FT /note="A -> V (in dbSNP:rs55948748)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040210" FT VARIANT 20331 FT /note="R -> H (in dbSNP:rs200217934)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040211" FT VARIANT 20359 FT /note="R -> K (in dbSNP:rs9808036)" FT /id="VAR_056088" FT VARIANT 20408 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040212" FT VARIANT 20564 FT /note="R -> K (in dbSNP:rs72646869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040213" FT VARIANT 20718 FT /note="V -> I (in dbSNP:rs2303838)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040214" FT VARIANT 20726 FT /note="S -> P (in dbSNP:rs72646873)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040215" FT VARIANT 20892 FT /note="T -> N" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040216" FT VARIANT 20894 FT /note="S -> R (in dbSNP:rs750847940)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040217" FT VARIANT 21125 FT /note="D -> E (in dbSNP:rs534340303)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040218" FT VARIANT 21403 FT /note="P -> S (in dbSNP:rs55980498)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040219" FT VARIANT 21730 FT /note="R -> C (in dbSNP:rs56141309)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040220" FT VARIANT 21747 FT /note="R -> Q (in dbSNP:rs55853138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040221" FT VARIANT 21851 FT /note="C -> R (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs55713867)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040222" FT VARIANT 21925 FT /note="G -> R (in dbSNP:rs55801134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040223" FT VARIANT 21995 FT /note="R -> H (in dbSNP:rs56071233)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040224" FT VARIANT 22045 FT /note="A -> V (in dbSNP:rs55903402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040225" FT VARIANT 22149 FT /note="R -> H (in dbSNP:rs55677134)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040226" FT VARIANT 22160 FT /note="V -> I (in dbSNP:rs55885640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040227" FT VARIANT 22261 FT /note="I -> T (in dbSNP:rs55837610)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040228" FT VARIANT 22306 FT /note="K -> N (in dbSNP:rs56019808)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040229" FT VARIANT 22357 FT /note="R -> H (in dbSNP:rs10164753)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040230" FT VARIANT 22408 FT /note="L -> P (in dbSNP:rs56399205)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040231" FT VARIANT 22537 FT /note="Q -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040232" FT VARIANT 22584 FT /note="P -> L (in dbSNP:rs55992239)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040233" FT VARIANT 22646 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040234" FT VARIANT 22670 FT /note="T -> A (in dbSNP:rs56201325)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040235" FT VARIANT 22770 FT /note="A -> D (in dbSNP:rs55991022)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040236" FT VARIANT 22801 FT /note="A -> T (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs764005465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040237" FT VARIANT 22823 FT /note="R -> W (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs369098292)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040238" FT VARIANT 22968 FT /note="E -> Q (in dbSNP:rs55762754)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040239" FT VARIANT 23074 FT /note="P -> L (in dbSNP:rs55713856)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040240" FT VARIANT 23079 FT /note="L -> F (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040241" FT VARIANT 23282 FT /note="D -> N (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040242" FT VARIANT 23303 FT /note="H -> Y (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040243" FT VARIANT 23306 FT /note="R -> C (in dbSNP:rs744426)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040244" FT VARIANT 23515 FT /note="A -> S (in a lung squamous cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040245" FT VARIANT 23551 FT /note="E -> Q (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040246" FT VARIANT 23807 FT /note="S -> N (in dbSNP:rs3813243)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040247" FT VARIANT 23872 FT /note="D -> N (in an ovarian serous carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040248" FT VARIANT 23891 FT /note="V -> A (in dbSNP:rs55984930)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040249" FT VARIANT 23933 FT /note="Y -> H (in dbSNP:rs3813245)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040250" FT VARIANT 23939 FT /note="T -> M (in dbSNP:rs56372592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040251" FT VARIANT 23952 FT /note="F -> L (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040252" FT VARIANT 24098 FT /note="A -> G (in dbSNP:rs56391938)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040253" FT VARIANT 24098 FT /note="A -> T (in dbSNP:rs4894028)" FT /id="VAR_056089" FT VARIANT 24119 FT /note="N -> S (in dbSNP:rs3813246)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040254" FT VARIANT 24133 FT /note="V -> I (in dbSNP:rs56340968)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040255" FT VARIANT 24159 FT /note="V -> A (in a head and neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040256" FT VARIANT 24239 FT /note="T -> A (in dbSNP:rs56018860)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040257" FT VARIANT 24265 FT /note="E -> K (in dbSNP:rs56341835)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040258" FT VARIANT 24584 FT /note="I -> T (in dbSNP:rs12463674)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040259" FT VARIANT 24781 FT /note="I -> T (in dbSNP:rs3731745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040260" FT VARIANT 24799 FT /note="R -> H (in dbSNP:rs56044609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040261" FT VARIANT 24954 FT /note="D -> H (in dbSNP:rs56307213)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040262" FT VARIANT 24980 FT /note="T -> M (in dbSNP:rs3731746)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040263" FT VARIANT 25659 FT /note="R -> H (in dbSNP:rs55850344)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040264" FT VARIANT 25679 FT /note="A -> T (in dbSNP:rs56365600)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040265" FT VARIANT 25720 FT /note="P -> A (in dbSNP:rs56137800)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040266" FT VARIANT 25821 FT /note="T -> K (in dbSNP:rs55933739)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040267" FT VARIANT 25859 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs375422359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040268" FT VARIANT 25879 FT /note="N -> K (in dbSNP:rs56264840)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040269" FT VARIANT 25923 FT /note="A -> V (in dbSNP:rs55634791)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040270" FT VARIANT 26045 FT /note="V -> I (in dbSNP:rs56309296)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040271" FT VARIANT 26059 FT /note="K -> E (in a lung small cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040272" FT VARIANT 26134 FT /note="I -> V (in dbSNP:rs3829746)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040273" FT VARIANT 26477 FT /note="R -> C (in dbSNP:rs56057221)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040274" FT VARIANT 26843 FT /note="D -> Y (in dbSNP:rs56330345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040275" FT VARIANT 27346 FT /note="K -> R (in dbSNP:rs1186947794)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040276" FT VARIANT 27652 FT /note="R -> C (in dbSNP:rs191482653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040277" FT VARIANT 27728 FT /note="G -> V (in dbSNP:rs55898359)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040278" FT VARIANT 27754 FT /note="F -> L (in dbSNP:rs55940667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040279" FT VARIANT 27755 FT /note="I -> T (in dbSNP:rs9808377)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7569978" FT /id="VAR_040280" FT VARIANT 27929 FT /note="I -> V (in dbSNP:rs139506970)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040281" FT VARIANT 28132 FT /note="I -> L (in dbSNP:rs77853750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040282" FT VARIANT 28168 FT /note="R -> Q (in dbSNP:rs72648238)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040283" FT VARIANT 28538 FT /note="R -> H (in dbSNP:rs149567378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040284" FT VARIANT 28572 FT /note="I -> T (in dbSNP:rs114026724)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040285" FT VARIANT 28948 FT /note="A -> T (in dbSNP:rs148617456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040286" FT VARIANT 28986 FT /note="I -> V (in dbSNP:rs535151633)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040287" FT VARIANT 28993 FT /note="G -> E (in dbSNP:rs376628842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040288" FT VARIANT 28998 FT /note="L -> V (in dbSNP:rs373049260)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040289" FT VARIANT 29070 FT /note="V -> M (in dbSNP:rs747122)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040290" FT VARIANT 29090 FT /note="I -> V (in dbSNP:rs16866391)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040291" FT VARIANT 29419 FT /note="R -> C (in dbSNP:rs750303653)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040292" FT VARIANT 29479 FT /note="L -> P (in dbSNP:rs1310673663)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040293" FT VARIANT 29880 FT /note="S -> L (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040294" FT VARIANT 29976 FT /note="D -> E (in dbSNP:rs72648256)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040295" FT VARIANT 30042 FT /note="S -> G (in dbSNP:rs72648257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040296" FT VARIANT 30107 FT /note="R -> C (in dbSNP:rs142525903)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040297" FT VARIANT 30125 FT /note="S -> F (in dbSNP:rs191484894)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040298" FT VARIANT 30211 FT /note="L -> P (in dbSNP:rs62621206)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040299" FT VARIANT 30412 FT /note="I -> T (in dbSNP:rs62621236)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040300" FT VARIANT 30617 FT /note="T -> S (in a renal chromophobe cancer sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040301" FT VARIANT 30674 FT /note="T -> I (in dbSNP:rs56027402)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040302" FT VARIANT 30809 FT /note="V -> I (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs397517769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040303" FT VARIANT 30818 FT /note="F -> I (in dbSNP:rs56009327)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040304" FT VARIANT 30825 FT /note="E -> K (in dbSNP:rs55915651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040305" FT VARIANT 30856 FT /note="I -> T (in dbSNP:rs55660660)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040306" FT VARIANT 30887 FT /note="G -> D (in dbSNP:rs56066673)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040307" FT VARIANT 30887 FT /note="G -> S (in dbSNP:rs56233675)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040308" FT VARIANT 30897 FT /note="R -> H (in dbSNP:rs3731749)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040309" FT VARIANT 30907 FT /note="R -> H (in dbSNP:rs55676195)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040310" FT VARIANT 30946 FT /note="R -> H (in dbSNP:rs55704830)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040311" FT VARIANT 31081 FT /note="I -> F (in dbSNP:rs72648270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040312" FT VARIANT 31107 FT /note="R -> C (in dbSNP:rs72648272)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040313" FT VARIANT 31124 FT /note="A -> G (in dbSNP:rs72648273)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040314" FT VARIANT 31156 FT /note="N -> S (in dbSNP:rs149001703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040315" FT VARIANT 31246 FT /note="P -> T (in dbSNP:rs55653324)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040316" FT VARIANT 31330 FT /note="R -> H (in dbSNP:rs4894028)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040317" FT VARIANT 31690 FT /note="C -> R (in dbSNP:rs56061641)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040318" FT VARIANT 31724 FT /note="R -> Q (in dbSNP:rs55742743)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040319" FT VARIANT 31725 FT /note="V -> I (in dbSNP:rs55675869)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040320" FT VARIANT 31732 FT /note="G -> S (in dbSNP:rs55880786)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040321" FT VARIANT 31886 FT /note="V -> I (in dbSNP:rs2278196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040322" FT VARIANT 32097 FT /note="R -> C (in dbSNP:rs56273463)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040323" FT VARIANT 32171 FT /note="T -> N (in a lung large cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040324" FT VARIANT 32248 FT /note="V -> I (in dbSNP:rs34924609)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040325" FT VARIANT 32281 FT /note="Q -> H (in dbSNP:rs55886356)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040326" FT VARIANT 32323 FT /note="R -> H (in dbSNP:rs55669553)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040327" FT VARIANT 32411 FT /note="R -> W (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs756924372)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040328" FT VARIANT 32558 FT /note="I -> V (in dbSNP:rs56347248)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040329" FT VARIANT 32610 FT /note="M -> V (in dbSNP:rs56173891)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040330" FT VARIANT 32637 FT /note="G -> V (in dbSNP:rs3731752)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040331" FT VARIANT 32742 FT /note="E -> Q (in dbSNP:rs148525155)" FT /evidence="ECO:0000269|PubMed:23033978" FT /id="VAR_069433" FT VARIANT 32922 FT /note="V -> A (in dbSNP:rs55945684)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040332" FT VARIANT 32943 FT /note="L -> R (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040333" FT VARIANT 32953 FT /note="R -> H (in dbSNP:rs3829747)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040334" FT VARIANT 32996 FT /note="R -> Q (in CMD1G; dbSNP:rs199642423)" FT /evidence="ECO:0000269|PubMed:16465475" FT /id="VAR_026693" FT VARIANT 33213 FT /note="V -> L (in dbSNP:rs55866005)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040335" FT VARIANT 33242 FT /note="R -> C (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1003158162)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040336" FT VARIANT 33387 FT /note="T -> M (in dbSNP:rs56001826)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040337" FT VARIANT 33419 FT /note="E -> D (in dbSNP:rs56308529)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040338" FT VARIANT 33536 FT /note="V -> M (in dbSNP:rs55865284)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040339" FT VARIANT 33568 FT /note="K -> Q (in dbSNP:rs56365812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040340" FT VARIANT 33616 FT /note="E -> K (in dbSNP:rs56324595)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040341" FT VARIANT 33620 FT /note="P -> L (in dbSNP:rs16866380)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040342" FT VARIANT 33886 FT /note="E -> V (in dbSNP:rs55725279)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040343" FT VARIANT 33899 FT /note="I -> T (in dbSNP:rs55880440)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040344" FT VARIANT 33904 FT /note="L -> P (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040345" FT VARIANT 33955 FT /note="T -> I (in dbSNP:rs55842557)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040346" FT VARIANT 34115 FT /note="V -> A (in dbSNP:rs16866378)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040347" FT VARIANT 34306 FT /note="I -> N (in TMD; dbSNP:rs281864928)" FT /evidence="ECO:0000269|PubMed:12891679" FT /id="VAR_026694" FT VARIANT 34315 FT /note="L -> P (in TMD; dbSNP:rs267607156)" FT /evidence="ECO:0000269|PubMed:12145747" FT /id="VAR_026695" FT MUTAGEN 32207 FT /note="K->A: Disrupts catalytic activity." FT /evidence="ECO:0000269|PubMed:9804419" FT MUTAGEN 32341 FT /note="Y->E: No phosphorylation on tyrosine." FT /evidence="ECO:0000269|PubMed:9804419" FT CONFLICT 132 FT /note="T -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 255 FT /note="P -> H (in Ref. 3; CAD12455/CAD12456/CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT 1472..1474 FT /note="QTA -> ANC (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 1730 FT /note="G -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 3919 FT /note="P -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 4525 FT /note="R -> K (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 6619 FT /note="R -> E (in Ref. 1; CAA62189 and 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 7145 FT /note="D -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 7441 FT /note="S -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 8038 FT /note="A -> E (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8225 FT /note="Q -> H (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 8850 FT /note="A -> P (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9693 FT /note="C -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 9892 FT /note="I -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10205 FT /note="I -> V (in Ref. 3; CAD12456 and 9; AAP80791)" FT /evidence="ECO:0000305" FT CONFLICT 10305 FT /note="G -> R (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 10566 FT /note="R -> K (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 10779 FT /note="R -> H (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11424 FT /note="E -> D (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 11511 FT /note="A -> V (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11626 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 11838 FT /note="K -> N (in Ref. 1; CAA62189)" FT /evidence="ECO:0000305" FT CONFLICT 12994 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 13795..13797 FT /note="YKF -> IQI (in Ref. 11)" FT /evidence="ECO:0000305" FT CONFLICT 14590 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 14792 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 15974 FT /note="E -> K (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 16234..16235 FT /note="TK -> QR (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17238 FT /note="R -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 17423 FT /note="R -> S (in Ref. 3; CAD12456)" FT /evidence="ECO:0000305" FT CONFLICT 19734 FT /note="V -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20517 FT /note="G -> A (in Ref. 1; CAA62188 and 3; CAD12455)" FT /evidence="ECO:0000305" FT CONFLICT 20622 FT /note="L -> H (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 20775 FT /note="A -> P (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 21625 FT /note="Y -> I (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 21795..21800 FT /note="PGPVLN -> ARPSPQ (in Ref. 13; CAA45939)" FT /evidence="ECO:0000305" FT CONFLICT 22176 FT /note="C -> W (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22816 FT /note="A -> D (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 22837 FT /note="T -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 24176 FT /note="I -> M (in Ref. 1; CAA62188 and 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 24181 FT /note="S -> F (in Ref. 13; CAA45940)" FT /evidence="ECO:0000305" FT CONFLICT 25731 FT /note="P -> S (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26573 FT /note="M -> V (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 26846..26848 FT /note="IVE -> HRK (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 27879 FT /note="G -> A (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 28936 FT /note="D -> N (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29222 FT /note="A -> T (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29518 FT /note="F -> L (in Ref. 1; CAA62188)" FT /evidence="ECO:0000305" FT CONFLICT 29701 FT /note="T -> P (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29873 FT /note="E -> G (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 29878 FT /note="T -> Q (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30209 FT /note="K -> E (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30256 FT /note="A -> R (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30496 FT /note="V -> I (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30534 FT /note="Y -> H (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 30748 FT /note="S -> L (in Ref. 14; CAA45938/CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 31303 FT /note="W -> V (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 32060 FT /note="V -> A (in Ref. 1; CAA62188 and 14; CAA45938/ FT CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33084 FT /note="D -> N (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33120 FT /note="R -> W (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33382 FT /note="A -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33424 FT /note="S -> P (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33526 FT /note="Q -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33633 FT /note="T -> I (in Ref. 1; CAA62188 and 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 33716 FT /note="Y -> V (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 33995 FT /note="V -> A (in Ref. 15; CAD28458)" FT /evidence="ECO:0000305" FT CONFLICT 34071 FT /note="N -> G (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT CONFLICT 34082 FT /note="C -> R (in Ref. 14; CAA49245)" FT /evidence="ECO:0000305" FT CONFLICT 34253 FT /note="G -> R (in Ref. 5; AAI07798)" FT /evidence="ECO:0000305" FT STRAND 4..10 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 15..18 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 23..33 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 36..45 FT /evidence="ECO:0007829|PDB:2A38" FT TURN 48..50 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 55..59 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 62..69 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 72..74 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 76..84 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 87..98 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 102..108 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 113..116 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 119..131 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 134..139 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 142..144 FT /evidence="ECO:0007829|PDB:1YA5" FT STRAND 147..155 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 158..166 FT /evidence="ECO:0007829|PDB:2A38" FT HELIX 168..170 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 172..180 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 183..194 FT /evidence="ECO:0007829|PDB:2A38" FT STRAND 199..205 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 209..213 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 225..233 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 236..241 FT /evidence="ECO:0007829|PDB:6FWX" FT STRAND 1850..1852 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1858..1863 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1866..1869 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1871..1876 FT /evidence="ECO:0007829|PDB:6DL4" FT TURN 1891..1893 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1894..1899 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1908..1916 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 1919..1929 FT /evidence="ECO:0007829|PDB:6DL4" FT STRAND 2076..2082 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2087..2090 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2095..2105 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2108..2113 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2122..2130 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2133..2138 FT /evidence="ECO:0007829|PDB:1G1C" FT HELIX 2143..2145 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2147..2155 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2158..2169 FT /evidence="ECO:0007829|PDB:1G1C" FT STRAND 2797..2799 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2804..2807 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2812..2820 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2826..2829 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2838..2845 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2848..2853 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2858..2860 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2862..2868 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2871..2880 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2884..2886 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2891..2894 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2899..2907 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2914..2916 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2924..2932 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2935..2940 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 2945..2947 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2949..2955 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2958..2967 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2971..2973 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2978..2981 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 2986..2994 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3000..3003 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3012..3019 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3022..3027 FT /evidence="ECO:0007829|PDB:5JDD" FT HELIX 3032..3034 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3036..3042 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3045..3053 FT /evidence="ECO:0007829|PDB:5JDD" FT STRAND 3504..3507 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3512..3515 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3520..3527 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3533..3538 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3547..3554 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3557..3562 FT /evidence="ECO:0007829|PDB:8OVU" FT HELIX 3567..3569 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3571..3579 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 3582..3593 FT /evidence="ECO:0007829|PDB:8OVU" FT STRAND 7948..7951 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7956..7958 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7964..7975 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7977..7981 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7983..7986 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 7991..7996 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8001..8008 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8011..8013 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8015..8023 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8026..8036 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8044..8047 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8052..8055 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8060..8071 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8073..8078 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8087..8094 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8097..8104 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8107..8109 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8111..8119 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8122..8133 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8140..8143 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8151..8154 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8156..8166 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8169..8174 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8183..8190 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8193..8201 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8203..8205 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8207..8215 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8218..8226 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8233..8236 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8244..8247 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8249..8261 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8263..8268 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8276..8284 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8287..8294 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8297..8299 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8301..8309 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8315..8320 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8335..8337 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8343..8354 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8358..8361 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8368..8377 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8380..8385 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 8390..8392 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8394..8401 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8406..8415 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8420..8423 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8436..8444 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8451..8454 FT /evidence="ECO:0007829|PDB:3B43" FT TURN 8463..8465 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8466..8468 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8472..8481 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8488..8495 FT /evidence="ECO:0007829|PDB:3B43" FT STRAND 8500..8507 FT /evidence="ECO:0007829|PDB:3B43" FT HELIX 9506..9510 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9518..9525 FT /evidence="ECO:0007829|PDB:7NIP" FT HELIX 9530..9543 FT /evidence="ECO:0007829|PDB:7NIP" FT STRAND 9582..9587 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9592..9595 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9600..9608 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9616..9619 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9628..9635 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9638..9643 FT /evidence="ECO:0007829|PDB:5JOE" FT HELIX 9648..9650 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9652..9658 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9661..9670 FT /evidence="ECO:0007829|PDB:5JOE" FT STRAND 9674..9676 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9681..9684 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9689..9697 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9703..9706 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9717..9722 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9725..9732 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9735..9737 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9739..9745 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9748..9757 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9763..9765 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9770..9772 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9778..9786 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9790..9795 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9803..9811 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9814..9819 FT /evidence="ECO:0007829|PDB:7AHS" FT HELIX 9824..9826 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9828..9835 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 9841..9850 FT /evidence="ECO:0007829|PDB:7AHS" FT STRAND 12680..12682 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12687..12690 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12691..12693 FT /evidence="ECO:0007829|PDB:6I0Y" FT STRAND 12695..12705 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12709..12712 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12719..12722 FT /evidence="ECO:0007829|PDB:1TIU" FT STRAND 12723..12728 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12731..12736 FT /evidence="ECO:0007829|PDB:1WAA" FT HELIX 12741..12743 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12745..12751 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 12754..12763 FT /evidence="ECO:0007829|PDB:1WAA" FT STRAND 14223..14228 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14232..14240 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14252..14259 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14275..14281 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14288..14296 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14308..14314 FT /evidence="ECO:0007829|PDB:4O00" FT STRAND 14319..14322 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14325..14327 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14331..14334 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14339..14349 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14352..14357 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14368..14372 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14374..14381 FT /evidence="ECO:0007829|PDB:8BXR" FT HELIX 14386..14388 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14390..14397 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14402..14412 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14419..14424 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14431..14436 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14446..14455 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14462..14468 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14470..14475 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14484..14492 FT /evidence="ECO:0007829|PDB:8BW6" FT STRAND 14506..14509 FT /evidence="ECO:0007829|PDB:8BXR" FT STRAND 14522..14524 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14528..14534 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14549..14555 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14568..14576 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 14584..14592 FT /evidence="ECO:0007829|PDB:8BVO" FT STRAND 15216..15224 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15227..15233 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15245..15252 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15268..15273 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15282..15290 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 15305..15307 FT /evidence="ECO:0007829|PDB:8OS3" FT STRAND 16533..16538 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16541..16546 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16559..16566 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16585..16592 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16600..16609 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 16623..16626 FT /evidence="ECO:0007829|PDB:8OMW" FT STRAND 20520..20528 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20531..20537 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20549..20556 FT /evidence="ECO:0007829|PDB:8OSD" FT HELIX 20568..20570 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20573..20580 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 20587..20594 FT /evidence="ECO:0007829|PDB:8OSD" FT STRAND 21506..21509 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21515..21518 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21532..21539 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21546..21551 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21553..21560 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 21568..21577 FT /evidence="ECO:0007829|PDB:8ORL" FT STRAND 22291..22296 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22299..22303 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22319..22324 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22340..22345 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22354..22361 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22367..22377 FT /evidence="ECO:0007829|PDB:1BPV" FT HELIX 22381..22384 FT /evidence="ECO:0007829|PDB:1BPV" FT STRAND 22883..22890 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22895..22900 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22912..22919 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22926..22932 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22934..22939 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22947..22956 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22970..22972 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22982..22987 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 22992..22996 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23009..23016 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23023..23035 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23043..23052 FT /evidence="ECO:0007829|PDB:3LPW" FT STRAND 23568..23575 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23581..23586 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23596..23605 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23612..23618 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23620..23625 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23633..23642 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23671..23676 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23679..23683 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23697..23704 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23711..23716 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23720..23725 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23733..23742 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23769..23776 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23781..23786 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23798..23805 FT /evidence="ECO:0007829|PDB:8BNQ" FT TURN 23806..23808 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23811..23815 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23820..23827 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 23835..23843 FT /evidence="ECO:0007829|PDB:8BNQ" FT STRAND 25439..25443 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25448..25451 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25465..25472 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25479..25481 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25486..25493 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25501..25509 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 25514..25517 FT /evidence="ECO:0007829|PDB:8OT5" FT STRAND 26130..26137 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26142..26147 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26157..26166 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26173..26179 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26181..26186 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26194..26203 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 26206..26212 FT /evidence="ECO:0007829|PDB:8OTY" FT STRAND 31458..31464 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31469..31472 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31475..31487 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31490..31495 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31498..31500 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31504..31520 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31524..31526 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31528..31535 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31540..31555 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31563..31568 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31573..31583 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31586..31591 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31600..31606 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31608..31617 FT /evidence="ECO:0007829|PDB:3LCY" FT HELIX 31620..31623 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31625..31632 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31637..31647 FT /evidence="ECO:0007829|PDB:3LCY" FT STRAND 31856..31859 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31864..31867 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31872..31879 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31885..31890 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31893..31895 FT /evidence="ECO:0007829|PDB:2J8O" FT STRAND 31899..31907 FT /evidence="ECO:0007829|PDB:2J8H" FT TURN 31908..31910 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31911..31916 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31921..31923 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31925..31933 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31936..31952 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 31956..31959 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 31961..31967 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31973..31982 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31985..31992 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 31997..32000 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32002..32005 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32007..32013 FT /evidence="ECO:0007829|PDB:2J8H" FT HELIX 32020..32022 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32024..32032 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32035..32046 FT /evidence="ECO:0007829|PDB:2J8H" FT STRAND 32053..32061 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32063..32070 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32076..32078 FT /evidence="ECO:0007829|PDB:2NZI" FT STRAND 32082..32089 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32095..32111 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32117..32125 FT /evidence="ECO:0007829|PDB:6YGN" FT HELIX 32142..32154 FT /evidence="ECO:0007829|PDB:6YGN" FT STRAND 32167..32170 FT /evidence="ECO:0007829|PDB:6YGN" FT TURN 32175..32177 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32178..32186 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32188..32197 FT /evidence="ECO:0007829|PDB:1TKI" FT TURN 32198..32201 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32202..32209 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32214..32228 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32237..32243 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32246..32251 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32259..32263 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32265..32267 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32272..32291 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32301..32303 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32304..32310 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32314..32316 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32330..32336 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32338..32340 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32343..32346 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32353..32369 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32379..32388 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32395..32398 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32403..32410 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32417..32419 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32423..32428 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32430..32433 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32436..32438 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32447..32457 FT /evidence="ECO:0007829|PDB:1TKI" FT HELIX 32466..32472 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32474..32476 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32483..32489 FT /evidence="ECO:0007829|PDB:1TKI" FT STRAND 32504..32506 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32512..32520 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32526..32531 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32538..32547 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32550..32555 FT /evidence="ECO:0007829|PDB:2BK8" FT HELIX 32560..32562 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32564..32571 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32576..32585 FT /evidence="ECO:0007829|PDB:2BK8" FT TURN 32586..32588 FT /evidence="ECO:0007829|PDB:2BK8" FT STRAND 32720..32726 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32731..32734 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32739..32749 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32752..32757 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32765..32767 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32768..32773 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 32774..32776 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32777..32784 FT /evidence="ECO:0007829|PDB:6HCI" FT HELIX 32787..32789 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32791..32799 FT /evidence="ECO:0007829|PDB:6HCI" FT STRAND 32802..32813 FT /evidence="ECO:0007829|PDB:6HCI" FT TURN 33294..33297 FT /evidence="ECO:0007829|PDB:3QP3" FT STRAND 33299..33305 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33310..33313 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33318..33328 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33331..33336 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33345..33352 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33355..33360 FT /evidence="ECO:0007829|PDB:6H4L" FT HELIX 33365..33367 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33369..33377 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33380..33391 FT /evidence="ECO:0007829|PDB:6H4L" FT STRAND 33489..33492 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33497..33503 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33509..33512 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33514..33516 FT /evidence="ECO:0007829|PDB:1TNM" FT STRAND 33523..33526 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33532..33538 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33540..33547 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33556..33560 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33571..33577 FT /evidence="ECO:0007829|PDB:1NCT" FT STRAND 33777..33783 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33788..33794 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33796..33806 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33809..33814 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33821..33830 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33833..33838 FT /evidence="ECO:0007829|PDB:3PUC" FT HELIX 33843..33845 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33847..33855 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 33858..33869 FT /evidence="ECO:0007829|PDB:3PUC" FT STRAND 34060..34071 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34078..34088 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34091..34096 FT /evidence="ECO:0007829|PDB:4UOW" FT TURN 34104..34106 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34107..34112 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34115..34122 FT /evidence="ECO:0007829|PDB:4UOW" FT HELIX 34125..34127 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34129..34136 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34138..34148 FT /evidence="ECO:0007829|PDB:4UOW" FT STRAND 34254..34258 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34263..34268 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34271..34283 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34286..34291 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34300..34302 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34304..34308 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34310..34319 FT /evidence="ECO:0007829|PDB:3KNB" FT HELIX 34322..34324 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34326..34334 FT /evidence="ECO:0007829|PDB:3KNB" FT STRAND 34337..34348 FT /evidence="ECO:0007829|PDB:3KNB" FT CONFLICT Q8WZ42-6:3732 FT /note="L -> F (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" FT CONFLICT Q8WZ42-6:5139 FT /note="R -> M (in Ref. 3; CAD12457)" FT /evidence="ECO:0000305" SQ SEQUENCE 34350 AA; 3816030 MW; DEB216410AD560D9 CRC64; MTTQAPTFTQ PLQSVVVLEG STATFEAHIS GFPVPEVSWF RDGQVISTST LPGVQISFSD GRAKLTIPAV TKANSGRYSL KATNGSGQAT STAELLVKAE TAPPNFVQRL QSMTVRQGSQ VRLQVRVTGI PTPVVKFYRD GAEIQSSLDF QISQEGDLYS LLIAEAYPED SGTYSVNATN SVGRATSTAE LLVQGEEEVP AKKTKTIVST AQISESRQTR IEKKIEAHFD ARSIATVEMV IDGAAGQQLP HKTPPRIPPK PKSRSPTPPS IAAKAQLARQ QSPSPIRHSP SPVRHVRAPT PSPVRSVSPA ARISTSPIRS VRSPLLMRKT QASTVATGPE VPPPWKQEGY VASSSEAEMR ETTLTTSTQI RTEERWEGRY GVQEQVTISG AAGAAASVSA SASYAAEAVA TGAKEVKQDA DKSAAVATVV AAVDMARVRE PVISAVEQTA QRTTTTAVHI QPAQEQVRKE AEKTAVTKVV VAADKAKEQE LKSRTKEVIT TKQEQMHVTH EQIRKETEKT FVPKVVISAA KAKEQETRIS EEITKKQKQV TQEAIRQETE ITAASMVVVA TAKSTKLETV PGAQEETTTQ QDQMHLSYEK IMKETRKTVV PKVIVATPKV KEQDLVSRGR EGITTKREQV QITQEKMRKE AEKTALSTIA VATAKAKEQE TILRTRETMA TRQEQIQVTH GKVDVGKKAE AVATVVAAVD QARVREPREP GHLEESYAQQ TTLEYGYKER ISAAKVAEPP QRPASEPHVV PKAVKPRVIQ APSETHIKTT DQKGMHISSQ IKKTTDLTTE RLVHVDKRPR TASPHFTVSK ISVPKTEHGY EASIAGSAIA TLQKELSATS SAQKITKSVK APTVKPSETR VRAEPTPLPQ FPFADTPDTY KSEAGVEVKK EVGVSITGTT VREERFEVLH GREAKVTETA RVPAPVEIPV TPPTLVSGLK NVTVIEGESV TLECHISGYP SPTVTWYRED YQIESSIDFQ ITFQSGIARL MIREAFAEDS GRFTCSAVNE AGTVSTSCYL AVQVSEEFEK ETTAVTEKFT TEEKRFVESR DVVMTDTSLT EEQAGPGEPA APYFITKPVV QKLVEGGSVV FGCQVGGNPK PHVYWKKSGV PLTTGYRYKV SYNKQTGECK LVISMTFADD AGEYTIVVRN KHGETSASAS LLEEADYELL MKSQQEMLYQ TQVTAFVQEP KVGETAPGFV YSEYEKEYEK EQALIRKKMA KDTVVVRTYV EDQEFHISSF EERLIKEIEY RIIKTTLEEL LEEDGEEKMA VDISESEAVE SGFDSRIKNY RILEGMGVTF HCKMSGYPLP KIAWYKDGKR IKHGERYQMD FLQDGRASLR IPVVLPEDEG IYTAFASNIK GNAICSGKLY VEPAAPLGAP TYIPTLEPVS RIRSLSPRSV SRSPIRMSPA RMSPARMSPA RMSPARMSPG RRLEETDESQ LERLYKPVFV LKPVSFKCLE GQTARFDLKV VGRPMPETFW FHDGQQIVND YTHKVVIKED GTQSLIIVPA TPSDSGEWTV VAQNRAGRSS ISVILTVEAV EHQVKPMFVE KLKNVNIKEG SRLEMKVRAT GNPNPDIVWL KNSDIIVPHK YPKIRIEGTK GEAALKIDST VSQDSAWYTA TAINKAGRDT TRCKVNVEVE FAEPEPERKL IIPRGTYRAK EIAAPELEPL HLRYGQEQWE EGDLYDKEKQ QKPFFKKKLT SLRLKRFGPA HFECRLTPIG DPTMVVEWLH DGKPLEAANR LRMINEFGYC SLDYGVAYSR DSGIITCRAT NKYGTDHTSA TLIVKDEKSL VEESQLPEGR KGLQRIEELE RMAHEGALTG VTTDQKEKQK PDIVLYPEPV RVLEGETARF RCRVTGYPQP KVNWYLNGQL IRKSKRFRVR YDGIHYLDIV DCKSYDTGEV KVTAENPEGV IEHKVKLEIQ QREDFRSVLR RAPEPRPEFH VHEPGKLQFE VQKVDRPVDT TETKEVVKLK RAERITHEKV PEESEELRSK FKRRTEEGYY EAITAVELKS RKKDESYEEL LRKTKDELLH WTKELTEEEK KALAEEGKIT IPTFKPDKIE LSPSMEAPKI FERIQSQTVG QGSDAHFRVR VVGKPDPECE WYKNGVKIER SDRIYWYWPE DNVCELVIRD VTAEDSASIM VKAINIAGET SSHAFLLVQA KQLITFTQEL QDVVAKEKDT MATFECETSE PFVKVKWYKD GMEVHEGDKY RMHSDRKVHF LSILTIDTSD AEDYSCVLVE DENVKTTAKL IVEGAVVEFV KELQDIEVPE SYSGELECIV SPENIEGKWY HNDVELKSNG KYTITSRRGR QNLTVKDVTK EDQGEYSFVI DGKKTTCKLK MKPRPIAILQ GLSDQKVCEG DIVQLEVKVS LESVEGVWMK DGQEVQPSDR VHIVIDKQSH MLLIEDMTKE DAGNYSFTIP ALGLSTSGRV SVYSVDVITP LKDVNVIEGT KAVLECKVSV PDVTSVKWYL NDEQIKPDDR VQAIVKGTKQ RLVINRTHAS DEGPYKLIVG RVETNCNLSV EKIKIIRGLR DLTCTETQNV VFEVELSHSG IDVLWNFKDK EIKPSSKYKI EAHGKIYKLT VLNMMKDDEG KYTFYAGENM TSGKLTVAGG AISKPLTDQT VAESQEAVFE CEVANPDSKG EWLRDGKHLP LTNNIRSESD GHKRRLIIAA TKLDDIGEYT YKVATSKTSA KLKVEAVKIK KTLKNLTVTE TQDAVFTVEL THPNVKGVQW IKNGVVLESN EKYAISVKGT IYSLRIKNCA IVDESVYGFR LGRLGASARL HVETVKIIKK PKDVTALENA TVAFEVSVSH DTVPVKWFHK SVEIKPSDKH RLVSERKVHK LMLQNISPSD AGEYTAVVGQ LECKAKLFVE TLHITKTMKN IEVPETKTAS FECEVSHFNV PSMWLKNGVE IEMSEKFKIV VQGKLHQLII MNTSTEDSAE YTFVCGNDQV SATLTVTPIM ITSMLKDINA EEKDTITFEV TVNYEGISYK WLKNGVEIKS TDKCQMRTKK LTHSLNIRNV HFGDAADYTF VAGKATSTAT LYVEARHIEF RKHIKDIKVL EKKRAMFECE VSEPDITVQW MKDDQELQIT DRIKIQKEKY VHRLLIPSTR MSDAGKYTVV AGGNVSTAKL FVEGRDVRIR SIKKEVQVIE KQRAVVEFEV NEDDVDAHWY KDGIEINFQV QERHKYVVER RIHRMFISET RQSDAGEYTF VAGRNRSSVT LYVNAPEPPQ VLQELQPVTV QSGKPARFCA VISGRPQPKI SWYKEEQLLS TGFKCKFLHD GQEYTLLLIE AFPEDAAVYT CEAKNDYGVA TTSASLSVEV PEVVSPDQEM PVYPPAIITP LQDTVTSEGQ PARFQCRVSG TDLKVSWYSK DKKIKPSRFF RMTQFEDTYQ LEIAEAYPED EGTYTFVASN AVGQVSSTAN LSLEAPESIL HERIEQEIEM EMKEFSSSFL SAEEEGLHSA ELQLSKINET LELLSESPVY PTKFDSEKEG TGPIFIKEVS NADISMGDVA TLSVTVIGIP KPKIQWFFNG VLLTPSADYK FVFDGDDHSL IILFTKLEDE GEYTCMASND YGKTICSAYL KINSKGEGHK DTETESAVAK SLEKLGGPCP PHFLKELKPI RCAQGLPAIF EYTVVGEPAP TVTWFKENKQ LCTSVYYTII HNPNGSGTFI VNDPQREDSG LYICKAENML GESTCAAELL VLLEDTDMTD TPCKAKSTPE APEDFPQTPL KGPAVEALDS EQEIATFVKD TILKAALITE ENQQLSYEHI AKANELSSQL PLGAQELQSI LEQDKLTPES TREFLCINGS IHFQPLKEPS PNLQLQIVQS QKTFSKEGIL MPEEPETQAV LSDTEKIFPS AMSIEQINSL TVEPLKTLLA EPEGNYPQSS IEPPMHSYLT SVAEEVLSPK EKTVSDTNRE QRVTLQKQEA QSALILSQSL AEGHVESLQS PDVMISQVNY EPLVPSEHSC TEGGKILIES ANPLENAGQD SAVRIEEGKS LRFPLALEEK QVLLKEEHSD NVVMPPDQII ESKREPVAIK KVQEVQGRDL LSKESLLSGI PEEQRLNLKI QICRALQAAV ASEQPGLFSE WLRNIEKVEV EAVNITQEPR HIMCMYLVTS AKSVTEEVTI IIEDVDPQMA NLKMELRDAL CAIIYEEIDI LTAEGPRIQQ GAKTSLQEEM DSFSGSQKVE PITEPEVESK YLISTEEVSY FNVQSRVKYL DATPVTKGVA SAVVSDEKQD ESLKPSEEKE ESSSESGTEE VATVKIQEAE GGLIKEDGPM IHTPLVDTVS EEGDIVHLTT SITNAKEVNW YFENKLVPSD EKFKCLQDQN TYTLVIDKVN TEDHQGEYVC EALNDSGKTA TSAKLTVVKR AAPVIKRKIE PLEVALGHLA KFTCEIQSAP NVRFQWFKAG REIYESDKCS IRSSKYISSL EILRTQVVDC GEYTCKASNE YGSVSCTATL TVTEAYPPTF LSRPKSLTTF VGKAAKFICT VTGTPVIETI WQKDGAALSP SPNWRISDAE NKHILELSNL TIQDRGVYSC KASNKFGADI CQAELIIIDK PHFIKELEPV QSAINKKVHL ECQVDEDRKV TVTWSKDGQK LPPGKDYKIC FEDKIATLEI PLAKLKDSGT YVCTASNEAG SSSCSATVTV REPPSFVKKV DPSYLMLPGE SARLHCKLKG SPVIQVTWFK NNKELSESNT VRMYFVNSEA ILDITDVKVE DSGSYSCEAV NDVGSDSCST EIVIKEPPSF IKTLEPADIV RGTNALLQCE VSGTGPFEIS WFKDKKQIRS SKKYRLFSQK SLVCLEIFSF NSADVGEYEC VVANEVGKCG CMATHLLKEP PTFVKKVDDL IALGGQTVTL QAAVRGSEPI SVTWMKGQEV IREDGKIKMS FSNGVAVLII PDVQISFGGK YTCLAENEAG SQTSVGELIV KEPAKIIERA ELIQVTAGDP ATLEYTVAGT PELKPKWYKD GRPLVASKKY RISFKNNVAQ LKFYSAELHD SGQYTFEISN EVGSSSCETT FTVLDRDIAP FFTKPLRNVD SVVNGTCRLD CKIAGSLPMR VSWFKDGKEI AASDRYRIAF VEGTASLEII RVDMNDAGNF TCRATNSVGS KDSSGALIVQ EPPSFVTKPG SKDVLPGSAV CLKSTFQGST PLTIRWFKGN KELVSGGSCY ITKEALESSL ELYLVKTSDS GTYTCKVSNV AGGVECSANL FVKEPATFVE KLEPSQLLKK GDATQLACKV TGTPPIKITW FANDREIKES SKHRMSFVES TAVLRLTDVG IEDSGEYMCE AQNEAGSDHC SSIVIVKESP YFTKEFKPIE VLKEYDVMLL AEVAGTPPFE ITWFKDNTIL RSGRKYKTFI QDHLVSLQIL KFVAADAGEY QCRVTNEVGS SICSARVTLR EPPSFIKKIE STSSLRGGTA AFQATLKGSL PITVTWLKDS DEITEDDNIR MTFENNVASL YLSGIEVKHD GKYVCQAKND AGIQRCSALL SVKEPATITE EAVSIDVTQG DPATLQVKFS GTKEITAKWF KDGQELTLGS KYKISVTDTV SILKIISTEK KDSGEYTFEV QNDVGRSSCK ARINVLDLII PPSFTKKLKK MDSIKGSFID LECIVAGSHP ISIQWFKDDQ EISASEKYKF SFHDNTAFLE ISQLEGTDSG TYTCSATNKA GHNQCSGHLT VKEPPYFVEK PQSQDVNPNT RVQLKALVGG TAPMTIKWFK DNKELHSGAA RSVWKDDTST SLELFAAKAT DSGTYICQLS NDVGTATSKA TLFVKEPPQF IKKPSPVLVL RNGQSTTFEC QITGTPKIRV SWYLDGNEIT AIQKHGISFI DGLATFQISG ARVENSGTYV CEARNDAGTA SCSIELKVKE PPTFIRELKP VEVVKYSDVE LECEVTGTPP FEVTWLKNNR EIRSSKKYTL TDRVSVFNLH ITKCDPSDTG EYQCIVSNEG GSCSCSTRVA LKEPPSFIKK IENTTTVLKS SATFQSTVAG SPPISITWLK DDQILDEDDN VYISFVDSVA TLQIRSVDNG HSGRYTCQAK NESGVERCYA FLLVQEPAQI VEKAKSVDVT EKDPMTLECV VAGTPELKVK WLKDGKQIVP SRYFSMSFEN NVASFRIQSV MKQDSGQYTF KVENDFGSSS CDAYLRVLDQ NIPPSFTKKL TKMDKVLGSS IHMECKVSGS LPISAQWFKD GKEISTSAKY RLVCHERSVS LEVNNLELED TANYTCKVSN VAGDDACSGI LTVKEPPSFL VKPGRQQAIP DSTVEFKAIL KGTPPFKIKW FKDDVELVSG PKCFIGLEGS TSFLNLYSVD ASKTGQYTCH VTNDVGSDSC TTMLLVTEPP KFVKKLEASK IVKAGDSSRL ECKIAGSPEI RVVWFRNEHE LPASDKYRMT FIDSVAVIQM NNLSTEDSGD FICEAQNPAG STSCSTKVIV KEPPVFSSFP PIVETLKNAE VSLECELSGT PPFEVVWYKD KRQLRSSKKY KIASKNFHTS IHILNVDTSD IGEYHCKAQN EVGSDTCVCT VKLKEPPRFV SKLNSLTVVA GEPAELQASI EGAQPIFVQW LKEKEEVIRE SENIRITFVE NVATLQFAKA EPANAGKYIC QIKNDGGMRE NMATLMVLEP AVIVEKAGPM TVTVGETCTL ECKVAGTPEL SVEWYKDGKL LTSSQKHKFS FYNKISSLRI LSVERQDAGT YTFQVQNNVG KSSCTAVVDV SDRAVPPSFT RRLKNTGGVL GASCILECKV AGSSPISVAW FHEKTKIVSG AKYQTTFSDN VCTLQLNSLD SSDMGNYTCV AANVAGSDEC RAVLTVQEPP SFVKEPEPLE VLPGKNVTFT SVIRGTPPFK VNWFRGAREL VKGDRCNIYF EDTVAELELF NIDISQSGEY TCVVSNNAGQ ASCTTRLFVK EPAAFLKRLS DHSVEPGKSI ILESTYTGTL PISVTWKKDG FNITTSEKCN IVTTEKTCIL EILNSTKRDA GQYSCEIENE AGRDVCGALV STLEPPYFVT ELEPLEAAVG DSVSLQCQVA GTPEITVSWY KGDTKLRPTP EYRTYFTNNV ATLVFNKVNI NDSGEYTCKA ENSIGTASSK TVFRIQERQL PPSFARQLKD IEQTVGLPVT LTCRLNGSAP IQVCWYRDGV LLRDDENLQT SFVDNVATLK ILQTDLSHSG QYSCSASNPL GTASSSARLT AREPKKSPFF DIKPVSIDVI AGESADFECH VTGAQPMRIT WSKDNKEIRP GGNYTITCVG NTPHLRILKV GKGDSGQYTC QATNDVGKDM CSAQLSVKEP PKFVKKLEAS KVAKQGESIQ LECKISGSPE IKVSWFRNDS ELHESWKYNM SFINSVALLT INEASAEDSG DYICEAHNGV GDASCSTALT VKAPPVFTQK PSPVGALKGS DVILQCEISG TPPFEVVWVK DRKQVRNSKK FKITSKHFDT SLHILNLEAS DVGEYHCKAT NEVGSDTCSC SVKFKEPPRF VKKLSDTSTL IGDAVELRAI VEGFQPISVV WLKDRGEVIR ESENTRISFI DNIATLQLGS PEASNSGKYI CQIKNDAGMR ECSAVLTVLE PARIIEKPEP MTVTTGNPFA LECVVTGTPE LSAKWFKDGR ELSADSKHHI TFINKVASLK IPCAEMSDKG LYSFEVKNSV GKSNCTVSVH VSDRIVPPSF IRKLKDVNAI LGASVVLECR VSGSAPISVG WFQDGNEIVS GPKCQSSFSE NVCTLNLSLL EPSDTGIYTC VAANVAGSDE CSAVLTVQEP PSFEQTPDSV EVLPGMSLTF TSVIRGTPPF KVKWFKGSRE LVPGESCNIS LEDFVTELEL FEVQPLESGD YSCLVTNDAG SASCTTHLFV KEPATFVKRL ADFSVETGSP IVLEATYTGT PPISVSWIKD EYLISQSERC SITMTEKSTI LEILESTIED YAQYSCLIEN EAGQDICEAL VSVLEPPYFI EPLEHVEAVI GEPATLQCKV DGTPEIRISW YKEHTKLRSA PAYKMQFKNN VASLVINKVD HSDVGEYSCK ADNSVGAVAS SAVLVIKARK LPPFFARKLK DVHETLGFPV AFECRINGSE PLQVSWYKDG VLLKDDANLQ TSFVHNVATL QILQTDQSHI GQYNCSASNP LGTASSSAKL ILSEHEVPPF FDLKPVSVDL ALGESGTFKC HVTGTAPIKI TWAKDNREIR PGGNYKMTLV ENTATLTVLK VGKGDAGQYT CYASNIAGKD SCSAQLGVQE PPRFIKKLEP SRIVKQDEFT RYECKIGGSP EIKVLWYKDE TEIQESSKFR MSFVDSVAVL EMHNLSVEDS GDYTCEAHNA AGSASSSTSL KVKEPPIFRK KPHPIETLKG ADVHLECELQ GTPPFHVSWY KDKRELRSGK KYKIMSENFL TSIHILNVDA ADIGEYQCKA TNDVGSDTCV GSIALKAPPR FVKKLSDIST VVGKEVQLQT TIEGAEPISV VWFKDKGEIV RESDNIWISY SENIATLQFS RVEPANAGKY TCQIKNDAGM QECFATLSVL EPATIVEKPE SIKVTTGDTC TLECTVAGTP ELSTKWFKDG KELTSDNKYK ISFFNKVSGL KIINVAPSDS GVYSFEVQNP VGKDSCTASL QVSDRTVPPS FTRKLKETNG LSGSSVVMEC KVYGSPPISV SWFHEGNEIS SGRKYQTTLT DNTCALTVNM LEESDSGDYT CIATNMAGSD ECSAPLTVRE PPSFVQKPDP MDVLTGTNVT FTSIVKGTPP FSVSWFKGSS ELVPGDRCNV SLEDSVAELE LFDVDTSQSG EYTCIVSNEA GKASCTTHLY IKAPAKFVKR LNDYSIEKGK PLILEGTFTG TPPISVTWKK NGINVTPSQR CNITTTEKSA ILEIPSSTVE DAGQYNCYIE NASGKDSCSA QILILEPPYF VKQLEPVKVS VGDSASLQCQ LAGTPEIGVS WYKGDTKLRP TTTYKMHFRN NVATLVFNQV DINDSGEYIC KAENSVGEVS ASTFLTVQEQ KLPPSFSRQL RDVQETVGLP VVFDCAISGS EPISVSWYKD GKPLKDSPNV QTSFLDNTAT LNIFKTDRSL AGQYSCTATN PIGSASSSAR LILTEGKNPP FFDIRLAPVD AVVGESADFE CHVTGTQPIK VSWAKDSREI RSGGKYQISY LENSAHLTVL KVDKGDSGQY TCYAVNEVGK DSCTAQLNIK ERLIPPSFTK RLSETVEETE GNSFKLEGRV AGSQPITVAW YKNNIEIQPT SNCEITFKNN TLVLQVRKAG MNDAGLYTCK VSNDAGSALC TSSIVIKEPK KPPVFDQHLT PVTVSEGEYV QLSCHVQGSE PIRIQWLKAG REIKPSDRCS FSFASGTAVL ELRDVAKADS GDYVCKASNV AGSDTTKSKV TIKDKPAVAP ATKKAAVDGR LFFVSEPQSI RVVEKTTATF IAKVGGDPIP NVKWTKGKWR QLNQGGRVFI HQKGDEAKLE IRDTTKTDSG LYRCVAFNEH GEIESNVNLQ VDERKKQEKI EGDLRAMLKK TPILKKGAGE EEEIDIMELL KNVDPKEYEK YARMYGITDF RGLLQAFELL KQSQEEETHR LEIEEIERSE RDEKEFEELV SFIQQRLSQT EPVTLIKDIE NQTVLKDNDA VFEIDIKINY PEIKLSWYKG TEKLEPSDKF EISIDGDRHT LRVKNCQLKD QGNYRLVCGP HIASAKLTVI EPAWERHLQD VTLKEGQTCT MTCQFSVPNV KSEWFRNGRI LKPQGRHKTE VEHKVHKLTI ADVRAEDQGQ YTCKYEDLET SAELRIEAEP IQFTKRIQNI VVSEHQSATF ECEVSFDDAI VTWYKGPTEL TESQKYNFRN DGRCHYMTIH NVTPDDEGVY SVIARLEPRG EARSTAELYL TTKEIKLELK PPDIPDSRVP IPTMPIRAVP PEEIPPVVAP PIPLLLPTPE EKKPPPKRIE VTKKAVKKDA KKVVAKPKEM TPREEIVKKP PPPTTLIPAK APEIIDVSSK AEEVKIMTIT RKKEVQKEKE AVYEKKQAVH KEKRVFIESF EEPYDELEVE PYTEPFEQPY YEEPDEDYEE IKVEAKKEVH EEWEEDFEEG QEYYEREEGY DEGEEEWEEA YQEREVIQVQ KEVYEESHER KVPAKVPEKK APPPPKVIKK PVIEKIEKTS RRMEEEKVQV TKVPEVSKKI VPQKPSRTPV QEEVIEVKVP AVHTKKMVIS EEKMFFASHT EEEVSVTVPE VQKEIVTEEK IHVAISKRVE PPPKVPELPE KPAPEEVAPV PIPKKVEPPA PKVPEVPKKP VPEEKKPVPV PKKEPAAPPK VPEVPKKPVP EEKIPVPVAK KKEAPPAKVP EVQKGVVTEE KITIVTQREE SPPPAVPEIP KKKVPEERKP VPRKEEEVPP PPKVPALPKK PVPEEKVAVP VPVAKKAPPP RAEVSKKTVV EEKRFVAEEK LSFAVPQRVE VTRHEVSAEE EWSYSEEEEG VSISVYREEE REEEEEAEVT EYEVMEEPEE YVVEEKLHII SKRVEAEPAE VTERQEKKIV LKPKIPAKIE EPPPAKVPEA PKKIVPEKKV PAPVPKKEKV PPPKVPEEPK KPVPEKKVPP KVIKMEEPLP AKVTERHMQI TQEEKVLVAV TKKEAPPKAR VPEEPKRAVP EEKVLKLKPK REEEPPAKVT EFRKRVVKEE KVSIEAPKRE PQPIKEVTIM EEKERAYTLE EEAVSVQREE EYEEYEEYDY KEFEEYEPTE EYDQYEEYEE REYERYEEHE EYITEPEKPI PVKPVPEEPV PTKPKAPPAK VLKKAVPEEK VPVPIPKKLK PPPPKVPEEP KKVFEEKIRI SITKREKEQV TEPAAKVPMK PKRVVAEEKV PVPRKEVAPP VRVPEVPKEL EPEEVAFEEE VVTHVEEYLV EEEEEYIHEE EEFITEEEVV PVIPVKVPEV PRKPVPEEKK PVPVPKKKEA PPAKVPEVPK KPEEKVPVLI PKKEKPPPAK VPEVPKKPVP EEKVPVPVPK KVEAPPAKVP EVPKKPVPEK KVPVPAPKKV EAPPAKVPEV PKKLIPEEKK PTPVPKKVEA PPPKVPKKRE PVPVPVALPQ EEEVLFEEEI VPEEEVLPEE EEVLPEEEEV LPEEEEVLPE EEEIPPEEEE VPPEEEYVPE EEEFVPEEEV LPEVKPKVPV PAPVPEIKKK VTEKKVVIPK KEEAPPAKVP EVPKKVEEKR IILPKEEEVL PVEVTEEPEE EPISEEEIPE EPPSIEEVEE VAPPRVPEVI KKAVPEAPTP VPKKVEAPPA KVSKKIPEEK VPVPVQKKEA PPAKVPEVPK KVPEKKVLVP KKEAVPPAKG RTVLEEKVSV AFRQEVVVKE RLELEVVEAE VEEIPEEEEF HEVEEYFEEG EFHEVEEFIK LEQHRVEEEH RVEKVHRVIE VFEAEEVEVF EKPKAPPKGP EISEKIIPPK KPPTKVVPRK EPPAKVPEVP KKIVVEEKVR VPEEPRVPPT KVPEVLPPKE VVPEKKVPVP PAKKPEAPPP KVPEAPKEVV PEKKVPVPPP KKPEVPPTKV PEVPKAAVPE KKVPEAIPPK PESPPPEVPE APKEVVPEKK VPAAPPKKPE VTPVKVPEAP KEVVPEKKVP VPPPKKPEVP PTKVPEVPKV AVPEKKVPEA IPPKPESPPP EVFEEPEEVA LEEPPAEVVE EPEPAAPPQV TVPPKKPVPE KKAPAVVAKK PELPPVKVPE VPKEVVPEKK VPLVVPKKPE APPAKVPEVP KEVVPEKKVA VPKKPEVPPA KVPEVPKKPV LEEKPAVPVP ERAESPPPEV YEEPEEIAPE EEIAPEEEKP VPVAEEEEPE VPPPAVPEEP KKIIPEKKVP VIKKPEAPPP KEPEPEKVIE KPKLKPRPPP PPPAPPKEDV KEKIFQLKAI PKKKVPEKPQ VPEKVELTPL KVPGGEKKVR KLLPERKPEP KEEVVLKSVL RKRPEEEEPK VEPKKLEKVK KPAVPEPPPP KPVEEVEVPT VTKRERKIPE PTKVPEIKPA IPLPAPEPKP KPEAEVKTIK PPPVEPEPTP IAAPVTVPVV GKKAEAKAPK EEAAKPKGPI KGVPKKTPSP IEAERRKLRP GSGGEKPPDE APFTYQLKAV PLKFVKEIKD IILTESEFVG SSAIFECLVS PSTAITTWMK DGSNIRESPK HRFIADGKDR KLHIIDVQLS DAGEYTCVLR LGNKEKTSTA KLVVEELPVR FVKTLEEEVT VVKGQPLYLS CELNKERDVV WRKDGKIVVE KPGRIVPGVI GLMRALTIND ADDTDAGTYT VTVENANNLE CSSCVKVVEV IRDWLVKPIR DQHVKPKGTA IFACDIAKDT PNIKWFKGYD EIPAEPNDKT EILRDGNHLY LKIKNAMPED IAEYAVEIEG KRYPAKLTLG EREVELLKPI EDVTIYEKES ASFDAEISEA DIPGQWKLKG ELLRPSPTCE IKAEGGKRFL TLHKVKLDQA GEVLYQALNA ITTAILTVKE IELDFAVPLK DVTVPERRQA RFECVLTREA NVIWSKGPDI IKSSDKFDII ADGKKHILVI NDSQFDDEGV YTAEVEGKKT SARLFVTGIR LKFMSPLEDQ TVKEGETATF VCELSHEKMH VVWFKNDAKL HTSRTVLISS EGKTHKLEMK EVTLDDISQI KAQVKELSST AQLKVLEADP YFTVKLHDKT AVEKDEITLK CEVSKDVPVK WFKDGEEIVP SPKYSIKADG LRRILKIKKA DLKDKGEYVC DCGTDKTKAN VTVEARLIKV EKPLYGVEVF VGETAHFEIE LSEPDVHGQW KLKGQPLTAS PDCEIIEDGK KHILILHNCQ LGMTGEVSFQ AANAKSAANL KVKELPLIFI TPLSDVKVFE KDEAKFECEV SREPKTFRWL KGTQEITGDD RFELIKDGTK HSMVIKSAAF EDEAKYMFEA EDKHTSGKLI IEGIRLKFLT PLKDVTAKEK ESAVFTVELS HDNIRVKWFK NDQRLHTTRS VSMQDEGKTH SITFKDLSID DTSQIRVEAM GMSSEAKLTV LEGDPYFTGK LQDYTGVEKD EVILQCEISK ADAPVKWFKD GKEIKPSKNA VIKADGKKRM LILKKALKSD IGQYTCDCGT DKTSGKLDIE DREIKLVRPL HSVEVMETET ARFETEISED DIHANWKLKG EALLQTPDCE IKEEGKIHSL VLHNCRLDQT GGVDFQAANV KSSAHLRVKP RVIGLLRPLK DVTVTAGETA TFDCELSYED IPVEWYLKGK KLEPSDKVVP RSEGKVHTLT LRDVKLEDAG EVQLTAKDFK THANLFVKEP PVEFTKPLED QTVEEGATAV LECEVSRENA KVKWFKNGTE ILKSKKYEIV ADGRVRKLVI HDCTPEDIKT YTCDAKDFKT SCNLNVVPPH VEFLRPLTDL QVREKEMARF ECELSRENAK VKWFKDGAEI KKGKKYDIIS KGAVRILVIN KCLLDDEAEY SCEVRTARTS GMLTVLEEEA VFTKNLANIE VSETDTIKLV CEVSKPGAEV IWYKGDEEII ETGRYEILTE GRKRILVIQN AHLEDAGNYN CRLPSSRTDG KVKVHELAAE FISKPQNLEI LEGEKAEFVC SISKESFPVQ WKRDDKTLES GDKYDVIADG KKRVLVVKDA TLQDMGTYVV MVGAARAAAH LTVIEKLRIV VPLKDTRVKE QQEVVFNCEV NTEGAKAKWF RNEEAIFDSS KYIILQKDLV YTLRIRDAHL DDQANYNVSL TNHRGENVKS AANLIVEEED LRIVEPLKDI ETMEKKSVTF WCKVNRLNVT LKWTKNGEEV PFDNRVSYRV DKYKHMLTIK DCGFPDEGEY IVTAGQDKSV AELLIIEAPT EFVEHLEDQT VTEFDDAVFS CQLSREKANV KWYRNGREIK EGKKYKFEKD GSIHRLIIKD CRLDDECEYA CGVEDRKSRA RLFVEEIPVE IIRPPQDILE APGADVVFLA ELNKDKVEVQ WLRNNMVVVQ GDKHQMMSEG KIHRLQICDI KPRDQGEYRF IAKDKEARAK LELAAAPKIK TADQDLVVDV GKPLTMVVPY DAYPKAEAEW FKENEPLSTK TIDTTAEQTS FRILEAKKGD KGRYKIVLQN KHGKAEGFIN LKVIDVPGPV RNLEVTETFD GEVSLAWEEP LTDGGSKIIG YVVERRDIKR KTWVLATDRA ESCEFTVTGL QKGGVEYLFR VSARNRVGTG EPVETDNPVE ARSKYDVPGP PLNVTITDVN RFGVSLTWEP PEYDGGAEIT NYVIELRDKT SIRWDTAMTV RAEDLSATVT DVVEGQEYSF RVRAQNRIGV GKPSAATPFV KVADPIERPS PPVNLTSSDQ TQSSVQLKWE PPLKDGGSPI LGYIIERCEE GKDNWIRCNM KLVPELTYKV TGLEKGNKYL YRVSAENKAG VSDPSEILGP LTADDAFVEP TMDLSAFKDG LEVIVPNPIT ILVPSTGYPR PTATWCFGDK VLETGDRVKM KTLSAYAELV ISPSERSDKG IYTLKLENRV KTISGEIDVN VIARPSAPKE LKFGDITKDS VHLTWEPPDD DGGSPLTGYV VEKREVSRKT WTKVMDFVTD LEFTVPDLVQ GKEYLFKVCA RNKCGPGEPA YVDEPVNMST PATVPDPPEN VKWRDRTANS IFLTWDPPKN DGGSRIKGYI VERCPRGSDK WVACGEPVAE TKMEVTGLEE GKWYAYRVKA LNRQGASKPS RPTEEIQAVD TQEAPEIFLD VKLLAGLTVK AGTKIELPAT VTGKPEPKIT WTKADMILKQ DKRITIENVP KKSTVTIVDS KRSDTGTYII EAVNVCGRAT AVVEVNVLDK PGPPAAFDIT DVTNESCLLT WNPPRDDGGS KITNYVVERR ATDSEVWHKL SSTVKDTNFK ATKLIPNKEY IFRVAAENMY GVGEPVQASP ITAKYQFDPP GPPTRLEPSD ITKDAVTLTW CEPDDDGGSP ITGYWVERLD PDTDKWVRCN KMPVKDTTYR VKGLTNKKKY RFRVLAENLA GPGKPSKSTE PILIKDPIDP PWPPGKPTVK DVGKTSVRLN WTKPEHDGGA KIESYVIEML KTGTDEWVRV AEGVPTTQHL LPGLMEGQEY SFRVRAVNKA GESEPSEPSD PVLCREKLYP PSPPRWLEVI NITKNTADLK WTVPEKDGGS PITNYIVEKR DVRRKGWQTV DTTVKDTKCT VTPLTEGSLY VFRVAAENAI GQSDYTEIED SVLAKDTFTT PGPPYALAVV DVTKRHVDLK WEPPKNDGGR PIQRYVIEKK ERLGTRWVKA GKTAGPDCNF RVTDVIEGTE VQFQVRAENE AGVGHPSEPT EILSIEDPTS PPSPPLDLHV TDAGRKHIAI AWKPPEKNGG SPIIGYHVEM CPVGTEKWMR VNSRPIKDLK FKVEEGVVPD KEYVLRVRAV NAIGVSEPSE ISENVVAKDP DCKPTIDLET HDIIVIEGEK LSIPVPFRAV PVPTVSWHKD GKEVKASDRL TMKNDHISAH LEVPKSVRAD AGIYTITLEN KLGSATASIN VKVIGLPGPC KDIKASDITK SSCKLTWEPP EFDGGTPILH YVLERREAGR RTYIPVMSGE NKLSWTVKDL IPNGEYFFRV KAVNKVGGGE YIELKNPVIA QDPKQPPDPP VDVEVHNPTA EAMTITWKPP LYDGGSKIMG YIIEKIAKGE ERWKRCNEHL VPILTYTAKG LEEGKEYQFR VRAENAAGIS EPSRATPPTK AVDPIDAPKV ILRTSLEVKR GDEIALDASI SGSPYPTITW IKDENVIVPE EIKKRAAPLV RRRKGEVQEE EPFVLPLTQR LSIDNSKKGE SQLRVRDSLR PDHGLYMIKV ENDHGIAKAP CTVSVLDTPG PPINFVFEDI RKTSVLCKWE PPLDDGGSEI INYTLEKKDK TKPDSEWIVV TSTLRHCKYS VTKLIEGKEY LFRVRAENRF GPGPPCVSKP LVAKDPFGPP DAPDKPIVED VTSNSMLVKW NEPKDNGSPI LGYWLEKREV NSTHWSRVNK SLLNALKANV DGLLEGLTYV FRVCAENAAG PGKFSPPSDP KTAHDPISPP GPPIPRVTDT SSTTIELEWE PPAFNGGGEI VGYFVDKQLV GTNEWSRCTE KMIKVRQYTV KEIREGADYK LRVSAVNAAG EGPPGETQPV TVAEPQEPPA VELDVSVKGG IQIMAGKTLR IPAVVTGRPV PTKVWTKEEG ELDKDRVVID NVGTKSELII KDALRKDHGR YVITATNSCG SKFAAARVEV FDVPGPVLDL KPVVTNRKMC LLNWSDPEDD GGSEITGFII ERKDAKMHTW RQPIETERSK CDITGLLEGQ EYKFRVIAKN KFGCGPPVEI GPILAVDPLG PPTSPERLTY TERTKSTITL DWKEPRSNGG SPIQGYIIEK RRHDKPDFER VNKRLCPTTS FLVENLDEHQ MYEFRVKAVN EIGESEPSLP LNVVIQDDEV PPTIKLRLSV RGDTIKVKAG EPVHIPADVT GLPMPKIEWS KNETVIEKPT DALQITKEEV SRSEAKTELS IPKAVREDKG TYTVTASNRL GSVFRNVHVE VYDRPSPPRN LAVTDIKAES CYLTWDAPLD NGGSEITHYV IDKRDASRKK AEWEEVTNTA VEKRYGIWKL IPNGQYEFRV RAVNKYGISD ECKSDKVVIQ DPYRLPGPPG KPKVLARTKG SMLVSWTPPL DNGGSPITGY WLEKREEGSP YWSRVSRAPI TKVGLKGVEF NVPRLLEGVK YQFRAMAINA AGIGPPSEPS DPEVAGDPIF PPGPPSCPEV KDKTKSSISL GWKPPAKDGG SPIKGYIVEM QEEGTTDWKR VNEPDKLITT CECVVPNLKE LRKYRFRVKA VNEAGESEPS DTTGEIPATD IQEEPEVFID IGAQDCLVCK AGSQIRIPAV IKGRPTPKSS WEFDGKAKKA MKDGVHDIPE DAQLETAENS SVIIIPECKR SHTGKYSITA KNKAGQKTAN CRVKVMDVPG PPKDLKVSDI TRGSCRLSWK MPDDDGGDRI KGYVIEKRTI DGKAWTKVNP DCGSTTFVVP DLLSEQQYFF RVRAENRFGI GPPVETIQRT TARDPIYPPD PPIKLKIGLI TKNTVHLSWK PPKNDGGSPV THYIVECLAW DPTGTKKEAW RQCNKRDVEE LQFTVEDLVE GGEYEFRVKA VNAAGVSKPS ATVGPVTVKD QTCPPSIDLK EFMEVEEGTN VNIVAKIKGV PFPTLTWFKA PPKKPDNKEP VLYDTHVNKL VVDDTCTLVI PQSRRSDTGL YTITAVNNLG TASKEMRLNV LGRPGPPVGP IKFESVSADQ MTLSWFPPKD DGGSKITNYV IEKREANRKT WVHVSSEPKE CTYTIPKLLE GHEYVFRIMA QNKYGIGEPL DSEPETARNL FSVPGAPDKP TVSSVTRNSM TVNWEEPEYD GGSPVTGYWL EMKDTTSKRW KRVNRDPIKA MTLGVSYKVT GLIEGSDYQF RVYAINAAGV GPASLPSDPA TARDPIAPPG PPFPKVTDWT KSSADLEWSP PLKDGGSKVT GYIVEYKEEG KEEWEKGKDK EVRGTKLVVT GLKEGAFYKF RVRAVNIAGI GEPGEVTDVI EMKDRLVSPD LQLDASVRDR IVVHAGGVIR IIAYVSGKPP PTVTWNMNER TLPQEATIET TAISSSMVIK NCQRSHQGVY SLLAKNEAGE RKKTIIVDVL DVPGPVGTPF LAHNLTNESC KLTWFSPEDD GGSPITNYVI EKRESDRRAW TPVTYTVTRQ NATVQGLIQG KAYFFRIAAE NSIGMGPFVE TSEALVIREP ITVPERPEDL EVKEVTKNTV TLTWNPPKYD GGSEIINYVL ESRLIGTEKF HKVTNDNLLS RKYTVKGLKE GDTYEYRVSA VNIVGQGKPS FCTKPITCKD ELAPPTLHLD FRDKLTIRVG EAFALTGRYS GKPKPKVSWF KDEADVLEDD RTHIKTTPAT LALEKIKAKR SDSGKYCVVV ENSTGSRKGF CQVNVVDRPG PPVGPVSFDE VTKDYMVISW KPPLDDGGSK ITNYIIEKKE VGKDVWMPVT SASAKTTCKV SKLLEGKDYI FRIHAENLYG ISDPLVSDSM KAKDRFRVPD APDQPIVTEV TKDSALVTWN KPHDGGKPIT NYILEKRETM SKRWARVTKD PIHPYTKFRV PDLLEGCQYE FRVSAENEIG IGDPSPPSKP VFAKDPIAKP SPPVNPEAID TTCNSVDLTW QPPRHDGGSK ILGYIVEYQK VGDEEWRRAN HTPESCPETK YKVTGLRDGQ TYKFRVLAVN AAGESDPAHV PEPVLVKDRL EPPELILDAN MAREQHIKVG DTLRLSAIIK GVPFPKVTWK KEDRDAPTKA RIDVTPVGSK LEIRNAAHED GGIYSLTVEN PAGSKTVSVK VLVLDKPGPP RDLEVSEIRK DSCYLTWKEP LDDGGSVITN YVVERRDVAS AQWSPLSATS KKKSHFAKHL NEGNQYLFRV AAENQYGRGP FVETPKPIKA LDPLHPPGPP KDLHHVDVDK TEVSLVWNKP DRDGGSPITG YLVEYQEEGT QDWIKFKTVT NLECVVTGLQ QGKTYRFRVK AENIVGLGLP DTTIPIECQE KLVPPSVELD VKLIEGLVVK AGTTVRFPAI IRGVPVPTAK WTTDGSEIKT DEHYTVETDN FSSVLTIKNC LRRDTGEYQI TVSNAAGSKT VAVHLTVLDV PGPPTGPINI LDVTPEHMTI SWQPPKDDGG SPVINYIVEK QDTRKDTWGV VSSGSSKTKL KIPHLQKGCE YVFRVRAENK IGVGPPLDST PTVAKHKFSP PSPPGKPVVT DITENAATVS WTLPKSDGGS PITGYYMERR EVTGKWVRVN KTPIADLKFR VTGLYEGNTY EFRVFAENLA GLSKPSPSSD PIKACRPIKP PGPPINPKLK DKSRETADLV WTKPLSDGGS PILGYVVECQ KPGTAQWNRI NKDELIRQCA FRVPGLIEGN EYRFRIKAAN IVGEGEPREL AESVIAKDIL HPPEVELDVT CRDVITVRVG QTIRILARVK GRPEPDITWT KEGKVLVREK RVDLIQDLPR VELQIKEAVR ADHGKYIISA KNSSGHAQGS AIVNVLDRPG PCQNLKVTNV TKENCTISWE NPLDNGGSEI TNFIVEYRKP NQKGWSIVAS DVTKRLIKAN LLANNEYYFR VCAENKVGVG PTIETKTPIL AINPIDRPGE PENLHIADKG KTFVYLKWRR PDYDGGSPNL SYHVERRLKG SDDWERVHKG SIKETHYMVD RCVENQIYEF RVQTKNEGGE SDWVKTEEVV VKEDLQKPVL DLKLSGVLTV KAGDTIRLEA GVRGKPFPEV AWTKDKDATD LTRSPRVKID TRADSSKFSL TKAKRSDGGK YVVTATNTAG SFVAYATVNV LDKPGPVRNL KIVDVSSDRC TVCWDPPEDD GGCEIQNYIL EKCETKRMVW STYSATVLTP GTTVTRLIEG NEYIFRVRAE NKIGTGPPTE SKPVIAKTKY DKPGRPDPPE VTKVSKEEMT VVWNPPEYDG GKSITGYFLE KKEKHSTRWV PVNKSAIPER RMKVQNLLPD HEYQFRVKAE NEIGIGEPSL PSRPVVAKDP IEPPGPPTNF RVVDTTKHSI TLGWGKPVYD GGAPIIGYVV EMRPKIADAS PDEGWKRCNA AAQLVRKEFT VTSLDENQEY EFRVCAQNQV GIGRPAELKE AIKPKEILEP PEIDLDASMR KLVIVRAGCP IRLFAIVRGR PAPKVTWRKV GIDNVVRKGQ VDLVDTMAFL VIPNSTRDDS GKYSLTLVNP AGEKAVFVNV RVLDTPGPVS DLKVSDVTKT SCHVSWAPPE NDGGSQVTHY IVEKREADRK TWSTVTPEVK KTSFHVTNLV PGNEYYFRVT AVNEYGPGVP TDVPKPVLAS DPLSEPDPPR KLEVTEMTKN SATLAWLPPL RDGGAKIDGY ITSYREEEQP ADRWTEYSVV KDLSLVVTGL KEGKKYKFRV AARNAVGVSL PREAEGVYEA KEQLLPPKIL MPEQITIKAG KKLRIEAHVY GKPHPTCKWK KGEDEVVTSS HLAVHKADSS SILIIKDVTR KDSGYYSLTA ENSSGTDTQK IKVVVMDAPG PPQPPFDISD IDADACSLSW HIPLEDGGSN ITNYIVEKCD VSRGDWVTAL ASVTKTSCRV GKLIPGQEYI FRVRAENRFG ISEPLTSPKM VAQFPFGVPS EPKNARVTKV NKDCIFVAWD RPDSDGGSPI IGYLIERKER NSLLWVKAND TLVRSTEYPC AGLVEGLEYS FRIYALNKAG SSPPSKPTEY VTARMPVDPP GKPEVIDVTK STVSLIWARP KHDGGSKIIG YFVEACKLPG DKWVRCNTAP HQIPQEEYTA TGLEEKAQYQ FRAIARTAVN ISPPSEPSDP VTILAENVPP RIDLSVAMKS LLTVKAGTNV CLDATVFGKP MPTVSWKKDG TLLKPAEGIK MAMQRNLCTL ELFSVNRKDS GDYTITAENS SGSKSATIKL KVLDKPGPPA SVKINKMYSD RAMLSWEPPL EDGGSEITNY IVDKRETSRP NWAQVSATVP ITSCSVEKLI EGHEYQFRIC AENKYGVGDP VFTEPAIAKN PYDPPGRCDP PVISNITKDH MTVSWKPPAD DGGSPITGYL LEKRETQAVN WTKVNRKPII ERTLKATGLQ EGTEYEFRVT AINKAGPGKP SDASKAAYAR DPQYPPGPPA FPKVYDTTRS SVSLSWGKPA YDGGSPIIGY LVEVKRADSD NWVRCNLPQN LQKTRFEVTG LMEDTQYQFR VYAVNKIGYS DPSDVPDKHY PKDILIPPEG ELDADLRKTL ILRAGVTMRL YVPVKGRPPP KITWSKPNVN LRDRIGLDIK STDFDTFLRC ENVNKYDAGK YILTLENSCG KKEYTIVVKV LDTPGPPVNV TVKEISKDSA YVTWEPPIID GGSPIINYVV QKRDAERKSW STVTTECSKT SFRVANLEEG KSYFFRVFAE NEYGIGDPGE TRDAVKASQT PGPVVDLKVR SVSKSSCSIG WKKPHSDGGS RIIGYVVDFL TEENKWQRVM KSLSLQYSAK DLTEGKEYTF RVSAENENGE GTPSEITVVA RDDVVAPDLD LKGLPDLCYL AKENSNFRLK IPIKGKPAPS VSWKKGEDPL ATDTRVSVES SAVNTTLIVY DCQKSDAGKY TITLKNVAGT KEGTISIKVV GKPGIPTGPI KFDEVTAEAM TLKWAPPKDD GGSEITNYIL EKRDSVNNKW VTCASAVQKT TFRVTRLHEG MEYTFRVSAE NKYGVGEGLK SEPIVARHPF DVPDAPPPPN IVDVRHDSVS LTWTDPKKTG GSPITGYHLE FKERNSLLWK RANKTPIRMR DFKVTGLTEG LEYEFRVMAI NLAGVGKPSL PSEPVVALDP IDPPGKPEVI NITRNSVTLI WTEPKYDGGH KLTGYIVEKR DLPSKSWMKA NHVNVPECAF TVTDLVEGGK YEFRIRAKNT AGAISAPSES TETIICKDEY EAPTIVLDPT IKDGLTIKAG DTIVLNAISI LGKPLPKSSW SKAGKDIRPS DITQITSTPT SSMLTIKYAT RKDAGEYTIT ATNPFGTKVE HVKVTVLDVP GPPGPVEISN VSAEKATLTW TPPLEDGGSP IKSYILEKRE TSRLLWTVVS EDIQSCRHVA TKLIQGNEYI FRVSAVNHYG KGEPVQSEPV KMVDRFGPPG PPEKPEVSNV TKNTATVSWK RPVDDGGSEI TGYHVERREK KSLRWVRAIK TPVSDLRCKV TGLQEGSTYE FRVSAENRAG IGPPSEASDS VLMKDAAYPP GPPSNPHVTD TTKKSASLAW GKPHYDGGLE ITGYVVEHQK VGDEAWIKDT TGTALRITQF VVPDLQTKEK YNFRISAIND AGVGEPAVIP DVEIVEREMA PDFELDAELR RTLVVRAGLS IRIFVPIKGR PAPEVTWTKD NINLKNRANI ENTESFTLLI IPECNRYDTG KFVMTIENPA GKKSGFVNVR VLDTPGPVLN LRPTDITKDS VTLHWDLPLI DGGSRITNYI VEKREATRKS YSTATTKCHK CTYKVTGLSE GCEYFFRVMA ENEYGIGEPT ETTEPVKASE APSPPDSLNI MDITKSTVSL AWPKPKHDGG SKITGYVIEA QRKGSDQWTH ITTVKGLECV VRNLTEGEEY TFQVMAVNSA GRSAPRESRP VIVKEQTMLP ELDLRGIYQK LVIAKAGDNI KVEIPVLGRP KPTVTWKKGD QILKQTQRVN FETTATSTIL NINECVRSDS GPYPLTARNI VGEVGDVITI QVHDIPGPPT GPIKFDEVSS DFVTFSWDPP ENDGGVPISN YVVEMRQTDS TTWVELATTV IRTTYKATRL TTGLEYQFRV KAQNRYGVGP GITSACIVAN YPFKVPGPPG TPQVTAVTKD SMTISWHEPL SDGGSPILGY HVERKERNGI LWQTVSKALV PGNIFKSSGL TDGIAYEFRV IAENMAGKSK PSKPSEPMLA LDPIDPPGKP VPLNITRHTV TLKWAKPEYT GGFKITSYIV EKRDLPNGRW LKANFSNILE NEFTVSGLTE DAAYEFRVIA KNAAGAISPP SEPSDAITCR DDVEAPKIKV DVKFKDTVIL KAGEAFRLEA DVSGRPPPTM EWSKDGKELE GTAKLEIKIA DFSTNLVNKD STRRDSGAYT LTATNPGGFA KHIFNVKVLD RPGPPEGPLA VTEVTSEKCV LSWFPPLDDG GAKIDHYIVQ KRETSRLAWT NVASEVQVTK LKVTKLLKGN EYIFRVMAVN KYGVGEPLES EPVLAVNPYG PPDPPKNPEV TTITKDSMVV CWGHPDSDGG SEIINYIVER RDKAGQRWIK CNKKTLTDLR YKVSGLTEGH EYEFRIMAEN AAGISAPSPT SPFYKACDTV FKPGPPGNPR VLDTSRSSIS IAWNKPIYDG GSEITGYMVE IALPEEDEWQ IVTPPAGLKA TSYTITGLTE NQEYKIRIYA MNSEGLGEPA LVPGTPKAED RMLPPEIELD ADLRKVVTIR ACCTLRLFVP IKGRPAPEVK WARDHGESLD KASIESTSSY TLLIVGNVNR FDSGKYILTV ENSSGSKSAF VNVRVLDTPG PPQDLKVKEV TKTSVTLTWD PPLLDGGSKI KNYIVEKRES TRKAYSTVAT NCHKTSWKVD QLQEGCSYYF RVLAENEYGI GLPAETAESV KASERPLPPG KITLMDVTRN SVSLSWEKPE HDGGSRILGY IVEMQTKGSD KWATCATVKV TEATITGLIQ GEEYSFRVSA QNEKGISDPR QLSVPVIAKD LVIPPAFKLL FNTFTVLAGE DLKVDVPFIG RPTPAVTWHK DNVPLKQTTR VNAESTENNS LLTIKDACRE DVGHYVVKLT NSAGEAIETL NVIVLDKPGP PTGPVKMDEV TADSITLSWG PPKYDGGSSI NNYIVEKRDT STTTWQIVSA TVARTTIKAC RLKTGCEYQF RIAAENRYGK STYLNSEPTV AQYPFKVPGP PGTPVVTLSS RDSMEVQWNE PISDGGSRVI GYHLERKERN SILWVKLNKT PIPQTKFKTT GLEEGVEYEF RVSAENIVGI GKPSKVSECY VARDPCDPPG RPEAIIVTRN SVTLQWKKPT YDGGSKITGY IVEKKELPEG RWMKASFTNI IDTHFEVTGL VEDHRYEFRV IARNAAGVFS EPSESTGAIT ARDEVDPPRI SMDPKYKDTI VVHAGESFKV DADIYGKPIP TIQWIKGDQE LSNTARLEIK STDFATSLSV KDAVRVDSGN YILKAKNVAG ERSVTVNVKV LDRPGPPEGP VVISGVTAEK CTLAWKPPLQ DGGSDIINYI VERRETSRLV WTVVDANVQT LSCKVTKLLE GNEYTFRIMA VNKYGVGEPL ESEPVVAKNP FVVPDAPKAP EVTTVTKDSM IVVWERPASD GGSEILGYVL EKRDKEGIRW TRCHKRLIGE LRLRVTGLIE NHDYEFRVSA ENAAGLSEPS PPSAYQKACD PIYKPGPPNN PKVIDITRSS VFLSWSKPIY DGGCEIQGYI VEKCDVSVGE WTMCTPPTGI NKTNIEVEKL LEKHEYNFRI CAINKAGVGE HADVPGPIIV EEKLEAPDID LDLELRKIIN IRAGGSLRLF VPIKGRPTPE VKWGKVDGEI RDAAIIDVTS SFTSLVLDNV NRYDSGKYTL TLENSSGTKS AFVTVRVLDT PSPPVNLKVT EITKDSVSIT WEPPLLDGGS KIKNYIVEKR EATRKSYAAV VTNCHKNSWK IDQLQEGCSY YFRVTAENEY GIGLPAQTAD PIKVAEVPQP PGKITVDDVT RNSVSLSWTK PEHDGGSKII QYIVEMQAKH SEKWSECARV KSLQAVITNL TQGEEYLFRV VAVNEKGRSD PRSLAVPIVA KDLVIEPDVK PAFSSYSVQV GQDLKIEVPI SGRPKPTITW TKDGLPLKQT TRINVTDSLD LTTLSIKETH KDDGGQYGIT VANVVGQKTA SIEIVTLDKP DPPKGPVKFD DVSAESITLS WNPPLYTGGC QITNYIVQKR DTTTTVWDVV SATVARTTLK VTKLKTGTEY QFRIFAENRY GQSFALESDP IVAQYPYKEP GPPGTPFATA ISKDSMVIQW HEPVNNGGSP VIGYHLERKE RNSILWTKVN KTIIHDTQFK AQNLEEGIEY EFRVYAENIV GVGKASKNSE CYVARDPCDP PGTPEPIMVK RNEITLQWTK PVYDGGSMIT GYIVEKRDLP DGRWMKASFT NVIETQFTVS GLTEDQRYEF RVIAKNAAGA ISKPSDSTGP ITAKDEVELP RISMDPKFRD TIVVNAGETF RLEADVHGKP LPTIEWLRGD KEIEESARCE IKNTDFKALL IVKDAIRIDG GQYILRASNV AGSKSFPVNV KVLDRPGPPE GPVQVTGVTS EKCSLTWSPP LQDGGSDISH YVVEKRETSR LAWTVVASEV VTNSLKVTKL LEGNEYVFRI MAVNKYGVGE PLESAPVLMK NPFVLPGPPK SLEVTNIAKD SMTVCWNRPD SDGGSEIIGY IVEKRDRSGI RWIKCNKRRI TDLRLRVTGL TEDHEYEFRV SAENAAGVGE PSPATVYYKA CDPVFKPGPP TNAHIVDTTK NSITLAWGKP IYDGGSEILG YVVEICKADE EEWQIVTPQT GLRVTRFEIS KLTEHQEYKI RVCALNKVGL GEATSVPGTV KPEDKLEAPE LDLDSELRKG IVVRAGGSAR IHIPFKGRPT PEITWSREEG EFTDKVQIEK GVNYTQLSID NCDRNDAGKY ILKLENSSGS KSAFVTVKVL DTPGPPQNLA VKEVRKDSAF LVWEPPIIDG GAKVKNYVID KRESTRKAYA NVSSKCSKTS FKVENLTEGA IYYFRVMAEN EFGVGVPVET VDAVKAAEPP SPPGKVTLTD VSQTSASLMW EKPEHDGGSR VLGYVVEMQP KGTEKWSIVA ESKVCNAVVT GLSSGQEYQF RVKAYNEKGK SDPRVLGVPV IAKDLTIQPS LKLPFNTYSI QAGEDLKIEI PVIGRPRPNI SWVKDGEPLK QTTRVNVEET ATSTVLHIKE GNKDDFGKYT VTATNSAGTA TENLSVIVLE KPGPPVGPVR FDEVSADFVV ISWEPPAYTG GCQISNYIVE KRDTTTTTWH MVSATVARTT IKITKLKTGT EYQFRIFAEN RYGKSAPLDS KAVIVQYPFK EPGPPGTPFV TSISKDQMLV QWHEPVNDGG TKIIGYHLEQ KEKNSILWVK LNKTPIQDTK FKTTGLDEGL EYEFKVSAEN IVGIGKPSKV SECFVARDPC DPPGRPEAIV ITRNNVTLKW KKPAYDGGSK ITGYIVEKKD LPDGRWMKAS FTNVLETEFT VSGLVEDQRY EFRVIARNAA GNFSEPSDSS GAITARDEID APNASLDPKY KDVIVVHAGE TFVLEADIRG KPIPDVVWSK DGKELEETAA RMEIKSTIQK TTLVVKDCIR TDGGQYILKL SNVGGTKSIP ITVKVLDRPG PPEGPLKVTG VTAEKCYLAW NPPLQDGGAN ISHYIIEKRE TSRLSWTQVS TEVQALNYKV TKLLPGNEYI FRVMAVNKYG IGEPLESGPV TACNPYKPPG PPSTPEVSAI TKDSMVVTWA RPVDDGGTEI EGYILEKRDK EGVRWTKCNK KTLTDLRLRV TGLTEGHSYE FRVAAENAAG VGEPSEPSVF YRACDALYPP GPPSNPKVTD TSRSSVSLAW SKPIYDGGAP VKGYVVEVKE AAADEWTTCT PPTGLQGKQF TVTKLKENTE YNFRICAINS EGVGEPATLP GSVVAQERIE PPEIELDADL RKVVVLRASA TLRLFVTIKG RPEPEVKWEK AEGILTDRAQ IEVTSSFTML VIDNVTRFDS GRYNLTLENN SGSKTAFVNV RVLDSPSAPV NLTIREVKKD SVTLSWEPPL IDGGAKITNY IVEKRETTRK AYATITNNCT KTTFRIENLQ EGCSYYFRVL ASNEYGIGLP AETTEPVKVS EPPLPPGRVT LVDVTRNTAT IKWEKPESDG GSKITGYVVE MQTKGSEKWS TCTQVKTLEA TISGLTAGEE YVFRVAAVNE KGRSDPRQLG VPVIARDIEI KPSVELPFHT FNVKAREQLK IDVPFKGRPQ ATVNWRKDGQ TLKETTRVNV SSSKTVTSLS IKEASKEDVG TYELCVSNSA GSITVPITII VLDRPGPPGP IRIDEVSCDS ITISWNPPEY DGGCQISNYI VEKKETTSTT WHIVSQAVAR TSIKIVRLTT GSEYQFRVCA ENRYGKSSYS ESSAVVAEYP FSPPGPPGTP KVVHATKSTM LVTWQVPVND GGSRVIGYHL EYKERSSILW SKANKILIAD TQMKVSGLDE GLMYEYRVYA ENIAGIGKCS KSCEPVPARD PCDPPGQPEV TNITRKSVSL KWSKPHYDGG AKITGYIVER RELPDGRWLK CNYTNIQETY FEVTELTEDQ RYEFRVFARN AADSVSEPSE STGPIIVKDD VEPPRVMMDV KFRDVIVVKA GEVLKINADI AGRPLPVISW AKDGIEIEER ARTEIISTDN HTLLTVKDCI RRDTGQYVLT LKNVAGTRSV AVNCKVLDKP GPPAGPLEIN GLTAEKCSLS WGRPQEDGGA DIDYYIVEKR ETSHLAWTIC EGELQMTSCK VTKLLKGNEY IFRVTGVNKY GVGEPLESVA IKALDPFTVP SPPTSLEITS VTKESMTLCW SRPESDGGSE ISGYIIERRE KNSLRWVRVN KKPVYDLRVK STGLREGCEY EYRVYAENAA GLSLPSETSP LIRAEDPVFL PSPPSKPKIV DSGKTTITIA WVKPLFDGGA PITGYTVEYK KSDDTDWKTS IQSLRGTEYT ISGLTTGAEY VFRVKSVNKV GASDPSDSSD PQIAKEREEE PLFDIDSEMR KTLIVKAGAS FTMTVPFRGR PVPNVLWSKP DTDLRTRAYV DTTDSRTSLT IENANRNDSG KYTLTIQNVL SAASLTLVVK VLDTPGPPTN ITVQDVTKES AVLSWDVPEN DGGAPVKNYH IEKREASKKA WVSVTNNCNR LSYKVTNLQE GAIYYFRVSG ENEFGVGIPA ETKEGVKITE KPSPPEKLGV TSISKDSVSL TWLKPEHDGG SRIVHYVVEA LEKGQKNWVK CAVAKSTHHV VSGLRENSEY FFRVFAENQA GLSDPRELLL PVLIKEQLEP PEIDMKNFPS HTVYVRAGSN LKVDIPISGK PLPKVTLSRD GVPLKATMRF NTEITAENLT INLKESVTAD AGRYEITAAN SSGTTKAFIN IVVLDRPGPP TGPVVISDIT EESVTLKWEP PKYDGGSQVT NYILLKRETS TAVWTEVSAT VARTMMKVMK LTTGEEYQFR IKAENRFGIS DHIDSACVTV KLPYTTPGPP STPWVTNVTR ESITVGWHEP VSNGGSAVVG YHLEMKDRNS ILWQKANKLV IRTTHFKVTT ISAGLIYEFR VYAENAAGVG KPSHPSEPVL AIDACEPPRN VRITDISKNS VSLSWQQPAF DGGSKITGYI VERRDLPDGR WTKASFTNVT ETQFIISGLT QNSQYEFRVF ARNAVGSISN PSEVVGPITC IDSYGGPVID LPLEYTEVVK YRAGTSVKLR AGISGKPAPT IEWYKDDKEL QTNALVCVEN TTDLASILIK DADRLNSGCY ELKLRNAMGS ASATIRVQIL DKPGPPGGPI EFKTVTAEKI TLLWRPPADD GGAKITHYIV EKRETSRVVW SMVSEHLEEC IITTTKIIKG NEYIFRVRAV NKYGIGEPLE SDSVVAKNAF VTPGPPGIPE VTKITKNSMT VVWSRPIADG GSDISGYFLE KRDKKSLGWF KVLKETIRDT RQKVTGLTEN SDYQYRVCAV NAAGQGPFSE PSEFYKAADP IDPPGPPAKI RIADSTKSSI TLGWSKPVYD GGSAVTGYVV EIRQGEEEEW TTVSTKGEVR TTEYVVSNLK PGVNYYFRVS AVNCAGQGEP IEMNEPVQAK DILEAPEIDL DVALRTSVIA KAGEDVQVLI PFKGRPPPTV TWRKDEKNLG SDARYSIENT DSSSLLTIPQ VTRNDTGKYI LTIENGVGEP KSSTVSVKVL DTPAACQKLQ VKHVSRGTVT LLWDPPLIDG GSPIINYVIE KRDATKRTWS VVSHKCSSTS FKLIDLSEKT PFFFRVLAEN EIGIGEPCET TEPVKAAEVP APIRDLSMKD STKTSVILSW TKPDFDGGSV ITEYVVERKG KGEQTWSHAG ISKTCEIEVS QLKEQSVLEF RVFAKNEKGL SDPVTIGPIT VKELIITPEV DLSDIPGAQV TVRIGHNVHL ELPYKGKPKP SISWLKDGLP LKESEFVRFS KTENKITLSI KNAKKEHGGK YTVILDNAVC RIAVPITVIT LGPPSKPKGP IRFDEIKADS VILSWDVPED NGGGEITCYS IEKRETSQTN WKMVCSSVAR TTFKVPNLVK DAEYQFRVRA ENRYGVSQPL VSSIIVAKHQ FRIPGPPGKP VIYNVTSDGM SLTWDAPVYD GGSEVTGFHV EKKERNSILW QKVNTSPISG REYRATGLVE GLDYQFRVYA ENSAGLSSPS DPSKFTLAVS PVDPPGTPDY IDVTRETITL KWNPPLRDGG SKIVGYSIEK RQGNERWVRC NFTDVSECQY TVTGLSPGDR YEFRIIARNA VGTISPPSQS SGIIMTRDEN VPPIVEFGPE YFDGLIIKSG ESLRIKALVQ GRPVPRVTWF KDGVEIEKRM NMEITDVLGS TSLFVRDATR DHRGVYTVEA KNASGSAKAE IKVKVQDTPG KVVGPIRFTN ITGEKMTLWW DAPLNDGCAP ITHYIIEKRE TSRLAWALIE DKCEAQSYTA IKLINGNEYQ FRVSAVNKFG VGRPLDSDPV VAQIQYTVPD APGIPEPSNI TGNSITLTWA RPESDGGSEI QQYILERREK KSTRWVKVIS KRPISETRFK VTGLTEGNEY EFHVMAENAA GVGPASGISR LIKCREPVNP PGPPTVVKVT DTSKTTVSLE WSKPVFDGGM EIIGYIIEMC KADLGDWHKV NAEACVKTRY TVTDLQAGEE YKFRVSAING AGKGDSCEVT GTIKAVDRLT APELDIDANF KQTHVVRAGA SIRLFIAYQG RPTPTAVWSK PDSNLSLRAD IHTTDSFSTL TVENCNRNDA GKYTLTVENN SGSKSITFTV KVLDTPGPPG PITFKDVTRG SATLMWDAPL LDGGARIHHY VVEKREASRR SWQVISEKCT RQIFKVNDLA EGVPYYFRVS AVNEYGVGEP YEMPEPIVAT EQPAPPRRLD VVDTSKSSAV LAWLKPDHDG GSRITGYLLE MRQKGSDFWV EAGHTKQLTF TVERLVEKTE YEFRVKAKND AGYSEPREAF SSVIIKEPQI EPTADLTGIT NQLITCKAGS PFTIDVPISG RPAPKVTWKL EEMRLKETDR VSITTTKDRT TLTVKDSMRG DSGRYFLTLE NTAGVKTFSV TVVVIGRPGP VTGPIEVSSV SAESCVLSWG EPKDGGGTEI TNYIVEKRES GTTAWQLVNS SVKRTQIKVT HLTKYMEYSF RVSSENRFGV SKPLESAPII AEHPFVPPSA PTRPEVYHVS ANAMSIRWEE PYHDGGSKII GYWVEKKERN TILWVKENKV PCLECNYKVT GLVEGLEYQF RTYALNAAGV SKASEASRPI MAQNPVDAPG RPEVTDVTRS TVSLIWSAPA YDGGSKVVGY IIERKPVSEV GDGRWLKCNY TIVSDNFFTV TALSEGDTYE FRVLAKNAAG VISKGSESTG PVTCRDEYAP PKAELDARLH GDLVTIRAGS DLVLDAAVGG KPEPKIIWTK GDKELDLCEK VSLQYTGKRA TAVIKFCDRS DSGKYTLTVK NASGTKAVSV MVKVLDSPGP CGKLTVSRVT QEKCTLAWSL PQEDGGAEIT HYIVERRETS RLNWVIVEGE CPTLSYVVTR LIKNNEYIFR VRAVNKYGPG VPVESEPIVA RNSFTIPSPP GIPEEVGTGK EHIIIQWTKP ESDGGNEISN YLVDKREKKS LRWTRVNKDY VVYDTRLKVT SLMEGCDYQF RVTAVNAAGN SEPSEASNFI SCREPSYTPG PPSAPRVVDT TKHSISLAWT KPMYDGGTDI VGYVLEMQEK DTDQWYRVHT NATIRNTEFT VPDLKMGQKY SFRVAAVNVK GMSEYSESIA EIEPVERIEI PDLELADDLK KTVTIRAGAS LRLMVSVSGR PPPVITWSKQ GIDLASRAII DTTESYSLLI VDKVNRYDAG KYTIEAENQS GKKSATVLVK VYDTPGPCPS VKVKEVSRDS VTITWEIPTI DGGAPVNNYI VEKREAAMRA FKTVTTKCSK TLYRISGLVE GTMYYFRVLP ENIYGIGEPC ETSDAVLVSE VPLVPAKLEV VDVTKSTVTL AWEKPLYDGG SRLTGYVLEA CKAGTERWMK VVTLKPTVLE HTVTSLNEGE QYLFRIRAQN EKGVSEPRET VTAVTVQDLR VLPTIDLSTM PQKTIHVPAG RPVELVIPIA GRPPPAASWF FAGSKLRESE RVTVETHTKV AKLTIRETTI RDTGEYTLEL KNVTGTTSET IKVIILDKPG PPTGPIKIDE IDATSITISW EPPELDGGAP LSGYVVEQRD AHRPGWLPVS ESVTRSTFKF TRLTEGNEYV FRVAATNRFG IGSYLQSEVI ECRSSIRIPG PPETLQIFDV SRDGMTLTWY PPEDDGGSQV TGYIVERKEV RADRWVRVNK VPVTMTRYRS TGLTEGLEYE HRVTAINARG SGKPSRPSKP IVAMDPIAPP GKPQNPRVTD TTRTSVSLAW SVPEDEGGSK VTGYLIEMQK VDQHEWTKCN TTPTKIREYT LTHLPQGAEY RFRVLACNAG GPGEPAEVPG TVKVTEMLEY PDYELDERYQ EGIFVRQGGV IRLTIPIKGK PFPICKWTKE GQDISKRAMI ATSETHTELV IKEADRGDSG TYDLVLENKC GKKAVYIKVR VIGSPNSPEG PLEYDDIQVR SVRVSWRPPA DDGGADILGY ILERREVPKA AWYTIDSRVR GTSLVVKGLK ENVEYHFRVS AENQFGISKP LKSEEPVTPK TPLNPPEPPS NPPEVLDVTK SSVSLSWSRP KDDGGSRVTG YYIERKETST DKWVRHNKTQ ITTTMYTVTG LVPDAEYQFR IIAQNDVGLS ETSPASEPVV CKDPFDKPSQ PGELEILSIS KDSVTLQWEK PECDGGKEIL GYWVEYRQSG DSAWKKSNKE RIKDKQFTIG GLLEATEYEF RVFAENETGL SRPRRTAMSI KTKLTSGEAP GIRKEMKDVT TKLGEAAQLS CQIVGRPLPD IKWYRFGKEL IQSRKYKMSS DGRTHTLTVM TEEQEDEGVY TCIATNEVGE VETSSKLLLQ ATPQFHPGYP LKEKYYGAVG STLRLHVMYI GRPVPAMTWF HGQKLLQNSE NITIENTEHY THLVMKNVQR KTHAGKYKVQ LSNVFGTVDA ILDVEIQDKP DKPTGPIVIE ALLKNSAVIS WKPPADDGGS WITNYVVEKC EAKEGAEWQL VSSAISVTTC RIVNLTENAG YYFRVSAQNT FGISDPLEVS SVVIIKSPFE KPGAPGKPTI TAVTKDSCVV AWKPPASDGG AKIRNYYLEK REKKQNKWIS VTTEEIRETV FSVKNLIEGL EYEFRVKCEN LGGESEWSEI SEPITPKSDV PIQAPHFKEE LRNLNVRYQS NATLVCKVTG HPKPIVKWYR QGKEIIADGL KYRIQEFKGG YHQLIIASVT DDDATVYQVR ATNQGGSVSG TASLEVEVPA KIHLPKTLEG MGAVHALRGE VVSIKIPFSG KPDPVITWQK GQDLIDNNGH YQVIVTRSFT SLVFPNGVER KDAGFYVVCA KNRFGIDQKT VELDVADVPD PPRGVKVSDV SRDSVNLTWT EPASDGGSKI TNYIVEKCAT TAERWLRVGQ ARETRYTVIN LFGKTSYQFR VIAENKFGLS KPSEPSEPTI TKEDKTRAMN YDEEVDETRE VSMTKASHSS TKELYEKYMI AEDLGRGEFG IVHRCVETSS KKTYMAKFVK VKGTDQVLVK KEISILNIAR HRNILHLHES FESMEELVMI FEFISGLDIF ERINTSAFEL NEREIVSYVH QVCEALQFLH SHNIGHFDIR PENIIYQTRR SSTIKIIEFG QARQLKPGDN FRLLFTAPEY YAPEVHQHDV VSTATDMWSL GTLVYVLLSG INPFLAETNQ QIIENIMNAE YTFDEEAFKE ISIEAMDFVD RLLVKERKSR MTASEALQHP WLKQKIERVS TKVIRTLKHR RYYHTLIKKD LNMVVSAARI SCGGAIRSQK GVSVAKVKVA SIEIGPVSGQ IMHAVGEEGG HVKYVCKIEN YDQSTQVTWY FGVRQLENSE KYEITYEDGV AILYVKDITK LDDGTYRCKV VNDYGEDSSY AELFVKGVRE VYDYYCRRTM KKIKRRTDTM RLLERPPEFT LPLYNKTAYV GENVRFGVTI TVHPEPHVTW YKSGQKIKPG DNDKKYTFES DKGLYQLTIN SVTTDDDAEY TVVARNKYGE DSCKAKLTVT LHPPPTDSTL RPMFKRLLAN AECQEGQSVC FEIRVSGIPP PTLKWEKDGQ PLSLGPNIEI IHEGLDYYAL HIRDTLPEDT GYYRVTATNT AGSTSCQAHL QVERLRYKKQ EFKSKEEHER HVQKQIDKTL RMAEILSGTE SVPLTQVAKE ALREAAVLYK PAVSTKTVKG EFRLEIEEKK EERKLRMPYD VPEPRKYKQT TIEEDQRIKQ FVPMSDMKWY KKIRDQYEMP GKLDRVVQKR PKRIRLSRWE QFYVMPLPRI TDQYRPKWRI PKLSQDDLEI VRPARRRTPS PDYDFYYRPR RRSLGDISDE ELLLPIDDYL AMKRTEEERL RLEEELELGF SASPPSRSPP HFELSSLRYS SPQAHVKVEE TRKDFRYSTY HIPTKAEAST SYAELRERHA QAAYRQPKQR QRIMAEREDE ELLRPVTTTQ HLSEYKSELD FMSKEEKSRK KSRRQREVTE ITEIEEEYEI SKHAQRESSS SASRLLRRRR SLSPTYIELM RPVSELIRSR PQPAEEYEDD TERRSPTPER TRPRSPSPVS SERSLSRFER SARFDIFSRY ESMKAALKTQ KTSERKYEVL SQQPFTLDHA PRITLRMRSH RVPCGQNTRF ILNVQSKPTA EVKWYHNGVE LQESSKIHYT NTSGVLTLEI LDCHTDDSGT YRAVCTNYKG EASDYATLDV TGGDYTTYAS QRRDEEVPRS VFPELTRTEA YAVSSFKKTS EMEASSSVRE VKSQMTETRE SLSSYEHSAS AEMKSAALEE KSLEEKSTTR KIKTTLAARI LTKPRSMTVY EGESARFSCD TDGEPVPTVT WLRKGQVLST SARHQVTTTK YKSTFEISSV QASDEGNYSV VVENSEGKQE AEFTLTIQKA RVTEKAVTSP PRVKSPEPRV KSPEAVKSPK RVKSPEPSHP KAVSPTETKP TPTEKVQHLP VSAPPKITQF LKAEASKEIA KLTCVVESSV LRAKEVTWYK DGKKLKENGH FQFHYSADGT YELKINNLTE SDQGEYVCEI SGEGGTSKTN LQFMGQAFKS IHEKVSKISE TKKSDQKTTE STVTRKTEPK APEPISSKPV IVTGLQDTTV SSDSVAKFAV KATGEPRPTA IWTKDGKAIT QGGKYKLSED KGGFFLEIHK TDTSDSGLYT CTVKNSAGSV SSSCKLTIKA IKDTEAQKVS TQKTSEITPQ KKAVVQEEIS QKALRSEEIK MSEAKSQEKL ALKEEASKVL ISEEVKKSAA TSLEKSIVHE EITKTSQASE EVRTHAEIKA FSTQMSINEG QRLVLKANIA GATDVKWVLN GVELTNSEEY RYGVSGSDQT LTIKQASHRD EGILTCISKT KEGIVKCQYD LTLSKELSDA PAFISQPRSQ NINEGQNVLF TCEISGEPSP EIEWFKNNLP ISISSNVSIS RSRNVYSLEI RNASVSDSGK YTIKAKNFRG QCSATASLMV LPLVEEPSRE VVLRTSGDTS LQGSFSSQSV QMSASKQEAS FSSFSSSSAS SMTEMKFASM SAQSMSSMQE SFVEMSSSSF MGISNMTQLE SSTSKMLKAG IRGIPPKIEA LPSDISIDEG KVLTVACAFT GEPTPEVTWS CGGRKIHSQE QGRFHIENTD DLTTLIIMDV QKQDGGLYTL SLGNEFGSDS ATVNIHIRSI // ID TRAK1_HUMAN Reviewed; 953 AA. AC Q9UPV9; E9PDS2; J3KNT7; Q63HR0; Q659B5; Q96B69; DT 21-FEB-2001, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 186. DE RecName: Full=Trafficking kinesin-binding protein 1; DE AltName: Full=106 kDa O-GlcNAc transferase-interacting protein; DE AltName: Full=Protein Milton {ECO:0000303|PubMed:24995978}; GN Name=TRAK1; Synonyms=KIAA1042, OIP106; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=10470851; DOI=10.1093/dnares/6.3.197; RA Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:197-205(1999). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE RP [LARGE SCALE MRNA] OF 1-508 (ISOFORM 3). RC TISSUE=Kidney, and Salivary gland; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Kidney; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PROTEIN SEQUENCE OF 448-462; 535-552; 642-660; 676-685; 686-705; 717-728; RP 829-846 AND 932-945, FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, RP INTERACTION WITH KIF5B; OGT; RHOT1 AND RHOT2, SUBCELLULAR LOCATION, RP GLYCOSYLATION AT SER-447; SER-680; SER-719 AND THR-935, AND MUTAGENESIS OF RP SER-447; 658-PRO--THR-672; SER-829; SER-830 AND SER-938. RX PubMed=24995978; DOI=10.1016/j.cell.2014.06.007; RA Pekkurnaz G., Trinidad J.C., Wang X., Kong D., Schwarz T.L.; RT "Glucose regulates mitochondrial motility via Milton modification by O- RT GlcNAc transferase."; RL Cell 158:54-68(2014). RN [6] RP SUBCELLULAR LOCATION, INTERACTION WITH OGT, AND GLYCOSYLATION. RX PubMed=12435728; DOI=10.1074/jbc.m209384200; RA Iyer S.P.N., Akimoto Y., Hart G.W.; RT "Identification and cloning of a novel family of coiled-coil domain RT proteins that interact with O-GlcNAc transferase."; RL J. Biol. Chem. 278:5399-5409(2003). RN [7] RP INTERACTION WITH KIF5C, AND SUBCELLULAR LOCATION. RX PubMed=15644324; DOI=10.1074/jbc.m409095200; RA Brickley K., Smith M.J., Beck M., Stephenson F.A.; RT "GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain RT proteins: association in vivo and in vitro with kinesin."; RL J. Biol. Chem. 280:14723-14732(2005). RN [8] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOT1 AND RHOT2. RX PubMed=16630562; DOI=10.1016/j.bbrc.2006.03.163; RA Fransson S., Ruusala A., Aspenstroem P.; RT "The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in RT mitochondrial trafficking."; RL Biochem. Biophys. Res. Commun. 344:500-510(2006). RN [9] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH HGS. RX PubMed=18675823; DOI=10.1016/j.jmb.2008.07.045; RA Webber E., Li L., Chin L.S.; RT "Hypertonia-associated protein Trak1 is a novel regulator of endosome-to- RT lysosome trafficking."; RL J. Mol. Biol. 382:638-651(2008). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND MARKER FOR GASTRIC CANCER. RX PubMed=18986759; DOI=10.1016/j.canlet.2008.09.031; RA Zhang F., Ren G., Lu Y., Jin B., Wang J., Chen X., Liu Z., Li K., Nie Y., RA Wang X., Fan D.; RT "Identification of TRAK1 (Trafficking protein, kinesin-binding 1) as MGb2- RT Ag: a novel cancer biomarker."; RL Cancer Lett. 274:250-258(2009). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=19528298; DOI=10.1083/jcb.200811033; RA Li Y., Lim S., Hoffman D., Aspenstrom P., Federoff H.J., Rempe D.A.; RT "HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial RT distribution and transport."; RL J. Cell Biol. 185:1065-1081(2009). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-919, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] RP INVOLVEMENT IN DEE68. RX PubMed=28364549; DOI=10.1093/brain/awx002; RA Barel O., Malicdan M.C.V., Ben-Zeev B., Kandel J., Pri-Chen H., Stephen J., RA Castro I.G., Metz J., Atawa O., Moshkovitz S., Ganelin E., Barshack I., RA Polak-Charcon S., Nass D., Marek-Yagel D., Amariglio N., Shalva N., RA Vilboux T., Ferreira C., Pode-Shakked B., Heimer G., Hoffmann C., RA Yardeni T., Nissenkorn A., Avivi C., Eyal E., Kol N., Glick Saar E., RA Wallace D.C., Gahl W.A., Rechavi G., Schrader M., Eckmann D.M., RA Anikster Y.; RT "Deleterious variants in TRAK1 disrupt mitochondrial movement and cause RT fatal encephalopathy."; RL Brain 140:568-581(2017). RN [15] RP INVOLVEMENT IN DEE68. RX PubMed=28940097; DOI=10.1007/s00439-017-1843-2; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Expanding the genetic heterogeneity of intellectual disability."; RL Hum. Genet. 136:1419-1429(2017). RN [16] RP ERRATUM OF PUBMED:28940097. RX PubMed=29288388; DOI=10.1007/s00439-017-1859-7; RA Anazi S., Maddirevula S., Salpietro V., Asi Y.T., Alsahli S., Alhashem A., RA Shamseldin H.E., AlZahrani F., Patel N., Ibrahim N., Abdulwahab F.M., RA Hashem M., Alhashmi N., Al Murshedi F., Al Kindy A., Alshaer A., RA Rumayyan A., Al Tala S., Kurdi W., Alsaman A., Alasmari A., Banu S., RA Sultan T., Saleh M.M., Alkuraya H., Salih M.A., Aldhalaan H., Ben-Omran T., RA Al Musafri F., Ali R., Suleiman J., Tabarki B., El-Hattab A.W., Bupp C., RA Alfadhel M., Al Tassan N., Monies D., Arold S.T., Abouelhoda M., RA Lashley T., Houlden H., Faqeih E., Alkuraya F.S.; RT "Correction to: Expanding the genetic heterogeneity of intellectual RT disability."; RL Hum. Genet. 137:105-109(2018). RN [17] RP INVOLVEMENT IN DEE68, AND VARIANT DEE68 PRO-329. RX PubMed=29846532; DOI=10.1093/brain/awy129; RA Sagie S., Lerman-Sagie T., Maljevic S., Yosovich K., Detert K., Chung S.K., RA Rees M.I., Lerche H., Lev D.; RT "Expanding the phenotype of TRAK1 mutations: hyperekplexia and refractory RT status epilepticus."; RL Brain 141:E55-E55(2018). CC -!- FUNCTION: Involved in the regulation of endosome-to-lysosome CC trafficking, including endocytic trafficking of EGF-EGFR complexes and CC GABA-A receptors (PubMed:18675823). Involved in mitochondrial motility. CC When O-glycosylated, abolishes mitochondrial motility. Crucial for CC recruiting OGT to the mitochondrial surface of neuronal processes CC (PubMed:24995978). TRAK1 and RHOT form an essential protein complex CC that links KIF5 to mitochondria for light chain-independent, CC anterograde transport of mitochondria (By similarity). CC {ECO:0000250|UniProtKB:Q960V3, ECO:0000269|PubMed:18675823, CC ECO:0000269|PubMed:24995978}. CC -!- SUBUNIT: Interacts with RHOT1 and RHOT2 (PubMed:16630562). Found in a CC complex with KIF5B, OGT, RHOT1 and RHOT2 (PubMed:24995978). Interacts CC with HGS (PubMed:18675823). Interacts with GABRA1 (By similarity). CC Interacts with KIF5C (PubMed:15644324). Interacts with OGT; stable CC interaction is not required for glycosylation of this protein by OGT. CC Isoform 1 interacts with OGT (PubMed:12435728, PubMed:24995978). CC {ECO:0000250|UniProtKB:Q6PD31, ECO:0000269|PubMed:12435728, CC ECO:0000269|PubMed:15644324, ECO:0000269|PubMed:16630562, CC ECO:0000269|PubMed:18675823, ECO:0000269|PubMed:24995978}. CC -!- INTERACTION: CC Q9UPV9; Q12840: KIF5A; NbExp=4; IntAct=EBI-1105048, EBI-713468; CC Q9UPV9; O15294: OGT; NbExp=3; IntAct=EBI-1105048, EBI-539828; CC Q9UPV9; Q8IXI2: RHOT1; NbExp=8; IntAct=EBI-1105048, EBI-1396430; CC Q9UPV9; Q8IXI1: RHOT2; NbExp=4; IntAct=EBI-1105048, EBI-1396563; CC Q9UPV9; Q2PQA9: Kif5b; Xeno; NbExp=3; IntAct=EBI-1105048, EBI-920191; CC Q9UPV9; P56558: Ogt; Xeno; NbExp=6; IntAct=EBI-1105048, EBI-7614183; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18986759}. Nucleus CC {ECO:0000269|PubMed:12435728}. Mitochondrion CC {ECO:0000269|PubMed:15644324, ECO:0000269|PubMed:16630562, CC ECO:0000269|PubMed:18675823, ECO:0000269|PubMed:19528298}. Early CC endosome {ECO:0000269|PubMed:18675823}. Endosome CC {ECO:0000269|PubMed:18675823}. Mitochondrion membrane CC {ECO:0000269|PubMed:24995978}. Cytoplasm, cell cortex CC {ECO:0000250|UniProtKB:Q6PD31}. Note=Predominantly associated with CC early endosome. The localization to early endosomes depends on its CC interaction with HGS/HRS (PubMed:18675823). Colocalizes with MGARP at CC the mitochondria (PubMed:19528298). {ECO:0000269|PubMed:18675823, CC ECO:0000269|PubMed:19528298}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Milton1 {ECO:0000303|PubMed:24995978}; CC IsoId=Q9UPV9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9UPV9-2; Sequence=VSP_010839, VSP_010840, VSP_010841; CC Name=3; CC IsoId=Q9UPV9-3; Sequence=VSP_045558, VSP_045559, VSP_045560; CC -!- TISSUE SPECIFICITY: High expression in spinal cord and moderate CC expression in all other tissues and specific brain regions examined. CC Expressed in all cell lines examined. {ECO:0000269|PubMed:18986759}. CC -!- DOMAIN: The C-terminal region is required for the early endosomal and CC mitochondrial localization. CC -!- PTM: O-glycosylated (PubMed:12435728, PubMed:24995978). Glycosylated by CC OGT; glycosylation in response to increased extracellular glucose CC levels is required for and leads to regulation of mitochondrial CC motility by OGT (PubMed:24995978). {ECO:0000269|PubMed:12435728, CC ECO:0000269|PubMed:24995978}. CC -!- DISEASE: Developmental and epileptic encephalopathy 68 (DEE68) CC [MIM:618201]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE68 is an autosomal recessive form characterized by CC onset of twitching and/or myoclonic jerks in infancy. The disorder CC progresses to refractory generalized tonic-clonic seizures, often CC resulting in status epilepticus, loss of developmental milestones, and CC early death. Other features include delayed development, axial CC hypotonia, spasticity of the limbs, and clonus. CC {ECO:0000269|PubMed:28364549, ECO:0000269|PubMed:28940097, CC ECO:0000269|PubMed:29846532}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Over-expressed in all investigated carcinomas, CC especially in gastric adenocarcinoma and signet-ring carcinoma and may CC serve as a marker of gastric cancer. CC -!- SIMILARITY: Belongs to the milton family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA82994.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AB028965; BAA82994.2; ALT_INIT; mRNA. DR EMBL; BX647199; CAH56169.1; -; mRNA. DR EMBL; AL713787; CAH56394.1; -; mRNA. DR EMBL; AC018358; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC093414; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC137935; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC015922; AAH15922.1; -; mRNA. DR CCDS; CCDS2695.1; -. [Q9UPV9-2] DR CCDS; CCDS43072.1; -. [Q9UPV9-1] DR CCDS; CCDS58826.1; -. [Q9UPV9-3] DR RefSeq; NP_001036111.1; NM_001042646.3. [Q9UPV9-1] DR RefSeq; NP_001252537.1; NM_001265608.1. DR RefSeq; NP_001252539.1; NM_001265610.1. [Q9UPV9-3] DR RefSeq; NP_055780.2; NM_014965.4. [Q9UPV9-2] DR RefSeq; XP_024309170.1; XM_024453402.2. [Q9UPV9-1] DR RefSeq; XP_054201670.1; XM_054345695.1. [Q9UPV9-1] DR AlphaFoldDB; Q9UPV9; -. DR SMR; Q9UPV9; -. DR BioGRID; 116570; 76. DR CORUM; Q9UPV9; -. DR FunCoup; Q9UPV9; 2545. DR IntAct; Q9UPV9; 71. DR MINT; Q9UPV9; -. DR STRING; 9606.ENSP00000328998; -. DR GlyCosmos; Q9UPV9; 8 sites, 1 glycan. DR GlyGen; Q9UPV9; 10 sites, 1 O-linked glycan (8 sites). DR iPTMnet; Q9UPV9; -. DR PhosphoSitePlus; Q9UPV9; -. DR BioMuta; TRAK1; -. DR DMDM; 13124654; -. DR jPOST; Q9UPV9; -. DR MassIVE; Q9UPV9; -. DR PaxDb; 9606-ENSP00000328998; -. DR PeptideAtlas; Q9UPV9; -. DR ProteomicsDB; 19736; -. DR ProteomicsDB; 85456; -. [Q9UPV9-1] DR ProteomicsDB; 85457; -. [Q9UPV9-2] DR ABCD; Q9UPV9; 1 sequenced antibody. DR Antibodypedia; 1603; 192 antibodies from 33 providers. DR DNASU; 22906; -. DR Ensembl; ENST00000327628.10; ENSP00000328998.5; ENSG00000182606.18. [Q9UPV9-1] DR Ensembl; ENST00000341421.7; ENSP00000340702.3; ENSG00000182606.18. [Q9UPV9-2] DR Ensembl; ENST00000449246.5; ENSP00000410717.1; ENSG00000182606.18. [Q9UPV9-3] DR GeneID; 22906; -. DR KEGG; hsa:22906; -. DR MANE-Select; ENST00000327628.10; ENSP00000328998.5; NM_001042646.3; NP_001036111.1. DR UCSC; uc003cky.5; human. [Q9UPV9-1] DR AGR; HGNC:29947; -. DR ClinPGx; PA128394593; -. DR CTD; 22906; -. DR DisGeNET; 22906; -. DR GeneCards; TRAK1; -. DR HGNC; HGNC:29947; TRAK1. DR HPA; ENSG00000182606; Tissue enhanced (heart muscle, skeletal muscle, tongue). DR MalaCards; TRAK1; -. DR MIM; 608112; gene. DR MIM; 618201; phenotype. DR OpenTargets; ENSG00000182606; -. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR VEuPathDB; HostDB:ENSG00000182606; -. DR eggNOG; KOG4360; Eukaryota. DR GeneTree; ENSGT00940000155697; -. DR HOGENOM; CLU_013450_0_0_1; -. DR InParanoid; Q9UPV9; -. DR OMA; PFDCRTP; -. DR OrthoDB; 10067624at2759; -. DR PAN-GO; Q9UPV9; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9UPV9; -. DR PathwayCommons; Q9UPV9; -. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-9013419; RHOT2 GTPase cycle. DR Reactome; R-HSA-9013425; RHOT1 GTPase cycle. DR SignaLink; Q9UPV9; -. DR Agora; ENSG00000182606; -. DR BioGRID-ORCS; 22906; 14 hits in 1160 CRISPR screens. DR ChiTaRS; TRAK1; human. DR GeneWiki; TRAK1; -. DR GenomeRNAi; 22906; -. DR Pharos; Q9UPV9; Tbio. DR PRO; PR:Q9UPV9; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9UPV9; protein. DR Bgee; ENSG00000182606; Expressed in secondary oocyte and 212 other cell types or tissues. DR ExpressionAtlas; Q9UPV9; baseline and differential. DR GO; GO:1904115; C:axon cytoplasm; IEA:GOC. DR GO; GO:0044295; C:axonal growth cone; IEA:Ensembl. DR GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; IDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl. DR GO; GO:0050811; F:GABA receptor binding; IBA:GO_Central. DR GO; GO:0017022; F:myosin binding; IBA:GO_Central. DR GO; GO:0030911; F:TPR domain binding; IEA:Ensembl. DR GO; GO:0019896; P:axonal transport of mitochondrion; IEA:Ensembl. DR GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl. DR GO; GO:0008333; P:endosome to lysosome transport; IDA:UniProtKB. DR GO; GO:0048311; P:mitochondrion distribution; IBA:GO_Central. DR GO; GO:0022008; P:neurogenesis; IBA:GO_Central. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0006493; P:protein O-linked glycosylation; ISS:UniProtKB. DR GO; GO:0006605; P:protein targeting; ISS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB. DR GO; GO:0047496; P:vesicle transport along microtubule; IBA:GO_Central. DR InterPro; IPR006933; HAP1_N. DR InterPro; IPR051946; Intracell_Traff-Reg. DR InterPro; IPR022154; TRAK1/2_C. DR PANTHER; PTHR15751; TRAFFICKING KINESIN-BINDING PROTEIN; 1. DR PANTHER; PTHR15751:SF11; TRAFFICKING KINESIN-BINDING PROTEIN 1; 1. DR Pfam; PF04849; HAP1_N; 1. DR Pfam; PF12448; Milton; 1. DR SMART; SM01424; HAP1_N; 1. DR SMART; SM01423; Milton; 1. PE 1: Evidence at protein level; KW Alternative splicing; Coiled coil; Cytoplasm; Direct protein sequencing; KW Disease variant; Endosome; Epilepsy; Glycoprotein; Membrane; Mitochondrion; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome. FT CHAIN 1..953 FT /note="Trafficking kinesin-binding protein 1" FT /id="PRO_0000058037" FT DOMAIN 47..354 FT /note="HAP1 N-terminal" FT REGION 359..509 FT /note="Interaction with HGS" FT /evidence="ECO:0000269|PubMed:18675823" FT REGION 472..495 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 658..672 FT /note="Interaction with OGT" FT /evidence="ECO:0000269|PubMed:24995978" FT REGION 777..796 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 104..356 FT /evidence="ECO:0000255" FT COILED 492..532 FT /evidence="ECO:0000255" FT COMPBIAS 786..796 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6PD31" FT MOD_RES 719 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q6PD31" FT MOD_RES 919 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CARBOHYD 447 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 680 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 719 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:24995978" FT CARBOHYD 935 FT /note="O-linked (GlcNAc) threonine" FT /evidence="ECO:0000269|PubMed:24995978" FT VAR_SEQ 1..97 FT /note="MALVFQFGQPVRAQPLPGLCHGKLIRTNACDVCNSTDLPEVEIISLLEEQLP FT HYKLRADTIYGYDHDDWLHTPLISPDANIDLTTEQIEETLKYFLL -> MQKFIEADYY FT ELDWYYEECSDVL (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045558" FT VAR_SEQ 1..96 FT /note="MALVFQFGQPVRAQPLPGLCHGKLIRTNACDVCNSTDLPEVEIISLLEEQLP FT HYKLRADTIYGYDHDDWLHTPLISPDANIDLTTEQIEETLKYFL -> MSLRDKGGEEE FT CFEYDCQDEERKPTHRQHDTQDLLEEV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010839" FT VAR_SEQ 583..630 FT /note="SATLHHWQQLAQPHLGGILDPRPGVVTKGFRTLDVDLDEVYCLNDFEE -> FT DHAGPRPLSVLLGDSLWSLIHLRKAGHLCHAYSFFFRDSHPRCWFEFL (in FT isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045559" FT VAR_SEQ 631..953 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_045560" FT VAR_SEQ 655..744 FT /note="AHHPGKCMSQTNSTFTFTTCRILHPSDELTRVTPSLNSAPTPACGSTSHLKS FT TPVATPCTPRRLSLAESFTNTRESTTTMSTSLGLVWLL -> GERSQARVTVSGSRSYP FT SRPQASPEEMQEPPAATEEEEEEEEEEGSGEGTTISPVNLAPFPEAEFWAILTSVPGTI FT RSGSLSVASARLCG (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010840" FT VAR_SEQ 745..953 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:17974005" FT /id="VSP_010841" FT VARIANT 329 FT /note="L -> P (in DEE68; uncertain significance; FT dbSNP:rs770281448)" FT /evidence="ECO:0000269|PubMed:29846532" FT /id="VAR_081639" FT MUTAGEN 447 FT /note="S->A: Reduced O-glycosylation of this protein." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 658..672 FT /note="Missing: Loss of interaction with OGT, but interacts FT with KIF5B and RHOT1/2 and is able to localize to FT mitochondria. Increased O-glycosylation of this protein by FT OGT." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 829 FT /note="S->A: Reduced O-glycosylation of this protein; when FT associated with A-830." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 830 FT /note="S->A: Reduced O-glycosylation of this protein; when FT associated with A-829." FT /evidence="ECO:0000269|PubMed:24995978" FT MUTAGEN 938 FT /note="S->A: Reduced O-glycosylation of this protein." FT /evidence="ECO:0000269|PubMed:24995978" FT CONFLICT 503 FT /note="S -> P (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT 638 FT /note="S -> F (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT Q9UPV9-2:631 FT /note="E -> EE (in Ref. 2; CAH56169)" FT /evidence="ECO:0000305" FT CONFLICT Q9UPV9-2:631 FT /note="E -> EEE (in Ref. 4; AAH15922)" FT /evidence="ECO:0000305" SQ SEQUENCE 953 AA; 106040 MW; E834BE07CF41D9A4 CRC64; MALVFQFGQP VRAQPLPGLC HGKLIRTNAC DVCNSTDLPE VEIISLLEEQ LPHYKLRADT IYGYDHDDWL HTPLISPDAN IDLTTEQIEE TLKYFLLCAE RVGQMTKTYN DIDAVTRLLE EKERDLELAA RIGQSLLKKN KTLTERNELL EEQVEHIREE VSQLRHELSM KDELLQFYTS AAEESEPESV CSTPLKRNES SSSVQNYFHL DSLQKKLKDL EEENVVLRSE ASQLKTETIT YEEKEQQLVN DCVKELRDAN VQIASISEEL AKKTEDAARQ QEEITHLLSQ IVDLQKKAKA CAVENEELVQ HLGAAKDAQR QLTAELRELE DKYAECMEML HEAQEELKNL RNKTMPNTTS RRYHSLGLFP MDSLAAEIEG TMRKELQLEE AESPDITHQK RVFETVRNIN QVVKQRSLTP SPMNIPGSNQ SSAMNSLLSS CVSTPRSSFY GSDIGNVVLD NKTNSIILET EAADLGNDER SKKPGTPGTP GSHDLETALR RLSLRRENYL SERRFFEEEQ ERKLQELAEK GELRSGSLTP TESIMSLGTH SRFSEFTGFS GMSFSSRSYL PEKLQIVKPL EGSATLHHWQ QLAQPHLGGI LDPRPGVVTK GFRTLDVDLD EVYCLNDFEE DDTGDHISLP RLATSTPVQH PETSAHHPGK CMSQTNSTFT FTTCRILHPS DELTRVTPSL NSAPTPACGS TSHLKSTPVA TPCTPRRLSL AESFTNTRES TTTMSTSLGL VWLLKERGIS AAVYDPQSWD RAGRGSLLHS YTPKMAVIPS TPPNSPMQTP TSSPPSFEFK CTSPPYDNFL ASKPASSILR EVREKNVRSS ESQTDVSVSN LNLVDKVRRF GVAKVVNSGR AHVPTLTEEQ GPLLCGPPGP APALVPRGLV PEGLPLRCPT VTSAIGGLQL NSGIRRNRSF PTMVGSSMQM KAPVTLTSGI LMGAKLSKQT SLR // ID WWOX_HUMAN Reviewed; 414 AA. AC Q9NZC7; A8K323; Q5MYT5; Q96KM3; Q96RF2; Q9BTT8; Q9NPC9; Q9NRF4; Q9NRF5; AC Q9NRF6; Q9NRK1; Q9NZC5; DT 22-NOV-2005, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2000, sequence version 1. DT 28-JAN-2026, entry version 210. DE RecName: Full=WW domain-containing oxidoreductase; DE EC=1.1.1.-; DE AltName: Full=Fragile site FRA16D oxidoreductase; DE AltName: Full=Short chain dehydrogenase/reductase family 41C member 1; GN Name=WWOX; Synonyms=FOR, SDR41C1, WOX1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [GENOMIC DNA] RP OF 1-35, AND TISSUE SPECIFICITY. RC TISSUE=Placenta; RX PubMed=10786676; RA Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., Aldaz C.M.; RT "WWOX, a novel WW domain-containing protein mapping to human chromosome RT 16q23.3-24.1, a region frequently affected in breast cancer."; RL Cancer Res. 60:2140-2145(2000). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 173-414, AND CHROMOSOMAL REARRANGEMENT. RX PubMed=10861292; DOI=10.1093/hmg/9.11.1651; RA Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., RA Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., RA Richards R.I.; RT "Common chromosomal fragile site FRA16D sequence: identification of the FOR RT gene spanning FRA16D and homozygous deletions and translocation breakpoints RT in cancer cells."; RL Hum. Mol. Genet. 9:1651-1663(2000). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=11719429; RA Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., RA Bergsagel P.L., Kiguchi K., Brenner A.J., Aldaz C.M.; RT "WWOX, the FRA16D gene, behaves as a suppressor of tumor growth."; RL Cancer Res. 61:8068-8073(2001). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 3 AND RP 7), VARIANTS LEU-98; SER-111; TRP-120; THR-179; PHE-272; ALA-282 AND RP HIS-314, AND INVOLVEMENT IN CANCERS. RX PubMed=11572989; DOI=10.1073/pnas.191175898; RA Paige A.J.W., Taylor K.J., Taylor C., Hillier S.G., Farrington S., RA Scott D., Porteous D.J., Smyth J.F., Gabra H., Watson J.E.V.; RT "WWOX: a candidate tumor suppressor gene involved in multiple tumor RT types."; RL Proc. Natl. Acad. Sci. U.S.A. 98:11417-11422(2001). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-179. RC TISSUE=Colon adenocarcinoma; RA Chang N.-S.; RT "Cloning of human WOX8 (WWOX v8)."; RL Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=14695174; RA Watanabe A., Hippo Y., Taniguchi H., Iwanari H., Yashiro M., Hirakawa K., RA Kodama T., Aburatani H.; RT "An opposing view on WWOX protein function as a tumor suppressor."; RL Cancer Res. 63:8629-8633(2003). RN [10] RP INTERACTION WITH MAPK8 AND TP53, AND MUTAGENESIS OF LYS-28; ASP-29 AND RP TYR-33. RX PubMed=12514174; DOI=10.1074/jbc.m208373200; RA Chang N.-S., Doherty J., Ensign A.; RT "JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) RT and inhibits WOX1-mediated apoptosis."; RL J. Biol. Chem. 278:9195-9202(2003). RN [11] RP INVOLVEMENT IN CANCERS. RX PubMed=15266310; DOI=10.1038/sj.bjc.6602023; RA Park S.-W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., RA Aldaz C.M.; RT "Frequent downregulation and loss of WWOX gene expression in human RT hepatocellular carcinoma."; RL Br. J. Cancer 91:753-759(2004). RN [12] RP FUNCTION, INTERACTION WITH TFAP2C AND TFAP2A, AND DOMAIN. RX PubMed=15548692; DOI=10.1158/0008-5472.can-04-2055; RA Aqeilan R.I., Palamarchuk A., Weigel R.J., Herrero J.J., Pekarsky Y., RA Croce C.M.; RT "Physical and functional interactions between the Wwox tumor suppressor RT protein and the AP-2gamma transcription factor."; RL Cancer Res. 64:8256-8261(2004). RN [13] RP INVOLVEMENT IN CANCERS. RX PubMed=15073125; DOI=10.1158/1078-0432.ccr-03-0096; RA Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., RA Rattan S., Cesari R., Nolli M.L., Williams N.N., Mori M., Kanematsu T., RA Croce C.M.; RT "The tumor suppressor gene WWOX at FRA16D is involved in pancreatic RT carcinogenesis."; RL Clin. Cancer Res. 10:2459-2465(2004). RN [14] RP INVOLVEMENT IN CANCERS. RX PubMed=15131042; DOI=10.1158/1078-0432.ccr-03-0594; RA Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., RA Huebner K., Edmonds P., Croce C.M.; RT "Loss of WWOX expression in gastric carcinoma."; RL Clin. Cancer Res. 10:3053-3058(2004). RN [15] RP INTERACTION WITH LITAF; WBP1; FAM189B AND SCOTIN, MUTAGENESIS OF RP 44-TRP--PRO-47 AND 85-TYR--PRO-88, DOMAIN, AND SUBCELLULAR LOCATION. RX PubMed=15064722; DOI=10.1038/sj.onc.1207680; RA Ludes-Meyers J.H., Kil H., Bednarek A.K., Drake J., Bedford M.T., RA Aldaz C.M.; RT "WWOX binds the specific proline-rich ligand PPXY: identification of RT candidate interacting proteins."; RL Oncogene 23:5049-5055(2004). RN [16] RP FUNCTION, INTERACTION WITH TP73, DOMAIN, MUTAGENESIS OF TYR-33 AND TYR-61, RP PHOSPHORYLATION AT TYR-33, AND SUBCELLULAR LOCATION. RX PubMed=15070730; DOI=10.1073/pnas.0400805101; RA Aqeilan R.I., Pekarsky Y., Herrero J.J., Palamarchuk A., Letofsky J., RA Druck T., Trapasso F., Han S.-Y., Melino G., Huebner K., Croce C.M.; RT "Functional association between Wwox tumor suppressor protein and p73, a RT p53 homolog."; RL Proc. Natl. Acad. Sci. U.S.A. 101:4401-4406(2004). RN [17] RP FUNCTION, AND INTERACTION WITH ERBB4. RX PubMed=16061658; DOI=10.1158/0008-5472.can-05-1150; RA Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., RA Sudol M., Croce C.M.; RT "WW domain-containing proteins, WWOX and YAP, compete for interaction with RT ErbB-4 and modulate its transcriptional function."; RL Cancer Res. 65:6764-6772(2005). RN [18] RP PHOSPHORYLATION AT TYR-287 BY TNK2, UBIQUITINATION, MUTAGENESIS OF TYR-287, RP AND INTERACTION WITH TNK2. RX PubMed=16288044; DOI=10.1158/0008-5472.can-05-1127; RA Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.; RT "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of RT Ack1 in polyubiquitination of tumor suppressor Wwox."; RL Cancer Res. 65:10514-10523(2005). RN [19] RP FUNCTION, INTERACTION WITH MDM2 AND TP53, PHOSPHORYLATION, AND SUBCELLULAR RP LOCATION. RX PubMed=16219768; DOI=10.1074/jbc.m505590200; RA Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.; RT "WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, RT and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds RT and stabilizes serine 46-phosphorylated p53."; RL J. Biol. Chem. 280:43100-43108(2005). RN [20] RP DISEASE. RX PubMed=16223882; DOI=10.1073/pnas.0505485102; RA Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., RA Yendamuri S., Han S.-Y., Amadori D., Huebner K., Croce C.M.; RT "WWOX gene restoration prevents lung cancer growth in vitro and in vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 102:15611-15616(2005). RN [21] RP FUNCTION, PHOSPHORYLATION AT TYR-33, SUBCELLULAR LOCATION, AND INTERACTION RP WITH HYAL2. RX PubMed=19366691; DOI=10.1074/jbc.m806688200; RA Hsu L.-J., Schultz L., Hong Q., Van Moer K., Heath J., Li M.-Y., Lai F.-J., RA Lin S.-R., Lee M.-H., Lo C.-P., Lin Y.-S., Chen S.-T., Chang N.-S.; RT "Transforming growth factor beta1 signaling via interaction with cell RT surface Hyal-2 and recruitment of WWOX/WOX1."; RL J. Biol. Chem. 284:16049-16059(2009). RN [22] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DVL1; DVL2 AND DVL3. RX PubMed=19465938; DOI=10.1038/onc.2009.120; RA Bouteille N., Driouch K., Hage P.E., Sin S., Formstecher E., Camonis J., RA Lidereau R., Lallemand F.; RT "Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor RT protein."; RL Oncogene 28:2569-2580(2009). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-12 AND SER-14, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH TMEM207. RX PubMed=22226915; DOI=10.1093/carcin/bgs001; RA Takeuchi T., Adachi Y., Nagayama T.; RT "A WWOX-binding molecule, transmembrane protein 207, is related to the RT invasiveness of gastric signet-ring cell carcinoma."; RL Carcinogenesis 33:548-554(2012). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [26] RP SUBCELLULAR LOCATION, INTERACTION WITH VOPP1, AND MUTAGENESIS OF TYR-33. RX PubMed=30285739; DOI=10.1186/s12915-018-0576-6; RA Bonin F., Taouis K., Azorin P., Petitalot A., Tariq Z., Nola S., RA Bouteille N., Tury S., Vacher S., Bieche I., Rais K.A., Pierron G., RA Fuhrmann L., Vincent-Salomon A., Formstecher E., Camonis J., Lidereau R., RA Lallemand F., Driouch K.; RT "VOPP1 promotes breast tumorigenesis by interacting with the tumor RT suppressor WWOX."; RL BMC Biol. 16:109-109(2018). RN [27] RP INVOLVEMENT IN SCAR12. RX PubMed=24456803; DOI=10.1186/1750-1172-9-12; RA Abdel-Salam G., Thoenes M., Afifi H.H., Koerber F., Swan D., Bolz H.J.; RT "The supposed tumor suppressor gene WWOX is mutated in an early lethal RT microcephaly syndrome with epilepsy, growth retardation and retinal RT degeneration."; RL Orphanet J. Rare Dis. 9:12-12(2014). RN [28] RP INVOLVEMENT IN DEE28, AND VARIANT DEE28 ARG-47. RX PubMed=25411445; DOI=10.1136/jmedgenet-2014-102748; RA Mignot C., Lambert L., Pasquier L., Bienvenu T., Delahaye-Duriez A., RA Keren B., Lefranc J., Saunier A., Allou L., Roth V., Valduga M., RA Moustaine A., Auvin S., Barrey C., Chantot-Bastaraud S., Lebrun N., RA Moutard M.L., Nougues M.C., Vermersch A.I., Heron B., Pipiras E., Heron D., RA Olivier-Faivre L., Gueant J.L., Jonveaux P., Philippe C.; RT "WWOX-related encephalopathies: delineation of the phenotypical spectrum RT and emerging genotype-phenotype correlation."; RL J. Med. Genet. 52:61-70(2015). RN [29] RP STRUCTURE BY NMR OF 51-101. RA Kowalski K., Merkel A.L., Colella A., Richards R.I., Booker G.W.; RT "Solution structure of the second WW domain of WWOX."; RL Submitted (FEB-2009) to the PDB data bank. RN [30] RP VARIANT PRO-291, AND INVOLVEMENT IN ESCR. RX PubMed=11956080; RA Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M., RA Croce C.M.; RT "Genetic alterations of the tumor suppressor gene WWOX in esophageal RT squamous cell carcinoma."; RL Cancer Res. 62:2258-2260(2002). RN [31] RP VARIANTS SCAR12 THR-47 AND ARG-372. RX PubMed=24369382; DOI=10.1093/brain/awt338; RA Mallaret M., Synofzik M., Lee J., Sagum C.A., Mahajnah M., Sharkia R., RA Drouot N., Renaud M., Klein F.A., Anheim M., Tranchant C., Mignot C., RA Mandel J.L., Bedford M., Bauer P., Salih M.A., Schuele R., Schoels L., RA Aldaz C.M., Koenig M.; RT "The tumour suppressor gene WWOX is mutated in autosomal recessive RT cerebellar ataxia with epilepsy and mental retardation."; RL Brain 137:411-419(2014). CC -!- FUNCTION: Putative oxidoreductase. Acts as a tumor suppressor and plays CC a role in apoptosis. Required for normal bone development (By CC similarity). May function synergistically with p53/TP53 to control CC genotoxic stress-induced cell death. Plays a role in TGFB1 signaling CC and TGFB1-mediated cell death. May also play a role in tumor necrosis CC factor (TNF)-mediated cell death. Inhibits Wnt signaling, probably by CC sequestering DVL2 in the cytoplasm. {ECO:0000250, CC ECO:0000269|PubMed:11719429, ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:15548692, ECO:0000269|PubMed:16061658, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:19366691, CC ECO:0000269|PubMed:19465938}. CC -!- SUBUNIT: Interacts with TP53, p73/TP73 and MAPK8. Interacts with CC MAPT/TAU, RUNX2 and HYAL2 (By similarity). Forms a ternary complex with CC TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. Interacts with CC DVL1, DVL2 and DVL3. May interact with FAM189B and SCOTIN. Interacts CC with TNK2. Interacts with TMEM207. Interacts (via WW domain) with VOPP1 CC (PubMed:30285739). {ECO:0000250, ECO:0000269|PubMed:12514174, CC ECO:0000269|PubMed:15064722, ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:15548692, ECO:0000269|PubMed:16061658, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16288044, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938, CC ECO:0000269|PubMed:22226915, ECO:0000269|PubMed:30285739}. CC -!- INTERACTION: CC Q9NZC7; O14641: DVL2; NbExp=2; IntAct=EBI-4320739, EBI-740850; CC Q9NZC7; P81408: ENTREP3; NbExp=6; IntAct=EBI-4320739, EBI-6366314; CC Q9NZC7; Q99732: LITAF; NbExp=5; IntAct=EBI-4320739, EBI-725647; CC Q9NZC7; Q8N114: SHISA5; NbExp=2; IntAct=EBI-4320739, EBI-2115556; CC Q9NZC7; P04637: TP53; NbExp=2; IntAct=EBI-4320739, EBI-366083; CC Q9NZC7; O15350: TP73; NbExp=4; IntAct=EBI-4320739, EBI-389606; CC Q9NZC7; O15350-1: TP73; NbExp=3; IntAct=EBI-4320739, EBI-389619; CC Q9NZC7; O15350-2: TP73; NbExp=5; IntAct=EBI-4320739, EBI-389623; CC Q9NZC7; Q96AW1: VOPP1; NbExp=7; IntAct=EBI-4320739, EBI-715058; CC Q9NZC7; Q96G27: WBP1; NbExp=4; IntAct=EBI-4320739, EBI-3867685; CC Q9NZC7; Q67FY2: Bcl9l; Xeno; NbExp=3; IntAct=EBI-4320739, EBI-5234367; CC Q9NZC7; Q60838: Dvl2; Xeno; NbExp=2; IntAct=EBI-4320739, EBI-641940; CC Q9NZC7; Q61527: Erbb4; Xeno; NbExp=3; IntAct=EBI-4320739, EBI-4398741; CC Q9NZC7-5; Q8NFV4-4: ABHD11; NbExp=3; IntAct=EBI-12040603, EBI-12318443; CC Q9NZC7-5; Q9NYB9-2: ABI2; NbExp=5; IntAct=EBI-12040603, EBI-11096309; CC Q9NZC7-5; Q9BWD1: ACAT2; NbExp=3; IntAct=EBI-12040603, EBI-1047273; CC Q9NZC7-5; Q5BKX5-3: ACTMAP; NbExp=3; IntAct=EBI-12040603, EBI-11976299; CC Q9NZC7-5; Q03154: ACY1; NbExp=3; IntAct=EBI-12040603, EBI-742064; CC Q9NZC7-5; P18825: ADRA2C; NbExp=3; IntAct=EBI-12040603, EBI-12015266; CC Q9NZC7-5; Q9NYG5-2: ANAPC11; NbExp=3; IntAct=EBI-12040603, EBI-12224467; CC Q9NZC7-5; P50995: ANXA11; NbExp=3; IntAct=EBI-12040603, EBI-715243; CC Q9NZC7-5; Q96B67: ARRDC3; NbExp=8; IntAct=EBI-12040603, EBI-2875665; CC Q9NZC7-5; Q86V38: ATN1; NbExp=3; IntAct=EBI-12040603, EBI-11954292; CC Q9NZC7-5; Q7L5A3: ATOSB; NbExp=3; IntAct=EBI-12040603, EBI-745689; CC Q9NZC7-5; Q5SWW7: C10orf55; NbExp=3; IntAct=EBI-12040603, EBI-12809220; CC Q9NZC7-5; Q6NUJ2: C11orf87; NbExp=3; IntAct=EBI-12040603, EBI-6660291; CC Q9NZC7-5; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-12040603, EBI-1104933; CC Q9NZC7-5; P40199: CEACAM6; NbExp=3; IntAct=EBI-12040603, EBI-4314501; CC Q9NZC7-5; Q8NE01: CNNM3; NbExp=3; IntAct=EBI-12040603, EBI-741032; CC Q9NZC7-5; Q16630-2: CPSF6; NbExp=3; IntAct=EBI-12040603, EBI-11088043; CC Q9NZC7-5; Q02930-3: CREB5; NbExp=3; IntAct=EBI-12040603, EBI-10192698; CC Q9NZC7-5; P02489: CRYAA; NbExp=3; IntAct=EBI-12040603, EBI-6875961; CC Q9NZC7-5; P67870: CSNK2B; NbExp=3; IntAct=EBI-12040603, EBI-348169; CC Q9NZC7-5; P78358: CTAG1B; NbExp=3; IntAct=EBI-12040603, EBI-1188472; CC Q9NZC7-5; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-12040603, EBI-751587; CC Q9NZC7-5; Q15038: DAZAP2; NbExp=6; IntAct=EBI-12040603, EBI-724310; CC Q9NZC7-5; Q9NQL9: DMRT3; NbExp=3; IntAct=EBI-12040603, EBI-9679045; CC Q9NZC7-5; G5E9A7: DMWD; NbExp=3; IntAct=EBI-12040603, EBI-10976677; CC Q9NZC7-5; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-12040603, EBI-744099; CC Q9NZC7-5; P00488: F13A1; NbExp=3; IntAct=EBI-12040603, EBI-2565863; CC Q9NZC7-5; Q8WU58: FAM222B; NbExp=5; IntAct=EBI-12040603, EBI-2807642; CC Q9NZC7-5; Q9BSK4: FEM1A; NbExp=3; IntAct=EBI-12040603, EBI-2515349; CC Q9NZC7-5; Q9NU39: FOXD4L1; NbExp=3; IntAct=EBI-12040603, EBI-11320806; CC Q9NZC7-5; Q12951-2: FOXI1; NbExp=3; IntAct=EBI-12040603, EBI-12018822; CC Q9NZC7-5; O43559: FRS3; NbExp=3; IntAct=EBI-12040603, EBI-725515; CC Q9NZC7-5; O75603: GCM2; NbExp=3; IntAct=EBI-12040603, EBI-10188645; CC Q9NZC7-5; P55040: GEM; NbExp=3; IntAct=EBI-12040603, EBI-744104; CC Q9NZC7-5; P14136: GFAP; NbExp=3; IntAct=EBI-12040603, EBI-744302; CC Q9NZC7-5; Q9BZE0: GLIS2; NbExp=3; IntAct=EBI-12040603, EBI-7251368; CC Q9NZC7-5; Q9Y223-2: GNE; NbExp=3; IntAct=EBI-12040603, EBI-11975289; CC Q9NZC7-5; P28799: GRN; NbExp=3; IntAct=EBI-12040603, EBI-747754; CC Q9NZC7-5; P49639: HOXA1; NbExp=3; IntAct=EBI-12040603, EBI-740785; CC Q9NZC7-5; P31273: HOXC8; NbExp=3; IntAct=EBI-12040603, EBI-1752118; CC Q9NZC7-5; P04792: HSPB1; NbExp=3; IntAct=EBI-12040603, EBI-352682; CC Q9NZC7-5; Q16082: HSPB2; NbExp=3; IntAct=EBI-12040603, EBI-739395; CC Q9NZC7-5; Q8IZ03: IFIT2; NbExp=3; IntAct=EBI-12040603, EBI-746217; CC Q9NZC7-5; Q0VD86: INCA1; NbExp=3; IntAct=EBI-12040603, EBI-6509505; CC Q9NZC7-5; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-12040603, EBI-1055254; CC Q9NZC7-5; Q92993: KAT5; NbExp=3; IntAct=EBI-12040603, EBI-399080; CC Q9NZC7-5; O60333-2: KIF1B; NbExp=3; IntAct=EBI-12040603, EBI-10975473; CC Q9NZC7-5; Q96G42: KLHDC7B; NbExp=3; IntAct=EBI-12040603, EBI-9478422; CC Q9NZC7-5; Q2WGJ6: KLHL38; NbExp=3; IntAct=EBI-12040603, EBI-6426443; CC Q9NZC7-5; Q92876: KLK6; NbExp=3; IntAct=EBI-12040603, EBI-2432309; CC Q9NZC7-5; P12035: KRT3; NbExp=3; IntAct=EBI-12040603, EBI-2430095; CC Q9NZC7-5; O76011: KRT34; NbExp=3; IntAct=EBI-12040603, EBI-1047093; CC Q9NZC7-5; O95678: KRT75; NbExp=3; IntAct=EBI-12040603, EBI-2949715; CC Q9NZC7-5; Q8IUC1: KRTAP11-1; NbExp=3; IntAct=EBI-12040603, EBI-1052037; CC Q9NZC7-5; Q14847-2: LASP1; NbExp=3; IntAct=EBI-12040603, EBI-9088686; CC Q9NZC7-5; Q99732: LITAF; NbExp=3; IntAct=EBI-12040603, EBI-725647; CC Q9NZC7-5; Q8TAP4-4: LMO3; NbExp=6; IntAct=EBI-12040603, EBI-11742507; CC Q9NZC7-5; Q71SY5: MED25; NbExp=3; IntAct=EBI-12040603, EBI-394558; CC Q9NZC7-5; Q13064: MKRN3; NbExp=3; IntAct=EBI-12040603, EBI-2340269; CC Q9NZC7-5; Q9HB07: MYG1; NbExp=3; IntAct=EBI-12040603, EBI-709754; CC Q9NZC7-5; Q9NP98: MYOZ1; NbExp=3; IntAct=EBI-12040603, EBI-744402; CC Q9NZC7-5; Q9NPC6: MYOZ2; NbExp=3; IntAct=EBI-12040603, EBI-746712; CC Q9NZC7-5; P19404: NDUFV2; NbExp=3; IntAct=EBI-12040603, EBI-713665; CC Q9NZC7-5; Q14511-2: NEDD9; NbExp=3; IntAct=EBI-12040603, EBI-11746523; CC Q9NZC7-5; P29474: NOS3; NbExp=3; IntAct=EBI-12040603, EBI-1391623; CC Q9NZC7-5; Q7RTU3: OLIG3; NbExp=3; IntAct=EBI-12040603, EBI-10225049; CC Q9NZC7-5; P32242: OTX1; NbExp=3; IntAct=EBI-12040603, EBI-740446; CC Q9NZC7-5; Q86TB9: PATL1; NbExp=5; IntAct=EBI-12040603, EBI-2562092; CC Q9NZC7-5; Q9HBE1-4: PATZ1; NbExp=5; IntAct=EBI-12040603, EBI-11022007; CC Q9NZC7-5; P55771: PAX9; NbExp=3; IntAct=EBI-12040603, EBI-12111000; CC Q9NZC7-5; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-12040603, EBI-10302990; CC Q9NZC7-5; Q9UBV8: PEF1; NbExp=3; IntAct=EBI-12040603, EBI-724639; CC Q9NZC7-5; Q99697-2: PITX2; NbExp=3; IntAct=EBI-12040603, EBI-12138495; CC Q9NZC7-5; Q494U1-3: PLEKHN1; NbExp=3; IntAct=EBI-12040603, EBI-12014286; CC Q9NZC7-5; Q9NRY6: PLSCR3; NbExp=3; IntAct=EBI-12040603, EBI-750734; CC Q9NZC7-5; P62937-2: PPIA; NbExp=3; IntAct=EBI-12040603, EBI-25884072; CC Q9NZC7-5; P23284: PPIB; NbExp=3; IntAct=EBI-12040603, EBI-359252; CC Q9NZC7-5; P17252: PRKCA; NbExp=3; IntAct=EBI-12040603, EBI-1383528; CC Q9NZC7-5; P60891: PRPS1; NbExp=3; IntAct=EBI-12040603, EBI-749195; CC Q9NZC7-5; P28062-2: PSMB8; NbExp=3; IntAct=EBI-12040603, EBI-372312; CC Q9NZC7-5; Q9BTL3: RAMAC; NbExp=3; IntAct=EBI-12040603, EBI-744023; CC Q9NZC7-5; Q9Y3C5: RNF11; NbExp=3; IntAct=EBI-12040603, EBI-396669; CC Q9NZC7-5; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-12040603, EBI-6257312; CC Q9NZC7-5; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-12040603, EBI-3957636; CC Q9NZC7-5; Q7Z5V6-2: SAXO4; NbExp=3; IntAct=EBI-12040603, EBI-12000762; CC Q9NZC7-5; Q15047-2: SETDB1; NbExp=3; IntAct=EBI-12040603, EBI-9090795; CC Q9NZC7-5; Q9H788: SH2D4A; NbExp=5; IntAct=EBI-12040603, EBI-747035; CC Q9NZC7-5; Q92529: SHC3; NbExp=5; IntAct=EBI-12040603, EBI-79084; CC Q9NZC7-5; Q16348: SLC15A2; NbExp=3; IntAct=EBI-12040603, EBI-12806032; CC Q9NZC7-5; Q99954: SMR3A; NbExp=3; IntAct=EBI-12040603, EBI-12067698; CC Q9NZC7-5; P09234: SNRPC; NbExp=3; IntAct=EBI-12040603, EBI-766589; CC Q9NZC7-5; Q96LM6: SPMIP9; NbExp=3; IntAct=EBI-12040603, EBI-743976; CC Q9NZC7-5; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-12040603, EBI-5235340; CC Q9NZC7-5; Q9BT92: TCHP; NbExp=3; IntAct=EBI-12040603, EBI-740781; CC Q9NZC7-5; Q9BXF9: TEKT3; NbExp=3; IntAct=EBI-12040603, EBI-8644516; CC Q9NZC7-5; Q92734: TFG; NbExp=3; IntAct=EBI-12040603, EBI-357061; CC Q9NZC7-5; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-12040603, EBI-11525489; CC Q9NZC7-5; Q3SY00: TSGA10IP; NbExp=5; IntAct=EBI-12040603, EBI-10241197; CC Q9NZC7-5; Q6NVU6: UFSP1; NbExp=3; IntAct=EBI-12040603, EBI-12068150; CC Q9NZC7-5; O95231: VENTX; NbExp=5; IntAct=EBI-12040603, EBI-10191303; CC Q9NZC7-5; Q14119: VEZF1; NbExp=3; IntAct=EBI-12040603, EBI-11980193; CC Q9NZC7-5; A5D8V6: VPS37C; NbExp=3; IntAct=EBI-12040603, EBI-2559305; CC Q9NZC7-5; O76024: WFS1; NbExp=3; IntAct=EBI-12040603, EBI-720609; CC Q9NZC7-5; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-12040603, EBI-12040603; CC Q9NZC7-5; P61981: YWHAG; NbExp=3; IntAct=EBI-12040603, EBI-359832; CC Q9NZC7-5; A0A0C4DGF1: ZBTB32; NbExp=6; IntAct=EBI-12040603, EBI-10188476; CC Q9NZC7-5; Q15915: ZIC1; NbExp=3; IntAct=EBI-12040603, EBI-11963196; CC Q9NZC7-5; P52742: ZNF135; NbExp=3; IntAct=EBI-12040603, EBI-7101455; CC Q9NZC7-5; Q96IQ9: ZNF414; NbExp=3; IntAct=EBI-12040603, EBI-744257; CC Q9NZC7-5; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-12040603, EBI-745520; CC Q9NZC7-5; Q96EJ4; NbExp=3; IntAct=EBI-12040603, EBI-750454; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14695174, CC ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:16219768, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938}. Nucleus CC {ECO:0000269|PubMed:14695174, ECO:0000269|PubMed:15064722, CC ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:19366691}. CC Mitochondrion {ECO:0000269|PubMed:14695174}. Golgi apparatus CC {ECO:0000269|PubMed:30285739}. Lysosome {ECO:0000269|PubMed:30285739}. CC Note=Partially localizes to the mitochondria (PubMed:14695174). CC Translocates to the nucleus upon genotoxic stress or TNF stimulation CC (By similarity). Translocates to the nucleus in response to TGFB1 CC (PubMed:19366691). Isoform 5 and isoform 6 may localize in the nucleus. CC Localized to the lysosome probably upon binding to VOPP1 CC (PubMed:30285739). {ECO:0000250, ECO:0000269|PubMed:14695174, CC ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:30285739}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Name=1; Synonyms=FOR II, FOR2, WWOXv1, WWOX v8; CC IsoId=Q9NZC7-1; Sequence=Displayed; CC Name=2; Synonyms=FOR I, FOR1, WOX2, WWOXv2; CC IsoId=Q9NZC7-2; Sequence=VSP_016367, VSP_016369; CC Name=3; Synonyms=FOR III, FOR3, WOX3; CC IsoId=Q9NZC7-3; Sequence=VSP_016364, VSP_016365; CC Name=4; Synonyms=FOR IV; CC IsoId=Q9NZC7-4; Sequence=VSP_016358, VSP_016359; CC Name=5; Synonyms=WWOXdelta6-8, WWOXv4; CC IsoId=Q9NZC7-5; Sequence=VSP_016363; CC Name=6; Synonyms=WWOXdelta5-8, WWOXv3; CC IsoId=Q9NZC7-6; Sequence=VSP_016360; CC Name=7; CC IsoId=Q9NZC7-7; Sequence=VSP_016362, VSP_016366; CC -!- TISSUE SPECIFICITY: Widely expressed. Strongly expressed in testis, CC prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and CC isoform 6 may only be expressed in tumor cell lines. CC {ECO:0000269|PubMed:10786676, ECO:0000269|PubMed:11719429}. CC -!- DOMAIN: The WW 1 domain mediates interaction with TP53, and probably CC TP73, TFAP2C, LITAF and WBP1. {ECO:0000269|PubMed:15064722, CC ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:15548692}. CC -!- PTM: Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 CC regulates interaction with TP53, TP73 and MAPK8. May also regulate CC proapoptotic activity. Phosphorylation by TNK2 is associated with CC polyubiquitination and degradation. {ECO:0000269|PubMed:15070730, CC ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:19366691}. CC -!- PTM: Ubiquitinated when phosphorylated by TNK2, leading to its CC degradation. {ECO:0000269|PubMed:16288044}. CC -!- DISEASE: Note=Defects in WWOX may be involved in several cancer types. CC The gene spans the second most common chromosomal fragile site (FRA16D) CC which is frequently altered in cancers (PubMed:10861292). Alteration of CC the expression and expression of some isoforms is associated with CC cancers. However, it is still unclear if alteration of WWOX is directly CC implicated in cancerogenesis or if it corresponds to a secondary effect CC (PubMed:10861292, PubMed:11572989, PubMed:15073125, PubMed:15131042, CC PubMed:15266310). {ECO:0000269|PubMed:10861292, CC ECO:0000269|PubMed:11572989, ECO:0000269|PubMed:15073125, CC ECO:0000269|PubMed:15131042, ECO:0000269|PubMed:15266310}. CC -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the CC esophagus. The most common types are esophageal squamous cell carcinoma CC and adenocarcinoma. Cancer of the esophagus remains a devastating CC disease because it is usually not detected until it has progressed to CC an advanced incurable stage. {ECO:0000269|PubMed:11956080}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. CC -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 12 (SCAR12) CC [MIM:614322]: A form of spinocerebellar ataxia, a clinically and CC genetically heterogeneous group of cerebellar disorders. Patients show CC progressive incoordination of gait and often poor coordination of CC hands, speech and eye movements, due to degeneration of the cerebellum CC with variable involvement of the brainstem and spinal cord. SCAR12 is CC additionally characterized by onset of generalized seizures in infancy, CC and delayed psychomotor development with intellectual disability. Some CC patients may also show spasticity. {ECO:0000269|PubMed:24369382, CC ECO:0000269|PubMed:24456803}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Developmental and epileptic encephalopathy 28 (DEE28) CC [MIM:616211]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. {ECO:0000269|PubMed:25411445}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR) CC family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAP94227.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/508/WWOX"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF211943; AAF27049.1; -; mRNA. DR EMBL; AF212843; AAF27050.1; -; Genomic_DNA. DR EMBL; AH009490; AAF78197.1; -; Genomic_DNA. DR EMBL; AF227526; AAF82053.1; -; mRNA. DR EMBL; AF227527; AAF82054.1; -; mRNA. DR EMBL; AF227528; AAF82055.1; -; mRNA. DR EMBL; AF227529; AAF82056.1; -; mRNA. DR EMBL; AF395123; AAK81727.1; -; mRNA. DR EMBL; AF395124; AAK81728.1; -; mRNA. DR EMBL; AF325432; AAL05449.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325427; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325428; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325430; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325431; AAL05449.1; JOINED; Genomic_DNA. DR EMBL; AF325429; AAL05450.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325427; AAL05450.1; JOINED; Genomic_DNA. DR EMBL; AF325432; AAL05451.1; -; Genomic_DNA. DR EMBL; AF325423; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325424; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325425; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325426; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AF325433; AAL05451.1; JOINED; Genomic_DNA. DR EMBL; AY256821; AAP94227.1; ALT_FRAME; mRNA. DR EMBL; AK290438; BAF83127.1; -; mRNA. DR EMBL; BT007445; AAP36113.1; -; mRNA. DR EMBL; BC003184; AAH03184.1; -; mRNA. DR CCDS; CCDS42196.1; -. [Q9NZC7-1] DR CCDS; CCDS42197.1; -. [Q9NZC7-3] DR RefSeq; NP_001278926.1; NM_001291997.1. DR RefSeq; NP_057457.1; NM_016373.4. [Q9NZC7-1] DR RefSeq; NP_570607.1; NM_130791.5. [Q9NZC7-3] DR PDB; 1WMV; NMR; -; A=51-101. DR PDBsum; 1WMV; -. DR AlphaFoldDB; Q9NZC7; -. DR SMR; Q9NZC7; -. DR BioGRID; 119707; 636. DR CORUM; Q9NZC7; -. DR FunCoup; Q9NZC7; 1428. DR IntAct; Q9NZC7; 194. DR MINT; Q9NZC7; -. DR STRING; 9606.ENSP00000457230; -. DR iPTMnet; Q9NZC7; -. DR PhosphoSitePlus; Q9NZC7; -. DR BioMuta; WWOX; -. DR DMDM; 74725363; -. DR jPOST; Q9NZC7; -. DR MassIVE; Q9NZC7; -. DR PaxDb; 9606-ENSP00000457230; -. DR PeptideAtlas; Q9NZC7; -. DR ProteomicsDB; 83364; -. [Q9NZC7-1] DR ProteomicsDB; 83365; -. [Q9NZC7-2] DR ProteomicsDB; 83366; -. [Q9NZC7-3] DR ProteomicsDB; 83367; -. [Q9NZC7-4] DR ProteomicsDB; 83368; -. [Q9NZC7-5] DR ProteomicsDB; 83369; -. [Q9NZC7-6] DR ProteomicsDB; 83370; -. [Q9NZC7-7] DR Pumba; Q9NZC7; -. DR Antibodypedia; 8291; 399 antibodies from 43 providers. DR DNASU; 51741; -. DR Ensembl; ENST00000355860.7; ENSP00000348119.3; ENSG00000186153.19. [Q9NZC7-3] DR Ensembl; ENST00000402655.6; ENSP00000384238.2; ENSG00000186153.19. [Q9NZC7-6] DR Ensembl; ENST00000406884.6; ENSP00000384495.2; ENSG00000186153.19. [Q9NZC7-5] DR Ensembl; ENST00000408984.7; ENSP00000386161.3; ENSG00000186153.19. [Q9NZC7-2] DR Ensembl; ENST00000566780.6; ENSP00000457230.1; ENSG00000186153.19. [Q9NZC7-1] DR Ensembl; ENST00000569818.1; ENSP00000454485.1; ENSG00000186153.19. [Q9NZC7-4] DR GeneID; 51741; -. DR KEGG; hsa:51741; -. DR MANE-Select; ENST00000566780.6; ENSP00000457230.1; NM_016373.4; NP_057457.1. DR UCSC; uc002ffi.3; human. [Q9NZC7-1] DR AGR; HGNC:12799; -. DR ClinPGx; PA37398; -. DR CTD; 51741; -. DR DisGeNET; 51741; -. DR GeneCards; WWOX; -. DR HGNC; HGNC:12799; WWOX. DR HPA; ENSG00000186153; Low tissue specificity. DR MalaCards; WWOX; -. DR MIM; 133239; phenotype. DR MIM; 605131; gene. DR MIM; 614322; phenotype. DR MIM; 616211; phenotype. DR OpenTargets; ENSG00000186153; -. DR Orphanet; 251510; 46,XY partial gonadal dysgenesis. DR Orphanet; 284282; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency. DR Orphanet; 708171; Facial dysmorphism-corpus callosum hypoplasia-infantile epileptic encephalopathy. DR Orphanet; 99977; Squamous cell carcinoma of the esophagus. DR VEuPathDB; HostDB:ENSG00000186153; -. DR eggNOG; KOG1208; Eukaryota. DR GeneTree; ENSGT00940000157389; -. DR HOGENOM; CLU_010194_44_0_1; -. DR InParanoid; Q9NZC7; -. DR OMA; PPAEKYW; -. DR OrthoDB; 9989144at2759; -. DR PAN-GO; Q9NZC7; 0 GO annotations based on evolutionary models. DR PhylomeDB; Q9NZC7; -. DR PathwayCommons; Q9NZC7; -. DR Reactome; R-HSA-1251985; Nuclear signaling by ERBB4. DR Reactome; R-HSA-8866904; Negative regulation of activity of TFAP2 (AP-2) family transcription factors. DR Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors. DR SignaLink; Q9NZC7; -. DR SIGNOR; Q9NZC7; -. DR Agora; ENSG00000186153; -. DR BioGRID-ORCS; 51741; 12 hits in 1160 CRISPR screens. DR ChiTaRS; WWOX; human. DR EvolutionaryTrace; Q9NZC7; -. DR GeneWiki; WWOX; -. DR GenomeRNAi; 51741; -. DR Pharos; Q9NZC7; Tbio. DR PRO; PR:Q9NZC7; -. DR Proteomes; UP000005640; Chromosome 16. DR RNAct; Q9NZC7; protein. DR Bgee; ENSG00000186153; Expressed in parotid gland and 201 other cell types or tissues. DR ExpressionAtlas; Q9NZC7; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:BHF-UCL. DR GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; ISS:BHF-UCL. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0016491; F:oxidoreductase activity; NAS:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl. DR GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:UniProtKB. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:BHF-UCL. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:BHF-UCL. DR GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL. DR GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW. DR CDD; cd09809; human_WWOX_like_SDR_c-like; 1. DR CDD; cd00201; WW; 2. DR FunFam; 2.20.70.10:FF:000032; WW domain containing oxidoreductase; 1. DR FunFam; 2.20.70.10:FF:000040; WW domain containing oxidoreductase; 1. DR FunFam; 3.40.50.720:FF:000353; WW domain-containing oxidoreductase; 1. DR Gene3D; 2.20.70.10; -; 2. DR Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1. DR InterPro; IPR036291; NAD(P)-bd_dom_sf. DR InterPro; IPR002347; SDR_fam. DR InterPro; IPR001202; WW_dom. DR InterPro; IPR036020; WW_dom_sf. DR InterPro; IPR042732; WWOX_SDR_c-like. DR PANTHER; PTHR24320; RETINOL DEHYDROGENASE; 1. DR PANTHER; PTHR24320:SF282; WW DOMAIN-CONTAINING OXIDOREDUCTASE; 1. DR Pfam; PF00106; adh_short; 1. DR Pfam; PF00397; WW; 2. DR PRINTS; PR00081; GDHRDH. DR SMART; SM00456; WW; 2. DR SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1. DR SUPFAM; SSF51045; WW domain; 2. DR PROSITE; PS01159; WW_DOMAIN_1; 2. DR PROSITE; PS50020; WW_DOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; Cytoplasm; Disease variant; KW Epilepsy; Golgi apparatus; Lysosome; Mitochondrion; NADP; KW Neurodegeneration; Nucleus; Oxidoreductase; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Tumor suppressor; KW Ubl conjugation; Wnt signaling pathway. FT CHAIN 1..414 FT /note="WW domain-containing oxidoreductase" FT /id="PRO_0000054815" FT DOMAIN 16..49 FT /note="WW 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00224" FT DOMAIN 57..90 FT /note="WW 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00224" FT REGION 1..23 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 125..414 FT /note="Interaction with MAPT" FT /evidence="ECO:0000250" FT REGION 209..273 FT /note="Mediates targeting to the mitochondria" FT /evidence="ECO:0000250" FT MOTIF 50..55 FT /note="Nuclear localization signal" FT /evidence="ECO:0000250" FT ACT_SITE 293 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 131..137 FT /ligand="NADP(+)" FT /ligand_id="ChEBI:CHEBI:58349" FT /evidence="ECO:0000250" FT BINDING 260 FT /ligand="substrate" FT /evidence="ECO:0000250" FT MOD_RES 12 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 14 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 33 FT /note="Phosphotyrosine" FT /evidence="ECO:0000269|PubMed:15070730, FT ECO:0000269|PubMed:19366691" FT MOD_RES 287 FT /note="Phosphotyrosine; by TNK2" FT /evidence="ECO:0000269|PubMed:16288044" FT VAR_SEQ 36 FT /note="N -> K (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016358" FT VAR_SEQ 37..414 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016359" FT VAR_SEQ 137..414 FT /note="GFETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKVEAMTLDLALLR FT SVQHFAEAFKAKNVPLHVLVCNAATFALPWSLTKDGLETTFQVNHLGHFYLVQLLQDVL FT CRSAPARVIVVSSESHRFTDINDSLGKLDFSRLSPTKNDYWAMLAYNRSKLCNILFSNE FT LHRRLSPRGVTSNAVHPGNMMYSNIHRSWWVYTLLFTLARPFTKSMQQGAATTVYCAAV FT PELEGLGGMYFNNCCRCMPSPEAQSEETARTLWALSERLIQERLGSQSG -> ATGSCH FT HRVLCCCPRTGGSGRDVLQQLLPLHALTRSSERRDGPDPVGAQREADPRTAWQPVRLSG FT AQSGWAHTPALCVSPHASARAGPLPNVPPTQIRKSKGNKSSHNRVKNLKYQWEAGNSWG FT KVSLFWGWARHRSLCFLVVACLKVKTCLVCRFRISLEKHQQFSFFYCYRIA (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:11719429" FT /id="VSP_016360" FT VAR_SEQ 138..213 FT /note="FETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKVEAMTLDLALLRS FT VQHFAEAFKAKNVPLHVLVCNAAT -> KASCHVGRTLKHTRVEELSLLPTAINRELPP FT PCTVLLSQNWRVWEGCTSTTAAAACPHQKLRAKRRPGPCGRSARG (in isoform FT 7)" FT /evidence="ECO:0000305" FT /id="VSP_016362" FT VAR_SEQ 173..352 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:11719429, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.7" FT /id="VSP_016363" FT VAR_SEQ 173..189 FT /note="HKAKVEAMTLDLALLRS -> KTKYHPPPEKCRIKIFH (in isoform FT 3)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016364" FT VAR_SEQ 190..414 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016365" FT VAR_SEQ 214..414 FT /note="Missing (in isoform 7)" FT /evidence="ECO:0000305" FT /id="VSP_016366" FT VAR_SEQ 353..363 FT /note="QQGAATTVYCA -> VSDCLVEGGHF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016367" FT VAR_SEQ 364..414 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10861292" FT /id="VSP_016369" FT VARIANT 47 FT /note="P -> R (in DEE28; dbSNP:rs730880292)" FT /evidence="ECO:0000269|PubMed:25411445" FT /id="VAR_072351" FT VARIANT 47 FT /note="P -> T (in SCAR12; dbSNP:rs587777128)" FT /evidence="ECO:0000269|PubMed:24369382" FT /id="VAR_070992" FT VARIANT 98 FT /note="P -> L (in dbSNP:rs144601717)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023916" FT VARIANT 111 FT /note="T -> S (in a Burkitt lymphoma cell line; FT dbSNP:rs114755364)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023917" FT VARIANT 120 FT /note="R -> W (in a primary colorectal tumor and a FT histiocytic lymphoma cell line; dbSNP:rs141361080)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023918" FT VARIANT 179 FT /note="A -> T (in dbSNP:rs11545029)" FT /evidence="ECO:0000269|PubMed:11572989, ECO:0000269|Ref.5" FT /id="VAR_023919" FT VARIANT 216 FT /note="L -> V (in dbSNP:rs7201683)" FT /id="VAR_052323" FT VARIANT 272 FT /note="L -> F (in dbSNP:rs186745328)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023920" FT VARIANT 282 FT /note="P -> A (in dbSNP:rs3764340)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023921" FT VARIANT 291 FT /note="L -> P (found in a esophageal cancer sample; somatic FT mutation; dbSNP:rs119487098)" FT /evidence="ECO:0000269|PubMed:11956080" FT /id="VAR_023922" FT VARIANT 314 FT /note="R -> H (in dbSNP:rs73572838)" FT /evidence="ECO:0000269|PubMed:11572989" FT /id="VAR_023923" FT VARIANT 372 FT /note="G -> R (in SCAR12; dbSNP:rs587777127)" FT /evidence="ECO:0000269|PubMed:24369382" FT /id="VAR_070993" FT MUTAGEN 28 FT /note="K->T: No effect on interaction with TP53. Abolishes FT interaction with MAPK8; when associated with V-29." FT /evidence="ECO:0000269|PubMed:12514174" FT MUTAGEN 29 FT /note="D->V: No effect on interaction with TP53. Abolishes FT interaction with MAPK8; when associated with T-28." FT /evidence="ECO:0000269|PubMed:12514174" FT MUTAGEN 33 FT /note="Y->F: Loss of phosphorylation." FT /evidence="ECO:0000269|PubMed:12514174, FT ECO:0000269|PubMed:15070730" FT MUTAGEN 33 FT /note="Y->R: Abolishes interaction with TP53, TP73, MAPK8 FT and ERBB4. Partial loss of interaction with TFAP2C. Loss of FT phosphorylation. Loss of the proapoptotic activity. FT Abolishes binding to VOPP1." FT /evidence="ECO:0000269|PubMed:12514174, FT ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:30285739" FT MUTAGEN 44..47 FT /note="WEHP->FEHA: Abolishes interaction with LITAF." FT /evidence="ECO:0000269|PubMed:15064722" FT MUTAGEN 61 FT /note="Y->R: No effect on interaction with TP73." FT /evidence="ECO:0000269|PubMed:15070730" FT MUTAGEN 85..88 FT /note="YLDP->ALDA: No effect on interaction with LITAF." FT /evidence="ECO:0000269|PubMed:15064722" FT MUTAGEN 287 FT /note="Y->A: Loss of phosphorylation by TNK2." FT /evidence="ECO:0000269|PubMed:16288044" FT STRAND 63..67 FT /evidence="ECO:0007829|PDB:1WMV" FT STRAND 73..80 FT /evidence="ECO:0007829|PDB:1WMV" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:1WMV" FT VARIANT Q9NZC7-3:182 FT /note="K -> E (found in a primary colorectal tumor and FT tumor cells; dbSNP:rs77067228)" FT /evidence="ECO:0000305" FT /id="VAR_082915" SQ SEQUENCE 414 AA; 46677 MW; E4D9A649E6CB05DF CRC64; MAALRYAGLD DTDSEDELPP GWEERTTKDG WVYYANHTEE KTQWEHPKTG KRKRVAGDLP YGWEQETDEN GQVFFVDHIN KRTTYLDPRL AFTVDDNPTK PTTRQRYDGS TTAMEILQGR DFTGKVVVVT GANSGIGFET AKSFALHGAH VILACRNMAR ASEAVSRILE EWHKAKVEAM TLDLALLRSV QHFAEAFKAK NVPLHVLVCN AATFALPWSL TKDGLETTFQ VNHLGHFYLV QLLQDVLCRS APARVIVVSS ESHRFTDIND SLGKLDFSRL SPTKNDYWAM LAYNRSKLCN ILFSNELHRR LSPRGVTSNA VHPGNMMYSN IHRSWWVYTL LFTLARPFTK SMQQGAATTV YCAAVPELEG LGGMYFNNCC RCMPSPEAQS EETARTLWAL SERLIQERLG SQSG //